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The aim of this thesis was to establish the extent of objective and subjective cognitive 
impairment in patients with resected colorectal cancer who required adjuvant 
chemotherapy treatment compared to those who did not. Specific objectives were to i) 
identify the extent and nature of cognitive impairments ii) explore changes in cognitive 
function over time and iii) identify relationships between cognitive function and 
psychosocial outcomes. The qualitative study aimed to further evaluate the lived 
experience of patients diagnosed with colorectal cancer undergoing adjuvant 
chemotherapy treatment over time. 
 
A mixed method longitudinal comparative study was conducted to address these 
objectives’. A convenience sample of 98 patients with resected colorectal cancer were 
recruited from 5 London based NHS Trusts. Participants consisted of 63 patients 
scheduled for 6 months adjuvant chemotherapy treatment and 35 patients who did not 
require any further systemic treatment. Each participant completed a 
neuropsychological test battery and psychosocial self-report questionnaires and/or a 
semi structured interview prior to the start of the treatment, during and 3 months after 
the end of treatment. 
 
The results showed objective cognitive impairment in a statistically significant (p<0.01) 
proportion (ranging from 42% -60% depending on the definition used) of participants 
in both patient groups at all assessment time points (from before chemotherapy 
treatment to 3 months after it finished); with very little change over time (small to 
medium effect sizes). Verbal memory, motor function and executive function were most 
affected in both groups. There was no significant association between overall objective 
cognitive impairment and fatigue, anxiety/depression or quality of life. All psychosocial 
outcomes were all highly correlated with cognitive symptoms at every time point. 
Cognitive symptoms (such as memory lapses and word findng problems) were also 
reported at every time point by participants in the interview study, which corroborated 
the results of the quantitative analysis.   
 
The results of this study address a gap in the literature and highlight the extent of 
cognitive impairments in patients with colorectal cancer. The clinical implications of the 
findings are discussed. 
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Chapter 1: Colorectal cancer, treatment and side effects  
1.1 Chapter Introduction 
This chapter provides relevant background information relating to colorectal cancer 
(CRC), available treatments and possible biological and psychological side effects. The 
chapter begins by providing some key statistics pertaining to the prevalence of CRC in 
the United Kingdom (UK), its key features and how it is detected and staged. It then 
highlights the available treatment options, with a focus on surgery and adjuvant 
chemotherapy treatment. The chapter concludes with a description of the most 
frequently observed side effects associated with colorectal surgery and chemotherapy.  
1.2 CRC  
Commonly known as bowel cancer, CRC includes both cancer of the colon (large bowel) 
and cancer of the rectum, accounting for 66% and 34% of CRC respectively (Cancer 
Research UK, 2015); with a gender distribution of 55% (22,800) diagnosed in males and 
45% (18,400) in females (Cancer Research UK, 2014). Figure 1.1 shows a further 
breakdown of CRC locations and the percentage occurrence within gender.  
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Figure 1.1 Pictorial representation of CRCs percentage distribution by anatomical 
site and gender (Cancer Research UK, with date of source) 
 
At approximately 5ft long, the colon is the first four sections of the large bowel, (as 
shown in Figure 1.2) and the fifth section is the rectum, all of which can develop cancer: 
1. Ascending colon runs up the right side of the abdomen. It is connected to the 
small intestine by a section of bowel called the caecum;  
2. Transverse colon runs across the body from right to left, under the stomach;  
3. Descending colon runs down the left side of the abdomen; and 
4. Sigmoid colon resembles an S-shaped bend that joins the descending colon to the 
rectum (Cancer Research UK, 2015). 
5. Rectum  
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Figure 1.2 Diagram showing the parts of the colon and rectum in the bowel 
 
As can be seen in Figure 1.2 the rectum starts in the last part of the large bowel and is 
where rectal cancer may develop.  
There are many forms of CRC, including adenocarcinomas, gastrointestinal carcinoid 
tumours, gastrointestinal stromal tumours, leiomyosarcomas and primary colorectal 
lymphomas (Appendix A). However, 95% of all diagnosed CRCs are adenocarcinomas, a 
type of cancer, which often begins as small polyps or growths (“adenomas”) in the inner 
lining of the colon or rectum and then spread to other layers (as described in Section 
1.6). The other tumour types listed above are much rarer cancers, which are treated 
differently from adenocarcinomas of the colon or rectum and are outside the remit of 
this thesis. The focus of this thesis is adenocarcinomas. All further references to CRC in 
this thesis pertain to adenocarcinomas. 
1.3  Detecting CRC  
Signs and symptoms of CRC may include blood in the stool, a change in bowel habits 
(e.g. diarrhea, constipation, or feeling that the bowel does not empty all the way); 
unexplained weight loss, or feeling continually fatigued (National Cancer Institute, 
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2015). In such cases, a person’s family doctor (GP) would normally refer them for 
further testing. 
Symptoms can sometimes be so severe that a person goes directly to their local 
hospital’s accident and emergency department (A&E). Approximately 24% of CRC cases 
are diagnosed because of patients being admitted to hospital via emergency 
presentations (NCIN, 2015).  
However, some people may have no symptoms at all, or they may experience very 
subtle symptoms, which do not make them ill.  This variance in symptom presentation 
and disease detection led to the implementation of the UK’s National Health Service 
(NHS) bowel-screening programme. The programme’s primary goal was to reduce 
mortality rates by detecting CRC in asymptomatic people at an early stage (Jones et al, 
2009), to allow earlier treatment. Research has shown that screening reduces mortality 
through the removal of precancerous polyps and by identifying earlier-stage cancers 
(Hardcastle et al, 1996; Kronborg, et al, 1996; Mandel et al, 1993).  
Screening was first implemented in England in July 2006 for 60-69 year olds and has 
since been rolled out across the whole of the UK (Scottish Bowel Screening Programme; 
Bowel Screening Wales; Northern Ireland Bowel Screening Programme, NHS Screening 
Programme) with the age limit extended to 74. People older than 74 may also self-refer 
into the programme (Morris, Whitehouse, Farrell, Nickerson et al, 2012). 
A screening kit, known as the faecal occult blood test (FOBT) is sent to all people aged 
between 60 and 74 biennially. Individuals use the kits at home and post a series of stool 
samples back to the NHS for testing.  If any traces of blood are found in the submitted 
stools the individual is asked to undergo further testing (Cancer Research UK, 2015).   
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Research has shown that screening with the current FOBT reduces the risk of dying 
from CRC by approximately 25% in patients who have used the test (Hewitson et al, 
2008). By October 2008, almost 2.1 million 60-69 year olds had been invited to 
participate in the screening programme; however only half of those people actually did 
so (Cancer Research UK, 2015).  Tests were returned by 49.6% of men and 54.4% of 
women invited (Logan, Patnick, Nickerson, Coleman et al, 2012), and uptake varied by 
both age and level of deprivation (von Wagner, Baio, Raine, Snowball et al, 2011).  
It remains unclear from the currently available data whether the screening programme 
will result in a greater rate of CRC survival as we do not know whether there are 
differences between people that participate in screening and those that do not, or if 
there are already significant differences in survival between these two groups.   
1.4 Prevalence  
CRC is the fourth most common cancer in the UK (Cancer Research UK, 2015) and the 
third most common in both genders, accounting for 13% of all male cancers and 11% of 
all female cancers (Office for National Statistics, 2013; ISD Scotland, 2013; Welsh Cancer 
Intelligence and Surveillance Unit, 2013; Northern Ireland Cancer Registry, 2013). It is 
the third most common cause of cancer death in the UK (lung being the most common), 
although it should be noted that mortality rates have been falling since the 1970s (Office 
for National Statistics, 2014; ISD Scotland, 2014; Northern Ireland Cancer Registry, 
2013). In 2012, an estimated 1.36 million CRC cases were diagnosed worldwide, with 
varying incidence rates between countries. Overall reported incidence rates for CRC 
started to decline towards the end of the 1990s (Jones, Morris, Thomas, Forman et al, 
2009) but have since risen following the introduction of the national bowel screening 
programmes.  
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1.5 Risk Factors 
The contributing non-modifiable and modifiable risk factors associated with developing 
CRC include age, inherited genetic disorders, lifestyle and environment (National Cancer 
Institute, 2015).  A detailed account of the evidence and reasoning for these factors is 
outside the scope of this thesis and therefore only the key risk factors have been listed 
in this section. 
1.5.1 Non-modifiable risk factors: 
Non-modifiable risk factors are those that the individual cannot control for and include 
age and hereditary factors.  
1.5.1.1 Age 
The likelihood of a CRC diagnosis increases progressively from the age of 40 and rises 
sharply after 50 (Ries, Harkins, Krapcho, Mariotto et al, 2006). Between 2009 and 2011, 
approximately 43% of CRC cases diagnosed in the UK were people aged 75 years and 
over and 95% were diagnosed in those 50 years and over (Cancer Research UK, 2015). 
However, a recent study (Siegel, Killer and Jemal, 2017) suggests that, this pattern is 
changing. Siegel et al (2017) reported that the incidence rates of CRC are rising in adults 
under 50 years old in America (Figure 1.3). The causes for this increase are still 
unknown, although factors that are believed to have contributed to it include increased 
rates of obesity, as well as changes in lifestyle patterns that have precipitated excess 
weight gain such as unhealthy dietary patterns and a sedentary lifestyle (Siegel, et al, 
2017; Doubeni, 2014; Huxley, Ansary‐Moghaddam, Clifton, Czernichow et al, 2009; 
Brownson, Boehmer and Luke, 2005; Ludwig, 2016; Nielsen & Popkin, 2003). 
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Figure 1.3 CRC Incidence and Mortality Trends by Age and Sex, United States, 1975-2014 (Siegel, Killer and Jemal, 2017). 
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1.5.1.2 Genetic disorders 
Other non-modifiable risk factors include a family history of colon cancer and polyps 
(National Cancer Institute, 2015). Tubular and villous adenomas, neoplastic polyps 
found in the colon or rectum, are precursor lesions of CRC (Janout & Kollárová, 2001). 
An individual with a history of adenomas has an increased risk of developing CRC. It can 
take between 5 and 10 years for such adenomas to become malignant (de Jong Morreau, 
Nagengast, Mathus-Vliegen, et al, 2005; Davies, Miller, & Coleman, 2005), therefore 
early detection and removal reduces the risk of developing CRC (Grande, 2008).  
People with a history of CRC or adenomatous polyps in one or more first-degree 
relatives are at increased risk of up to 20% (Skibber, Minsky, & Hoff, 2001), which is 
even stronger if the relative is younger than 60 years old (Haggar & Boushey, 2009) or if 
there is a history of CRC or adenomatous polyps in two or more first-degree relatives of 
any age (Boardman, Morlan, Rabe, Petersen et al, 2007). It is unclear why this is, but 
may be linked to inherited genes, shared environmental factors, or a combination of 
these (Haggar & Boushey, 2009).  
Approximately 5-10% of CRCs are a consequence of recognised hereditary conditions 
(Jackson-Thompson, Ahmed, German, Lai et al, 2006) such as familial adenomatous 
polyposis (FAP) and hereditary nonpolyposis CRC (HNPCC, otherwise known as Lynch 
Syndrome).  
1.5.2 Modifiable risk factors 
In contrast to non-modifiable risk factors, an individual could take steps to change the 




A substantial number of lifestyle factors may play an important role in the increased 
risk of developing CRC such as diet (Giovannucci, 2003) and lack of physical activity 
(Samad, Taylor, Marshall, & Chapman, 2005; Schnohr, Grønbæk, Petersen, Ole Hein, et 
al, 2005). Wolin and colleagues (2009) meta-analysis of 52 studies confirmed that there 
is an inverse association between physical actively and CRC in both men and women 
(i.e. the less physical activity the more CRC). Physical inactivity and excess body weight 
are also interrelated, such that the lack of physical activity in daily routines can also be 
attributed to the increased incidence of obesity in men and women, which is yet another 
factor associated with CRC (de Jong et al, 2005; Campbell, Cotterchio, Dicks, Parfrey et 
al, 2007). 
Other factors that research has shown to play a role in the increased risk of developing 
CRC include long-term cigarette smoking (Chao, Thun, Jacobs, Henley et al, 2000; Verla-
Tebit, Lilla, Hoffmeister, Brenner et al, 2006). Verla-Tebit and colleagues (2006) 
population based case-control study in Germany reported that when compared with 
non-smokers, there was an increased risk for smoking for 30 years or more (odds ratio 
(OR): 1.25, 95% Confidence Interval (CI): 0.90–1.75) and a significant risk increase for 
40 or more pack‐years of smoking (OR: 1.92, 95% CI: 1.13–3.28). The results of this 
study suggests that smoking for a long duration at a high cumulative dose increases the 
risk for CRC, particularly among women, and suggests that there is risk reduction after 
long-term smoking cessation (Verla-Tebit et al, 2006).  
As with smoking, excessive alcohol consumption may also be associated with increased 
risk of developing CRC (Tsong, Koh, Yuan, Wang, et al, 2007). Tsong and colleagues 
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(2007) found that compared with non-drinkers, middle-aged Chinese individuals who 
drank seven or more alcoholic drinks per week had a 72% increased risk of CRC. 
1.5.3 All risk factors 
CRC can develop because of complex modifiable and non-modifiable interactions 
between several factors, which make establishing a clear etiology of the disease difficult. 
For example, the increased risk associated with overweight and obesity may reflect 
differences in metabolic efficiency (de Jong et al, 2005). Studies suggest that individuals 
who use energy more efficiently may be at a lower risk of developing CRC (Boyle & 
Langman, 2000). Similarly, individuals who drink large amounts of alcohol are at 
increased risk and they may have diets low in essential nutrients, making tissues 
susceptible to the formation of cancer (World Cancer Research Fund, 2007). 
1.6 Diagnosis and staging of CRC 
The National Institute for Health and Clinical Excellence (NICE) has published clinical 
guidelines for the diagnosis and management of CRC. Diagnostic investigations include a 
physical examination and imaging (usually a computed tomography (CT) scan), the 
results of which are subsequently discussed at colorectal multidisciplinary team 
meetings (MDTs) (consisting of oncologists, surgeons, specialist nurses, radiologists, 
histopathologists and the MDT coordinator) where decisions are made in relation to the 
staging, prognosis and management of the tumour.  
Following a CRC diagnosis, the medical team will try to determine if the cancer has 
spread, and if so, how far. This process is known as ‘staging’. Staging the cancer is 
determined by the size of the tumour and whether the cancer has spread to other parts 
of the body such as the liver or lungs (known as metastasis). It helps establish how 
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serious the cancer is and how best to treat it. Staging is reported to be the strongest 
predictor of survival for patients with CRC (Compton & Greene, 2004).  
CRC survival is highly dependent upon the stage of disease at diagnosis and the earlier 
the stage at diagnosis, the higher the chance of survival (Haggar & Boushey, 2009). 
With survival rates of 90% reported for localised cases (Cancer Research UK, 2015), the 
sooner that CRC is diagnosed the better as there is a high probability that it can be cured 
when identified early (Winawer, Fletcher, Miller, Godlee et al, 1997; Winawer, Fletcher, 
Rex, Bond et al, 2003). In contrast to this, survival is significantly decreased for patients 
who have metastatic CRC (Gordon & Nivatvongs, 2007; Natarajan & Shuster, 2006). The 
estimated 5-year survival rates are less than 10% for patients who have metastatic 
disease that cannot be operated on. The tests and scans used to diagnosis CRC provide 
information about the clinical stage. 
Although it is not always possible to stage the cancer definitively until after an 
operation to remove it, pre-surgery scans, provide a good indication of stage, often 
allowing treatment decisions to be made prior to surgery. It is important to note that 
the tissue removed during surgery may show a more advanced cancer (known as the 
‘pathologic’ or ‘surgical’ stage), which will be different to the clinical stage.  Therefore, 
once the specimens have been analysed in the laboratory the results are combined with 
the clinical stage to give a more accurate pathological stage.   
The presentation of CRC is divided into three main clinical stages: 
1. Early stage disease 
2. Locally advanced disease with lymph node involvement 
3. Metastatic disease with distant metastasis (Hassan, Advani & Alex, 2013).  
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There are various methods of staging CRC. In the UK, the most commonly used staging 
system is the Tumour Node Metastes system (TNM) which is also the most widely used 
system worldwide. Constantly being updated, it is now in its eighth version (since 1 
January 2018) (Amin et al, 2017). Prior to January 2018, the Dukes system (detailed in 
section 1.6.2) was also widely used, but is now no longer referred to.  
1.6.1 TNM Staging:  
The TNM staging system, as defined by the American Joint Committee on Cancer (AJCC, 
2017), describes the size and extent of the primary tumour (T), whether any lymph 
nodes contain cancer cells (N), and whether it has spread to another part of the body 
(M). 
There are 5 stages of tumour size in CRC (see Figure 1.4):  
 TX – primary tumour cannot be assessed due to lack of information 
 T0 – there is no evidence of primary tumour  
 T1 – the tumour is only in the inner layer of the bowel 
 T2 – the tumour has grown into the muscle layer of the bowel wall 
 T3 –  the tumour has grown into the outer lining of the bowel wall; and  
 T4 - the tumour has grown through the outer lining of the bowel wall and 
directly invades other nearby organs or structures and/or perforates visceral 
peritoneum. (The peritoneum is a membrane made up of two layers. One layer 
lines the cavity and the other layer lines the organs.) 
o T4a Tumour perforates visceral peritoneum 




Figure 1.4 Pictorial representation of TNM staging 
 
 
There are three possible stages describing whether cancer cells are in the lymph nodes: 
 NX – lymph nodes cannot be assessed due to lack of information 
 N0 – there are no lymph nodes containing cancer cells 
 N1 – 1 to 3 lymph nodes close to the bowel contain cancer cells 
o N1a – 1 lymph node contains cancer cells 
o N1b – 2 to 3 lymph nodes contain cancer cells 
o N1c – tumour deposits in the lymph drainage area of a primary carcinoma 
 N2 – there are cancer cells in four or more nearby lymph nodes. 
o N2a – in 4 to 6 lymph nodes 
o N2 b – in 7 or more lymph nodes 
There are two stages of cancer spread (metastasis): 
 M0 – the cancer has not spread to other organs 
 M1 – the cancer has spread to other parts of the body. 
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o M1a – spread to just one organ (liver lung ovary  non-regional lymph 
nodes) 
o M1b – spread to more than one organ 
o M1c – in the peritoneum with/without other organ involvement. 
The T, N, and M values are taken together to determine the stage of the tumor and relate 
to its prognosis. They are initially recorded from the diagnostic tests (colonoscopy, CT 
scan and physical examination) prior to treatment and reported in the patient's medical 
record as documentation of the basis for treatment planning (Compton & Greene, 2004). 
Then once the tissue from the resected (i.e. surgically removed) colon and/or rectum 
has been examined (see figure 1.5), the CRC will be staged again (the pathological stage) 
and further treatment will be discussed at the MDT meeting.  
 





Once patients’ TNM categories have been determined after surgery (by examining the tissue 
removed during an operation), they are combined to assign the cancer a stage (BMJ, 2015) as 
set out in Table 1.1.  
Table 1.1: The American Joint Committee on Cancer Staging System January 2018 
Stage T N M Stage description 
 
0 Tis N0 M0 Earliest stage: also known as carcinoma in situ 
or intramucosal carcinoma (Tis). It has not 
grown beyond the inner layer (mucosa) of the 
colon or rectum. 
I T1 to 2 N0 M0 The cancer has grown through the muscularis 
mucosa into the submucosa (T1), and it may 
have grown into the muscularis propria (T2). It 
has not spread to nearby lymph nodes (N0) or 
to distant sites (M0). 
II A T3 N0 M0 The cancer has grown into the outermost layers 
of the colon or rectum but has not gone through 
them (T3). It has not reached nearby organs. It 
has not spread to nearby lymph nodes (N0) or 
to distant sites (M0). 
II B T4a N0 M0 The cancer has grown through the wall of the 
colon or rectum but has not grown into other 
nearby tissues or organs (T4a). It has not yet 
spread to nearby lymph nodes (N0) or to 
distant sites (M0). 
II C T4b N0 M0 The cancer has grown through the wall of the 
colon or rectum and is attached to or has grown 
into other nearby tissues or organs (T4b). It has 
not yet spread to nearby lymph nodes (N0) or 
to distant sites (M0). 
III A T1 to 2 N1/1c M0 The cancer has grown through the mucosa into 
the submucosa (T1), and it may have grown 
into the muscularis propria (T2). It has spread 
to 1 to 3 nearby lymph nodes (N1) or into areas 
of fat near the lymph nodes but not the nodes 
themselves (N1c). It has not spread to distant 
sites (M0). 
III A T1 N2a M0 The cancer has grown through the mucosa into 
the submucosa (T1). It has spread to 4 to 6 
nearby lymph nodes (N2a). It has not spread to 
distant sites (M0). 
III B T3 or T4a   N1/1c M0 The cancer has grown into the outermost layers 
of the colon or rectum (T3) or through the 
visceral peritoneum (T4a) but has not reached 
nearby organs. It has spread to 1 to 3 nearby 
lymph nodes (N1a or N1b) or into areas of fat 
near the lymph nodes but not the nodes 
themselves (N1c). It has not spread to distant 
sites (M0). 
III B T2 or T3 N2a M0 The cancer has grown into the muscularis 
propria (T2) or into the outermost layers of the 
colon or rectum (T3). It has spread to 4 to 6 
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Stage T N M Stage description 
 
nearby lymph nodes (N2a). It has not spread to 
distant sites (M0). 
III B T1 or T2 N2b M0 The cancer has grown through the mucosa into 
the submucosa (T1), and it may have grown 
into the muscularis propria (T2). It has spread 
to 7 or more nearby lymph nodes (N2b). It has 
not spread to distant sites (M0). 
III C T4a N2a M0 The cancer has grown through the wall of the 
colon or rectum (including the visceral 
peritoneum) but has not reached nearby organs 
(T4a). It has spread to 4 to 6 nearby lymph 
nodes (N2a). It has not spread to distant sites 
(M0). 
III C T3 or T4a N2b M0 The cancer has grown into the outermost layers 
of the colon or rectum (T3) or through the 
visceral peritoneum (T4a) but has not reached 
nearby organs. It has spread to 7 or more 
nearby lymph nodes (N2b). It has not spread to 
distant sites (M0). 
III C T4b N1 or 2 M0 The cancer has grown through the wall of the 
colon or rectum and is attached to or has grown 
into other nearby tissues or organs (T4b). It has 
spread to at least one nearby lymph node or 
into areas of fat near the lymph nodes (N1 or 
N2). It has not spread to distant sites (M0). 
IV A Any T Any N M1a The cancer may or may not have grown through 
the wall of the colon or rectum (Any T). It might 
or might not have spread to nearby lymph 
nodes (Any N). It has spread to 1 distant organ 
(such as the liver or lung) or distant set of 
lymph nodes, but not too distant parts of the 
peritoneum (the lining of the abdominal cavity) 
(M1a). 
IV B Any T Any N M1b The cancer might or might not have grown 
through the wall of the colon or rectum (Any T). 
It might or might not have spread to nearby 
lymph nodes (Any N). It has spread to more 
than 1 distant organ (such as the liver or lung) 
or distant set of lymph nodes, but not too 
distant parts of the peritoneum (the lining of 
the abdominal cavity) (M1b). 
IV C Any T Any N M1c The cancer might or might not have grown 
through the wall of the colon or rectum (Any T). 
It might or might not have spread to nearby 
lymph nodes (Any N). It has spread to distant 
parts of the peritoneum (the lining of the 
abdominal cavity), and may or may not have 




1.6.2 Dukes system 
As mentioned above, the Dukes system (A, B, C, D) (Dukes CE, 1940) was the original 
staging classification method but it has now been replaced by TNM. However, until the 
beginning of 2018, CRC teams in the UK also used the Dukes system (Cancer Research 
UK, 2015), which is divided into four groups as follows: 
 Dukes A - the cancer is only in the innermost lining of the bowel or growing into 
the muscle layer (90% 5 year survival) 
 Dukes B - the cancer has grown through the muscle layer of the bowel (70% 5 
year survival) 
 Dukes C -  the cancer has spread to at least one lymph node (30% 5 year 
survival) 
 Dukes D - widespread metastases (the cancer has spread to elsewhere in the 
body, such as the liver or lungs). 
The TNM system is reported to have a more precise definition of the degree of primary 
tumour extension and it defines the number of nodes involved (Gunderson et al, 2004). 
TNM is considered more helpful to clinicians preoperatively than the pathologically 
based Dukes classification (Compton & Greene, 2004) because it incorporates both 
clinical and pathological staging approaches. 
1.7 Treatments   
Treatment of CRC is either curative or palliative. Cancers that are confined within the 
colon wall may be curable (i.e. a survival rate of more than 5 years) with surgery 
whereas cancer that has spread widely is usually incurable, with treatment plans 
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focusing on improving quality of life (QoL) and symptoms (known as palliative care) 
(National Cancer Institute, 2015). 
Surgery is the primary course of treatment for most people with CRC (Cancer Research 
UK, 2015), with complete removal of all detectable tumours being the optimal 
treatment goal (Compton & Greene, 2004).  However, the treatment plan may include a 




iv. Biological treatments that increase the effectiveness of chemotherapy and 
prevent spreading of the cancer.  
Radiotherapy and biological treatments are outside the remit of this thesis and are only 
briefly discussed in this chapter.  The focus of this thesis is on curative treatments, 
which typically involve surgery followed by adjuvant chemotherapy treatment.  
The stage, grade and size of the tumour, together with the patient’s general health and 
fitness crudely determine the most favourable treatment course (Cancer Research UK, 
2015). It should be noted that there are also biological markers (e.g. certain 
physiological characteristics or genes) with prognostic and predictive value that play a 
crucial role in the management of advanced disease and the treatment of early stage 
forms (De Divitiis, Nasti, Montano, Fisichella, et al, 2014; Kim, Bae, Oh, Lee et al, 2015). 
However, these are not discussed further here, as this topic is not directly relevant to 




Eight out of ten CRC patients will have surgery (Cancer Research UK, 2015) for T1, T2 
and T3 disease. Depending on the location, size and type of tumour, surgery may range 
from a simple local resection (i.e. cut out of the bowel lining together with a border of 
healthy tissue) to a more complex procedure, which may, for example, also involve 
sphincter-preserving surgery in case of rectal cancers. In people with early stage CRC it 
is possible that the entire tumour along with any associated nodes will be removed, 
thereby curing the patient. 
Surgical treatment of a large tumour in the large bowel will involve the removal of the 
tumourous colon section (a “colectomy”), which may be in the right, left, or middle 
section of the colon (hence the terms “right hemi colectomy”, “left hemi colectomy”, 
“transverse colectomy” and “sigmoid colectomy”). Once the bowel section has been 
removed, the ends of the colon are re-joined, although it will sometimes be necessary to 
bring the end of the bowel out as an opening on the abdomen (known as a “stoma”), as 
shown in Figure 1.6. This will result in an ‘ileostomy’ when the small bowel is brought 
out on the abdominal wall or a ‘colostomy’ when the large bowel is brought out. These 
are usually temporary and reversible. Until reversed, a colostomy bag is fitted over the 
bowel opening to collect bowel motions (Cancer Research UK, 2015).  However, a 
proportion of patients with low rectal cancers will have a permanent colostomy (Hassan 






Figure 1.6: Pictorial representation of a colectomy and colostomy bag 
 
 
Since 1991, keyhole surgery (a “laparoscopic resection”) has been used where possible 
(Jacobs, Verdeja & Goldstein, 1991; Franklin, Ramos, Rosenthal, & Schuessler, 1993) to 
remove early stage bowel tumours. This type of operation typically takes longer to 
perform than a traditional ‘open’ operation but research suggests that it may cause less 
pain and facilitate quicker recovery (Cancer Research UK, 2015). A recent meta-analysis 
found that overall complications in the laparoscopic surgery group were much lower 
than those in the open surgery group, although they were equally effective in terms of 
oncological outcomes (Ma, Yang, Qin, & Wang, 2011).  
It is also important to note that there are differences in the surgical techniques used for 
rectal versus colon (and other common cancers) due to the increased risk of local 
recurrence and a poorer overall prognosis (Wolpin, Meyerhardt, Mamon, & Mayer, 




1.7.2 Adjuvant chemotherapy treatment 
 
In addition to surgery, a considerable proportion of patients will require chemotherapy 
and/or radiotherapy. Such treatments may be administered pre-surgery (i.e. “neo-
adjuvant” therapy) with the aim of shrinking the tumour, thus making surgery more 
effective. Alternatively, and more commonly, these therapies can be administered post-
surgery (“adjuvant” therapy) as a preventative measure with the aim of targeting 
residual cancerous cells. Large randomized clinical trials examining the effectiveness of 
adjuvant chemotherapy following curative CRC resection have consistently 
demonstrated an improvement in survival rates, and is the current standard of care 
(National Institutes of Health, 1990).  
Chemotherapy is a chemical drug treatment, which destroys fast-growing dividing 
cancerous (“cytotoxic”) cells. Unfortunately, non-cytotoxic cells are also constantly 
growing and dividing and are collaterally targeted by many chemotherapy treatments 
(e.g. bone marrow cells, hair follicle cells and the lining of the digestive system), which 
can lead to several adverse side effects (as detailed in section 1.8.1.2) (Cancer Research 
UK, 2015).  
When administered, the chemotherapeutic agents are absorbed into the bloodstream 
and carried throughout the body. There are several methods of delivering 
chemotherapy including: 
 an injection into the bloodstream (usually through a vein); 
 through a drip (intravenous infusion) into the bloodstream; or 
 orally in tablet or capsule form.  
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The chemotherapeutic agents circulate around the body in the bloodstream and target 
fast-dividing cells, destroying them or prohibiting them from spreading. The systemic 
nature of this therapy means that it is effective at targeting cancerous cells anywhere in 
the body, including potential metastases (Cancer Research UK, 2015).  
Adjuvant chemotherapy is routinely recommended following curative surgical resection 
of T3 (node-positive) colon cancer (i.e. T3, N1+), T2 (node-negative (T2, N0) colon 
cancer in which high-risk features are present and T2 to T3 rectal cancer (Benson et al, 
2004; Figueredo et al, 2004). Although, the optimal timeframe from surgery to the 
commencement of chemotherapy in CRC patients is presently unclear, it usually begins 
approximately 4 to 12 weeks after surgery (Biagi, Raphael, Mackillop, Kong, et al, 2011). 
Several meta-analyses have found that there is a significant adverse association 
between the time following surgery to a late start of adjuvant chemotherapy and 
survival. Ideally, adjuvant chemotherapy should begin within eight weeks following 
surgery for an optimal survival outcome (Biagi et al, 2011; Des Guetz, Nicolas, Perret, 
Morere, et al, 2010).  
Adjuvant chemotherapy for CRC is usually administered as a treatment course over a 6-
month period. The current standard duration is based on studies carried out in the 
1990s using 5-fluorouracil (5FU) (O’Connell, Laurie, Kahn, Fitzgibbons Jr et al, 1998; 
Des Guetz, 2010). In most cases there will be between 8 and 12 cycles (depending on 
the regimen prescribed) where a single cycle can last from a few hours to a few days, 
every 2 or 3 weeks (Cancer Research UK, 2015).  
The most commonly administered adjuvant chemotherapy drugs used to treat CRC 
(Table 1.2) include: 
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Table 1.2: List of adjuvant chemotherapy drugs most often used to treat CRC 
Single agent or combination  Generic name 
5-FU/LV 5-FU = fluorouracil 
LV=  leucovorin* 
Capecitabine Capecitabine 
CAPEOX CAPE =  Capecitabine 
OX = Oxaliplatin 
FOLFIRI FOL =  leucovorin 
F = fluorouracil 
IRI = irinotecan 
FOLFOX FOL =  leucovorin 
F = fluorouracil 
OX = Oxaliplatin 
*Levoleucovorin can be used instead of leucovorin 
 
Please refer to Appendix B for a full explanation of each of the regimens for colon cancer 
and the number of cycles involved.  
Clinicians usually make chemotherapy treatment decisions jointly with the patient 
following a discussion of all available options (per NICE recommendations). These 
discussions usually cover the reasons why a medicine might be unsuitable for the 
patient, the probability of recurrence (with and without further treatment), possible 
side effects, and mode of delivery, considering the patient’s clinical condition and 
preferences (NICE, 2006). 
1.7.3 Radiotherapy  
Radiotherapy uses high-energy x-rays to permanently damage cellular DNA, causing 
cancerous cells to die and healthy cells to suffer temporary damage. Radiotherapy is 
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often used to treat locally advanced rectal cancer and it may be used before or after 
surgery, mainly to shrink the cancer or slow its growth. It can be administered from the 
outside the body (external radiotherapy) or inside the body (internal radiotherapy) 
(Cancer Research UK, 2015).  Radiotherapy is rarely used to treat colon cancer, whereas 
the benefits of pre-operative chemoradiotherapy (i.e. chemotherapy and radiotherapy 
together) have been established for rectal cancer (Wolpin, et al, 2007).  
1.7.4 Biological Therapy 
Biological therapies are drugs that can help the body to control the growth of cancer 
cells. Some biological therapies such as cetuximab (Erbitux) can be used to treat 
advanced or metastatic CRC. Cetuximab is usually administered along with 
chemotherapy drugs for advanced colon cancer to help patients to live longer (Cancer 
Research UK, 2015). 
1.8 Side effects 
With increased survival rates, it has become even more important to focus attention on 
the patient’s experience of inevitable associated biological and psychological side effects 
related to CRC treatments. One possible side effect of chemotherapy treatment is 
cognitive change, the subject of this thesis. The relevant literature is discussed in detail 
in Chapters 2 to 5 inclusive. To understand the complete experience of patients with 
CRC, some of the most common physical side effects of surgery and adjuvant 
chemotherapy treatment are briefly reviewed in this section. 
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1.8.1 Biological side effects  
Despite the advances in surgical and chemotherapy treatments, they are not without 
their risks and both can lead to a number of side effects in the short and long term.  
1.8.1.1 Surgery 
Side effects of colorectal surgery will depend mainly on the type of surgery and amount 
of bowel or rectum removed and overall health. The resected area will differ depending 
on where the tumour is located. For example, if the tumour is located in the rectum a 
low anterior resection may be required which will preserve the sphincter complex but 
may cause incontinence (Zingmond, Maggard, O'Connell, & Liu, 2003). If fitted, there 
may also be difficulties with the stoma (e.g. infections and leakages) and the patient will 
need to learn how to manage with it.    
Although a more complicated procedure, several studies have reported the advantages 
of laparoscopic - surgery over open surgery including a reduction in pain, shorter 
hospital stay, quicker recovery of bowel function and improved cosmetic results 
(Kennedy, Heise, Rajamanickam, & Harms et al, 2009; Chapman, Levitt, Hewett, Woods 
et al, 2001; Kieran & Curet, 2004; Yong, Deane, Monson, & Darzi, 2001).  
After surgery, most patients will be unable to eat or drink properly for a few days until 
their bowel has started to function normally. Most patients will experience loose stools 
and/or diarrhea for some time afterwards, and diarrhea alternating with constipation is 
also common particularly if a large part of the bowel has been removed (Cancer 
Research UK, 2015). As mentioned above, the extent and nature of symptoms such as 
incontinence, increased stool frequency, difficulties in evacuation, urgency and pain are 
related to several factors such as the nature of the surgery and type of adjuvant therapy 
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(Hassan & Cima, 2007).  
Minor post-surgical complications include pain and tenderness in the localised area, 
which can be relieved with opioid analgesics. Minor wound infections, wound 
dehiscence and urinary tract infections may also be experienced. More serious surgical 
complications include an anastomotic leak (where the sutures or staples holding the 
two ends of the digestive tract together break or come apart such that the fluids inside 
the digestive tract leak into the abdomen), pneumonia, haemorrhage, kidney failure, 
stoma problems (Lemmens, Janssen-Heijnen, Houterman, & Verheij et al, 2007) and 
death. 
Advances in surgical technique, anaesthesia, intensive care therapy, antibiotic 
treatments, thromboprophylaxis, and other supportive measures have resulted in an 
increase in surgical safety for CRC procedures (Longo, Virgo, Johnson, &, Oprian et al, 
2000; Lykke & Nielsen, 2004). An accurate pre-surgical assessment is critical, 
particularly for patients suffering from comorbidities, as several specific comorbid 
conditions including chronic obstructive pulmonary disease (COPD) and deep vein 
thrombosis (DVT) have been reported to correlate to more frequent development of 
complications (Lemmens et al, 2007). For example, Lemmens and colleagues (2007) 
found that colon patients who suffered from DVT at the time of their cancer diagnosis 
more often had surgical complications (67% versus 30%), more minor infections (44% 
versus 11%), major infections (56% versus 10%), pneumonia (22% versus 2%) and 
thromboembolic complications (11% versus 3%).  
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1.8.1.2 Adjuvant chemotherapy treatment 
As described above, chemotherapy drugs target all rapidly dividing cells in the body and 
do not discriminate between cancerous and healthy cells.  The range of side effects 
experienced depends on the agents administered, as well as the dosage and form of 
administration (i.e. intravenously or orally). For example, Oxaliplatin drugs are known 
to cause nausea, numbness of the lips, sensitivity to cold and numbness and tingling of 
the hands and feet (Wolpin et al, 2007; Cancer Research UK, 2015). Side effects tend to 
start 2 to 3 weeks after the first chemotherapy cycle.  
The use of Oxaliplatin has increased over recent years and more patients are living with 
its long-term side effects. Chemotherapy-induced peripheral neuropathy (CIPN) is the 
most common dose-limiting side effect of Oxaliplatin, and it can have a negative 
influence on patients’ QoL (Mols, Beijers, Lemmens, van den Hurk, et al, 2013; Mols, 
Beijers, Vreugdenhil, & van de Poll-Franse, 2014). “Characterized by paraesthesia of the 
hands and feet and exacerbated by exposure to cold, it is the primary toxic effect 
associated with oxaliplatin” (Wolpin, et al, 2007). Patients receiving a dose reduction 
because of acute neuropathy remain at risk of developing long-term CIPN (Beijers, Mols, 
Tjan-Heijnen, Faber, et al, 2015) and chronic neuropathy has been found to persist in 
60% of patients a year or more after the cessation of chemotherapy (Mols et al, 2013; 
Matsumoto, Nishimura, Kanai, Mori, et al, 2008; Park, Lin, Krishnan, Goldstein et al, 
2011).  
The most common side effects associated with adjuvant chemotherapy for CRC are 
tiredness and fatigue, nausea, diarrhoea, sore mouth, hair loss or thinning, and sore 
eyes (Cancer Research UK, 2015, Coates et al, 1983). To help manage nausea and 
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vomiting antiemetic drugs are usually administered before or after chemotherapy 
(Hesketh, 2009). Additionally, the reduction in red blood cells can induce anaemia and 
subsequent breathlessness and fatigue (O’Shaughnessy, 2003; Kayl, Wefel, & Meyers, 
2006). All patients react differently to treatments and some may not experience any 
side effects at all whilst others may suffer from some or all of them.  
1.8.2 Psychological and psycho social side effects 
The psychological side effects often associated with cancer include anxiety, depression 
and fatigue, and cognitive side effects (such as memory, attention and concentration 
impairment).  Each of these side effects can “cause additional suffering, weaken 
adherence to prescribed treatments, and threaten patients’ return to health” (Adler & 
Page, 2008, p. 1). Due to improvements in the prognosis and survival of patients with 
CRC, many individuals are now able to resume their daily routine following treatment 
whilst some continue their daily routine during treatment. It is important that the 
psychosocial impact of CRC and its treatment is understood so that it can be 
appropriately managed, as acknowledged by the International Psychosocial Oncology 
Society who have recommended further research into the psychosocial impact of cancer 
on the individual (Holland, Watson, & Dunn, 2011). The commonly reported 
psychosocial difficulties reported by CRC patients are described below. 
Research suggests that one third of cancer patients suffer from some type of diagnosed 
mental disorder during active treatment (Singer, Das-Munshi, & Brähler, 2010). 
Although anxiety and depression are often discussed together and do interact (see 
below), they are distinct (Watson, Weber, Assenheimer, Clark et al, 1995) and 
particularly in relation to cancer, they may have different trajectories from diagnosis to 
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end of treatment and long-term follow-up (Ando, Iwamitsu, Kuranami, Okazaki et al, 
2009; Den Oudsten, Van Heck, Van der Steeg, Roukema et al, 2010; Kangas, Henry, & 
Bryant, 2007).  Taking each in turn: 
1.8.2.1 Anxiety 
Anxiety has been described as being “centered on the emotion of fear and involves 
feelings of worry, apprehension, and dread” (Watson et al, 1995). It can adversely affect 
quality of life and negatively influence compliance to treatment (Greer, Pirl, Park, Lynch, 
et al, 2008). Prolonged feelings of anxiety can also lead to fatigue (Bower, Ganz, 
Desmond, Bernaards, et al., 2006).  
The prevalence of self-reported clinical levels of anxiety in the general adult population 
is estimated at 12.6% (Crawford, Henry, Crombie, & Taylor, 2001) compared with up to 
30% in people with cancer (Roy-Byrne, Davidson, Kessler, Asmundson, et al, 2008; 
Stark, Kiely, Smith, Velikova, et al, 2002). Anxiety in relation to cancer often reflects a 
reaction to the diagnosis (Vardy & Tannock, 2007), anticipated treatment, and is often 
transient (Linden, Vodermaier, MacKenzie, & Greig,, 2012). Anxiety is likely to decrease 
after completion of primary treatment (Thomas et al, 2001). 
1.8.2.2 Depression 
Depression is dominated by the emotion of sadness and is associated with feelings of 
sorrow, hopelessness, and gloom (Watson et al, 1995), as well as fear, anger and grief 
(Aapro & Cull, 1999).  Symptoms of depression include fatigue, sleep difficulty, and 
appetite loss (Artherholt & Fann, 2012). As with anxiety, depression can have an 
adverse effect on functional status and QoL (Carr, Goudas, Lawrence, Pirl, et al, 2002; 
Pirl, 2004). It can also have an adverse effect on treatment compliance, hospital stay 
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duration, and capability for self-care (DiMatteo, Lepper & Croghan, 2000; McDaniel, 
Musselman, Porter, Reed, et al, 1995). It is considered important that depression is 
diagnosed and treated appropriately.  
There is no consensus in research regarding the incidence of clinical depression in 
cancer patients. There are studies, which have found no difference in the incidence of 
depression in cancer patients compared to the general population (approximately 6%) 
(Keating, Nørredam, Landrum, Huskamp, et al, 2005) whilst other studies have found 
that it is more than 4 times higher, with the greatest rates of depression found in those 
with advanced forms of cancer (40-50%) (Honda & Goodwin, 2004; Hewitt & Rowland, 
2002; Fallowfield, Ratcliffe, Jenkins, & Saul, 2001; Derogatis, Morrow, Fetting, Penman, 
et al, 1983).   
It is also important to note that there may be an interaction between anxiety and 
depression (van Dam, Boogerd, Schagen, Muller, et al., 1998; Castellon, Ganz, Bower, 
Petersen, et al., 2004). Mood changes may cause a reduction or be the consequence of a 
deterioration in QoL. Research has found that patients with cancer who also suffer from 
comorbid depression experience worse anxiety, pain, fatigue, and functioning than 
other cancer patients, allegedly resulting in more difficulty adhering to cancer 
treatments (Walker, Hansen, Martin, Symeonides, et al, 2014). 
1.8.2.3 Fatigue 
Research has shown that fatigue is one of the most prevalent symptoms experienced by 
cancer patients (Hoffman, Ryan, Figueroa-Moseley, Jean-Pierre, et al, 2007) and is often 
associated with chemotherapy treatment (Dikken & Sitzia, 1998).  Fatigue has been 
reported to occur in most patients across a wide range of cancer types (Cella, Davis, 
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Breitbart, Curt, et al 2001; Irvine, Vincent, Graydon, Bubela, et al, 1994; Stone et al, 
1999). Fifty-two percent (149 of 287) of patients with localized CRC in Vardy and 
colleagues study (2014) reported fatigue at (or soon after) diagnosis, compared to 26% 
(19 of 72) of the healthy control subjects (p<0.0001) (Vardy, Dhillon, Pond, Rourke, et 
al, 2014).  
Cancer-related fatigue is characterised by feelings of tiredness, weakness, and lack of 
energy and has been described as a “persistent, subjective sense of tiredness related to 
cancer and cancer treatment that interferes with usual functioning” (Mock, Atkinson, 
Barsevick, Cella, et al, 2000). In healthy individuals, symptoms of fatigue (that occur in 
normal everyday life) typically diminish following adequate sleep (Servaes, Verhagen, & 
Bleijenberg, 2002b), however cancer-related fatigue is not relieved by rest or sleep, nor 
does it correspond to the level of exertion in people with cancer (Glaus, Crow, & 
Hammond, 1996; Morrow , Shelke, Roscoe, Hickok, et al, 2005).  
Cancer-related fatigue can have a profound impact on daily living (Curt, Breitbart, Cella,  
Groopman, et al, 2000) and several studies have reported an association between 
fatigue, depression, anxiety and mood disturbances (Broeckel, Jacobsen, Horton, 
Balducci, et al, 1998; Bower, Ganz, Desmond, Rowland, et al, 2000; Dimeo, Stieglitz, 
Novelli‐Fischer, Fetscher, et al, 1999; Stone, Richards, A'hern, & Hardy, 2000; Vardy et 
al, 2014).  Fatigue has also been found to be associated with cognitive impairment in 
some cancer studies (Servaes, Verhagen, & Bleijenberg, 2002).  
It is important to note that fatigue can occur because of the cancer itself but it may also 
occur as a side effect of radiotherapy and/or chemotherapy treatment (Hofman, Ryan,  
Figueroa-Moseley, Jean-Pierre, et al, 2007) in an estimated 34% of breast cancer 
54 
 
survivors (Bower et al., 2006).  It remains unclear how long the fatigue persists after 
treatment (Hofman et al, 2007), although it was found that 35% of breast cancer 
patients reported fatigue between 1and 5 years after completion of their treatment, and 
34% between 5 and 10 years (Bower et al, 2006).  
1.8.3 Cognitive Impairment 
Another commonly reported chemotherapy related treatment side effect is 
deterioration in cognitive function, often referred to as “chemobrain” or “chemofog,” by 
breast cancer patients. Cognitive impairment is the focus of this thesis and will be 
discussed in detail in Chapters 2 to 5 inclusive.    
1.9 Summary 
This chapter has summarized what CRC is, and outlined the available treatments and 
the associated side effects of surgery and adjuvant chemotherapy. The incidence and 
survival rate of CRC is high, as is the prevalence of treatment-related side effects. 
Therefore, it is vital that the appropriate information and support is made available to 
all patients with CRC so that the impact of the disease and treatment process on daily 
tasks and QoL is minimized. 
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Chapter 2: Cognition, Cognitive Functioning and Cognitive 
Impairment in Cancer Patients  
 
2.1 Introduction 
This chapter introduces the concept of cognition and cognitive function, outlining the 
domains that are encompassed within such functioning. It then examines impaired 
cognitive functioning, using both objective and subjective assessments in patients with 
cancer. It also highlights some of the challenges involved in measuring any type of 
cognitive impairment and outlines other factors that may affect cognition. 
2.2 Overview of cognitive functioning 
Cognition is "the mental action or process of acquiring knowledge and understanding 
through thought, experience, and the senses” (Oxford English Dictionary, 2016). It is a 
generic term that dates to the 15th century.   
Cognitive function is a multidimensional concept (Jansen, Miaskowski, Dodd, Dowling, & 
Kramer, 2005). There are distinct functions that the brain uses to execute behaviours 
referred to as “domains”. One schema for considering domains of cognitive functioning 
and their corresponding components are set out in Table 2.1 (Jansen et al, 2005; Rich & 
Troyer, 2008). All of these cognitive domains are considered necessary for normal daily 
functioning (Jansen et al, 2005; Olin, 2001; Ryan, Morrow, Bromet & Parkinson, 1987).  
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Table 2.1: Overview of Cognitive Domains (adapted from both Jansen et al, 2005 and Rich & Troyer, 2008)  
Cognitive Domain Components Description  Consequences of impairment  




Selective attention: The ability to examine 
relevant inputs, thoughts, and actions while 
ignoring those that distract or are irrelevant 
(Gazzaniga, Ivry, & Mangun, 2002; Grober, 
2002; Heilman, Valenstein, & Watson, 1997). 
Sustained attention: The ability to maintain 
attention towards a stimulus over an 
extended period (Filley, 2002).  
Divided attention: the ability to focus on 
multiple tasks simultaneously 
Alternating attention: the ability to switch 
between sources of information.  
Reduced awareness or ability to focus on tasks 
(Groth-Marnat, 2000) 
Concentration Sustained attention or 
vigilance  
The ability to focus and sustain attention 
toward a stimulus for a period of time (Filley, 
2002; Lezak, Howieson, Loring & Fischer, 
2004.). 
As above 
Executive function  Initiation 
Planning  
Cognitive flexibility 
Higher order cognitive abilities that are 
necessary for appropriate, socially 
responsible and effective conduct (Goodwin, 
Decreased ability to categorise or compare 
information, prepare or organise strategies, and 
respond to changing stimuli. Impairment may also 
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Cognitive Domain Components Description  Consequences of impairment  
Self-monitoring 
Self- regulation 
2012).  These include a) planning: The ability 
to formulate and consider different 
approaches to a task and to conduct an 
effective approach to achieve a goal; b) 
abstract thinking: the ability to create 
generalised concepts from discrete instances; 
c) response inhibition: The ability to produce 
an uncommon response instead of an 
automatic response; d) switching: The ability 
to alternate between different types of 
information or different response categories 
limit ability to solve problems, achieve goals, or be 
creative, adaptive, or flexible (Jansen et al, 2005). 
Processing speed  The ability to rapidly process simple and 
complex information and respond to 
information (Freeman & Broshek, 2002). 
Impacts the ability to perform tasks quickly and 
accurately. It can contribute to learning and 
attention issues 
Language Verbal or written 
expression 
Includes a) receptive language: The ability to 
comprehend orally or visually presented 
verbal information, and b) 
expressive language: The ability to produce 
words or sentences 
Inability to communicate (Jansen et al, 2005) 
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Cognitive Domain Components Description  Consequences of impairment  
Language processing  Reception 
Repetition 
Involves representing, comprehending and 
communicating symbolic information, either 
written or spoken (Gazzaniga et al., 2002). 
 
As above 





Movements and actions of the muscles, such 
as speed, strength and coordination. 
Problems with dexterity, gait changes, weakness 
and tremors (Jansen et al, 2005). 
Visuospatial skill Perception 
Construction 
The ability to process and interpret visual 
information regarding where things are 
situated in space (Spreen & Strauss, 1998) 
 
Altered perceptions or an inability to recognize 
familiar objects, which could affect performance of 
manual tasks. 
Memory Short term memory 





The ability to acquire, store, retrieve and use 
new information (Grober, 2002).  




Different areas of the brain are activated during cognitive processing.  For example, 
sensory input from the environment is registered in various parts of the brain located in 
both hemispheres. All input is then screened and processed (with the left cerebral 
hemisphere predominantly processing verbal information, and the right hemisphere, 
visuospatial information) and usually an appropriate behavioural response is produced 
(Vardy & Tannock, 2007).  
Cognitive domains are not necessarily mutually exclusive. Some domains are so 
inextricably linked that impairment in one invariably affects another (Lezak et al, 2004). 
For example, the input of information required for information processing requires 
“attention” which is in turn necessary for “memory” (Jansen et al, 2005).  
2.3 Cognitive function in patients with cancer 
Cognitive assessment for people with cancer has increased since the early 1990’s (Kayl, 
Collins and Wefel, 2008) and may be split into objective cognitive function and 
subjective cognitive function. 
2.3.1 Assessing objective cognitive function 
Neuropsychological tests are routinely used to measure objective cognitive function 
(Freeman & Broshek, 2002) in the “cancer and cognition” literature. Most 
comprehensive neuropsychological batteries used in such studies have included 
assessment of cognitive function across multiple domains, typically those detailed in 
Table 2.1. Several neuropsychological measures are often included in a test battery that 
the cancer patient is asked to work through, usually lasting several hours (Freeman & 
Broshek, 2002). Most neuropsychologists recommend a comprehensive battery of 
neuropsychological measures as the gold standard for assessing cognitive function, but 
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vary in opinion as to which tests, and how many, should be incorporated into a battery 
(Vardy, Rourke & Tannock, 2007).  More than 40 neuropsychological tests have been 
used in “cancer and cognition” research to date (Jansen et al, 2005; Dwek, Rixon, Hurt, 
Simon & Newman, 2017). As these tests have different psychometric properties and 
may involve different aspects of the cognitive domain, it is difficult to compare findings 
across studies. In addition, often a test will tap into more than one domain as illustrated 
in Chapter 3, Section 3.6, and Table 3.3. This further complicates the task of identifying 
which specific domains are responsible for the performance on a particular test. 
There are hundreds of neuropsychological tests available for use. Test selection is very 
important and will vary with the hypotheses being evaluated. Measures chosen for the 
neuropsychological assessment of patients with cancer should be psychometrically 
sound with established reliability and validity and appropriate normative studies (Kayl 
et al, 2008). (The importance of normative data is discussed below). They should also 
include assessment of the full range of psychological functions (Jansen et al, 2005).  The 
neuropsychological (NP) tests used in this thesis were chosen in accordance with the 
International Cognition and Cancer Task Force’s (ICCTF) recommendations (Wefel, 
Vardy, Ahles & Schagen, 2011) and the purpose and goals of this study and are detailed 
in Chapter 7. The tests are also discussed within six domains (attention, concentration, 
motor function, executive function, verbal and visual memory) as set out in Chapter 7.  
2.3.1.1 Objective cognitive impairment (OCI) 
To evaluate whether an individual or group of individuals score(s) on a particular NP 
test suggest impaired performance it is first necessary to establish what constitutes a 
normal score. There are various methods for doing this. 
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Normative data:   
One method is by reference to data already collected from a group of healthy individuals 
with similar demographic characteristics to the sample under investigation (Mitrushina, 
Boone, Razani & D'Elia, 2005) at the analysis stage. Such data is known as normative 
data and is often used to compare cognitive performance in the “cancer and cognition” 
literature (Mitrushina et al, 2005). 
Normative data establishes a baseline distribution for a score, against which the patient 
score can be compared. Published normative data from healthy controls usually contain 
large sample sizes, which are likely to provide good estimates of the population 
parameter under investigation (e.g. attention) (Wefel, Saleeba, Buzdar & Meyers, 2010). 
It is important when using normative data to consider potential sample differences (e.g. 
socio demographic factors such as age and education) that relate to the parameter being 
investigated and may differ significantly between the sample population in the study 
and the control population (Wefel et al, 2010). Age, gender, intelligence and education 
are all factors that could influence cognitive function (Ferguson & Ahles, 2003).  As 
further discussed in Section 2.4, it is important to note that other factors such as 
(including but not limited to) fatigue, anxiety and depression may also affect cognitive 
function (Ferguson & Ahles, 2003; Minisini, Atalay, Bottomley, Puglisi, et al, 2004), and 
therefore are often assessed in “cancer and cognition” studies in order to determine 
their impact (if any) on cognitive function (Vardy & Tannock, 2007). 
Control/comparison groups 
Whilst normative data is often considered the “gold standard” for comparing cognitive 
performance in the “cancer and cognition” literature (Mitrushina et al, 2005), data may 
also be collected from a “control group”. There are different types of control group. One 
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type is a healthy control group. Similar to normative data, the data collected from a 
healthy group of individuals with homogeneous demographic characteristics, which 
match the subject/sample in question, is used as the frame of reference. Alternatively, 
(or in addition to the healthy controls), a group of individuals who have the same cancer 
diagnosis but receive different treatments may be used. This may enable researchers to 
establish, the relative effects of a specific treatment. The ICCTF is of the opinion that the 
relative neurological effects of a treatment such as chemotherapy can be established if 
appropriate assessment time points and comparison groups (such as patients who 
receive the same ensemble of treatments (e.g. surgery) with or without chemotherapy 
treatment) are used in a study (Wefel et al, 2011).  
Ideally several control groups will be used (i.e. both local controls and published 
normative data) in the same period as the patient group (Wefel et al, 2011). Both groups 
would undergo the same cognitive assessments in the same timeframe as the group of 
interest. The ICCTF believes that this approach can help to establish whether cognitive 
impairment is present, and whether apparent changes in cognitive function are due to 
practice effect (i.e. a change over time attributed to familiarity with the assessment 
rather than a true improvement) or are secondary to the cancer itself, the treatment, or 
both (Wefel et al, 2011). 
Choosing a control group against which to assess whether patients with cancer suffer 
any OCI during and/or after treatment is not straightforward. Different types of control 
group can lead to different results. For example, Argyriou and colleagues, (2011) 
observed that most impairment occurred “if the chemotherapy patients’ cognitive 
performance is compared with normative data” but that “there is less impairment if a 
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control group is used for comparison and little to no impairment if baseline data from the 
patients themselves are used”.   
Categorising OCI  
Another difficulty in evaluating impairments in cognitive function is determining what 
constitutes impairment: “What is the appropriate cut off point for categorising 
impairment?” Once a control group has (or groups have) been chosen, an impairment 
criterion needs to be established in order to assess the relative performance of the 
participant in comparison to the normal/comparative population(s). The definition of 
OCI is complex because NP test batteries include numerous tests which are each 
individually scored (Vardy et al, 2007). 
There is a wide range of impairment criteria used in the “cancer and cognition” 
literature to define cognitive impairment. A definition of OCI is usually based on cut off 
scores for the individual NP tests (Jansen et al, 2005). Various cut-off criteria have been 
used to define OCI including 1, 1.5 and 2 standard deviations (SD) below the normative 
group mean score (or mean score of an appropriate control group) on one or more NP 
tests   (Lezak, Howieson & Loring, 2012) using standardised T or Z scores. Others have 
calculated global deficit scores and defined OCI as having a global deficit score (Vardy et 
al, 2015). In the “cancer and cognition” literature published to date there is no standard 
or consistency in the definition of cognitive impairment used in studies (Vardy et al, 




2.3.2 Assessing subjective cognitive function  
Subjective cognitive function is the perceived, self-reported view of one’s own mental 
function (Biegler, Alejandro Chaoul & Cohen, 2009). In contrast to objectively measured 
cognitive function, subjective cognitive function is measured using self-report 
questionnaires, diaries and/or interviews/focus groups. 
2.3.2.1 Subjective cognitive impairment (SCI) 
SCI refers to an individual’s perceived cognitive difficulties experienced in daily life, 
such as problems with concentration, memory, learning and language (Pullens, De Vries, 
& Roukema, 2010). As with NP measures, there are a variety of self-report measures 
available for assessing subjective cognitive functioning (Pullens et al, 2010). Such 
measures assess the impact of cognitive impairment on the individuals’ everyday life 
(Hutchinson, Hosking, Kichenadasse, Mattiske & Wilson, 2012), providing an 
understanding of treatment outcomes from the patients’ perspective (Kayl et al, 2008). 
As mentioned above, they range from diary entries to interviews and/or questionnaires.  
Similar, to the research in relation to OCI, studies to date have used a variety of 
measures to assess SCI in patients with cancer (Table 2.2). For example, Pullens, De 
Vries & Roukema’s (2010) systematic review found that 10 different standardised self-
report questionnaires and nine non-validated questionnaires and/or semi-structured 
interviews were used across 27 studies to measure SCI.  
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Table 2.2: An example of the range of subjective cognitive measures used in a the “cancer and cognition” studies reviewed in 
Chapter 3  
Number of studies (First author) Measure used  
3 Studies: 
Hermelink et al, 2007; Mehnert et al, 2007; Weis et al, 2008 
Fragebogen erlebter Defizite der Aufmerksamkeit 
(questionnaire of experienced attention deficits) (FEDA)  
3 Studies: 
Donovan et al, 2005; Ahles et al, 2008; Ahles et al, 2010 
Multiple Ability Self-Report Questionnaire (MASQ)  
2 Studies:  
Bender et al, 2006; Bender et al, 2008 
Patient’s Assessment of Own Functioning (PAOF)  
5 Studies: 
Castellon et al, 2004; Jenkins et al, 2006; Quesnel et al, 2009; 
Jenkins et al, 2004; Schilder et al, 2009 
Cognitive Failure Questionnaire (CFQ)  
3 Studies: 
Jansen et al, 2008; Cimprich et al 2005; Cimprich 1999 
Attentional Function Index (AFI)  
2 Studies: 
Hurria et al, 2006; Von AhD et al, 2009 
Squire Memory Self-Rating Questionnaire (SSRQ)  
15 Studies: 
Schagen et al, 1999; Schagen et al, 2002; van Dam et al, 1998; 
Hermelink et al, 2007; Mehnert et al, 2007; Quesnel et al, 2009; 
Weis et al, 2009; Ahn et al, 2006; Galalae et al 2005; Schilder et 
al, 2009; Debess et al, 2010; Jansen et al, 2011; Hedayati et al, 
2012; Cruzado et al, 2014; Hermelink et al, 2015 
European Organization for Research and Treatment of Cancer 
quality of life core questionnaire (EORTC QLQ-C30)  
2 Studies:  
Ahn et al, 2006; Galalae et al 2005 
EORTC Breast Cancer Specific (EORTC QLQ-BR23)  
1 Study: 
Weis et al, 2009. 
Multidimensional Fatigue Inventory (MFI-20)  
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Number of studies (First author) Measure used  
4 Studies:  
Downie et al 2006; Vardy et al 2006; Biglia et al 2012; Lange et 
al, 2014 
The Functional Assessment of Cancer Therapy—Cognitive 
Function Instrument) (FACT-Cog) 
10 Studies: 
Schagen et al, 1999; Schagen et al, 2002; van Dam et al, 1998; 
Downie et al, 2006; Berglund et al 1991; Mehlsen et al, 2009; 
Servaes et al, 2002; Shilling & Jenkins 2007: Schilder et al, 
2009; Kopplemans et al, 2012 
Interviews/ self-constructed questionnaires  
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As can be seen in Table 2.2 the European Organisation for Research and Treatment of 
Cancer Quality of Life Questionnaire (EORTC QLQ-C30) (Aaronson et al, 1993; Kayl et al, 
2008) was most often used prior to 2010. The EORTC QLQ-C30 is a cancer specific 
quality of life questionnaire that assesses subjective cognitive functioning based on one 
question concerning memory and another concerning concentration problems 
occurring during the previous week. More recently, Wagner and colleagues (2009) 
developed another questionnaire, the Functional Assessment of Cancer Therapy—
Cognitive Function Instrument (FACT-Cog) which was based on qualitative input 
obtained from cancer patients (who reported cognitive concerns) and from oncologists 
and nurses (Wagner, Sweet, Butt, Lai & Cella 2009). It assesses SCI using language found 
to be relevant to cancer patients experiencing cognitive problems. Both questionnaires 
are cancer specific and consequently focus on issues that are important to patients with 
cancer. Generic instruments are intended to be applicable to a wide range of health 
problems (Fitzpatrick et al, 1992). Whereas disease specific questionnaires such as the 
FACT Cog are more sensitive to small differences that might be significant to patients 
who have cancer and to any changes that may occur over time during the treatment for 
the specific disease (Cella et al, 1993). The FACT-Cog assesses the nature and severity of 
cognitive deficits and the impact of such deficits on the patients’ quality of life. The 
FACT-Cog has 37 items whereas the EORTC QLQ-C30 has two items concerned with 
cognition.   
2.4 OCI “versus” SCI 
The type of data gathered by NP assessments and self-reports is not the same. Self-
report questionnaires require participants to have insight into their own functioning, 
including the ability to identify their own disease-related deficits and preserved skills 
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(Roessler-Górecka, Iwański & Seniów 2013) whereas objective NP assessments are 
performance-based tests to assess cognitive functioning (Harvey, 2012).  Therefore, 
they are conceptually different measurement tools. 
There is an argument that NP tests are not designed to measure functioning in everyday 
situations. In addition, NP tests are administered at one point in time therefore they 
may not tap into the same domains as self-report measures which typically ask about 
experiences over a period of time (Wagner et al, 2009). 
As will be discussed in Chapter 3, the incidence of both OCI and SCI varies widely across 
studies. Each does reportedly occur in a subset of patients with cancer. However, even 
when both objective and subjective cognitive impairment are found to be present, the 
two are not necessarily related (Hutchinson et al, 2012). For example, in a breast cancer 
study examining self-reported cognitive problems in women receiving adjuvant 
treatment, it was found that 71% of patients reported memory problems four weeks 
after the final chemotherapy session whilst only 30% showed objective decline at that 
time (Shilling & Jenkins, 2007).  
There have been some studies, which have found a significant relationship between 
objective and subjective measures. For example, Mehnert and colleagues (2007) found a 
significant correlation between poorer performance on objective measures of working 
memory, selective attention, visuo-spatial working memory and visual delayed recall 
and more self-reported cognitive changes in cancer patients treated with 
chemotherapy. Reid-Arndt and colleagues (2010) also found a significant correlation 
between self-reported cognitive functioning and immediate memory and response 
inhibition.   
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Whilst various explanations have been proposed for such discrepancies, further 
research is required to fully understand why this difference between self-reported 
cognitive complaints and objectively measured cognitive functioning occurs. It has been 
suggested that it is important therefore that future studies include both objective and 
subjective measures (O’Farrell, MacKenzie, & Collins, 2013) and examine the impact of 
all cognitive problems on daily functioning and quality of life (Ahles & Saykin, 2001). 
This thesis will examine the relationship between cognitive impairment and health 
related quality of life (HRQoL) (Chapters 5 and 9).  
2.5 Factors commonly associated with cognitive function 
When assessing cognition it is important to consider the range of potential factors that 
may have the ability to influence cognitive outcomes. These factors could confound the 
results found when assessing cognitive impairment (objective and subjective) in 
patients with cancer, and lead to inaccurate results.  
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2.5.1 Indirect and direct effects of chemotherapy 
2.5.1.1 Direct effects of chemotherapy on the central nervous system  
 
There are several interacting pathogenetic mechanisms involved in treating cancer with 
chemotherapy, which may affect the cognitive ability of cancer survivors (Argyriou, 
Assimakopoulos, Iconomou, Giannakopoulou & Kalofonos, 2011).  
As mentioned in Chapter 1, chemotherapy drugs are used to prevent the cancer cells 
from multiplying and spreading to other tissues. However, they can also have toxic 
effects on normal cells (Skeel and Khleuf, 2007). Although chemotherapy drugs do not 
usually cross the blood-brain barrier (i.e. the physical barrier whereby cells at three key 
interfaces form barriers between the blood and the central nervous system (CNS)), 
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there are some that do via direct or indirect mechanisms, potentially contributing to 
CNS toxicity (Simó, Rifà-Ros, Rodriguez-Fornells  & Bruna 2013). For example, Meyers 
and Perry (2008) found that platinum-based agents such as Oxaliplatin have been 
associated with CNS neurological toxicity. As mentioned in Chapter 1, Oxaliplatin is 
often used to treat CRC. Data from animal studies suggest that higher levels of 
chemotherapy may cross the blood-brain barrier than previously thought and even 
small doses of chemotherapy can cause cell death in structures vital for cognition 
(Dietrich, Han, Yang, Mayer-Prösche & Noble, 2006). 
Recent structural imaging studies have found an association between chemotherapy 
treatment and a volume reduction of both grey and white matter and altered white 
matter integrity (Inagaki et al, 2007; McDonald, Conroy, Ahles, West, & Saykin, 2010; 
Deprez et al, 2011, 2012). This decrease may persist in a subgroup of patients (Saykin, 
Ahles & McDonald, 2003; Inagaki et al, 2007; McDonald et al, 2010; de Ruiter et al, 2012; 
Koppelmans et al, 2012).  Reduced white matter integrity and impaired hippocampal 
neurogenesis are thought to represent major cell-biological mechanisms underlying the 
typical cognitive complaints reported by cancer survivors, including deficits in 
attention, memory and processing speed (Monje & Dietrich, 2012). 
2.5.1.2 Anaemia 
Anaemia (a deficiency in red blood cells) has been associated with an increased risk of 
OCI in several chronic illnesses, including renal disease (Stivelman, 2000) and vascular 
dementia (Milward et al, 1999). 
Cancer patients often experience symptoms of anaemia (Nowrousian, 2002; Ludwig et 
al, 2004) and it is frequently associated with an advanced stage of the disease, 
72 
 
worsening during chemotherapy or radiotherapy treatment (Nowrousian, 2002). The 
prevalence of anaemia varies depending on the type of cancer (Knight, Wade & Balducci, 
2004; Groopman & Itri, 1999) with approximately 40% of patients with early-stage 
colon tumors (Knight et al, 2004) and 50% of patients with solid tumours presenting 
with anaemia at diagnosis (Bohlius, Weingart, Trelle, & Engert, 2006). In addition, the 
incidence of chemotherapy-induced anaemia depends on the intensity of the treatment, 
which may increase with cumulative cycles (Jansen et al, 2005). It has been reported 
that prior to chemotherapy treatment, 44% of patients with breast cancer had anaemia, 
which increased to 60% after 6 cycles of chemotherapy (Tas et al, 2002). However, 71% 
of patients with colon cancer had anaemia before initiation of chemotherapy and Tas 
and colleagues (2002) reported that there was no difference observed in post treatment 
haemoglobin values compared with pre-treatment values in this patient group.  
Recent studies have found that epoetin alfa treatment (used to increase haemoglobin 
levels and thereby reduce anaemia) may maintain or improve objectively measured 
cognitive functions in patients with cancer through both direct and indirect mechanisms 
(Ferrario et al, 2004). These findings suggest that declines in haemoglobin levels during 
chemotherapy treatment are associated with adverse changes in cognitive functioning 
(Jacobsen, 2004). Consequently, it is arguable that chemotherapy-induced anaemia may 
also cause cognitive impairment (Cunningham, 2003). 
There are numerous symptoms associated with anaemia, the primary one being fatigue, 
which can impair a patient’s ability to carry out normal daily activities (Cella, 1997). 
However, fatigue is a multifactorial syndrome that is not only caused by anaemia, 
therefore attempting to establish the relative contribution of anaemia to fatigue is a 
very complex undertaking. Even when anaemia improves, not all the symptoms of 
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fatigue might be relieved because fatigue can be present independently of anaemia 
(Ahlberg, Ekman, Gaston-Johansson, & Mock, 2003; Tchen et al, 2003; Mock, 2004). 
2.5.1.3 Chemotherapy induced menopause/hormonal changes 
Hormonal changes either dependent on or independent of cancer therapy could be a 
contributory factor to cognitive impairment (Kaiser, Bledowski & Dietrich, 2014). While 
more pronounced cognitive deterioration has been reported for combined 
chemotherapeutic and anti-hormonal treatment when compared with chemotherapy 
alone (Bender et al, 2006), other studies have found that hormonal changes do not 
contribute to OCI (Hermelink et al, 2008).  
Hormonal changes secondary to chemotherapy-induced menopause may indirectly 
adversely affect cognitive function because of the decreased levels in neuro-protective 
oestrogen hormones. However, a study of 110 patients with breast cancer failed to 
reveal a significant association between either hormone level or menopausal symptoms, 
and OCI (as measured by the High-Sensitivity Cognitive Screen) following adjuvant 
chemotherapy (Tchen et al, 2003). There was a higher incidence of moderate or severe 
OCI in the patient’s receiving chemotherapy than in the healthy controls (16% v 4%) 
and they experienced more menopausal symptoms (median FACT-ES scores, 58 v 64; p 
< .0001). 
Patients treated with hormonal therapies for prostate or breast cancer may experience 
cognitive impairment because of reduced testosterone and oestrogen levels (Ahles & 
Saykin, 2007). Oestrogen deficiency in chemotherapy-induced menopause occurs faster 
than in normal menopause and it is associated with impairments in learning and 
memory, particularly verbal memory (Cutter, Norbury, & Murphy, 2003). It is uncertain 
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whether this accelerated decrease in oestrogen causes greater cognitive impairments 
(Shilling, Jenkins, Fallowfield, & Howell, 2001). The antioxidant and neuro protective 
effects of testosterone and oestrogens, and the importance of oestrogens in maintaining 
telomere length are highlighted in several trials (Vardy et al, 2007; Walker, Drew, 
Antoon, Kalueff & Beckman, 2012) which suggest that reduced concentrations of these 
hormones secondarily to hormonal therapy can cause chemotherapy related cognitive 
impairment (CRCI) even when administered without chemotherapy. 
2.5.2 Concomitant effects of cancer and its treatment  
Since many patients diagnosed with cancer suffer with anxiety, depression and/or 
fatigue (see Chapter 1) it is important to consider their effect when assessing both OCI 
and SCI. 
2.5.2.1 Anxiety 
Although anxiety has not consistently been a proven risk factor for OCI (Vearncombe et 
al, 2009; Cimprich, Ronis, & Trask, 2005; Mandleblatt et al, 2014), high levels of anxiety 
have been shown to be associated with poorer performance on cognitive tests as a 
result of decreased attentional control (Eysenck & Calvo, 1992).  SCI appears to be more 
strongly associated with anxiety symptoms than OCI (van Dam et al, 1998; Jenkins et al, 
2006; Pullens, De Vries, Van Warmerdam, Van De Wal & Roukema, 2013), with anxiety 
being one of the most common psychiatric disorders among women with breast cancer 
(Maass, Roorda, Berendsen, Verhaak & de Bock, 2015).  
As mentioned in Chapter 1, anxiety can develop as a reaction to being diagnosed with a 
life-threatening disease (Vardy and Tannock, 2007). It may also be related to actual 
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treatment. Breast cancer studies have reported increased levels of anxiety in patients 
undergoing chemotherapy treatment compared to other treatments (Schreier and 
Williams, 2007). There is also evidence of a relationship between SCI and anxiety at the 
end of chemotherapy treatment and for up to two years after completion of systemic 
therapy (Pullens et al, 2010; Schagen et al, 1999; van Dam et al, 1998; Hermelink et al, 
2007; Schilder et al, 2009).  Anxiety could continue to be a significant problem for many 
women years after the diagnosis of breast cancer (Hodgkinson, Butow, Fuchs et al, 
2007).  Hodgkinson and colleagues (2007) found a prevalence of 9.4% in women 
evaluated between two and ten years after cancer diagnosis, which was considerably 
higher than age-adjusted community prevalence rates (5.9%) in Australia (Hodgkinson 
et al, 2007).  These anxiety rates were found to be equivalent to those reported by 
women within the first 3 months of diagnosis (8.6%) and by women with advanced 
stage disease (6%) (Kissane, Grabsch, Love et al, 2004). Both studies used the Hospital 
Anxiety and Depression Scale (HADS) to measure anxiety.   
2.5.2.2 Depression 
There is not usually a significant correlation found between OCI and depression (van 
Dam et al, 1998; Schagen et al, 1999; Brezden et al, 2000; Ahles, Saykin, Furstenberg , et 
al, 2002; Schagen et al, 2002; Tchen et al, 2003; Castellon et al, 2004; Bender et al, 2006; 
Jenkins et al, 2006; Mar Fan et al, 2005; Wefel et al, 2004; Wieneke & Dienst, 1995; 
Cimprich et al, 2005; Cull et al, 1996; Eberhardt,  Dilger, Musial et al, 2006). However, as 
with the findings regarding anxiety, numerous studies in the “cancer and cognition” 
literature have shown a relationship between depression and SCI (van Dam et al, 1998; 
Cimprich, 1999; Castellon et al, 2004; Cimprich et al, 2005; Cull et al, 1996; Bender et al, 
2006; Jenkins et al, 2006; Vearncombe et al, 2009).  Jenkins and colleagues (2006) 
76 
 
found that 55% of breast cancer patients who were about to start adjuvant 
chemotherapy treatment reported psychological distress (on the General Health 
Questionnaire) (Goldberg & Williams, 1988), compared with 62% about to start 
endocrine therapy and/or radiotherapy, and 16% in healthy controls. At 6 months, the 
incidence was 51%, 24% and 18% respectively (Jenkins et al, 2006). 
2.5.2.3 Fatigue 
As discussed in Chapter 1, Section 1.8.2.3, fatigue is the most commonly reported 
symptom associated with chemotherapy treatment (Ashbury, Findlay, Reynolds & 
McKerracher, 1998; Downie et al, 2006;), affecting 75% to 95% of cancer patients 
(Vardy & Tannock, 2007).  Fatigue is often significantly associated with SCI but not with 
OCI (van Dam et al, 1998; Schagen et al, 1999; Servaes, Verhagen, & Bleijenberg, 2002; 
Tchen et al, 2003; Castellon et al, 2004; Bender et al, 2006; Mar Fan et al, 2005; Shilling, 
Jenkins, Morris, Deutsch & Bloomfield et al, 2005; Jenkins et al, 2006; Kreukels et al, 
2006, Vardy et al, 2015).  
2.5.3 Patient factors 
2.5.3.1 Genetics 
Research has indicated that various genetic and other confounding factors are also 
implicated in the genesis of CRCI (Saykin, Ahles, McDonald, 2003). However, this is 
outside the remit of this thesis. 
2.5.3.2 Age, education and intelligence  
Older age, level of education and intelligence are often associated with poorer cognitive 




The negative effects of older age on objective cognitive functions are well documented 
(Deary, Corley, Gow et al, 2009), including cognitive decline in the domains of 
processing speed, attention and executive function. Thus, it is possible that 
chemotherapy exacerbates the effects of old age on cognitive function for cancer 
patients. Ono and colleagues meta- analysis (2015) suggested that cognitive decline 
associated with chemotherapy for breast cancer might interact with age, whereby older 
patients may have a higher risk of developing and/or experiencing persistent OCI after 
chemotherapy.  
Lange and colleagues (2014) assessed 123 women with breast cancer over the age of 65 
after surgery, but before the start of adjuvant treatment. Compared with normative data 
based on age and education, 41% of the patients had OCI (mainly impaired visual 
episodic memory) pre-treatment, which is significantly higher than what would be 
expected when looking at healthy population norms. It is also a higher percentage than 
the 20% to 30% of breast cancer patients aged 45 to 55 years who exhibited pre-
treatment OCI in Ahles and colleagues study (2012). Lange contends that their findings 
support the hypothesis that elderly patients may be more sensitive to the impact of 
cancer on cognition. This is consistent with the link between biological processes 
underlying cancer, ageing, neuro-degeneration and a cognitive decline as proposed by 
Ahles and colleagues (2012).  Larger, longitudinal studies are necessary to investigate 
whether or not cancer therapies accelerate cognitive ageing (Ahles et al, 2012) and to 
properly determine the duration of OCI after chemotherapy (Vardy & Tannock, 2007). 
In relation to SCI, Hurria and colleagues (2006) found that more than 60% of elderly 
breast cancer patients perceived pre-existing memory problems and were more likely 
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to report further memory deterioration after chemotherapy. It is also worthwhile 
noting that aging is often associated with increasing comorbidities (e.g. cardiovascular 
disease) and functional decline, that have themselves been associated with cognitive 
impairment (Joly et al, 2015).  
IQ and Education:  
IQ and the level of education in study patients have also been found to significantly 
moderate the magnitude of post-chemotherapy cognitive impairment in cross sectional 
studies (Joly et al, 2015). Chemotherapy patients with fewer years spent in education 
tended to show greater OCI than those with higher levels of education. Having more 
years in education is associated with higher cognitive functioning (Cimprich, So, Ronis & 
Trask, 2005).  Mandelblatt and colleagues (2014) found that breast cancer patients aged 
between 60 and 94 had similar NP scores to the controls. However, patients with more 
advanced disease stage had lower executive function than early stage cancer, with 
significantly higher impairment among older, non-white, less-educated women and 
those with greater comorbidity. 
2.6 Quality of life 
 
In recent years, there has been an increase in the attention directed towards the impact 
of cancer and its treatment on quality of life (QoL) (Arriba, Fader, Frasure & Von 
Gruenigen, 2010). QoL is a multidimensional person-centred concept, encompassing an 
assessment of one's perceived health status and well-being in different life domains and 
includes both physical and mental health components (Bowling, 1991; Campbell 
Converse, & Rodgers, 1976; Cella and Tulsky, 1993) as well as overall satisfaction with 
life.  In the context of an illness, this concept may be narrowed to health related QoL 
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(HRQoL) involving domains, which are specifically related to health and/or disease, 
including physical, social, emotional, cognitive, sexual and functional outcomes 
(Kirshner & Guyatt, 1985; Cella et al, 1993).  
Since the 1990’s there has been quite a lot of research examing QoL in patients 
diagnosed with CRC (Schag, Garz, Wing, Sim & Lee, 1994; Sprangers, Taal, Aaronson & 
Te Velde, 1995; Allal, Bieris, Pelloni, et al., 2000).  Ramsey and colleagues (2000) 
examined QoL in survivors of CRC and found that the impact of CRC (for all stages) on 
HRQoL was greatest in the first 2 to 3 years after diagnosis.  Pain, functional well-being, 
and social well-being were affected most substantially across all stages of CRC and times 
from diagnosis. Although those patients who were diagnosed with stage 4 disease and 
lived longer than 3 years experienced relatively high HRQoL. Ramsey and colleagues 
(2000) noted that HRQoL for patients with CRC is likely affected by both the burden of 
the disease itself and the treatment regimens that are administered (which as discussed 
earlier are accompanied by various side effects). 
As mentioned, one possible side effect that has been associated with chemotherapy 
treatment for solid tumors is cognitive impairment. Cognitive status, whether alone or 
in combination with other factors can significantly influence an individual’s perception 
of QoL (Abrahamson, Clark, Perkins, & Arling, 2012). Deficits in various cognitive 
domains such as memory, attention and executive function, for example, may negatively 
affect an individual’s life in various ways (Pan, et al, 2015) and a number of QoL 
domains (Mitchell, Kemp,  Benito-León, Reuber, 2010). For example, impaired verbal 
abilities may lead to communication difficulties thus hindering a person’s ability to 
maintain social roles (Kiely, 2014). Attention deficits may affect routine daily activities 
such as eating, bathing and personal hygiene (Bronnick, et al, 2006); deficits in 
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attention, memory and executive function may be linked with the mechanisms of the 
chronicity of pain (Attal, et al, 2014); an awareness of cognitive impairment may cause 
depression (Jorm, 2001). An adverse effect on a patient’s HRQoL due to impaired 
cognitive function (whether objective or subjective) may have implications for daily 
functioning which could prevent a return to work or normal social life (Wefel et al, 
2011), and affect interpersonal relationships and leisure activities (Mitchell, et al, 2010). 
The clinical relevance of cognitive changes in patients with solid tumours is therefore 
significant, particularly in light of the increasing number of long-term cancer survivors 
in the population. In some patients, fear of this possible side effect may influence 
treatment decisions. For example, those offered adjuvant chemotherapy treatment as a 
preventative measure (rather than a cure) might choose not to undergo the treatment if 
they believe that it may affect their ability to return to work.  
It is interesting that although there is evidence from other populations (e.g., traumatic 
brain injury, multiple sclerosis) that cognitive functioning is an individual variable that 
can affect functioning in various QoL domains (e.g. social functioning) (Girard et al., 
1996; Hanks, Rapport, Millis, & Deshpande, 1999; Rao, Leo, Bernardin, & Unverzagt, 
1991), the link between functional outcomes and cognitive deficits among cancer 
survivors has yet to be clearly analysed and developed (Reid Arndt, et al 2009). The 
magnitude and course of CRCI and its precise impact on HRQoL is still uncertain. 
However, with the increase in survival times, HRQoL has become a meaningful patient-
reported outcome measure for individuals with cancer (Arndt, 2004). Improving 
HRQoL, along with preventing avoidable ill health, is an increasingly important aspect of 
health promotion (World Health Organisation, 1998). The relationship between OCI and 





This chapter introduced the concept of cognition, cognitive functioning, and its 
measurement. It outlined the domains of cognitive functioning that are essential to an 
individual’s ability to function independently. It also highlighted the complexities 
associated with the measurement (both objective and subjective) and interpretation of 
NP assessments in relation to patients with cancer. The current evidence regarding 
CRCI is discussed in more depth in the following three chapters.    
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This chapter provides a review of the literature concerning the relationship between 
chemotherapy treatment for adult patients diagnosed with solid tumours (such as 
breast, colon and testicular) and OCI. 
3.2 Background    
Since the early 1980s, there has been increasing interest in the psycho-oncological 
research community regarding the cognitive impact of systemic chemotherapy 
(Silberfarb, Philibert, and Levine, 1980; Oxman & Silberfarb, 1980). As mentioned in 
Chapter 1, a commonly patient-reported post-chemotherapy treatment side effect is 
deterioration in cognitive function, colloquially referred to as “chemobrain” or 
“chemofog” (Olin, 2001; Anderson-Hanley, Sherman, Riggs, Agocha, & Compas, 2003; 
Phillips & Bernhard, 2003; Tannock, Ahles, Ganz & van Dam, 2004).  
3.3 Prevalence  
One of the first studies to report on the association between chemotherapy and the 
development of cognitive deficits was authored by Silberfarb and colleagues in 1980. A 
short battery of NP tests was administered to 50 cancer patients and it was reported 
that chemotherapy was “the major variable associated with cognitive impairment”. 
However, systematic NP research examining the relationship did not begin in earnest 
until the mid-1990s to early 2000s (Brezden, Phillips, Abdolell, Bunston, & Tannock, 
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2000; Ahles, Saykin, Furstenberg, Cole et al, 2002; van Dam, Boogerd, Schagen, Muller et 
al, 1998; Wienke & Dienst, 1995). This coincided with the establishment of adjuvant 
chemotherapy as the new standard of care for treatment of most breast tumours 
(Abrams, 2001). 
The first of such papers, in 1995 found that 75% (21 of 28) of breast cancer patients in 
the study who had completed chemotherapy showed moderate impairment on one or 
more NP measure when compared with published norms from healthy individuals 
(Wienneke & Dienst, 1995). The researchers noted that performance of the 
chemotherapy group as a whole was significantly below estimated premorbid function 
in areas of verbal and visual memory, mental flexibility and speed of processing, 
attention and concentration, visuo-spatial ability, and motor function.  
That study was followed by van Dam and colleagues’ seminal paper published in 1998. 
They assessed the prevalence of OCI in high-risk breast cancer patients randomised to 
high (n=34) or standard (n=36) dose adjuvant chemotherapy treatment followed by 
hormonal treatment compared with a control group of breast cancer patients who did 
not undergo adjuvant chemotherapy treatment (n=34). Cognitive impairment on the NP 
assessments was found in 32% of the patients having high dose chemotherapy, 17% of 
those on standard dose and only 9% of the controls. The researchers interpreted these 
results as evidence of neurotoxicity caused by systemic chemotherapy and an implied 
dose relationship between adjuvant chemotherapy treatment and OCI. Table 3.1 
summarises the “cancer and cognition” studies published between 1995 and 2018, 
which examined CRCI in patients with solid tumours highlighting the incidence of 
cognitive impairment found.  
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As Table 3.1 indicates 18 cross sectional studies following van Dam’s study (1998)  
supported a link between chemotherapy and OCI (Schagen et al, 1999; Brezden et al, 
2000; Ahles et al., 2002; Schagen et al, 2002; Tchen et al., 2003; Castellon et al., 2004; 
Poppelreuter et al, 2004; Wefel et al., 2004a;Downie et al, 2006; Scherwath et al, 2006; 
Mehnert et al, 2007; Ahles et al, 2008; Bender et al, 2008; Schagen et al, 2008; Schilder 
et al, 2009; Reid Arndt et al, 2009; Von Ah et al, 2009; Kopplemans et al, 2012). 
However, 4 studies published during the same time period (i.e. 1999 to 2017) found no 
such relationship (Freeman et al, 2002; Donovan et al, 2005, Pedersen et al, 2009; 
Prokasheva et al, 2011).  
Of the NP studies to date that have found a relationship between chemotherapy and OCI, 
it occurs in at least one cognitive domain in 8% (Scherwath et al, 2006) to 75% (Wienke 
& Dienst, 1995) of patients with cancer treated with chemotherapy, according to the 
definition of OCI used by each researcher (Table 3.1). (The issue of the definition of OCI 
employed by researchers is discussed in Section 3.4.4).  
Although these early studies have been pivotal in drawing attention to the issue of CRCI, 
the studies that found OCI have not been consistent in their findings (Hodgson, 2008). 
The lack of consensus regarding prevalence of OCI in the “cancer-cognition” literature is 
most likely due to the heterogeneity of patients, methods and measurement in the 
studies. As indicated in Table 3.1, there is wide variation in study design, patient 
populations (type of cancer, disease severity, and management), and instruments used 
to assess cognition, criteria for defining OCI and/or method of analysis (Shilling, Jenkins, 
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Language: COWA 
Memory: Verbal selective 
reminding, BVRT 







Up to 38% 








- No difference in 




Longitudinal 74 BC T1: 12  days 
pre surgery  
 
DS forward & backward, 



























% OCI % SCI Significant 
Relationships 
T2: 15 days 
post-surgery 
norms, mean 
test scores at 







of loss of attention 
due, in part, to 





















BC no CT 
2 years post 
CT/ diagnosis 
Domains not specified 
RAVLT, CFT, DS, Digit 
symbol, TMT A & B, D2 Test, 
Stroop, Word Fluency from 
Dutch Aphasia Society Test, 










32%: BC high 






9%: no CT. 
SCI in 12%-


































BC post CT 
(CMF) 
 
BC no CT 
>6 months post 
CT 
∼ 2 years 
Domains not specified 
RAVLT, FFTT, FVRT, FBCT, 
FVST, Stroop, TMT A & B, D2 
test, CFT, Word fluency from 
SAN, Digit Symbol, DS, Visual 










28%: BC CT 
 



























in BC CT 
 
OCI unaffected by 
anxiety, 
depression, 
fatigue, & time 
since treatment & 
not related to SCI. 
 






SCI appeared to be 




































BC on CT 
 






6 domains: memory, 
language, visual motor, 
spatial, attention & 
concentration, self-
regulation & planning  
HSCS (25 min) 
POMS BC on CT: 48% 
  

















T1:Pre surgery;  
T2: 2 weeks 
post-surgery;  




For non BC: 
post MMG & 3 
months later 






T1: BC group 
scored 
significantly 
lower than HC 













- T1: mean scores of 
attentions tests for 
both groups fell 
w/in normal 


















10 years post 
CT 
8 domains:  
Verbal ability: WAIS-III 
vocab, WRAT-3 reading, 
BNT, COWA;  
Spatial ability: WAIS-III 


































% OCI % SCI Significant 
Relationships 
Verbal learning: CVLT; 
Verbal memory: WMS-R;  
Visual memory: WMS-R; 
Psychomotor function:  
WAIS-III Digit Symbol, 
TMT A & B;  
Motor function: Finger 
tapping;  
At   Attention:  CPT  














BC CT  
 
BC no CT 
2-5 years post 
diagnosis 
6 domains:  
Memory, attention/ 
concentration; processing 




Tests: TMT A&B, Category 
Test, GP, HVLT, Faces I & II,  
PASAT, RBANS, Stroop word 
& colour, COWAT, Sensory 
perceptual exam (2h). 
 











BC on CT 
 
BC post CT 





TMT A&B; Category Test; 
GP; HVLT; Faces I & II; 
PASAT; RBANS; Sensory 





Checklist 90-R,  
SSA 
Self-rate EF, PF 






CT worse than 
post CT 
 





































% OCI % SCI Significant 
Relationships 





















BC on CT on 
epoetin alpha 
 
BC on CT on 
placebo 
Pre-CT, pre 
cycle 4 & 6 
months post CT 




LASA (QoL);  
FACT A 
No difference 
in groups at 6 
months 































BC no CT 
∼4 years post 
treatment 
7 domains: verbal function, 
memory 
,attention/concentration, 
speed of information 
processing, motor 
functioning, visuospatical 
functioning & mental 
flexibility: 
RAVLT, CFT copy & recall, 
DS, Digit Symbol, TMT A & B; 
D2 Test, Stroop; Word 

















standard:13%   
 
No CT:11%  








observed in all CT 
groups, but control 













BC <50 years 















worse -  slower 
reaction time 





















% OCI % SCI Significant 
Relationships 























BPI (3 items) 
























2-6 weeks post 
CT 
HSCS 
TMT A & B; CPT 
FACT F;  




- BC experienced 











BC post CT 
 
BC no CT 
 
HC 





8 domains:  
Verbal Fluency: COWAT; 
Verbal learning: CVLT 
Verbal memory: WMS;  
Visual memory: WMS-R 
Visual Repro I & II, RCF - 
recall;  
Visuospatial Function: 
Block design, RCF -Copy 
Psychomotor Speed: Digit 
Symbol, TMT A & B 
Reaction Time: Cal CAP 
Executive Attention: 
PASAT, Stroop (2h) 
CFQ 








worse than BC 



















fatigue but not 





























T1: Pre CT 





MMSE <24 at 













between OCI & SCI  




Longitudinal 77 Mixed solid 
tumours 
T1: Pre CT 
T2: Pre Cycle 4 




time in TMT 
















to 19 years. 
post diagnosis 
LMI & II; Digit span; TMT; 







below the 10th 











































% OCI % SCI Significant 
Relationships 
deficits in at 






84 BC  Pre CT Attention: WAIS-R/III DS, 
WAIS-R Digit Symbol; 
WAIS-R Arithmetic; WAIS-
III LN; WMS-III MC; TMTA; 
Memory: HVLT; VSRT, 
NVSRT; ROCFT;  
Language: COWA; BNT; 
MAE Sequential 
Commands;  
Executive function: TMTB; 
Category Test; WAIS-III 
Similarities;  
Visuo spatial: WAIS-R BD; 
ROCFT Copy; JLO  




























18 BC  T1: Pre CT 
T2: 6 months 
T3: 18 months 
7 domains 
Attention: WAIS-R DS & 
arithmetic 
Processing Speed: WAIS-R 
Digit symbol, TMTA 
Learning: VSRT & NVSRT 
long term storage 
Memory: VSRT & NVSRT 
delayed recall 
Executive: TMTB; CT; WAIS-
R Similarities;  
Visuo spatial: WAIS-R Block 
Design 




61% decline in 
≥1 tests 
between T1 & 
T2 
 













184 BC  18 days pre 
surgery 
DS; TMT; TS & TW AFI;  
SDS;  
POMS-SF 










between OCI & 


















% OCI % SCI Significant 
Relationships 
range for 





OCI. Older age 
associated 
with poorer 























BC no CT, 
just RT 
∼1 year 5 domains:  
Episodic memory: CVLT, 
WMS-III - visual repro;  
Attention: DS, Spatial Span, 
TMT A & B;  
Complex cognition: Digit 
Symbol; Motor: Finger 
Oscillation Test;  
Language: COWA 
















(1 & 2 year 






BC post CT 
 
HC 
T1: after 3 




T2: 1 year post 
T1  (CT n=91) 
(HC n=81) 
 
T3: 2 years 
post T2 (CT 
n=83) (HC 
n=81) 
6 domains (memory, 
language, attention/ 
concentration, visual 
motor, spatial & self-
regulation):  
HSCS, TMT A & B, CCP 
 
FACT F;  






from 16% to 
4.4% & 3.8%  
& in HC from 5 
% to 3.6% & 
0% 
- No significant 
difference in 
overall QoL 
between BCs & 




























Decline in 34% 
CT vs. 19% HC 
SCI related to 

























T2: 4 weeks 
post CT (6 
months in HCs) 
Executive Function: 
Stroop;  
Working memory: Spatial 
































surgery pre CT  
 
T2: 1 week 
after CT  
 
T3: 1 year after 
T2 
6 domains:  
Attention: DS, TMTB 
Concentration: DVT;  
Verbal learning & memory: 
RAVLT,  Rivermead 
Behavioural Memory Test;  
Visual Learning & memory: 
RCFT 
Psychomotor Efficiency: GP 
TMTA;  






memory in CT 
groups:  
 
CT& Tam  
deterioration 



















21 BC post CT 2-6 weeks 
post CT 
5 domains: verbal memory, 
language, attention & 
concentration, visual 
motor/spatial ability & self-





FACT G  
FACT F  





























in all.  
 
No correlation 
between HSCS & 
subjective 


























28 BC aged >65 
years 
T1: Pre CT 
 
T2: 6 months 
post CT 
7 domains:  
Attention: TMT A;  
Verbal memory: HVLT-R; 
Visual memory: RCFT;  
Verbal function: WRAT-R 
reading subtest, BNT, 
COWAT:  
Spatial function: WAIS-III 
Block design, RCFT;  
Psychomotor function: 
WAIS-III Digit symbol, TMT 
A& B;  
Executive function: TMT B, 
Stroop colour & word, 
COWAT  
(45 mins) 






11%  at  T1 
  
25% decline 

















45 BC aged >65 
years 
T1: Pre CT   
 
T2: 6 months 
post CT 





































% OCI % SCI Significant 
Relationships 












BC who will 
have CT 
 















5 domains:  
Verbal memory: WMS; 
AVLT 
Visual memory: Complex 
figure;  
Executive function: Stroop; 
Working memory: DS; 
Spatial span; 
Letter/number sequencing 




B, F (patients 
only)  
FACT ES  
GHQ -12 
 
CT: Decline in 
20% at T2, 
18% at T3  
 
no CT: 26% 
T2 & 14% T3  
 
HC: 18% T2 & 
11% T3   
 












ment found in 
22% CT, 16% 
















with BCFQ scores  
 




No differences in 
SCI between BC & 
HC.   
 





on OCI measures 















T1: Pre CT  
 
T2:12 months 
post T1 (i.e. 6 
6 domains: focused-
sustained attention; 
working -verbal -visual 




high dose CT 
than controls 
over time 






















































BC no CT 
5 years post 
CT 
TMT A&B; TAP; Test d2; 
WMS-R; VLMT (Form A); 
ROCFT; RWT; LPS(<2 h) 
 









3%: No CT 
- -  














years of CT 
< 65 & 2 
CRC w/in 2 
years of CT 





BC no CT 
(just for 
FACT-Cog) 
3 assessments, 7 
– 90 days apart 
 
T1: after 3 
cycles & w/in 
2 years of CT 
 
T2: ∼ 17 days 
later 
 
T3: ∼ 17 days 
later 
 
Eng Speakers (n=20)- HSCS,  
 
All participants: CogHealth 







on HSCS: 30% 
(6/20) had 
mod-severe 
CI at T1; 5% 





> 1 SD below 
mean for 





>1 SD below 
mean for 








>1 SD below 









perception of their 























Longitudinal 109 BC  T1: PreOp CT  
 
T2: before last 
CT (approx. 5 
months post 
T1) 














pre CT;  
 
27% had OCI 











between OCI & 



























5 years post 
CT 
TMT A&B; TAP; D2 Test; 
VLMT; WMS-R; ROCFT; 












3% in no CT 
group (<5th 
percentile on 























BC CT  
 
BC no CT 
T1: Pre CT 
  
T2: 1 month 
post CT 
  
T3: 6 months 








T2 & T3 only  
 
GHQ -12  
FACT B 




T2; 60 % at 
T3.  
 
64 %  poor 
concentratio
n T2; 42% at 
T3 
 
SCI was unrelated 
to OCI; but was 
associated with 
psychological 
distress and QoL.  















pre CT, RT or 
HT 
8 domains:  
Verbal ability: WRAT-3, 
Vocabulary (WASI),  




















between any of 




















% OCI % SCI Significant 
Relationships 
Verbal memory: CVLT-II, 
Logical Memory I & II 
(WMS-III);  
Visual Memory: Faces I & II 
(WMS-III);  
Working memory: PASAT; 
Processing Speed: TMT, 
Color word interference 
test; GP, Digit Symbol;  
Sorting: Sorting Test; 
Distractibility: CPT;  












































2 years post 
treatment 
5 domains:  
Attention: DVT, TMTA, DS 
Learning & memory: RVLT, 
ROCF, RBMTS, FWS, TMT;  
Psychomotor speed: GP, 
DSST;  

























Longitudinal 32 BC CT < 65 T1: Pre CT  
 
T2: week after 
cycle 4 
 
T3: 1 week 






















































































6 months post 
treatment 











S+RT: 17.50%  
 












OCI & SCI.  
 












T1: pre CT 
post-surgery 
 
T2: w/in 2 
months post 
CT 
8 domains:   
Executive function: PASAT, 
TMT B, WCST;  
Language function: BNT, 
COWA; 
Motor: GP; Processing 
speed:Digit Symbol (WAIS-
III), Symbol Search (WAIS-
III), TMTA;  
Verbal learning & memory: 
CVLT,  
Logic memory II (WMS-II);  
Visual learning & memory: 
RVLT, Family Pictures II 
(WMS-II);  
Visuospatial function: Block 












































CCCs, DS & Letter Number 
sequencing 





Longitudinal 14 NSCL T1: pre-
treatment  
 
T2: 1 month 
post CT  
 
T3: 7 months 
post CT 




Block Desgin;  












OCI on ≥ 1 of 













between OCI & 
age, mood fatigue 








BC CT  (50- 
65 years) 
 
BC HT  (50- 
65 years) 
T1: Pre CT 
  
T2: 1 month 
post CT  
 
T3: 1 year 
post T2 
8 domains:  
Executive Function: PASAT, 
TMTB, WCST;  
Language function: Boston 
naming test, COWA 
Motor: GP;  
Processing Speed: Digit 
symbol, Symbol search, 
TMTA;  
Verbal Learning & Memory: 
CVLT, Logical memory II, 
WMS-III;  
Visual Learning & Memory: 
RVLT, Family pics II;  
POMS OCI at T2:  
 
BC CT: 34% 
BC HT:13%  
 
OCI at T3:  
 
BC CT: 11%  
 
BC HT: 10% 
 
 
CT patients who 
were also on HT 
at T3 tended to 
perform more 
poorly on NP 
tests than those 
not on HT - 
particularly on 
processing speed 


















% OCI % SCI Significant 
Relationships 
Visuospatial Function: Block 
design;  
Working memory:  CCCs; 
Arithmetic, DS, Letter-
number sequence & spatial 
span (all WAIS-III). 
 






















Episodic Memory: Verbal: 
CVLT 
Nonverbal: Visual 
Reproduction subtest of 
WMS‐III; 
Attention: DS, Spatial Span, 
TMT A and Ruff 2 & 7 Test 
Complex Cognition: Digit 
Symbol (of WAIS‐III),  TMT 















































HC < 65 







n & 3 months  
 
HC: interval of 
12 -16 weeks 
Processing speed: WAIS-III 
Coding & Symbol  
search, TMT A & B 
Working memory: WAIS -III 
Arithmetic, DS & Letter 
number sequencing;  
Visuospatial ability: RCTF-C  
Visual memory: RCTF-IR, 
RCTF -DR, RCTF - 
recognition 
Verbal memory: RAVL, 
WMS-III LM-IR & LM-DR 
Verbal fluency: WF-animals, 
WF-F, WF-N 













Decline on > 2 
NP measures: 
BC 29%,  
Cardiac: 25%  




on ≥3 NP 
measures in BC: 
24%  Cardiac: 
33%  
HC: 25%  





















































2 - 7 years 
post 
treatment 
Processing speed: WAIS-III 
CD & SS, TMT A & B
  
Working memory: WAIS-III 
A, DS, LN  
Visuospatial construction: 
RCFT Copy  
Visual learning & memory: 
RCFT Recall & recognition 
Verbal learning & memory: 
WMS-III Imm & delayed 
recall, RAVLT  
Verbal fluency: Animals, F & 
N words 









CT: 5.6%  
 




no. of NP tests 
scored in 
impaired range. 
No difference in 
proportion of OCI 
patients in CT 
group compared 
to no CT group (X 













2 years post 
CT 
8 domains:  
Verbal memory: RAVLT 
(Dutch short version) 
WMS -R  memory subtest, 
Visual Association test 
Working memory: WAIS-III 
LN 
Attention/concentration: 
Stroop Card 1 & 2, TMTA 
Mental flexibility: Stroop 
card 3, TMT B 
Information processing 
speed: Fepsy reaction times 
Manual motor speed: Fepsy 
finger tapping 
















(28% of CT & 





























































BC CT <70 
 




T1: Pre CT 
 
T2: After 1st 
CT 
 
T3: 3 months 
post CT 
Verbal memory: RAVLT  
Visual memory: CFT 
Attention & concentration: 
DS, VMS, Ruff 2&7 
Executive Function: TMT 
Speed of information 
processing: SDMT 
Verbal fluency: VFT 













WAIS-III PC - 





CT reported more 
cognitive 
difficulties than 
non-CT at T2 
which returned to 






46 BC CT 1 month post 
CT 
5 domains:  
Immediate memory: WMS-
III  logical mem I WMS-III 
visual reproduction I 




Rey AVLT Delayed Recall 
Attention: TMT A, WAIS-III 
DS 
Executive Functioning: TMT 
B , Stroop 


















- OCI had no 
significant impact 






































































% OCI % SCI Significant 
Relationships 

















64% had no 
scores at or 
below the 7th 
percentile of 
HC cut-off; 
21% had 1 
test below 

















T1 -Pre CT  
 
T2- 1 month 
post CT  
Verbal learning & memory: 
AVLT 
Visual memory: WMS -III 
Visual reproduction imm 
delayed & recognition 
Working memory: WAIS-III 
Backward DS  
Processing speed: SDMT 
oral version 
HADS 




multiple tests.  
 
Affected 









wellbeing at T1 
significantly 
associated with 



















% OCI % SCI Significant 
Relationships 
Attention: TEA Visual 
elevator & telephone 
search 
Executive function: WAIS-III 
Matrix reasoning, Stroop, 












Longitudinal 90 BC CT T1: 9 months 




T2: ∼26 days 
later (n=96) 
 
























10 patients had 
both OCI & SCI;  
 
22 only SCI  











BC no CT 
 
HCs 
T1: Pre CT 
 
T2: 1 month 
post CT 
 
T3: 6 months 
post CT 
 
T4: 18 months 
post CT 
7 domains: 
Verbal ability: WASI, D-
KEFS 
Verbal memory: CVLTest-
II,20 Logical Memory I & II 
(WMS-III) 
Visual memory: Faces I & II 
(WMS-III) 
Processing speed: Digit 
Symbol-Coding (WAIS-III), 
TMT, Color word 
interference test, GP 



















CT also has 
effect on 
verbal ability 
























% OCI % SCI Significant 
Relationships 









BC CT < 60 
 
HC 
T1: Pre CT  
 



























objective tests & 
subjective ratings 
of cog function 
Reid Arndt 
2010 








T3: 1 year 
post CT 
(n=33) 






















at each time 
point. 




each domain for 














T2: 6 months 
post T1 
 
T3: 6 months 
post T2 
5 domains: 
Motor: GP, Finger Tapper 
Language: COWAT, BNT 
Attention/concentration/wo
rking memory: TMT, WAIS-



















SCI in CT 
group went 
up over time: 
 
T1 = 27%, 
T2 = 43%,  





T1, 30%  
T2, 39%  
T3, 38% 
 
Non CT:  
T1 = 32% 
T2 = 35% 






















between OCI & 
SCI 
 
Wefel 2010 Longitudinal 42 BC CT  T1: pre CT 
(N=42) 
 










T4: > 13 
months post 
CT (N=28) 
4 domains :  
Attention: WAIS-R DS 
Processing speed: WAIS-R 
Digit symbol, TMT A 
Learning & memory: HVLT 
Verbal memory: Buschke 
Selective Reminding Test 
Visual memory: BVRT 
Executive Function: MAE 
COWA, TMTB 
 
FACT B  
BDI  
STAI 
21% 9 of 42) 
pre CT;  
 
65% (24 of 
37) at T2 
 
61% (17 of 










and 29% (5 of 
17) evidenced 











- Learning & 
memory declined 
most frequently 













but late decline 
may be 
associated with 


















































BC no CT 
 
>18 months 
post CT (i.e. 2-
5 years post 
diagnosis) 






40% in both 

























SCI unrelated to 
NP performance 
Memory deficits 
were observed in 
BC patients who 
receive either CT 














31 no CT, 38  
had 1 CT cycle 
& 53 had 2 or 
more CT 
cycles 
5 domains:  
Attention, concentration & 
working memory: SWM & 
CRT 
Learning & memory: HVLT 
R, PAL 
Speed of information 
processing: TMT A, CWI 
1&2 
Executive Function: CWI 
3&4, IED  





IES;  SCIN  


















20% had an 
increase in 
SCI from T1 
to T2 - larger 
%'s in CT 
groups:  
 
29% in I-CT 
group;  
 
25% in multi 
CT group; 







in SCI & a decline 
in OCI from T1 to 
T2. 
  
An increase of SCI 










































6 domains:  
Attention: WAIS-R DS 
Psychomotor speed: WAIS-R 
Digit symbol, TMT A 
Language: COWA 
Learning & memory: HVLT 
T1-3 






























Biglia 2012 Longitudinal 40 BC CT < 65 T0: pre CT 
  
T1: I month 
post T0 
 
T2: 3 months 
post T1 
 
T3: 6 months 
post CT 
MMSE, Attentive matrices, 
DS forward, TMT A & B, 
Phonemic word fluency, 
Short story imm recall, 
Short story delayed recall, 






































was 3.18, i.e 





SCI unrelated to 
OCI.  
 
SCI  associated 
with depression, 
anxiety, reported 
sadness &  
some items of the 


















% OCI % SCI Significant 
Relationships 






























T3: 6 months 
after start of 
CT 
 




Cognitive Stability Index 
(30 mins) - has 10 subtests 
for 4 domains: Attention, 
memory, response speed & 
processing speed 













improve at 3 
months 
follow-up 




scores tend to be 
















21 years post 
CT 
MMSE - used to screen 
 
6 domains:  
Processing speed: LDTS, 
Stroop colour word test 
Learning & memory: 15-
WLT,  
Visuospatial ability: DOT 
Verbal fluency (executive 
function): WFT 
Psychomotor speed & 
dexterity: PPB 
Interview on 



































BC CT were 
more likely 















SCI was not 
related to OCI  
Andries  
2013  




























% OCI % SCI Significant 
Relationships 
T1: end of CT  
 
T2: 6 months 
post T1 
Visuo-spatial memory:, 
(Clock Drawing Test, CDT, 
Rey Complex Figure, copy 
and recall), 
Information processing 
speed: TMT-A, TMT-B 
Verbal memory (Rey 
Auditory Verbal Learning 





Y2),   
 
Depression: 
GDS for > 65 
years old; BDI 
<65 years old 
















after CT  
Cruzado 
2014 




CT (n=73)  
 
T3: 6 months 
post last CT 
(n=54 
Attention & visual-motor 
ability: TMTA 
Executive function: Digit 
symbol, Inter Stroop, TMT 
B  
Verbal memory: Imm-Mem, 
Imm-Mem-Q Delayed-Mem, 
Delayed-Mem-Q 




















at least 1 test 
 























123 BC > 65 
years 

























% OCI % SCI Significant 
Relationships 
Episodic memory: Verbal - 
G&B procedure; Visual - 
RCF 
Working memory: WAIS-III 
Arithmetic, DS  &  LN 
Information processing 
speed: TMTA 
Executive function: TMT B, 
Verbal fluency: category 
(animal) & Letter P 
FACIT -
Fatigue;  





29 % on 1 
test,  
 
12% on ≥2 
tests 




















6% had anxiety;  
10% depression 














Post op & pre 
systemic 
therapy 
Attention, working memory 
& processing speed:  
DS, TMT A, DST, Driving 
scenes. 
Language: Boston naming 
test, Category fluency 
Executive Function: TMT B, 
COWAT, Figure drawing 
Learning & memory: Logical 
memory I & II, List A & B 
immediate recall, List A 
short recall delay, long 
delay 
Visuo spatial: Figure 
drawing copy (55 mins) 
Structured 
survey  






























higher levels of 
anxiety, 
depression, 





fatigue, & current 
physical or 
emotional 
function were not 
associated with 


































Pre CT Attention: TAP, TMTA & 
computerised equivs 
Memory & Learning: DS, 
VLMT  & computerised 
equivalents 
Executive function: TMT B, 

























above the pop 




  SCI associated 
with Go/Nogo 
omission errors & 
more pronounced 
in BCs. 
The effect of 
having cancer on 
Go/Nogo errors 
was mediated by 
PTSD symptoms 
Hess 2015 Longitudinal 231 Ovarian CT T1: Pre CT 
 






T4: 6 months 
post CT 
Headminder Clinical 
Research Tool (a 
computerised cognitive 
function test) (3 domains) 
processing speed, motor 
reaction time & attention 
FACT O  
FACT Ntx  
HADS;  
PAF 


















CRC No CT 
 
T1: pre CT 
  
T2: 6 months 
(n =137, 90, 
4 domains:  
Attention & working 
memory: DS, spatial span & 
LN 
FACT F  





43% CRC CT 
& no CT   
5% HC 
SCI was more 
common at 



































52 & 72 
respec) 
 
T3: 12 months 
(n =118, 87, 
41 & 70 
respec) 
 
T4: 24 months 
(n = 99 & 72 
CRC CT & No 
CT) 
Processing speed: Digit 
symbol, TMT A & B 
Verbal learning & memory: 
HVLT  
Visual learning & memory: 
BVMT 
 
CANTAB: Attention & 
complex reaction time,  
Attention & simple reaction 
time, Discriminability -  
memory, Verbal learning & 





39% CRC CT 




46% CRC CT 
& no CT 
13% HC 
T4: 
36% CRC CT 























than HCs at 
in no CT 
group (16%; 








groups at T3 





was only weakly 
associated with 





who had CT had 
SCI at T2 (32%) 
'v' non CT (16%) 
with 
no significant 
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Key: BC: Breast cancer; CRC: Colorectal cancer; SCLC: Small cell lung cancer; NSCL: Non-small cell lung cancer: HC: healthy controls; CT: Chemotherapy treatment; RT: Radiotherapy 
treatment; HT: Hormone treatment; Tam: Tamoxofin.  OR: Odds ratio;  
AVLT: Auditory Verbal Learning Test; BNT: Boston Naming Test; BVMT-R: Brief Visuospatial Memory Test Revised; BVRT: Benton Visual Retention Test; Cal CAP:  California 
Computerized Assessment Package; CANTAB: Cambridge Neuropsychological Test Automated Battery; CCCs: Consonant Trigrams; CCP/CPT: Conner’s Continuous Performance Test; 
CCST: Cognitive Capacity Screening Test; CFT: Complex Figure Test; CLOX: Clock drawing task; COWA: Controlled Oral Word Association Test;CRT: Headminder Clinical Research 
Tool; CST: Concept Shifting Test; CVLT: The California Verbal Learning Test; CW: Color-Word Interference Test; DKEFS: Delis-Kaplan Executive Function Scale; DS: Digit Span of the 
Wechsler adult intelligence scale; Digit Symbol: Digit symbol of the Wechsler adult intelligence scale; DSST: Digit Symbol Substitution Test; D2: D2 Test; DVT: Digit Vigilance Test;  
EXIT 25: Executive Interview (25 item); FFTT: Fepsy Finger Tapping Task; FVRT: Fepsy Visual Reaction test; FBCT: Fepsy Binary Choice test; FVST: Fepsy Visual Searching test; 
FWS: Four-Word Short-Term Memory Test; Gordon CPT: Gordon Continuous Performance Test; GP: Grooved Pegboard; GRIP: Grip Strength; HAWIE-R: Hamburg-Wechsler-
Intelligenztest fu¨r Erwachsene, Revision 1991 (Wechsler Adult Intelligence. Scale-Revised, German version); HRNB: Halstead-Reitan Neuropsychological Test Battery; HSCS: High 
Sensitivity Cognitive Screen; HVLT-R: The Hopkins Verbal Learning Test; IED: Intra-Extra Dimensional Set Shifting; ISPOCD battery: International Study of Postoperative Cognitive 
Dysfunction; JLO: Judgment of Line Orientation; LDCT: Letter-Digit Coding Test; LGT3:Lern- und Geda¨chtnistest (Learning and Memory-Test); LM1 & II: Logical Memory I & II; LPS: 
Leistungspru¨fsystem (Achievement measure system); MAE: Multilingual Aphasia Examination; MMSE: Mini- Mental State Examination; MOCA: Montreal cognitive assessment; 
MWT-B: Multiple-Choice-Vocabulary-Test; NCPC: Necker Cube Pattern Control test; NVSRT: Nonverbal Selective Reminding Test; PAL:Paired Associates Learning; PASAT: Paced 
Auditory Serial-Addition Task; RAVL/RAVLT: Rey Auditory Verbal Learning Test; RBANS: Repeatable Battery for the Assessment of Neuropsychological Status; RBMTS: Rivermead 
Behavioral Memory Test; Rey CFT/ RCFT/ ROCFT: Rey-Osterrieth Complex Figure test; RWT: Regensburg Word Fluency Test; S.A.N Test: Word fluency subtest from the S.A.N. test; 
Stroop: Stroop Test; SCWT: Stroop Color and Word Test; SDMT: Symbol Digit Modalities Test; SWM: Spatial Working Memory; TAP: Test battery for attentional performance; TEA 
VE: Visual Elevator & TEA TS: Telephone Search; TMT A&B: Trial Making Test Part A & Part B; TS: Three Shapes; TW: Three Words; VFT: Verbal Fluency Test; VLT/VLMT: Verbal 
Learning Test ; VMS: Visual Memory Span (Subtests of the WMS-R); VSRT: Verbal Selective Reminding Test; WAIS–III: Wechsler Adult Intelligence Scale –III; WAIS-III LN: WAIS-III 
letter number sequencing;   WAIS-R: Wechsler Adult Intelligence Scale Revised; WAIS-R BD: Wechsler Adult Intelligence Scale Revised - Block Design; WCST: Wisconsin Card Sorting 
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Test; WCST CR: Wisconsin Card Sorting Test – number of correct responses;  WF-animals:  category fluency—animals; WF-F/ WF-N: phonological fluency—words beginning with F 
and N; WMS-R: Wechsler memory scale-revised; WMS III LM: Wechsler Memory Scale third edition subtest Logical Memory; WRAT – 3: The Wide Range Achievement Test, Third 
Edition;  
Brief MAACL:  Brief Multiple Affect Adjective Check List; ADLs: activities of daily living; AFI: Attentional Functional Index; AMNART (Whitney 2008); BAI: Beck Anxiety Inventory; 
BCFQ: Broadbent cognitive failures questionnaire; BCPT: The Breast Cancer Prevention Trial; BDI: Beck Depression Inventory; BDI-II: Becks Depression Inventory-Second Edition; 
BF13: Item 3 of Brief Fatigue Inventory; BPI: Brief Pain Inventory; CCI/ Comorbid medical conditions: Charlson comorbidity index; CDS: Cognitive Difficulties Scale; CES-D: Centre 
for Epidemiological Studies Depression Inventory; CFQ: The cognitive failures questionnaire; Checklist 90-R: the Symptom Checklist 90-Revised; CIS: Checklist Individual Strength; 
CIQ: Community Integration Questionnaire; DRS: Dementia Rating Scale; DSM III R: Diagnostic and Statistical Manual of Mental Disorders-III—Revised; ECQ: Everyday Cognition 
Questionnaire; EPQ -18: The Eysenck Personality Questionnaire (18 items); FEDA: self-perceived cognitive deficits; FSI: The Fatigue Symptom Inventory; GDS: Geriatric Depression 
Scale;  GHQ-12: General Health Questionnaire 12; GPS: General Perceived Self-Efficacy; HADS: Hospital and Depression Scale; HSCL-25: The Hopkins symptom checklist – 25;  IADLs 
instrumental activities of daily living; IES: The Impact of Event Scale; ISI: Insomnia Severity Index; KPS: Karnofsky performance status; LFS: Lee Fatigue Scale; MADRS: Montgomery 
Asberg Depression Rating Scale; MAQ: The Mental Abilities Questionnaire;  MASQ: Multiple ability self-report questionnaire; MFI-20: Multidimensional fatigue inventory; Mini MAC: 
Mini‐Mental Adjustment to Cancer; MMPI: Minnesota Multiphasic Personality Inventory; MMSE: Mini‐Mental State Examination;  MOS SF-36: (Fatigue subscale): Medical Outcomes 
Study, general health survey, short form; PAF: patients perceptions of cognition; PAOF: Patient’s Assessment of Own Functioning; PDI: Psychological Distress Inventory; PHQ: 
Patient Health Questionnaire; POMS: Profile of Mood States; POMS-SF: Profile of Mood States –Short Form;  PSI:  Physical Symptoms Inventory; PSS:  Perceived Stress Scale; PTSD: 
Post traumatic stress disorder; SCIN: Scale for Chemotherapy-Induced Neurotoxicity; SDS: Symptom Distress Scale; SIP-8 (Mobility & Ambulation subscales): Sickness Impact Profile 
; STAI-Y:  Spielberger State-Trait Anxiety Inventory; SRS: Squire Self-Report Scale; SSA: Social Support Appraisal scale; SSRQ: Squire Memory Scale; SSQT: Social Support 
Questionnaire of  Transactions; STAI: State Trait Anxiety Inventory; STAI-Y1 and Y2: State and Trait Anxiety Inventory Premorbid; TSLS: Transactions Satisfaction with Life Scale; 
VAMS: Visual Analog Mood Scale; VIQ: American version of the Nelson Adult Reading Test; WRAT-3: The wide range achievement test-3; ZSDS: Zung Self-Rating Depression Scale 
EORTC QLQ-C30: European Organization for Research and Treatment of Cancer Quality of Life questionnaire; FACT A: Functional Assessment of Chronic Illness Therapy FACT B: 
Functional Assessment of Chronic Illness Therapy –Breast; FACT C: Functional Assessment of Chronic Illness Therapy – Colorectal; FACT Cog: Functional Assessment of  Cancer 
Therapy - cognitive function; FACT ES: Functional Assessment of Chronic Illness Therapy - Endocrine; FACT F: Functional Assessment of Chronic Illness Therapy - Fatigue subscale; 
FACT G: Functional Assessment of Chronic Illness Therapy - General; FACT L: Functional Assessment of Chronic Illness Therapy – Lung; FACT O: Functional Assessment of Chronic 
Illness Therapy – Ovarian; FACT – ntx: neuropathy scale; FACIT: Fatigue: Functional Assessment of Chronic Illness Therapy –fatigue; LASA (QoL): linear analog scale assessment of 
quality of life. 
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3.4 Methodological issues associated with OCI studies 
3.4.1 Study design: Cross sectional “vs” longitudinal  
The early studies in this area (such as Wienneke & Dienst 1995, and van Dam et al, 
1998) were retrospective and cross sectional in design, which meant that it was not 
possible to know whether OCI was already present prior to chemotherapy treatment or 
was attributable to the treatment itself (Cimprich et al., 2010; Schilder et al., 2010; 
Wefel et al., 2004a). Without pre-chemotherapy treatment evaluations of cognitive 
function, it was possible that the early studies both underestimated and/or 
overestimated the prevalence of OCI (Hodgson, 2008). Underestimations might have 
occurred as a result of failing to capture subtle losses in higher functioning individuals 
whose scores had declined but still fell within normal limits (Wefel et al., 2004a). In 
Wefel and colleagues, (2004b) pre-chemotherapy study there were no overall mean 
differences in cognitive function between patients and normative data (obtained from 
the general population). Within-subject analyses, however, revealed that 61% of the 
participants were found to have had cognitive declines in learning, attention, and 
processing speed. If there had not been a pre-chemotherapy treatment assessment, 
46% would not have had detectable OCI because their post-chemotherapy treatment 
assessment scores were within the normal range. This finding is extremely important, 
as OCI is often subtle (Janelsins, Kesler, Ahles, & Morrow, 2014) and it demonstrates the 
limitation of restricting the analysis to a comparison to normative data. 
Overestimation might have occurred because such studies were unable to detect 
changes from baseline (Olin, 2001; Ahles et al., 2002; Wefel et al., 2004). Later studies 
have found that up to 41% of patients with solid tumours have shown pre-
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chemotherapy treatment OCI (see Section 3.5.2) which was probably misattributed to a 
relationship with chemotherapy in earlier cross sectional studies (Hodgson 2008). 
These issues led researchers to conduct more prospective longitudinal studies in the 
early 2000s, which included baseline measurements prior to chemotherapy combined 
with multiple assessments over time to determine how an individual’s objective 
cognitive performance changed over the course of chemotherapy treatment. 
Increasingly, longitudinal studies began to appear which presented stronger evidence of 
the role of chemotherapy treatment in CRCI (Ahles et al., 2010; Bender et al., 2006; 
Hurria et al, 2006; Jansen et al, 2011; Minisini et al., 2008; Quesnel et al., 2009; Schagen 
et al, 2006; Shilling et al, 2005; Stewart et al., 2008; Vearncombe et al., 2009; Wefel et al, 
2004b; Wefel et al., 2010). However, these studies were not without their 
methodological limitations as will be discussed below.  
3.4.2 Time of assessment 
There is great variation in the time at which OCI is assessed in the literature. Early 
cross-sectional studies (i.e. pre-2005) ranged from 6 months (Wienke & Dienst, 1998; 
Schagen et al, 1999, Freeman et al, 2002) to 2 years after chemotherapy treatment (van 
Dam et al, 1998; Brezden et al, 2000; Castellon et al, 2002). 
Multiple assessment points are used increasingly by researchers, but the timing of the 
assessment(s) vary widely across studies (Table 3.1). Not all longitudinal studies 
include a pre-chemotherapy treatment baseline assessment. The timings of the first 
assessments range from pre-surgery (Cimprich et al, 1998; Cimprich et al, 2001; Vardy 
et al, 2006; Hermelink et al, 2007) to immediately after surgery but prior to 
chemotherapy (Bender et al, 2006), to first assessments conducted during 
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chemotherapy treatment (Brezden et al, 2000; Mar Fan et al, 2005) and sometimes the 
first assessment is not until after the end of chemotherapy treatment (Reid Arndt et al, 
2010).  The interval between assessments also varies, from months to years. Generally, 
a shorter interval between assessments enables the onset of cognitive change to be 
identified more accurately. This variability in the timing of baseline and subsequent 
measures makes it difficult to compare results across studies, which led the ICCTF to 
make recommendations for subsequent longitudinal studies to begin with a pre-
treatment assessment (Wefel et al, 2011). 
3.4.3 Controls/comparison groups 
As discussed in Chapter 2, Section 2.3.1.1 various control/comparison groups have been 
used by researchers for the purposes of establishing impairment. The type of control 
group used is an important methodological consideration when exploring the course 
and duration of OCI. There is debate in the psycho-oncology field regarding the most 
appropriate comparison groups: norms for individual tests, and/or matched healthy 
controls given the same battery of tests, administered under identical conditions as the 
patient group, and/or another patient group who experience similar levels of distress 
(Ahles et al, 2008). 
As can be seen in Table 3.1, numerous longitudinal studies (i.e. 21 out of 45 (i.e. 46.67 
%) of those listed) (Oxman et al, 1980; Cimprich et al, 1998; Iconomou et al, 2004; 
Jacobsen et al, 2004; Wefel et al, 2004b; Hurria et al, 2006a; Hurria et al, 2006b; 
Hermelink et al, 2007; Jansen et al, 2008; Whitney et al, 2008; Weis et al, 2009; Reid 
Ardnt et al, 2010; Wefel et al, 2010; Skaali et al, 2011; Biglia et al, 2012; Andries et al, 
2013; Cruzado et al, 2014; Hess et al, 2015; Klemp, 2017; Morin & Midlarsky, 2018; 
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Ramalho et al 2018) did not use a control and/or comparison group. One reason could 
be that in longitudinal studies there is an assumption that each participant serves as his 
or her own control for disease and host effects. 
In studies that have used a control group, 9 (11.7%) of those listed in Table 3.1 used just 
healthy controls (usually matched for age and education) (Cimprich et al, 2001; Servaes 
et al, 2002; Tchen et al, 2003/ Mar Fan et al, 2005; Shilling et al, 2005; Schilder et al, 
2009; Von Ah et al, 2009; Debess et al, 2010; Kopplemans et al, 2012 and Mandelblatt et 
al, 2014). However, Hodgson and colleagues (2008), argue that a reliance on healthy 
controls alone does not account for cancer-related factors other than chemotherapy that 
might contribute to cognitive changes. Healthy controls may therefore preclude the 
consideration of the effects on cognition of the cancer itself.  
Of the included studies, 34 (i.e. approximately 44%) used a cancer control group, most 
likely in an effort to account for the cancer and host factors (e.g. van Dam et al, 1998; 
Schagen et al, 2002; Ahles et al, 2002; Castellon et al, 2002; Donovan et al, 2005; Bender 
et al., 2006, Scherwath et al, 2006; Mehnert et al, 2007; Shilling et al, 2007; Bender et al, 
2008, Schagen et al 2008; Stewart et al, 2008; Collins et al, 2009; Pedersen et al, 2009; 
Verncombe et al, 2009; Tagar et al, 2010; Prokasheva et al, 2011; Sales et al, 2018). 
Furthermore, by using a cancer control group in the longitudinal studies researchers 
have been able to ensure consistency between the groups in test-retest intervals (Wefel 
et al, 2010). However, some of these studies appear to ignore the fact that such 
comparison groups would often be receiving alternative treatments which may 
potentially have had an effect on cognition (such as hormonal therapies, and/or 
radiotherapy ). The ability to compare patients to normative samples as well as to 
locally tested comparison groups is considered ideal (Ahles et al 2008; Wefel et al, 
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2011). Eleven studies used both healthy controls and a cancer control group (Castellon 
et al, 2004; Jenkins et al, 2006; Schagen et al, 2006; Vardy et al, 2006; Ahles et al, 2008; 
Jim et al, 2009; Quesnel et al, 2009; Ahles et al, 2010; Hedayati et al, 2012; Vardy et al, 
2015; Lange et al, 2018).  
Several studies used cancer control groups specifically because they were interested in 
comparing the effect of alternative treatments (Donovan et al, 2005; Bender et al, 2006; 
Schagen et al, 2008; Stewart et al, 2008; Collins et al, 2009; Quesnel et al, 2009) which is 
the approach taken in this thesis. 
Differences in control groups probably contribute to the differences in reported rates of 
OCI across the studies (Wefel et al, 2010) and prevent direct comparisons. However, as 
outlined in Chapter 9, the use of a control group is critical in longitudinal study designs 
to control for practice effects of repeated testing, as recommended by the ICCTF (Wefel 
et al, 2011). 
3.4.4 Definition of OCI 
As discussed in Chapter 2, Section 2.3.1, various methods exist which can determine 
what constitutes below normal performance on NP tests. Individual test or domain 
scores may be used, and different cut-off points selected per test and/or test battery. 
There is no established “gold standard” for defining OCI or a universally accepted 
classification system for lower than expected cognitive performance (Ahles et al, 2008) 
in the “cancer and cognition” literature.  
Researchers have used various cut-off points to determine whether there is OCI (Dwek 
et al, 2016). Some studies converted the NP test scores (raw scores) into standardised 
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scores using published normative data adjusted for age, education, and gender, defining 
impairment based on standard deviations below the mean. This procedure enables 
comparisons to be drawn across different tests with different units of measurement 
(number of correct words, time taken, etc.) and different distributions (e.g. normal, 
skewed etc) and is discussed in detail in Chapter 8. The number of standard deviations 
considered as indicative of impairment has also varied across the studies, as has the 
number of tests required (Vardy, Rourke & Tannock, 2007). For example 1, 1.5 and 2 
standard deviations (SD) below the normative group mean score on between 1 to 4 NP 
assessments have been used as cut offs indicative of impairment (Lezak et al, 2012). 
Other studies have used an actuarial approach that weights the number and severity of 
below average scores in a NP battery, ignoring scores in the average range or better 
(Wefel et al, 2011). 
The extent of OCI found to exist in a study often depends on the definition used by the 
researchers.  For example, Vardy and colleagues (2015) found that diagnosis of CRC 
itself prior to the start of chemotherapy treatment led to substantial OCI when 
compared with healthy controls. Depending on the criteria used, they found that the 
rates of OCI in patients with localised CRC ranged from 36% to 52% between pre-
chemotherapy treatment to 24 months later, compared with 6% to 19% in healthy 
controls.   
3.4.5 Sample characteristics 
The majority of studies in patients with solid tumours have been conducted on female 
breast cancer patients (Janelsins et al, 2014) (see Table 3.1).  Consequently, little was 
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known about OCI in men or in patients with other types of cancer until relatively 
recently. 
Additionally, most studies have included heterogeneous samples, ranging from the 
inclusion of participants with different types of cancer (e.g. Silberfarb, 1980; Kibiger et 
al, 2003; Iconomou et al, 2004; Jacobsen et al, 2004; Poppelreuter et al, 2004; Morin & 
Midlarsky, 2018) to participants with different stages of cancer, and participants who 
were treated with different chemotherapy regimens (e.g. Iconomou et al, 2004) with 
potentially different side effects (as mentioned in Chapter 1). For example, Iconomou 
and colleagues (2004) did not analyse differences in the 102 cancer patients who took 
part in their study, although they acknowledged that the great heterogeneity of cancer 
diagnoses and the wide variety of chemotherapy regimens may have been responsible 
for the lack of side effects found. 
Differences in chemotherapy dosage may also contribute to differences in OCI. Weinke 
& Dienst (1995) reported that the cognitive impairment found in their cross-sectional 
breast cancer study was not related to depression, type of chemotherapy or time since 
treatment, but was positively related to the length of chemotherapy treatment, 
suggesting a dose response relationship. This was later confirmed by van Dam and 
colleagues (1998) who found that a large proportion of the breast cancer patients 
receiving high dose chemotherapy (32%) were assessed as having OCI when compared 
with those on standard dose treatment (17%). This was further supported by Schagen 
and colleagues, (2006). However opposite findings were reported by Mehnert and 
colleagues (2007) and by Schwerth and colleagues (2006) who found that a greater 
proportion of those patients on standard dose chemotherapy treatment were assessed 
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as having OCI (13% compared with 8% in both studies) although there were no 
significant group differences were observed. 
In some studies, the participants were also receiving additional treatments such as 
hormone therapy or radiation therapy (Jansen et al, 2008). Without a systematic 
examination, such variations in treatment regimens and cancer stage make it difficult to 
isolate the effects of chemotherapy on cognition. 
3.4.6 Sample size 
As can be seen in Table 3.1, participant numbers have ranged from 11 (Oxman et al, 
1980) to 196 breast cancer patients (Kopplemans et al, 2012), to 231 ovarian cancer 
patients (Hess et al, 2015), 182 testicular patients (Schagen et al, 2008), 362 CRC 
patients (Vardy et al, 2015) and 119 participants from a mixed cancer population 
(Poppelreuter et al, 2004).  Researchers frequently acknowledge that the small to 
moderate sample sizes are a limitation (Brezden et al, 2000; Schagen et al, 2002; 
Castellon et al, 2004; Wefel et al, 2004b; Bender et al, 2006; Hurria et al, 2006; 
Scherwath et al, 2006; Mehnert et al, 2007; Jansen et al, 2008; Mehlsen et al, 2009; 
Schilder et al, 2009; Reid-Arndt et al, 2009; Reid-Arndt et al, 2010; Tagar et al, 2010; 
Prokasheva et al, 2011; Biglia et al, 2012; Cruzado et al, 2014). It is possible that smaller 
samples have lacked the power to detect associations (Hermelink et al., 2007; Wefel et 
al., 2004b).  
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3.5 Trajectory and affected cognitive domains 
3.5.1 Onset 
Early neuropsychological studies in cancer patients with solid tumours examined 
cognition following systemic treatment at a single point in time without a pre-treatment 
assessment (Janelsins et al, 2011). The timing of the assessment varied widely from 6 
months (Wieneke & Dienst, 1995; Schagen et al, 1999), through 2 years (van Dam et al, 
1998; Brezden et al, 2000), 10 years (Ahles et al, 2002) and up to 20 years (Kopplemans 
et al, 2012) post-chemotherapy treatment. Although these particular cross sectional 
studies did find some evidence of OCI at the time of assessment it is not possible to 
determine when the onset of such impairments began.   
One of the first prospective studies examining CRCI in breast cancer patients (n=18) 
was carried out by Wefel and colleagues (2004b), with measures taken prior to 
chemotherapy treatment (T1), 3 weeks post-chemotherapy (i.e. approximately 6 
months after the first assessment)(T2), and 18 months after T2(T3). They found that 6 
(33%) breast cancer patients demonstrated OCI on at least 2 NP tests prior to starting 
chemotherapy treatment. As mentioned in Section 3.4.1, this suggests that it is possible 
that early cross-sectional studies overestimated CRCI.  
3.5.2 Pre-chemotherapy  
Following Wefel and colleagues’ study (2004b) pre-chemotherapy cognitive 
compromise has been found in several longitudinal studies (Hurria et al, 2006a; 
Hermelink et al, 2007; Jansen et al, 2008; Hermelink et al, 2015; Vardy et al, 2015; 
Lange et al, 2018). Studies with this design have reported OCI in 36% to 52% of CRC 
patients (Vardy et al, 2015) and between 17% and 33% in breast and testicular tumours 
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(Wefel et al, 2004; Vearncombe et al 2009; Wefel et al, 2011). It has been suggested that 
the tumours and previous surgeries can cause cognitive impairment in patients with 
lower cognitive reserve (Ahles et al, 2010). (Cognitive reserve is defined as an innate 
and developed cognitive capacity that can limit a person’s vulnerability to brain insults 
(Hardy et al, 2018)). Yao and colleagues (2016) found evidence of executive function 
impairment in patients with breast cancer prior to surgery relative to healthy controls.  
In 2007 Hermelink and colleagues assessed cognitive function after diagnosis but prior 
to surgery, and then again prior to the final chemotherapy treatment. They observed 
impaired cognitive function in one third of the participants prior to any treatment 
whatsoever, during a time known to be particularly stressful. They assert that this was a 
possible indication of OCI at this time being related to stress-response symptoms, which 
may interfere with performance during NP testing. This raises the possibility that 
earlier cross sectional studies attributed OCI to treatment, when in fact it may have 
already existed prior to treatment. It is arguable that any such OCI found prior to the 
commencement of systemic treatment in a subset of cancer patients may have been due 
to the effects of stress, fatigue or the toxic by-products of the cancer itself (Anderson-
Hanley et al, 2003).  
Although it is unclear whether lower-than-expected pre-treatment cognitive function is 
attributable to an adverse effect of the cancer itself or to other unidentified factors, the 
results of these studies underscore the importance of designing future studies with a 




3.5.3 Course  
In the studies that report OCI there is conflicting data regarding its course. When OCI is 
measured over time in longitudinal studies, there is great variation in the when or how 
often cognitive function is measured; making it difficult to assess the course of OCI or 
compare results across studies (see Table 3.2). For example, in the first longitudinal 
study Wefel and colleagues (2004b) measured OCI prior to chemotherapy treatment, 
approximately 6 months later and then 1 year post chemotherapy treatment.  Whereas 
Mar Fan and colleagues (2005) assessed OCI after 3 cycles of chemotherapy (i.e. mid-
chemotherapy treatment), 1 year later and 2 years after that; and Weiss and colleagues 
(2009) did not assess OCI for the first time until 9 months post-chemotherapy 
treatment, then approximately 26 days later and again 6 months after the second 
assessment.   
Nevertheless, in the first longitudinal study Wefel and colleagues (2004b) found that 
OCI was present prior to chemotherapy treatment in 33% of the participants (4 women 
exhibited impairment on 2 tests and 2 exhibited impairment on more than 2 tests). By 
the time of the second assessment, 61% (i.e. approx. 11) of the 18 participants in the 
study experienced a decline in one or more aspects of objective cognitive functioning, 
and by 18 months, 50% of breast cancer patients who experienced cognitive decline at 
the second assessment showed improvement whereas 50% remained stable. These 
findings suggest that for a subset of patients’ OCI experienced during systemic 





Table 3.2: Table of longitudinal studies (post 2000) that have explored the course of OCI in patients with solid tumours 
Author & 
year 





T2: 6 months 
T3: 18 months 
 
18 BC 
T2: 61% exhibited a decline in 1 or more domains 
T3: 50% of those that experienced declines improved & 50% remained stable 
In some patients 
Mar Fan 
2005 
T1: after 3 cycles of 
CT  
(CT n=104) (HC 
n=102) 
 
T2: 1 year post T1  
(CT n=91) (HC n=81) 
 
T3: 2 years post T2 
(CT n=83) (HC n=81) 
 
Over the 2 years of follow-up, the proportion of patients with moderate-severe 
cognitive impairment improved from 16% to 4%.  
 
All the patients with moderate-severe impairment at T1 who underwent subsequent 
assessment improved to a level of mild impairment or better. 
  
Of patients and controls who scored as having mild impairment or better at T1, 3 






T2: 1 week after CT  
T3: 1 year after T2 
 
19  BC had CT only 
15  BC - CT & 
tamoxifen 
12 DCIS (just surgery) 
 
Women who received CT plus tamoxifen exhibited deterioration on measures of 
visual memory and verbal working memory and reported more memory complaints. 
Women who received CT alone also exhibited deteriorations in verbal working 
memory. Conversely, cognitive function scores improved in women who received no 





T2: 6 months post-CT 
Seven patients (25%) experienced a decline in cognitive function, defined as a 1-SD 
decline from pre- to post testing in two or more neuropsychological domains. I.e. from 
before CT to 6 months after CT 










T2: 6 months 
T3: 18 months 
The results from this study suggest that only a small proportion of women receiving 
adjuvant treatments for breast cancer experience objective measurable change in 
their concentration & memory. It is reassuring that the majority are either unaffected 
or even improve over time. 
 
Decline in 20% on CT at 6 months & 18% at 18 months compared with  
26% & 14% no CT  (at 6 & 18 months respectively) and  





T1: Pre-CT  
T2: 12 months post-
T1 (i.e. 6 months 
post-CT) 
 
28 BC high dose CT 
39 BC standard dose 
CT 







Group n No. impaired at T1 
(%) 
No. impaired at T2 
(%) 
No. having cog 
deterioration 
from T1 to T2 (%) 
Standard CT 39 5 (12.8)  4 (10.3)  5 (12.8) 
High dose CT 28 6 (21.4)  6 (21.4)  7 (25.0) 
No CT 57 17 (29.8)  13 (22.8)  10 (17.5) 
HC 60 6 (10.0)  4 (6.7)  4 (6.7)  
 
No  
Vardy 2006 T1, T2 & T3 approx. 
17 days apart from 
each other. Patients 
had had 3 cycles of CT 
& were w/in 2 years 
of CT  
A large practice effect was seen for the HSCS, with moderate– severe cognitive 
impairment decreasing from 30 to 5% between the first and second assessment 
Yes – when using 
the HSCS- practice 




T1: pre neo-adjuvant 
CT 
Towards the completion of CT, approximately 25% of patients showed a decline, 
whereas another 25% demonstrated improvement of cognitive function 
28% improved, 





Time of assessment Course  Improvement? 





T1: Pre-CT;  
T2: week after cycle 
4; 
T3: 1 week post-CT; 
T4: 6 months post-CT 
After completion of CT, only mean visuospatial skill (p<0.001) and total cognitive 
scores (p<0.002) decreased over time. In contrast, mean executive function (p<0.014) 
scores improved over time. 
 
10 women (33%) had a decrease of ≥ 1 SD on ≥ 2 tests after completion of CT. 
Decreased scores of at ≥ 1 SD were found most often for visuospatial skills (40%), 
motor function (13%), immediate memory (13%), language (13%), delayed memory 
(13%), and attention (7%). 
 
In contrast, 5 women (17%) had an increase in ≥ 1 SD for ≥ 2 tests after CT. 





T1: pre CT  
T2: end of CT 
(2 groups: BC CT & BC 
no CT) 
A threefold greater risk of cognitive decline in CT patients compared with the 
hormonal patients (31% and 12%, respectively), even after statistically accounting 
for age, education, intelligence, fatigue, psychological distress, and regression to the 
mean between T1 & T2. 
There was no difference in the frequency of reliable cognitive improvement (5% in CT 
group; 6% in hormonal group; p = 0:82). 
 
Short period – 
decline between 
T1 & T2  
Collins 2009 T1: Pre-CT;  
T2: 1 month post-CT  
T3: 1 year post-T2 
 
 
T1 to T2: a significantly higher rate of cognitive decline in CT group than HT group:  
34 vs. 13%;  
No difference in rate of cognitive improvement 8% in each group. 
 
At T3, there was no significant difference between the CT group and HT group with 
respect to frequency of reliable cognitive decline: 11 vs 10%; or improvement: 11 vs 
5%.    
 




noted in the short 
term are 
no longer evident 








Time of assessment Course  Improvement? 
Mehlsen  
2009 
T1: Pre CT and 4 days 
after hospitalisation 
for BC & Cardiac 
respectively 
 
T2: 4-6 weeks post CT 
25 weeks after T1 for 
Cardiac group 
12-16 weeks post-T1 
for HC 
Among the cancer patients, 29% showed decline on > 2 cognitive measures v  
25% and 17% in cardiac patients and HCs, respectively.  
Improvement on 3 or more cognitive measures was found in: 
24% of cancer patients,  
33% of cardiac patients, and  
25% of HCs 




T2: After 1st CT 
T3: 3 months post-CT 
 
 
41 BC CT 
40 BC no CT 
45 HC 
T1:  the average performance of all BC patients was inferior on two measures of 
attention when compared with HCs.  
 
T2 & T3 all BC patients showed decreased verbal memory, as compared with T1.  
 




affected and still 
impaired at T3. 
But average 
performance of 








T2: 1 month post-CT 
 
136 BC CT 
21 BC no CT 
 
16.9% BC CT declined on  a number of measures but there was improvement in visual 
memory and executive function consistent with practise effects 
Yes, in some 
domains – but 






90 BC all post CT 
T1: end of hospital 
rehab 
T2: approx. 1 month 
post T1 
At T3, 19 of the 90 tested patients (21%) were found to have clinically relevant 
cognitive deficits according to author criterion. (49 patients showed no signs of 
impairment) 
Prevalence of OCI 
significantly 
decreased as 
time elapsed after 





Time of assessment Course  Improvement? 
T3: approx. 6 months 
post T2 
treatment, 










T2: 1 month post-CT 
T3: 6 months post-CT 
T4: 18 months post-
CT 
 
60 BC CT 
72 BC no CT 
45 HCs 
 
The data suggest that CT has an acute effect on verbal ability, which resolved over 
time.  
 







T2: 1 month post-CT 
(approx. 6 months 
post-T1) 
 
120 BC CT 
208 controls 
 
CT group:  
 
14.9% showed a decline on cognitive shifting test (P = 0.002)  
 
12.2% showed a trend of improvement on delayed memory (P = 0.023). 
Yes in memory  





T1: 6 months post-CT 
(n=39 BC CT) 
T2: 12 months post-
CT (n=33 BC CT) 
 
 
< 20 % of participants across tests evidenced deficits in delayed memory, processing 

















domain for a 






T2: during CT (2.9 
months after T1) 
 
T3: shortly after CT (7 
months after T1) 
 





Before CT, 21% (9 of 42) evidenced cognitive dysfunction. 
 
T2 to T3, 65% (24 of 37) demonstrated cognitive decline.  
 
At T4, 61% (17 of 28) evidenced cognitive decline after cessation of treatment. 
Within this group of patients, 71% (12 of 17) evidenced continuous decline from T2 
to T3, and 29% (5 of 17) evidenced new delayed cognitive decline 
In some but more 











T0 to T3 - mean scores showed a significant worsening in the global cognitive 
functioning and in the visual selective attention while processing speed significantly 
improved during time, probably due to practice effect. (Used the MMSE). Note 42% of 




Yes in processing 
speed only 






T2: Post-surgery pre 
CT 
T3: 6 months after 
start of CT 
T4: 3 months post-T3 
Memory scores for women with BC were significantly lower than those for HCs over 
time, even after controlling for age and education. Memory & response speed scores 
were lower after CT than before (P< 0.01 for both).  
Whilst scores for response speed and memory declined immediately after CT was 







Time of assessment Course  Improvement? 
 
18 BC CT 
45 BC HT 




Processing speed and attention improved significantly over time in all groups, a result 
consistent with a practice effect 
Cruzado 
2014 
T1: pre-CT (n=81)  
T2: pre last-CT (n=73)  




At T1: 30 patients (37 %) had OCI. 
At T2: 27 patients (37 %) experienced OCI.  
At T3: 21 of 54 patients (39 %) were classified as showing OCI.  
 
A total of 31 % of patients experienced a statistically significant impairment in TMTA 
and 39 % in TMTB (binomial test, P=0.000) in each of the three assessment periods.  
 
A total of 28 patients (52 %) showed a decline from T1 to T2;  
Improvement in some tests was observed in 15 patients (28 %) in this period. 
 
A total of 29 patients (54 %)  showed clinical improvement T2 to T3, whereas 18 (33 
%) of them showed worsening in at least one test 
Yes some do – 
others get worse 
 












T1: pre-CT  
T2: 6 months  
T3: 12 months  
T4: 24 months  
 
173 CRC CT 





Adjusting for practice effect, rates of OCI were  
39%, 46%, and 36% at 6, 12, and 24 months, respectively, in the localized CRC group, 
compared with 6% and 13% in HCs at T2 and T3, respectively (all P < .001) 
 
There was OCI in 48% to 52% of patients with localized CRC at all time points, 
compared with 13% to 19% of HCs (all P < .001) 
 
After adjusting for practice effect, 20% of patients with localized CRC had significant 







Time of assessment Course  Improvement? 
 24% of patients with CRC had deterioration greater than expected from T1 to T3, 
compared with 7% of HCs.  
 
There was a non-significant trend for more cognitive decline in patients with localized 
CRC who received CT than in those that did not (32% v 23%, respectively) 
 
Key: BC: breast cancer; CRC: colorectal cancer; HC: healthy controls; CT: chemotherapy treatment; DCIS: ductal carcinoma in situ; NP: neuropsychological; OCI: Objective cognitive 
impairment; HSCS: High Sensitivity Cognitive Screen 
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As can be seen in Table 3.2, similar findings suggesting that OCI improves and/or 
resolves over time in a proportion of patient participants have also been reported in 15 
longitudinal studies since 2005 (Mar Fan et al, 2005; Jenkins et al, 2006; Vardy et al, 
2006; Jansen et al, 2008; Collins et al, 2009; Mehlsen et al, 2009; Quesnel et al ,2009; 
Vearncombe et al, 2009; Weiss et al, 2009; Ahles et al, 2010, Debess et al, 2010, Reid-
Arndt et al, 2010; Wefel et al 2010; Hedayati et al, 2012; Cruzado et al, 2014). Jansen 
and colleagues (2011) reported substantial improvement in all domains affected by 
chemotherapy treatment 6 months after completion of treatment. However, impairment 
may only resolve over time in some domains. For example, in Ahles and colleagues 
(2010) study the negative impact of chemotherapy treatment on verbal ability resolved 
over time but not in relation to processing speed. Cruzado and colleagues (2014) 
reported similar findings in their study involving patients with CRC, where 54 % of the 
patients experienced an improvement within 6 months following the end of 
chemotherapy treatment, although 18 patients were found to have worse results in at 
least one of the nine tests undertaken. 
It should also  be noted that improvements have reportedly ranged from just prior to 
the end of chemotherapy treatment (Hermelink et al, 2007) to 1- 3 months post-
chemotherapy treatment (Debess et al, 2010), to 8 months after the last chemotherapy 
treatment (Collins et al, 2009, Jenkins et al, 2006). OCI at longer term follow-up may not 
be as pronounced as during or just after treatment. For example, Ono and colleagues 
(2015) argued that breast cancer patients may have recovered from short-term 
cognitive impairment associated with chemotherapy and/or developed compensatory 
cognitive strategies after experiencing a series of chemotherapy doses.  
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Studies involving other solid tumours have also reported that OCI improves in a subset 
of patients treated with chemotherapy over time. For example, Whitney and colleagues 
(2008) found that by 7 months after the end of chemotherapy treatment, most of the 
cognitive decline experienced (before and just after treatment) actually dissipated in a 
subset of lung cancer patients that had exhibited decline at 1-month post chemotherapy 
treatment. (Immediately prior to chemotherapy treatment (i.e. T1) 71% of the 
participants demonstrated OCI. At 1-month post treatment (T2) 62% demonstrated 
cognitive decline in at least 1 of 6 NP tests. All patients who completed the 7-month 
follow up assessment showed improvements on measures for which they showed 
decline at T2). However, as can be seen in Table 3.2, there are also studies which have 
found that the trajectory of OCI can worsen rather than improve (Bender et al, 2006; 
Hurria et al, 2006; Schagen et al, 2006; Stewart et al, 2008; Wefel et al, 2010; Biglia et al, 
2012).   
3.5.4 Duration 
Early cross sectional studies indicate that significant cognitive impairments persist for 1 
year or longer in a sizeable subgroup of breast cancer patients (ranging from 13% to 
39%), (Ahles et al, 2002; Castellon et al, 2004; Schagen et al, 1999; Scherwath et al, 
2006; van Dam et al, 1998). Several other cross sectional studies have reported 
symptoms lasting from 3 months to 20 years post-chemotherapy treatment (Schagen et 
al, 1999; Ahles et al, 2002; Wefel et al, 2004b; Koppelmans et al, 2012). Whereas a 
number of longitudinal studies have reported symptoms lasting from shortly after 
chemotherapy treatment up to 2 years post-chemotherapy treatment in a subset of 
patients (Quesnel et al, 2009; Wefel et al, 2010; Cruzado et al, 2014; Vardy et al, 2014), 
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as presented in Table 3.2. Given the variability in time and frequency of assessments, 
measures and definitions of OCI used, research designs and samples across the studies 
it is not possible to state the precise duration of OCI.   
A review of the literature to date suggests that the duration of OCI is unknown (Cruzado 
et al, 2014). As described in Section 3.5.3, some researchers have even suggested that it 
is transitory (Ahles et al, 2002; Schagen et al, 2002; Vearncombe et al, 2009) whereas 
others have reported that it could last indefinitely for some patients (Ahles et al, 2012)  
3.6 NP tests used to determine which cognitive domains are most 
affected  
The ICCTF (Wefel et al, 2011) reports that memory, processing speed, and executive 
function seem to be most vulnerable to adverse effects of chemotherapy. Whereas 
Anderson-Hanley and colleagues (2003) earlier meta-analysis (which examined 30 
studies) suggested that the domains of verbal memory and executive function are 
particularly affected. Jansen and colleagues (2005) review of 16 studies, found that only 
visual memory was significantly impaired across all comparison types. Therefore, it 
would appear that all cognitive domains (outlined in Chapter 2) have reportedly been 
implicated in at least one “cancer and cognition” study listed in Table 3.1 (Ahles et al, 
2010; Collins et al, 2013; Jansen et al, 2011; Kyale et al, 2010; Quesnel et al, 2009; Tager 
et al, 2010; Vearncombe et al, 2009).  
As can be seen in Table 3.1, many researchers utilise different batteries of NP tests: Of 
the 77 studies listed in Table 3.1, 41 (53%) reportedly included assessments on 
memory, 32 (41.6%) on attention and 24 (31%) on executive function. However, as can 
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also be seen in Table 3.1, not all researchers specified which domains were assessed. In 
a review of 43 breast cancer studies published between 1960 and 2011, Cheung, Tan 
and Chan (2012) found that memory was the most frequently assessed domain. They 
also reported that 79% of the studies assessed executive function while 56% assessed 
language and 51% assessed perception.  
It is important to note that there is a considerable degree of inconsistency in the 
mapping of NP tests onto cognitive domains across studies (Dwek et al, 2016; Bernstein 
et al, 2017), and each test measures more than one domain. An example of a few tests 
that measure different domains can be seen in Table 3.3 (Freeman & Broshek, 2002). 
 
Table 3.3: Some examples of neurocognitive measures that assess more than one 

















Trails B X X X X X 
 
Category Test X X 
 X   
Grooved Pegboard 
    
X 
 




   X 
HVLT Recognition X X 







*Each measure appears under more than one domain of skill because no designed test measures only one function discretely. 




In addition, researchers do not always measure the same domains and if they do, they 
frequently use different tests to assess the same domains. Therefore, it is arguable that 
this inconsistency pertaining to the most vulnerable cognitive domains is attributable to 
the researchers’ assignment of a given test to a particular cognitive domain, as well as to 
the multifactorial nature of the NP tests themselves.  Furthermore, in some studies a NP 
test has been used to measure more than one domain of cognitive function and other 
studies simply report global difficulties rather than domain-specific ones (e.g., Schagen 
et al, 1999; Scherwath et al, 2006; Wieneke & Dienst, 1995).  
3.7 Summary  
As has been demonstrated above, the nature and severity of OCI reported in a study 
depends very much on the design (Anderson-Hanley et al, 2003; Falleti et al, 2005; 
Jansen et al, 2005). It is generally acknowledged that the large number of 
methodological issues have caused significant difficulty when interpreting the available 









This chapter provides a review of the literature concerning the relationship between 
chemotherapy treatment for adult cancer patients diagnosed with solid tumours (such 
as breast, colon and testicular) and subjective cognitive impairment (SCI). It then goes 
on to discuss the relationship between OCI and SCI and the consequences of both in 
terms of quality of life.  
4.2 Background 
As discussed in Chapter 2, patient self-reports (including quantifiable questionnaires, 
interviews, focus groups and diary entries) provide another approach to assessing 
cognitive function and impairment. This chapter concentrates on the studies that have 
measured SCI via scorable self-reported questionnaires and/or interview or focus 
groups.  
SCI is often assessed alongside OCI in the “cancer and cognition” studies that examine 
and evaluate cognitive changes.  As can be seen in in Chapter 3, Table 3.1, more than 
half of the included studies utilised subjective assessments in addition to the NP 
measures. Bray, Dhillon and Vardy’s (2018) systematic review evaluating self-reported 
cognitive function and its associations with NP tests and patient-reported outcomes in 
adult cancer patients who received chemotherapy treatment for a solid cancer (in 
studies reported between 1936 and December 2017) found that 50% of the 101 




Studies in patients with breast cancer suggest that up to 70% of women receiving 
chemotherapy self-report some degree of SCI (Boykoff, Moieni and Subramanian, 2009). 
In van Dam and colleagues (1998) seminal paper they reported that 12%-38% of breast 
cancer patients on high-dose chemotherapy reported SCI, 11%-31% in the standard 
chemotherapy dose group and 6% in the patients who only had surgery (as measured 
by the two items in the European Organization for Research and Treatment of Cancer 
Quality of Life questionnaire (EORTC QLQ-C30) and interviews).  However, as with the 
studies that examine OCI, there is a large variation in the amount of SCI reported across 
studies. For example, in a later breast cancer study, Shilling and colleagues (2007) found 
that 71% and 61% of participants reported problems with memory at one month and 
six months respectively after chemotherapy treatment, 64% reported problems with 
concentration one month after chemotherapy and 42% six months after the end of 
chemotherapy treatment.   
Various studies describe different percentages of prevalence of SCI, resulting in a lack of 
clarity (Pullens, De Vries, & Roukema, 2010).  Eleven studies included in Pullens and 
colleagues (2010) review described prevalence of SCI as ranging from 21% to 90%. As 
with OCI, this variation in percentages is most likely to be a reflection of the different 
definitions and measures used in the literature to date.  
 
It should also be noted that often SCI is not of primary interest in the “cancer and 
cognition” literature. Bray and colleagues (2018) found that fewer than 20% of the 
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studies included in their review defined self-reported cognitive symptoms as the 
primary outcome, and mostly this was a secondary outcome or was not specified. 
4.4 Methodological issues  
All of the issues discussed in Chapter 3, Sections 3.4.1 (Study design), 3.4.2 (Time of 
assessment), 3.4.3 (Controls/comparison groups) and 3.4.5 (Sample characteristics) are 
equally applicable in the evaluation of SCI, particularly where SCI is measured alongside 
OCI. These issues are briefly described in relation to SCI in this section.  
4.4.1 Study design: Cross sectional “vs” longitudinal 
There is significant variation between studies in relation to design (whether interview 
type studies or questionnaire studies). As with OCI studies, some are cross sectional 
(e.g. Cimprich, 1999; Schagen et al, 1999; Von Ah et al, 2009) whilst others are 
longitudinal (e.g. Jenkins et al, 2006; Jansen et al, 2008; Quesnel et al, 2009). In Bray and 
colleagues (2018) systematic review they found that out of 101 included studies 48 
(47%) were cross sectional and 38 (38%) were longitudinal, with varying sample sizes 
ranging from 9 to a population study of 1889 participants (Amidi et al, 2015; Dumas et 
al, 2013), with approximately 50% of the studies having less than 100 participants 
(Bray, Dhillon & Vardy, 2018).    
Similarly only three of the twenty qualitative interview/focus group studies detailed in 
Table 4.1 are longitudinal (Kanaskie & Loeb, 2015; Mitchell 2007; Mitchell & Turton, 
2011). Consequently, the majority of such studies to date have precluded any 
examination of the cancer/chemotherapy journey specifically in relation to cognitive 
changes experienced by these patients over time. Whilst all three of the longitudinal 
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studies aimed to capture participants’ experiences and perceptions of cognitive 
impairment over time, one study interviewed 7 breast cancer patients who had already 
completed chemotherapy treatment within the past 12 months (Kanaskie & Leob, 
2015). One study interviewed participants up to 10 times during their chemotherapy 
treatment (Mitchell, 2007) and the other study interviewed participants halfway 
through chemotherapy treatment, and then on completion of chemotherapy treatment 
(Mitchell & Turton, 2011). 
4.4.2 Definition of SCI  
As discussed in Chapter 2, SCI refers to perceived cognitive difficulties experienced by 
an individual in their everyday life, such as problems with concentration, memory, 
learning and language (Pullens et al, 2010; Hutchinson et al, 2012). However, as in the 
OCI studies, researchers have used different definitions of SCI, making it difficult to 
interpret the data.  
In Pullens and colleagues (2010) systematic review, it was found that only 7 out of the 
27 included studies described the definition of SCI (Schagen et al, 1999; Schagen et al, 
2002; Von AhD et al, 2009; Bender et al, 2008; Cimprich et al, 2005; Cimprich et al, 
1999, Schilder et al, 2009). Some studies reported a theoretical definition, whereas 
others reported cut-off points or percentiles that patients at least needed to rate in 
order for them to be considered as having SCI. For example, several studies (Schagen et 
al, 1999; Schagen et al, 2002; Schilder et al, 2009) interviewed breast cancer patients 
about cognitive problems (memory, attention, thinking and language) encountered in 
daily life and asked them to  indicate on a 5-point Likert scale the extent to which 
problems in each of these domains occurred in their daily activities. Scores ranged from 
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0 (not at all) to 4 (extremely). Only patients who rated their cognitive problem as at 
least 2 (moderate) in a distinct domain were considered as having a complaint about 
their cognitive functioning in the related domain.  
4.4.3 Measures 
Researchers use various measures to evaluate SCI. Bray and colleagues (2018) 
systematic review found considerable diversity in the selection of self-reported 
cognitive measures used.  An earlier systematic review examining (amongst other 
effects) the prevalence and course of SCI in breast cancer patients (Pullens et al, 2010) 
found that in the 27 studies included in the review 10 different self-report 
questionnaires were used to measure SCI. Additionally, some included studies used the 
subscales from questionnaires such as health status questionnaires, whilst nine authors 
used “self-made” and non-validated questionnaires and/or semi-structured interviews 
to examine SCI (Schagen et al, 1999; Schagen et al, 2002; van Dam et al, 1998; Downie et 
al, 2006; Berglund et al, 1991; Mehlsen et al, 2009; Servaes et al, 2002; Shilling & 
Jenkins, 2007; Schilder et al, 2009). 
As discussed in Chapter 2 (Section 2.3.2.1) and highlighted in Chapter 3, Table 3.1, 
researchers who have examined SCI alongside OCI have used the Questionnaire for Self-
Perceived Deficits in Attention (FEDA) (Mehnert et al, 2007; Schilder et al, 2010; 
Downie et al, 2006), the CFQ (Castellon et al, 2002; Castellon et al, 2004; Shilling et al, 
2005; Jenkins et al, 2006; Schilder et al, 2009; Quesnel et al, 2009), the cancer-specific 
Functional Assessment of Cancer Therapy-Cognitive (FACT-Cog) (Wagner et al, 2009) 
and the two  ”cognitive failure” items in the EORTC QLQ-C30, (van Dam et al, 1998; 
Schagen et al, 1999; Schagen et al, 2002; Weiss et al, 2009; Poppelreuter et al, 2009; 
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Iconomou et al, 2004; Schagen et al, 2008; Hermelink et al, 2007; Hermelink et al, 2010) 
(See Chapter 3, Table 3.1).  Bray and colleagues (2018) found that the EORTC QLQ-C30 
was the most commonly used questionnaire (up until 2017), and was included in 33 of 
the 101 reviewed studies. The use of different measures makes comparisons across the 
studies highly problematic. 
The FACT-Cog has been increasingly used (Downie et al, 2006; Vardy et al, 2006; Lange 
et al, 2014) since the mid-2000s.  It is the first measure to be developed and validated 
with a sample of adults with cancer (Wagner et al, 2009). As mentioned in Chapter 2, it 
is a self-report measure that was developed as part of the FACT measurement system to 
assess the nature and severity of cognitive deficits among cancer patients as well as the 
impact of these deficits on patients’ QoL. It has four subscales: symptoms of perceived 
cognitive impairments (PCI) (20 items), perceived cognitive abilities (PCA) (9 items), 
overall quality of life in relation to cognition (CogQoL) (4 items), and comments made 
by others (Oths) (4 items). Each item is rated on a seven point Likert scale according to 
how accurate the statement has been over the past week. Whilst higher scores indicate 
fewer symptoms (on PCI), better cognitive abilities (on PCA), better QoL (on overall QoL 
in relation to cognition), and more positive comments from others, there is no 
universally accepted definition of what constitutes a cognitive symptom or a cut-off 
score for the FACT-COG or its subscales (Vardy et al, 2017).   
There appear to be fewer studies that have used interviews and/or focus groups to 
examine SCI. A search of the literature produced just 20 qualitative studies (using 
interviews and/or focus groups) since the early 2000’s that have explored patients’ 
experiences of cognitive change in depth. These are displayed in Table 4.1.
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Table 4.1: Summary of interview and focus group studies in relation to perceptions of cognitive impairment since 2000 
 
 
First author & 
year 
Study design and 
methods 




Analysis used Major themes 




PROMIS scale &  









in a community 





previous year, 2 
completed 
treatment > 1 year 
ago, and  
2 still on 
treatment 
Content analysis 
procedure -  
informed by 
Sandelowski’s 




6 major themes:  
Cognitive problems 
Effects on employment 
Emotional response 
Search for answers 
Coping mechanisms 
The providers role 





Four focus groups:  
6–8 in each  
Plus one in-depth 
interview (1–3 
hours) with each 
participant 
Breast (n=74) Exploratory pilot 
study  
≥1 year post end 
of  adjuvant RT 
and/or CT  
Ethnographic 
content analysis 
(referred to by 
Crabtree and Miller 
as template text 
analysis.) 
Survivors report 




No categorization of 
type of cognitive 
changes but problems 






First author & 
year 
Study design and 
methods 




Analysis used Major themes 
 speed of processing 





diminished QoL and 
work ability. 





(Part of a larger 
study) 
Early stage 
breast (n=20)  
 
To describe the 
information and 
support needs of 
participants as a 
basis for developing 
specific 
interventions to 
meet the needs of 
this population.  
7 - 60 months post 








Focus group:  
4 English speaking 
4 Chinese 
Breast (n=43) To gather in-depth 
descriptions from 
multi-ethnic Asian 






based CT within 







74 open codes were 
created and categorized 






First author & 
year 
Study design and 
methods 




Analysis used Major themes 
speaking groups 






(i)  demographics, 
(ii) perception of 
top 5 contributing 
factors of  
cognitive changes 
(iii) how receptive 
they were on a 
scale of 1 to 10, to 
receive CT if CT 




impact on family 











2. impact of cognitive 
changes  
3. coping strategies. 








Receiving CT - had 
received between 




20 out of 21 patients 







First author & 
year 
Study design and 
methods 

















Goals of the 




the nature of the 
symptoms; (ii) 
assess frequency 
and severity of 
symptoms and (iii) 
gain a better 
understanding of 
the meaning and 




3 and 6 cycles of 
treatment. 
Assessments took 
place 2 to 6 weeks 
after the previous 
intravenous CT. 
and impact of 
symptoms.  
Initially two team 
members discussed 
themes and ratings 
emerging from the 
interviews, and 
developed a coding 
system. 
increased forgetfulness 
(of names, words, places 




were intermittent and 
unpredictable. Problems 
with memory were 
reported to affect all 
aspects of life. At work 
they interfered with 
productivity, and at 
home patients 
complained about 
misplacing objects and 
forgetting whether 
chores had been 
completed 
6 Fitch et al 2008 Cross sectional 
 
Breast (n=15) 
CRC (n=8)  
Exploratory study 
to understand and 
document 
experiences with 





using all interviews, 
Descriptions of cognitive 
changes provided clear 
evidence that the 





First author & 
year 
Study design and 
methods 




Analysis used Major themes 




changes in cognitive 
functioning 
following treatment  
 
 including pilot 
interviews. 
 
daily living, social and 
work-related activities.  
Approx.  ¼ of 
participants expected 
the changes to be 
temporary; the rest 
were uncertain or 
expected it to be 
permanent.  
Experienced emotional 
distress was linked to 




something that was of 
importance to them.  
Participants used a 
variety of strategies to 
cope with the changes. 





aged 42 – 59 
To better 
understand the 







Five essential themes 





First author & 
year 
Study design and 
methods 









month apart and 
a written journal 
cognitive change 
following CT and to 
more fully elucidate 
the impact of the 
phenomenon on 
personal and social 
relationships and 
how women cope 
with these changes 
in relation to their 
daily roles and 
responsibilities.  
within past 12 
months 
research was used 
to uncover the 
meaning of the lived 
experience 
of cognitive change 
following CT  
1. noticing the difference 
2. experiencing 
cognitive changes  
3. interacting socially  
4. coping and  
5. looking forward 
8 Mitchell T 2007 Longitudinal 
 








1. identify common 
and unique 
symptoms of social 
and emotional 





through the process 
Participants met 
with their 
researcher up to 









Eight major themes 
emerged:  
1.striving for normality 
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Analysis used Major themes 
of receiving CT 
treatment; 
3. describe common 
and unique 
strategies employed 
by individuals to 
cope with the social 
and emotional 
effects of toxicity. 
6. anxiety,  
7.chemotherapy 
process, and  
8. participating in the 
research. 
Concentration and 
memory loss were sub 
themes of flagging.  


















1. CI as told by 




treatment, and T2: 
on completion of 
treatment. 
All 4 participants 
had or were due 
to have ≥ 4 
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Study design and 
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two focus groups 
(n = 6, n = 7) 
Plus CFQ  -25 
Breast (n=13)  To investigate 
women’s awareness 
of CRCI, perception 
of cognitive 
limitations in 
carrying out daily 
tasks and 
subsequent return 
to work decisions 




months to 10 
years ago 





(Crabtree & Miller 
1992). 
 
Four main themes:  
1. awareness of 
cognitive changes 
during and following CT, 
2. cognitive ability and 
confidence in return to 
work  
3. impact of cognitive 
changes on work ability 
and  
4. information on the 
cognitive side effects of  
CT 






Breast (n=31) To examine the 
need for 
interventions 
related to perceived 
cognitive problems 
from the 
3 phases of 
data collection 4 
months after the 




were used to 
quantify & generate 
frequencies on 
Three major themes:  
1. Awareness of 
cognitive problems 
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patients and of 
healthcare staff.  
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involved in care of 
the women 
participating in 






phase 1.  
interviewees’ 
statements on types 












were applied.  
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Analysis used Major themes 




Breast (n=18) To provide an in-
depth description of 
the experience of 
CRCI and identify 
related information 
that women would 
find useful prior to 













used to prepare, 
organize, and 
report the data (Elo 
& Kyngas, 2007).  
 
‘Life with chemobrain’ 
was identified as the 
overarching theme.  
Three subthemes:  
1.How I changed,  
2.How I cope, and  
3.How to teach me 
 
Most women reported 
problems with short-
term memory, focusing, 
word finding, reading 
and driving.   










old at time of 
diagnosis 
To explore impact 
of chemobrain on 





received treatment.  
Specific objectives 
were to:  
Undergoing or had 




according to the 
definition used 
earlier by Cheung 







1996).      
Data were analysed 
using thematic 
analysis (Braun & 
Six themes:   
1. uncertainty about the 
origin of the chemobrain 
experience;  
2. persistent but 
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Study design and 
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Analysis used Major themes 
interviews (lasting 
between 40 and 
90 minutes) 
(i) describe how 
chemobrain may be 
experienced by 
Australian women;  
(ii) explore areas of 














Clarke, 2006). A 
field diary was kept 
by the researcher, 
with reflections and 
comments included 
in data collection & 
analysis phases 
(Groenewald, 
2004). Data analysis 
involved open-














3. simple function 
turned complex;  
4. losing functional 
independence in family 
life;  
5. strategies to maintain 
function; and  
6. need for recognition 
of subjective experience 





First author & 
year 
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Analysis used Major themes 
14 Potrata et al 
2009  














To obtain a more in-
depth 
understanding of CI 




and the strategies 
used to cope with 
them. 










transplant) on its 
own or in 
combinations.  
 
Less than 1 year 
from diagnosis, 
between 1–5 
years and more 










term memory, poor 
recall and lack of 
concentration were 
observed and/or 
expressed in at least 10 
out of 15 patients, all of 
them long(er)-term 




with personal and 
professional lives, and 
for some patients these 
were described as 
permanent. Patients 
used various coping 
strategies, from denial, 
taking notes, writing 
diaries, reading simpler 
texts, using talking 
books and videos, to 





First author & 
year 
Study design and 
methods 




Analysis used Major themes 
counting medication to 
cope with cognitive 
impairment. 
15 Raffa & Martin 
2010  
Cross sectional  
 
Interview 
Breast (n=1) Case study about 
the experience of 
‘chemo‐fog’, 
chemo‐brain’ 
15 years after CT Not described Symptoms are usually 
difficult to describe and 
involve domains of 
cognition such as 
attention, concentration, 
memory, speed of 
information processing, 
multitasking, or ability 
to organize information. 
Deficits are reported to 
persist. The magnitude 
of the negative impact 
on QoL depends, as does 
the condition itself, on 
multiple and varied 
factors. 
16 Rust & Davis 
2013 
Cross sectional  
 
Focus group 






Completed CT and 
radiation at least 
one year prior to 
the study 
Analysis was based 
on grounded theory 
(Tavakol, Torabi, 
& Zeinaloo, 2006). 
Participants were 
Four themes:  






First author & 
year 
Study design and 
methods 




Analysis used Major themes 
experiences with CI 
from chemobrain, 
and the impact of 
chemobrain on QoL. 
asked open-ended 
questions to elicit 
conversation 
regarding the issues 
they faced, their 
experiences with CI, 
and the impact of 
chemobrain on 
their lives.  
Open coding 
involved examining 
the data in discrete 
parts for differences 
and similarities, and 
then identifying 
themes within the 




developed (Miles & 
Huberman, 1994; 




3.stigma of chemobrain,  





First author & 
year 
Study design and 
methods 




Analysis used Major themes 





interviews (part of 
an objective 
study) 








T2: 4 weeks after 
the final CT 
session (n=93)  
6 months in the 
non-CT group 
n=49 
T3: 12 months 
after the final CT 
session (n=85)  




Not described Quotes illustrate the 
types and extent of 
problems faced by these 
women. 
Main findings of CT 
patients:  
Patient noticed changes 
in: 
Memory: 83% at T2; 
60% at T3  
Concentration 78% at 
T2; 45% at T3 
Family and friends 
noticed change in 
patient’s: 
Memory 53% at T2; 
39% at T3  
Concentration: 32% at 





First author & 
year 
Study design and 
methods 




Analysis used Major themes 
Patient concerned about 
changes in: 
Memory 34% at T2, 
39% at T3;  
Concentration 28% at 
T2; 40% at T3 
18 Skoogh et al 
2012 






To learn more 
about possible long-
term effects of CT in 
everyday activities 
related to cognitive 
demands. Focused 
on specific activities 
and behaviour in 
everyday life that 
may depend on 
cognitive function.  
On average 15 




identify distinct and 
concrete behaviour 
elements such as 
“word dropping” or 




themes such as 
“communicating” 
and “forgetfulness”. 
Identified 59 questions 
mainly reflecting one 
specific cognitive 
domain:  
6 were judged to reflect 
attention, 26 memory, 5 
visual-spatial ability, 7 
language, 2 speed and  
13 executive function. 
19 Von Ah D et al 
2013  
Cross sectional  
 
Breast (n=22) To obtain a better 
understanding of 
breast cancer 
All at least 1 year 
post CT treatment 
A conventional 
content analysis 
approach was used 







First author & 
year 
Study design and 
methods 










perceived CI, its 
























All survivors found 
these impairments 
frustrating, and some 
also reported these 
changes as detrimental 
to self-confidence and 





First author & 
year 
Study design and 
methods 




Analysis used Major themes 
















Phase 1: to solicit & 
record descriptions 







development of a 
questionnaire to 
assess CI using 
language relevant 
to patients.)  




generated in phase 
1.  
Completed 3 or 
more cycles of CT 
within the 
previous 6 months 
and had reported 
a disruption in 
cognitive function 












from patient focus 
groups & 
interviews. These 
themes were used 
to generate items 
for the FACT -Cog 
measure. 
Patients reported 
deficits in: word-finding, 
forgetfulness, lack of 
mental clarity, impaired 
concentration, delayed 
reaction time, and 
psychomotor slowing. 
Patients described these 
deficits as frustrating 
and depressing - they 
interfere with work and 
ability to drive. 
Key: CT: chemotherapy; CI: cognitive impairment; CRCI: chemotherapy related cognitive impairment; BC: Breast Cancer; PROMIS: Patient-Reported Outcomes Measurement 
Information System; FACT-G: Functional Assessment of Cancer Therapy: General; FACT-F:  Functional Assessment of Cancer Therapy: Fatigue; FACT-ES: Functional Assessment of 
Cancer Therapy: Endocrine Subscale; HSCS: High Sensitivity Cognitive Screen; CFQ -25: The Cognitive Failures Questionnaire – 25; CFQ: The Cognitive Failures Questionnaire; BDI: 
Becks Depression Inventory 
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4.5 Trajectory and cognitive domains 
4.5.1 Onset 
As with the OCI studies, although early cross sectional studies such as van Dam and 
colleagues (1998) found evidence of SCI post-chemotherapy treatment, it was not until 
the early 2000s when studies properly examined the onset of such impairments. 
4.5.2 Pre-chemotherapy  
In 1999, Cimprich was one of the first researchers to concentrate solely on pre-surgery 
assessments. In her study, she found that only 27% of newly diagnosed breast cancer 
patients rated themselves as cognitively well functioning when performing key 
activities. Similarly, to the findings regarding OCI, SCI has been found to exist in a subset 
of cancer patients prior to the commencement of chemotherapy treatment (Sanford et 
al, 2014; Skaali et al, 2011; Hermlink et al, 2015). For example, Skalli and colleagues 
(2011) found that 16% of testicular cancer patients reported SCI affecting daily 
functioning after surgery and prior to the start of any additional treatment. However, 
Vardy and colleagues (2017) found that patients with CRC reported cognitive symptoms 
at rates commensurate with those in the general population prior to chemotherapy 
treatment.  
4.5.3 Course  
As with OCI, in the studies that found SCI there is conflicting data regarding its course.  
In a purely subjective longitudinal study (i.e. one that used only a brief clinical interview 
and self-report questionnaires but no NP measures), of the 595 participants undergoing 
treatment for solid tumours, Kholi and colleagues (2007) found that problems with 
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concentration were reported by 48% of patients (5% severe) prior to the 
commencement of chemotherapy treatment (T1); 67% (18% severe) during treatment 
(T2) and 58% (8% severe) at 6 months following chemotherapy treatment (T3). 
Problems with memory were reported by 53% at T1 (4% severe), 67% at T2 (18% 
severe), and 68% at T3 (11% severe). Whilst there were cognitive problems reported 
prior to chemotherapy treatment, it was found that patients tended to report SCI more 
during and after chemotherapy (Kohli et al, 2007) with the course of SCI being reported 
as worse during chemotherapy treatment. 
A later longitudinal study that examined the cognitive effects of chemotherapy in 61 
older post-menopausal women with breast cancer also found that a higher percentage 
of women in the chemotherapy group reported SCI after chemotherapy, with 27% pre-
chemotherapy treatment (T1), 43% 6 months later/within 1 month of completing 
chemotherapy (T2) and 46%, six months after T2 (T3). However, the percentage of 
those reporting memory problems in the non-chemotherapy group did not change 
much, with 32% at T1, 35% at T2 and 31% at T3 (Tagar et al, (2010).  
These two studies contrast with Shilling & Jenkins (2007), who found that self-reported 
difficulties decrease over time. They found that 71% and 61% of participants reported 
problems with memory at one and six month’s respectively post-chemotherapy 
treatment, 64% reported problems with concentration one month after chemotherapy, 
and 42% six months after the end of chemotherapy treatment. Quesnel and colleagues 
(2009) study also found that patients receiving chemotherapy treatment reported more 
cognitive difficulties than those who did not receive it at the post-treatment assessment, 
followed by a return to the baseline level at the 3 month follow-up evaluation.  In a 
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systematic review, Hutchinson and colleagues (2012) found that the course and 
duration of SCI is unclear.   
4.5.4 Duration 
Perceived changes in memory and attention attributed to CRCI have been reported to 
exist immediately following chemotherapy treatment and up to a year later (Hutchinson 
et al, 2012). As with OCI, there are studies that suggest that SCI can persist for up to 10 
years following cancer diagnosis (Ahles et al, 2002).  
Post-2005 cross sectional and longitudinal studies that used the FACT-Cog to measure 
SCI in patients with cancer found that participants self-reported on-going SCI for 
multiple years following chemotherapy treatment. For example, Von Ah and colleagues 
(2009) cross sectional study in breast cancer found that participants self-reported on-
going symptoms for a mean period of 5 years after adjuvant chemotherapy (Von Ah et 
al, 2009). Similarly, Vardy and colleagues’ (2017) longitudinal study exploring SCI in 
patients with CRC who either did or did not receive chemotherapy found that cognitive 
symptoms increased in patients who received chemotherapy, peaked just after 
completing treatment and continued at the higher level for 2 years after diagnosis.  
4.6  Overview of affected cognitive domains 
Patients with cancer (particularly those with breast cancer) often complain of problems 
with memory and concentration (Phillips & Bernhard, 2003). In the context of the 
“cancer and cognition” literature, reports of SCI have been described as patients having 
difficulties with attention, concentration and memory (Wagner et al, 2009; Boykoff et al, 
2009; Downie et al, 2006; Cappiello et al, 2007; Cheung et al, 2012; Mulrooney, 2008; 
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Munir et al, 2010; Munir et al, 2011;  Myers, 2012;  Von Ah D et al, 2013; Rust & Davis, 
2013; Fitch et al, 2008). Downie and colleagues (2006) also found that 78% of breast 
cancer participants reported problems with language. Bray and colleagues (2018) 
systematic review found that not all of the included studies specified particular 
cognitive symptoms reported by participants, although when they were described, they 
predominantly involved reports of deficits in memory. 
The most frequently reported cognitive changes in interview and/or focus group 
studies appear to be in memory during chemotherapy treatment (Downie et al, 2006; 
Mitchell, 2007) and up to 12 months after the end of chemotherapy treatment (Myers, 
2012; Potrata et al, 2009; Shilling & Jenkins, 2007; Von Ah, 2013).  For example, almost 
all of the breast cancer patients receiving adjuvant chemotherapy treatment (20 of 21) 
interviewed for Downie and colleagues’ study (2006) reported difficulty with recent 
memory during chemotherapy treatment. They described increased forgetfulness of 
names, words, appointments and slower memory retrieval (Downie et al, 2006). 
Similarly a few years later Von Ah and colleague’s (2013) found that all of the 22 breast 
cancer participants who had undergone chemotherapy treatment at least 1 year earlier, 
reported short term memory impairments, 91% (n=20) reported long term memory 
impairments and 55% (n=12) reported issues with attention and concentration.   




From both the objective and subjective point of view, the difficulties encountered 
interpreting research in this area due to the methodological issues are further 
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complicated by the high rates of attrition encountered in such studies. Attrition is often 
a result of the advancement of residual disease, death or participants’ 
reluctance/unwillingness to discuss their cancer at follow-up as this can raise negative 
thoughts and feelings regarding a possible relapse of the disease (Jansen et al, 2008; 
Hodgson et al, 2013). 
4.7.2 Confounds 
As mentioned above, a number of relatively recent studies have found that a percentage 
of patients with solid tumours have OCI (Wefel et al, 2004; Hurria et al, 2006; Hermelink 
et al, 2007; Jansen et al, 2008; Lange et al, 2014; Mandelblatt et al, 2014; Hermelink et 
al, 2015; Vardy et al, 2015) and/or SCI (Cimprich, 1999; Mehlsen et al, 2009) even 
before starting adjuvant chemotherapy treatment. This could be attributed to other 
contributing factors as discussed in Chapter 2, Section 2.4 or perhaps there are common 
risk factors for both the development of cancer and cognitive changes?   
As can be seen from the studies discussed in this chapter and Chapter 3, the 
mechanisms underlying CRCI (whether objective or subjective) are still not well 
understood (Ahles & Saykin, 2007, Vardy et al, 2008 and Walker et al, 2012). 
4.8 Relationship between OCI and SCI 
As mentioned, studies examining cognition in patients with cancer often include both an 
objective and subjective measure of cognitive function (41 out of 77 in Table 3.1). 
However, this does not always mean that an association is examined. For example, Bray 
and colleagues (2018) found that the association between self-reported cognitive 
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symptoms and NP results was not reported in more than half of the studies (i.e. >50 out 
of 101 studies) included in their review.  
Even when it is examined, few studies have found a significant correlation between 
these measures (Hutchinson et al, 2012).  The majority of studies (that examined the 
relationship listed in Table 3.1) report no association between OCI and SCI (e.g. Cull, 
Hay, Love, Mackie, Smets, & Stewart, 1996; Klepstad, Hilton, Moen, Fougner, 
Borchgrevink, & Kaasa, 2002).  In Bray and colleagues (2018) systematic review, they 
found that 31 studies showed a lack of association between self-reported cognitive 
symptoms and NP results.  They described how a total of 14 included studies reported a 
significant association between OCI and SCI (correlation coefficients from 0.22 to 0.57)  
but found that the association was often restricted to a limited number of cognitive 
domains tested in the NP assessment (Bray et al, 2018).   
Patients frequently report that their own perception of the level of cognitive 
impairment is greater than that detected by NP assessments (van Dam et al, 1998; 
Schagen et al, 1999; Ahles et al, 2002; Castellon et al, 2004; Donovan et al, 2005; Cull et 
al, 1996; Servaes et al, 2002; Poppelreuter et al, 2004). 
SCI is often associated with anxiety and/or depression and/or fatigue (van Dam et al, 
1998; Ahles et al, 2002; Jenkins et al, 2006; Cimprich et al, 1999;Cimprich et al, 2005) 
rather than OCI. Bray and colleagues (2018) reported that 43 out of 44 studies found a 
moderate to strong association between self-reported cognitive function and other 
patient-reported outcomes. The main associations were between self-reported 




4.9 Impact of CRCI on QoL 
Patients’ perceptions of impairment are important due to the potential impact these 
may have on QoL (Hutchinson et al, 2012). Deficits in perceived concentration and 
memory can have a detrimental effect on an individual’s daily living, social and work 
related activities (Fitch, Armstrong, & Tsang, 2008). In 2009, Boykoff and colleagues 
interviewed 74 breast cancer patients who had completed treatment at least 12 months 
prior to the interviews, in order to explore the psychosocial ramifications of CRCI. Study 
results included descriptions of the general psychosocial influence of perceived 
cognitive changes, effect on interactions with healthcare providers, and consequences 
for social networks and work performance. It highlighted the fact that patients report 
diminished QoL and daily functioning as a consequence of CRCI. This corroborated 
Shilling and colleagues (2005) findings that described how perceived cognitive 
impairment during chemotherapy can have a ‘knock-on’ effect on patients’ QoL and may 
reduce their ability to make a smooth transition from treatment back to activities of 
normal everyday life such as returning to work (Mitchell & Turton, 2011). Less is known 
however about the relationship between OCI and HRQoL which is more closely 
examined in the following Chapter. 
4.10 Summary 
The presence, extent and course of any cognitive impairment (objective or subjective) 
and whether it causes observable difficulties for patients with solid tumours remain 
unclear. 
To date, most research examining CRCI has focused on only one type of cancer (Wefel et 
al, 2011) with varying results. Studies have mostly been concerned with female breast 
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cancer, making the results less generalizable to people with other types of cancer (de 
Ruiter et al, 2011; Skaali, Fosså, & Dahl, 2011). Research in only the female breast 
cancer population has also prevented an examination of possible gender differences. 
Few studies have been conducted in any other cancer populations, such as testicular 
cancer (Schagen et al, 2008), ovarian cancer (Correa & Hess, 2012), and prostate cancer 
(Nelson et al, 2008). Therefore, more longitudinal research is required in additional 
solid tumour cancer populations to fully understand the extent and course of OCI 
and/or SCI in these populations. Such studies will help to determine whether CRCI is a 
universal phenomenon or is more pronounced in the female breast cancer population. 
Furthermore, studies in other cancer populations will improve understanding of 
whether the different treatments (e.g. multi- and single-agent chemotherapies) for 
different cancers work by different mechanisms, which lead to OCI and/or SCI. It would 
be extremely helpful if research in this area could clarify which specific treatments 
might be expected to be detrimental and how long any specific side effects might last 
(Anderson-Hanley et al, 2003). Not only would this knowledge enable researchers to 
identify risk factors including disease-specific factors, demographic factors, 
psychological factors, and genetic factors (Janelsins et al, 2014), but it would also allow 
patients to make informed treatment choices and prepare for any potential impact on 
work and relationships (Anderson-Hanley et al, 2003). 
Moreover, the exact mechanism(s) involved in chemotherapy-related OCI and/or SCI 
are currently unclear. These inconsistent results are likely due to methodological issues 
(e.g., relatively small sample sizes, cross sectional designs, use of different NP tests, 
different reference data and performance cut offs for classifying cognitive impairment 
(Shilling, Jenkins, & Trapala, 2006)) and differences in study populations (stage and 
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severity of cancer, different chemotherapy treatment regimens (dosage and drugs) as 
well as additional varying adjunctive treatments).  
This discursive review has also highlighted the need for additional more focused 
systematic reviews of the literature, which will identify studies examining whether 
there is a relationship between HRQoL and objectively measured cognitive changes 





Chapter 5: Health-related quality of life and its association 
with objective cognitive changes in cancer patients who have 
solid tumours.   
 
5.1 Introduction 
The end of Chapter 4 highlighted the need to identify studies that specifically explore 
the relationship between HRQoL, and OCI in order to establish a broader picture of the 
consequences of CRCI. This chapter provides such an examination of the literature. It 
synthesises and reviews the primary research studies that have aimed to measure the 
relationship between OCI in patients with solid tumours who are undergoing or have 
had chemotherapy treatment and their HRQoL outcomes. 
5.2 Background 
As mentioned in Chapter 1, the effectiveness of chemotherapy drugs in treating a range 
of cancers has improved significantly in recent decades. Whether used alone, or in 
combination with other treatments or therapies, the result has been a marked reduction 
in disease recurrence and an increase in survival times. Not only has improved 
treatment contributed to improved survival but screening, and early detection of 
disease have also improved outcomes (See Chapter 1) (Fardell, Vardy, Shah, & Johnston, 
2011). Despite these strides forward, no pharmaceutical treatments are devoid of side 
effects. Chemotherapy drugs are no exception with a decline in cognitive function being 
one of the commonly reported side effects and the focus of this thesis. The evidence and 
estimates of the numbers of patients affected by self-reported and objective assessment 





previous chapters the “cancer and cognition” research has numerous methodological 
difficulties.  
5.3 HRQoL 
As discussed in Chapter 4, HRQoL is a multi-dimensional construct specifically related 
to health and illness (Kirshner & Guyatt, 1988; Cella et al, 1993). HRQoL encompasses 
the subjective perceptions of the positive and negative aspects of cancer patients’ 
symptoms, including physical, emotional, social, and cognitive functions as well as 
disease symptoms and side effects of treatment (Bottomley, 2002; Leplege & Hunt, 
1997).  
With the increase in survival times HRQoL has become a meaningful outcome measure 
for patients diagnosed with cancer (Arndt, Merx, Stegmaier, Ziegler, & Brenner, 2004). 
An understanding of a possible link between objective and/or subjective CRCI and the 
impact on various domains of HRQoL is necessary to fully understand the potential 
consequences of cancer and adjuvant chemotherapy treatment. Such knowledge may be 
a helpful catalyst in the development of more appropriate interventions designed to 
improve the process of coping and adjustment of these patients (Ahles, Saykin, 
Furstenberg, et al, 2005).  
A review of the literature to date revealed that HRQoL is often assessed at the same time 
as OCI in a large proportion of “cancer and cognition” studies (i.e. approx. 50% of the 
studies listed in Chapter 3, Table 3.1). The two most commonly used tools to assess 
HRQoL in the “cancer and cognition” literature are the European Organization for 
Research and Treatment of Cancer Quality of Life questionnaire (EROTC – QLQ C30) 





more of the questionnaires from the Functional Assessment of Cancer Treatment 
(FACT) battery (Functional Assessment of Chronic Illness Therapy, 2007) (Wagner, 
Sweet, Butt, Lai & Cella 2009). Both the EORTC – QLQ C30 and FACT-G are generic core 
HRQoL questionnaires supplemented by a range of tumour-, treatment- or symptom-
specific ‘modules’ as required (e.g. the FACT-B for breast cancer; FACT-C for colorectal 
cancer (CRC)).  
The EORTC – QLQ C30 is a 30 item self-report questionnaire designed to assess the 
HRQoL of patients with cancer participating in international clinical trials. It is 
composed of multi-item scales and single-item measures. These include five functional 
scales, three symptom scales, a global health status/QoL scale, and six single items.  
Whereas the FACT-G (now in Version 4) is a 27-item compilation of general questions 
divided into four primary QOL domains: Physical Well-Being, Social/Family Well-Being, 
Emotional Well-Being, and Functional Well-Being.  A comparison of the EORTC QLQ-C30 
and FACT-G characteristics is presented in Table 5.1.  
Table 5.1. A comparison of QLQ-C30 and FACT-G characteristics (Luckett et al, 
2011). 
 EORTC QLQ-C30 FACT-G 
Number of items  30  27 
Response options  Likert scales (4 or 7 options) Likert scale (5 options) 
Recall period  Past week  Past 7 days 
Item format  Questions  Statements 
Item organisation  Items are not always 
grouped into scales and 
never explicitly so 
Item are grouped into scales  
Scaling Five ‘functioning’ scales, 
measuring:  






 EORTC QLQ-C30 FACT-G 
 Physical functioning (PF; 
5 items) 
 Role functioning (RF; 2 
items) 
 Emotional functioning 
(EF; 4 items) 
 Social functioning (SF; 2 
items) 
 Cognitive functioning 
(CF; 2 items) 
 Physical well-being 
(PWB; 7 items) 
 Social/family well-being 
(SWB; 7 items) 
 Emotional well-being 
(EWB; 6 items) 
 Functional well-being 
(FWB; 7 items, including 
global QoL item) 
One three-item symptom 
scale measuring fatigue. 
Overall FACT-G score (total of 
all 27 items) 
Two two-item symptom 
scales measuring pain, 
nausea, and vomiting. 
 
Six single-item symptom 
scales measuring dyspnoea, 
insomnia, appetite loss, 
constipation, diarrhoea and 
financial impact. 
 
Overall global health 
status/QoL scale (2 items) 
 
Time to administer  11 min  5 to 10 minutes 
Administration Self, interviewer, computer Self, interviewer, computer 
 
As can be seen in Table 5.1, both instruments have subscales measuring key aspects of 
HRQoL (i.e. physical, emotional, social and functional), however the EROTC –QLQ C30 
also provides brief scales for cognitive functioning, financial impact and a range of 
symptoms that are either not assessed by the FACT G or are embedded within its 
wellbeing scale (Blazeby, 2OO5; Luckett, 2011). This difference is further highlighted by 
the fact that EROTC-QLQ C30 provides 5 “functioning” scales and 10 symptom scores 
compared to FACT-G, which only gives five summary scales (4 “well‐being” and 1 overall 





domains. Conroy and colleagues (2000) found that EROTC QLQ–C30’s social functioning 
scale assesses the impact on social activities and family life whereas the FACT–G social 
well-being subscale focuses on social support and relationships. Whilst both scales are 
widely used, they each measure markedly different aspects of HRQoL so very often a 
direct comparison of results between studies examining HRQoL is not possible given 
that they use different scales (Kemmler et al, 1999).  
5.4 OCI and HRQoL   
Prior to undertaking this systematic review, the Cochrane Library was searched for 
reviews on the subject matter. This revealed four meta-analyses all of which reviewed 
studies that examined cognitive impairment arising from chemotherapy treatment (Jim, 
2012; Lindner, 2014; Jansen, 2007; Jansen, 2005). There was also one systematic review 
that looked at the effectiveness of psychosocial interventions for cognitive dysfunction 
in cancer patients who received chemotherapy (Hines, 2014) and one critique of the 
literature on CRCI in women with breast cancer (Jansen, 2005).  Taken together, the 
reviews support the hypothesis that there is a risk of chemotherapy having a small to 
moderate negative impact on some cognitive domains (Jansen, 2005; Jim, 2012) in a 
proportion of cancer patients. However, as demonstrated in Chapter 3, given the 
considerable differences between studies (in terms of participants, disease severity, 
outcome measures and design) it is not possible to determine from the reviews how 
long the deficits last or who is at greatest risk. All reviews suggest that if the 
heterogeneity between future studies can be reduced, valuable information may be 
gained which could effectively inform suitable interventions for decreasing the effects of 






The primary aim of this systematic review was to identify and synthesise research 
concerned with the relationship between objectively measured cognitive impairment and 
HRQoL in adult patients who received chemotherapy for treatment of solid tumours. It 
also aimed to establish whether particular OCIs are associated with specific aspects of 
HRQoL.  
5.4.2 Methods 
5.4.2.1 Inclusion and exclusion criteria 
The search was limited to papers published in English post‐1980, as this period 
coincides with a prevalence of reporting and systematic investigation of CRCI (van Dam 
et al, 1998). 
Articles were restricted to those that had recruited patients aged 18+ years with a solid 
tumour such as breast, ovarian, CRC, prostate, and lung treated with chemotherapy. 
Studies of patients with brain tumours and central nervous system tumours were 
excluded because of the inherent effects of the tumour on cognition, as well as the fact that 
treatments often involve brain irradiation and surgical interventions that are known to 
cause additional direct effects on brain tissue secondary to the lesions (Roman & 
Sperduto, 1995; Weitzner & Meyers, 1997) and consequent changes in 
neuropsychological functioning (Anderson‐Hanley et al, 2003). 
Included studies were required to be full papers that assessed both objective cognition 
and HRQoL using standardised measures. In addition, to be included, studies needed to 





objectively measured cognitive deficits (global cognitive deficits and/or domain specific 
ones) and (global or domain specific) measures of HRQoL. Reviews, commentaries, case 
reports, dissertations, and conference abstracts were all excluded. 
5.4.2.2 Search Strategy 
On 6th June 2016 the following electronic databases were searched:  
 Web of Science Direct  
 Pubmed  
 Medline, Embase, PsycINFO and PsycARTICLES through OVIDSP  
 CINAHL through EBSCO  
using a combination of search terms that included all known terms for cancer, such as 
neoplasms and oncology. Treatment terms included chemotherapy and “systemic 
treatment”; the HRQoL and cognition terms included are fully set out in Figure 5.1. The 
researcher agreed the search terms with a specialist librarian and the supervisory team. 
The following search strategy was used to obtain the initial list of articles: 
Figure 5.1: Search terms used to find suitable studies for the systematic review 
 
Cancer terms Impairment terms Treatment terms Outcome 
Cancer Cognition Chemotherapy Quality of life (QoL) 
Oncology Cognitive 
impairment 
Systemic treatment Well being 





Cancer terms Impairment terms Treatment terms Outcome 
 Cognitive function   
 Cognitive decline   
 Cognitive failure   
 Chemobrain   
 Chemofog   
 Memory   
 Executive function   
 Processing speed   
 
The Boolean phrase ‘OR’ was placed between the terms listed vertically and the Boolean 
phrase ‘AND’ placed between those terms listed horizontally in the table. A combination 
of both text words and indexed terms (such as MeSH) were applied in each database. 
Search terms were modified as necessary for each electronic database searched. The 
reference lists of all included articles were also searched for additional studies. 
Articles published between 7 June 2016 and 1 July 2018, were also identified and the 
findings from these studies are summarised in Section 5.6.  
5.4.2.3 Study selection 
Once searches had been conducted and duplicates removed, retrieved articles were 





screened. The researcher assessed the abstracts using the eligibility criteria. A member 
of the supervisory team also independently screened 10% of all titles and abstracts 
retrieved using the search strategy to identify studies that potentially met the inclusion 
criteria. A list of the independently screened studies were crosschecked by the 
researcher for any areas of disagreement, of which there were none. All remaining 
articles were retrieved in full and screened for eligibility by the researcher, who then 
selected the relevant articles and crosschecked the relevance of these articles with the 





Figure 5.2: Flow chart of study selection  
 
 

















5.4.2.4 Data Extraction  
A data extraction form for this systematic review was developed by the researcher 
(Appendix D) and used to record general study details such as: 
• Authors, year of publication and country  
• Study design  
• Research question 
• Disease characteristics – type of cancer and severity  
• Treatment regime – surgery, chemotherapy, radiotherapy, combination 
treatments 
• Participant characteristics  
• Inclusion/exclusion criteria 
• Objective cognitive, HRQoL and other measures used – detail regarding 
characteristics of measures used, the time at which they were all 
administered 
• Results – analysis used, number of participants withdrawn, results of analysis 
• Limitations and/or anything else of note  
The data extraction form was piloted against five papers and was refined thereafter. 
The researcher and supervisory team agreed on the final form.  
5.4.2.5 Quality Assessment 
As  there  is  currently  no  agreed “gold standard” appraisal  tool  for observational studies, a 
quality‐scoring tool was developed on the basis of methodological quality assessment 
checklists from the NICE Methods for the development of NICE public health guidance 





the NICE checklists and adapted for the purposes of this review in order to ensure that 
the 5 recommended aspects of internal validity (i.e., a clearly focused question, selection 
of subjects, assessments, confounders, and statistical analysis), together with an overall 
assessment of the study, were addressed in the evaluation of quality. A total of 16 items 
were included that covered all aspects considered necessary to evaluate the quality of 
the evidence in relation to the research question: Is there a relationship between 
objectively measured cognitive changes in patients with solid tumours undergoing 
chemotherapy treatment and their health‐related quality of life outcomes? (Appendix E).  
Authors of original papers were emailed to obtain any missing data or details so that the 
quality of the study could be evaluated, rather than relying on the published paper. 
The overall assessment for each paper was calculated by considering all 16 items and 
then attributing scores between zero and four to the overall assessment of the study, 
considering the extent to which each study was internally and externally valid.  The higher 
the score, the less bias in the study and the more external validity. Two studies had the 
highest overall rating score of 4 (Vearncombe et al, 2009; Vardy et al, 2015), five 
studies scored 3 (Tchen/Mar Fan et al, 2005; van Dam et al, 1998; Reid-Arndt et al, 
2010; Jenkins et al, 2006; Schagen et al, 1999), nine scored 2 (Cruzado et al, 2014; 
Hess et al, 2015; Wefel et al, 2004; Reid-Arndt et al, 2009; Wefel et al, 2010; Hurria 
et al, 2006; Freeman et al, 2002; ;Mehnert et al, 2007; Whitney et al, 2007) and one 
was rated 0 (Iconomou et al, 2004).  Each included study was assessed by the 
researcher. Another member of the supervisory team then independently coded the 
quality of the studies to check the reliability of the quality assessment. Agreement 





used. Although the methodological quality of each study was evaluated and discussed, 
studies were not eliminated from this review because of poor quality. 
5.4.3 Results 
 
5.4.3.1 Identified studies 
Database searches identified 2769 citations, and 36 additional citations were retrieved 
from reference lists. Screening of titles and abstracts identified 365 potentially eligible 
articles (Figure 5.2). 
The full texts of 59 papers were reviewed, 20 satisfied the inclusion criteria. An 
examination of the reference lists did not identify any additional papers that met the 
inclusion criteria. Several papers were linked and consequently treated as a single 
study (works of Tchen et al 2003 and Fan et al 2005 were linked;  Shilling et al 2005 and 
Jenkins et al, 2006 were linked; and Vardy et al 2014 & 2015 were linked). This resulted 












Time of assessments 
and questionnaires 
Operational Definition of Cognitive 
Impairment (CI) 













T1: pre-CT (n=81)  
 
T2: pre last-CT (n=73)  
 
T3: 6 months post last CT 
(n=54) 
Raw scores converted into z scores 
(mean=0, SD=1) using published normative 
data adjusted for age, education, and 
gender. 
 
CI:   
(1) z scores of ≤−1.5 for more than one 
test; OR  












Breast 2 groups 
 
G1: after 4 cycles CT 
(n=8) 
 
G2: 6 to 12 months after 
CT (n=9) 
ANOVA to determine whether the 2 groups 










1 item re overall 
cognitive function  
 












T1: pre-CT (n=231) 
 
T2: prior to 4th cycle CT 
(n=218)   
 
T3: 3 weeks post CT 
(n=208)  
Impaired cognitive domain for each patient 
= the increased cognitive domain score 
from baseline for processing speed or 
motor reaction; and a decreased score for 
attention domain ≥1.5 standard error of 
measurement. 













Time of assessments 
and questionnaires 
Operational Definition of Cognitive 
Impairment (CI) 





T4: 6 months post CT 
(n=169) 
A cognitive index score (CIS) for each 
patient = total number of impaired 
cognitive domains at a time point.  
CIS ≥ 2 during CT = possible or probable 
acute CI. 









T1: pre CT (n=28) 
 
T2: 6 months post CT 
(n=28) 
Raw scores for each test converted into 
standardized scores using published 
normative data.  
 
CI: 



























T1: pre CT (n=102) 
 
T2: end of CT (n=80) 












G1: high-dose CT (n=24) 
 
G2: standard-dose CT 
(n=23) 
 
G3: early stage cancer no 
CT (n= 29) 
CI = z < -1.4 SD below the mean of zero in 1 
test parameter. 
 
Global CI score = four or more test 














Time of assessments 
and questionnaires 
Operational Definition of Cognitive 
Impairment (CI) 







Cross sectional  Breast  
 
 
1 month post CT (n=46) Raw test scores converted to z-scores 
utilizing age, education, and gender-based 
normative data.  
 
An average of each person’s z-scores for 
tests comprising each domain was 
computed 
 
Decline in cognition = (domain composite z 

















Longitudinal  Breast  
 
 
T1:1 month post CT 
(n=46) 
 
T2: 6 months post CT 
(n=39) 
 
T3: 1 year post CT (n=33) 
Individual test scores converted to z-scores 
utilizing age, education, and gender based 
normative data. 
 
Subtle CI = > 1 SD below the normative 
data mean,  
















G1: approx. 1.9 years 
post adjuvant CT (n= 39) 
 
G2: no CT but matched 
for age & time since 
treatment (n=34)  
CI = 2 ≥ SDs below the mean of the control 
group  
 
Overall impairment score (OSCI) for each 
individual patient = total number of tests 
















Time of assessments 
and questionnaires 
Operational Definition of Cognitive 
Impairment (CI) 







Longitudinal  Breast  
 
3 groups at each time 
points: 
 
G1: CT (n= 85) 
G2: Non CT (n= 43) 
G3: Healthy controls 
(n=49)  
 
T1: G1 assessed 21-83 
days post-surgery; G2 
assessed 22 -92 days 
post-surgery 
 
T2: 4 weeks post CT or 6 
months  
 
T3: 12 months post CT or 
18 months 
Group comparisons on cognitive test scores 
were made at T1 & T2 using one way and 
repeated measures ANOVA, Chi-squared or 
Mann-Whitney U tests as appropriate.  
 
A reliable change index (RCI) (Jacobson & 
Truax method) was calculated for each 
cognitive measure using the baseline and 








info & orientation 












Longitudinal  Breast 
 
T1: After 3 cycles of CT 
G1: resectable breast 
cancer patients (n=104) 
G2: healthy women 
(n=102) 
 
T2: 1 year after T1 
G1: resectable breast 
cancer patients (n=91) 
G2: healthy women 
(n=81) 
 
T3: 2 years after T1  
G1: resectable breast 
cancer patients (n=83) 
Overall classification of cognitive 
functioning was evaluated by the HSCS 
using an interpretive algorithm.  
 
 


















Time of assessments 
and questionnaires 
Operational Definition of Cognitive 
Impairment (CI) 




G2: healthy women 
(n=81) 









3 groups assessed 
approx. 2 years after last 
non-hormonal therapy: 
 
G1: high dose CT (n=34) 
G2: standard dose CT 
(n=36) 
G3: No CT (n=34) 
Test scores were converted into 
standardised z scores by use of the mean 
test score of the control group.  
 
A mean overall composite z score was 
computed.  
 
CI = 2 SDs below the mean of the control 
group on a test.  
 
Overall CI score was calculated for each 
individual patient by counting all tests on 
which the patient was impaired. 
 
DART 








Longitudinal  CRC  
 
T1: Pre CT 
G1: CT (n=173) 
G2: no CT (n = 116) 
G3: metastatic (n = 73) 
G4: HC (n= 72) 
 
T2: 6 months  
G1: CT (n=137) 
G2: No CT (n=90) 
G3: metastatic (n = 52) 
G4: HC (n=72) 
 
T3: 6 months  
Raw scores  
converted to demographically corrected T 
or Z scores (based on age, education, 
and sex), and a deficit score ranging from 0 
(no impairment, T score > 
39) to 5 (severe impairment, T score < 20) 
was derived. Deficit scores were averaged 
to determine Global Deficit Scores (GDS) to 
reflect overall cognitive performance. 
 
CI:   




















Time of assessments 
and questionnaires 
Operational Definition of Cognitive 
Impairment (CI) 




G1: CT (n=118) 
G2: no CT (n = 87) 
G3: metastatic (n = 41) 
G4: HC (n=70) 
 
T4: 6 months  
G1: CT (n=99) 
G2: no CT (n=72) 
 
2) 2 ≥ SDs below healthy controls on > 1 
cognitive test or  
≥1.5 SDs below healthy controls on ≥ 2 
tests. 
 







Longitudinal  Breast  
 
  
T1: After surgery pre CT 
G1: CT (n=138) 
G2: no CT (n = 21) 
 
T2: 4 weeks post CT 
G1: CT (n = 138) 
G2: no CT (n=21) 
Impairment on specific cognitive tests = 
significant decline identified using the 
Reliable Change Index (corrected for 
practice, RCIp).  
 
Impairment in each cognitive outcome 
measure was a decline of > 1.96 SD.  
 
“Multiple Test Decline” = significant decline 
on ≥ 2 cognitive tests. 
 














Time of assessments 
and questionnaires 
Operational Definition of Cognitive 
Impairment (CI) 













T1: pre CT (n=18) 
 
T2: 6 months post CT 
(n=18) 
 
T3: 1 year post CT (n=15) 
 
 
Raw scores were converted into z scores 
(mean=0, SD=1) using published normative 




(1) z scores ≤ −1.5 for more than one test 
OR  
(2) z scores ≤ −2.0 for just one test.  
 
The reliable change index 
(RCI) was used to determine the frequency 
of change in cognitive function from one 












T1: pre CT (n=42) 
 
T2: 2.9 months after 
T1(n=37) 
 
T3: 7 months after T1 
(n=33) 
 
T4: 13.1 months after T1 
(n=28) 











Time of assessments 
and questionnaires 
Operational Definition of Cognitive 
Impairment (CI) 







Longitudinal  Non-small cell 
lung cancer Stage 
3A or 3B.  
 
 
T1: pre CT 
 
T2: 1 month post CT 
 
T3: 7 months post CT 
(n=9) 
Raw scores converted into z scores 
(mean=0, SD=1) using published normative 




(1) z scores ≤ −1.5 for more than one test 
OR  
(2) z scores ≤ −2.0 for just one test.  
 
RCI was used to determine the frequency of 
change in cognitive function from one 











Key: CI: Cognitive impairment; CRC: Colorectal Cancer; CT: chemotherapy; S.D: standard deviation; ANOVA: Analysis of variance. 
BF13: Item 3 of Brief Fatigue Inventory; HADS: Hospital and Depression Scale; CES-D: Centre for Epidemiological Studies Depression Inventory; FACT – ntx: neuropathy scale;  PAF: patients perceptions 
of cognition; ADLs: activities of daily living; IADLs instrumental activities of daily living; KPS: Karnofsky performance status; Comorbid medical conditions: Charlson Comorbidity Index; GDS: Geriatric 
Depression Scale; FEDA: self-perceived cognitive deficits; MFI-20: Multidimensional fatigue inventory; WRAT-3: The wide range achievement test-3; POMS-SF: Profile of Mood States –Short Form; CIQ: 
Community Integration Questionnaire; BDI-II: Becks Depression Inventory-Second Edition; HSCL-25: The Hopkins symptom checklist – 25; DART: Dutch Adult Reading Test;  GHQ12: General Health 
Questionnaire 12; NART-2: National Adult Reading Test version 2; FACT F: Functional Assessment of Chronic Illness Therapy - Fatigue subscale; MMPI: Minnesota Multiphasic Personality Inventory; 
STAI: State Trait Anxiety Inventory; Premorbid VIQ: American version of the Nelson Adult Reading Test; PHQ: Patient Health Questionnaire. 
** The overall rating scores ranged from 0 (low) to 4 (high) and were obtained by adding together the scores for each of internal validity and external validity. The higher the score the less bias there is 
in the study and the more external validity. Each of internal validity and external validity had a possible score of 0, 1 or 2 (0 – no criteria fulfilled; 1 some of the criteria had been fulfilled; 2 all or most of 






5.4.3.2 Designs used in the included studies 
As can be seen in Tables 5.2 and 5.3 the included studies used a wide range of designs. 
This variation may also have contributed to the divergent set of results seen in the 17 
studies particularly if they were examining any potential relationships at different 
points in time and in different patient groups.  
Eleven studies (65%) (Hurria, 2006; Mehnert, 2007; Reid-Arndt 2009; Reid-Arndt 
2010; Shilling 2005; Jenkins, 2006; Tchen/Mar Fan 2005; Vearncombe, 2009; Wefel 
2004; Wefel 2010) were exclusively women with breast cancer; one was a mixed solid 
tumour patient group (Iconomou, 2004), two examined CRC patients (Cruzado, 2014) 
and one examined lung cancer patients (Whitney, 2008). In addition to variations in 
study samples, there were many differences in the designs and measurement points 
across the studies (Figure 5.3) that make it difficult to draw overall conclusions from 
this body of work. Twelve studies (Cruzado et al, 2014; Hurria et al 2006; Iconomou et 
al, 2004; Reid-Arndt et al , 2010; Shilling et al, 2005; Jenkins et al, 2006; Mar Fan et al, 
2005; Vearncombe et al, 2009; Wefel et al 2004; Wefel et al 2010; Whitney et al, 2008) 
were longitudinal, with ten (59%) having baseline assessments before chemotherapy 
treatment.  Four of the longitudinal studies with pre-treatment assessments (Cruzado et 
al, 2014; Hess et al, 2015; Vardy et al, 2015; Wefel et al, 2010) also examined cognition 
during chemotherapy treatment. Follow-up periods varied across the studies, ranging 
from end of treatment (Iconomou et al, 2004) to 2 years post treatment (Mar Fan, 
2005). One longitudinal study assessed cognition at three time points but not until after 






Figure 5.3. Pictorial representation of measurement time points in the studies 
included in the systematic review 
 
 
Eight studies (Freeman et al, 2002; Jenkins et al, 2006; Mar Fan et al 2005; Mehnert et 
al, 2007; Schagen et al, 1999; van Dam, 1998; Vardy et al, 2015; Vearncombe et al, 2009) 
included more than one group. Three compared groups with different types of 
treatment or stages of disease (e.g. standard dose chemotherapy compared to high dose 
(Mehnert et al, 2007; van Dam et al, 1998; Vearncombe et al, 2009). Two studies 
(Mehnert et al, 2007; Vardy et al, 2015) compared the different chemotherapy groups to 





chemotherapy patients to healthy controls (Shilling et al, 2005/Jenkins et al, 2006; 
Tchen et al, 2003/Mar Fan et al 2005; Vardy et al, 2015). The healthy control groups 
were peer nominated (i.e. friends and family of the patient participants’). The healthy 
controls were a useful comparator as they were matched for age and socioeconomic 
status, in all three studies. However, it is important to note that the cognitive evaluation 
in the patient group may be confounded by the stress associated with a cancer diagnosis 
and consequent surgery (Vardy et al, 2007). This raises the questions as to whether a 
healthy control group is the ideal comparator in this context. In an approach that 
attempted to cover this issue well Jenkins et al (2006) included both a non-
chemotherapy group (who had had surgery and had started endocrine therapy) as well 
as healthy controls (made up of friends and family of the patient participants, who may 
have also been stressed by the fact that a family member had received a cancer 
diagnosis for which they were being treated), which is considered to be ideal (Wefel et 
al, 2011).  
Eight studies recruited participants from one hospital site (Cruzado et al, 2014; 
Freeman et al, 2002; Hurria et al, 2006; Iconomou, 2004; Schagen et al, 1999; van Dam 
et al, 1998; Wefel et al 2004; Wefel et al 2010). The remaining nine studies recruited 
from two or more sites making these results potentially more generalisable. In one case, 
however, (Whitney et al, 2008) which was a multi-site study had a small sample size of 
14. This could be because it was a lung cancer sample, with quite an advanced disease 
stage.  Of the eight single site studies, four had sample sizes of fewer than 50 
participants despite long recruitment periods. For example, Hurria et al, (2006) only 
recruited 28 breast cancer participants over 2 years and Freeman et al (2002) was a 





(2014) and Iconomou et al (2004)) recruited in excess of 80 participants each (81 and 
102 respectively), but  both had high attrition rates (33% and 21% respectively) and 
neither was sufficiently powered. Overall, 59% of studies (Cruzado et al, van Dam et al, 
1998; Reid-Arndt et al 2009; Reid-Arndt et al, 2010; Wefel et al, 2010; Freeman et al, 
2002; Mehnert et al, 2007; 48, Iconomou et al 2004; Vearncombe et al, 2009) were 
underpowered and/or did not provide sample size justifications. 
5.4.3.3 Defining OCI 
The calculation and operational definition of what constitutes cognitive impairment 
varied widely across studies (see Table 5.1). More than half of the studies (n = 10) 
converted the raw neuropsychological scores into standardised z‐scores (mean = 0, SD 
= 1) using published normative data adjusted for age, education, and gender. However, 
the number of tests and the extent to which these z‐scores had to deviate to constitute 
cognitive impairment varied across the studies. Definitions of cognitive impairment 
included z‐scores of ≤ −1.4, −1.5, and −2 standard deviations (s.d) below the mean in 
between one and four tests. For example, Hurria et al (2006) classified participants as 
having cognitive impairment if they scored 2 or more s.d’s below published norms on 
two or more discrete tests, whereas Reid-Arndt and colleagues (2010) classified 
participants as having ‘subtle’ cognitive impairment if they scored 1 s.d below 
normative data mean, while more ‘severe’ impairment was defined as 1.5 - 2 plus s.d’s 
below the mean. (See Table 5.2 for the full list of operational definitions used.) The 
extent of OCI has been shown to be dependent on the method of analysis (Shilling et al, 
2006). As a consequence of the differences across the included studies, it is not possible 
to provide a simple estimate of the prevalence of OCI in patients treated with adjuvant 





methodological differences, all but two of the included studies in this review (Freeman 
et al, 2002; Iconomou et al, 2004) reported statistically significant OCI in some patients 
undergoing adjuvant chemotherapy treatment. 
5.4.3.4 Affected cognitive domains and assessment of OCI in the included 
studies  
The cognitive domains most affected varied widely across the studies included in this 
review. Four studies (Cruzado et al, 2014; Shilling et al, 2005 and Vearncombe et al, 
2007; Vardy et al, 2015) reported verbal memory as being most affected and 6 studies 
(Wefel et al, 2004; Vardy et al, 2015; Reid-Arndt et al 2009; Reid-Arndt et al, 2010; 
Wefel et al, 2010; Schagen et al, 1999) found that the most common domains showing 
decline were processing speed and executive function. Two studies (Freeman et al, 
2002; Iconomou et al, 2004) reported that objective cognitive performance remained 
constant throughout treatment.  
It is not surprising that cognitive decline was found across so many different domains in 
the included studies. As shown in Table 5.3, multiple tools were used, and many 
different cognitive domains as reported by the authors were measured. Not only did the 
studies assess different areas of cognition but they also used different tests to assess the 
same domains. Overall, there were more than 54 different measures used across 17 
studies to tap a variety of cognitive domains. Most of the studies (n=15) used a battery 
of neuropsychological tests assessing a range of domains. The different psychometric 
qualities of each of the measures may have influenced the conclusions drawn regarding 
the cognitive domains most affected by chemotherapy treatment. For example, no 





Mental State Examination (MMSE), which has been criticised for not being sensitive 
enough to detect subtle cognitive changes (Rugo & Ahles, 2003; Brown et al, 2003).  
This problem of diversity of assessments used has been recognised by the ICCTF as an 
issue that needs consideration in future research (Wefel et al, 2011). In an attempt to 
bring some homogeneity to all studies, the ICCTF recommended that in future trials 3 
core neuropsychological assessments (the Hopkins Verbal Learning Test–Revised, Trail 
Making Test, and the Controlled Oral Word Association of the Multilingual Aphasia 
Examination)(Benedict, 1998; Reitan, 1992; Benton & Hamsher, 1989; Mitrushina et al, 
2005; Strauss, Sherman & Spreen, 2006) be used to measure learning and memory, 
processing speed, and executive function, supplemented with additional tests of 
working memory capacity, on the basis of the researchers own preferences (Wefel et al, 
2011).  This was justified by the assertion that research has shown that the domains 
assessed by these tests are most affected by chemotherapy treatment (Wefel et al, 
2011). However, no study included in this review that was undertaken post‐ ICCTF's 
recommendations used the entire core battery to assess neuropsychological 
impairment although three earlier studies did (Freeman et al, 2002; Hurria et al, 2006; 
Wefel et al, 2010). 
5.4.3.5 Assessing HRQoL 
As mentioned in Section 5.2, HRQoL was assessed at the same time as cognition in all 
studies included in this review. As with the neuropsychological assessments, some 
studies analysed only global HRQoL scores (Mar Fan et al, 2005; Hess et al, 2015; Wefel 
et al, 2010; Iconomou et al, 2004) whereas others extended the analysis to the subscales 





Reid-Arndt et al, 2010; Whitney et al, 2007; Schagen et al, 1999; Vearncombe et al, 
2009). As can be seen in Table 5.3, five studies assessed HRQoL using the EORTC–QLQ 
C30; the remaining studies used one or more of the questionnaires from the FACT 
battery. Therefore, as with the cognitive domains measured, a direct comparison of 
results between studies using different scales is not possible (Kemmler et al, 1999).  
5.4.3.6 The relationship between OCI and HRQoL 
Only three (Mehnert et al, 2007; Vearncombe et al, 2009; Reid-Arndt et al, 2010) out of 
the 17 included studies found a significant relationship between OCI and HRQoL. Whilst 
all three studies examined the inter-relationships between various domains of HRQoL 
and specific impaired cognitive domains, Mehnert (2007) and Reid-Arndt (2010) 
specifically examined the presence of post treatment cognitive deficits whereas 
Vearncombe (2009) examined deficits over the course of treatment. 
The significant relationships were different in all three studies. For example, Mehnert et 
al, 2007 found that objective measures of verbal memory were associated with poorer 
HRQoL (as measured by EROTC QLQ C30) five years after treatment. Reid-Arndt et al, 
(2010) reported that poorer functional wellbeing (as measured by FACT B) was 
significantly associated with verbal fluency at twelve months post chemotherapy 
treatment (even though only a very small proportion of study participants 
demonstrated any OCI). The third study, Vearncombe et al, (2009) found that lower 
functional wellbeing pre-chemotherapy treatment as measured by FACT B significantly 
contributed to changes over the course of treatment in the cognitive domains of 
attention and executive function rather than declines in well‐being affecting cognitive 





domains of each of HRQoL and cognition, these three studies were arguably able to 
identify the more subtle effects of any relationships although none of them was without 
their limitations as detailed in Section 5.3.6 below. 
Mehnert and colleagues (2007) examined cognitive functioning in three different 
treatment groups (high dose chemotherapy; standard dose chemotherapy and non-
chemotherapy group) approximately five years after chemotherapy treatment (see 
Table 5.3). They reported a range of significant relationships between cognition and 
HRQoL across all of the groups, more specifically:  
i) in the standard dose group: impairment in working memory was significantly 
correlated with lower levels in physical functioning (PF) and emotional 
functioning (EF) group as measured by the EROTC-QLQ C30; impairment in 
simple reaction time was associated with lower social functioning (SF) and 
impairment in global attention was significantly correlated with lower levels of 
EF;  
ii) in the high dose group: impairment in global executive functions was correlated 
with PF and SF; impairment in simple reaction time was associated with lower 
role functioning (RF) and impairment in selective attention was significantly 
correlated with lower levels of EF and SF;  
iii) in the non-chemotherapy group: impairment in simple reaction time and verbal 
learning was correlated with lower levels in RF and impaired verbal recognition 
with lower levels in PF.  
None of the remaining studies included in this review reported any correlation between 





and colleagues (2006) did observe in the discussion section of their paper that those 
participants with the most dysfunction who improved also showed an improvement in 
overall global QoL.  Unfortunately, no statistics or specific details were provided to back 
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Key:  * = this is one of the ICCTF’s recommended core neurological assessments. EORTC QLQ C30: European Organization for Research and Treatment of Cancer Quality of Life questionnaire; FACT O: For patients with Ovarian 
cancer; FACT G: Functional Assessment of Cancer Therapy – General; FACT B: For patients with Breast cancer; FACT ES: For patients with Endocrine Symptoms; FACT L: For patients with Lung cancer; Imm-Mem: Immediate 
memory; Imm-Mem-Q: Immediate memory-questions; Delayed-Mem: Delayed memory; Delayed-Mem-Q: Delayed memory-questions; TMT A & B: Trial Making Test Part A & Part B; WAIS-R Digit Symbol: Wechsler Adult 
Intelligence Scale Revised Digit Symbol; MMSE: Mini- Mental State Examination;  CRT: Headminder Clinical Research Tool; WAIS-R Digit Span: Wechsler Adult Intelligence Scale Revised Digit Span; Stroop C-W: Stroop 
interference trial; 
HVLT-R: Hopkins Verbal Learning Test – Revised; RBANS: Repeatable Battery for the Assessment of Neuropsychological Status; Category Test; PASAT: Paced Auditory Serial-Addition Task; COWAT/COWA: Controlled Oral 
Word Association Test; Grooved Pegboard; Sensory Perceptual Exam; RCFT: Rey-Osterrieth Complex Figure test; WAIS-III: Wechsler Adult Intelligence Scale –III; WRAT-3: The Wide Range Achievement Test, Third Edition; 
MMSE: Mini- Mental State Examination; VLMT: Auditory Verbal Learning Test – German modified version;ROCFT: Rey-Osterrieth complex figure test; TAP: Test battery for attentional performance; Test D2: D2 cancellation 
test;RWT: Regensburg Word Fluency Test; LPS: achievement measure test; WMS-III Logical Memory: Wechsler Memory Scale – third edition Logical Memory; WMS-III Visual Reproduction: Wechsler Memory Scale – third 
edition Visual Reproduction; Faces I & II: Facial Recognition Tests; RAVLT/Rey AVLT: Rey Auditory Verbal Learning Test; FFTT: Fepsy finger-tapping task; FVRT: Fepsy visual reaction test; FBCT: Fey binary choice test; FVST: 
Fepsy visual searching test; S.A.N Test: Letter cancellation test; HSCS: High Sensitivity Cognitive Screen; CPT: Continuous Performance Test; DAST: Dutch Aphasia Society Test;  CANTAB Battery: RVP: Rapid Visual Information 
Processing; RTI: Reaction Time; VRM: Verbal Recognition Memory; SWM: Spatial Working Memory; MOT: Motor Screening; BVMT-R: Brief Visuospatial Memory Test Revised; SDMT: Symbol Digit Modalities Test; TEA: Test of 
Everyday Attention; Elevator & Telephone search; Perdue Pegboard; DKEFS: Delis-Kaplan Executive Function Scale; NVSRT: Nonverbal Selective Reminding Test; VSRT: Verbal Selective Reminding Test; Grooved Pegboard MAE 





One of the reasons for a lack of significant relationships in the studies included in this 
review could have been that some of them used a global cognitive impairment score 
and/or a global HRQoL score (e.g. van Dam et al, 1998), thereby masking any more 
subtle relationships or associations that may have existed.  For example, Tchen 
(2003)/Mar Fan et al (2005) and van Dam et al, (1998) calculated cognitive impairment 
by combining performance on cognitive tasks into one global impairment score. Tchen 
(2003)/Mar Fan et al (2005) reported that the overall classification of cognitive 
impairment by the HSCS was not correlated with HRQoL. Similarly, Iconomou et al 
(2004) reported that there was no significant relationship at baseline or after treatment 
between objective cognitive performance as measured by the MMSE and any of the 
QLQ-C30 subscales. In addition, Whitney et al (2010) did examine possible relationships 
between neuropsychological test results and HRQoL variables but did not find any 
statistically significant correlations at any of the three assessed time points. 
5.4.3.7 Methodological quality of included studies 
As mentioned above, the included studies used a wide range of designs and were of 
varying quality. Of the studies with the most robust methodological designs (Hess et al, 
2015; van Dam et al, 1998, Vearncombe et al, 2009, Jenkins et al, 2006, Mar Fan et al, 
2005; Vardy et al, 2015; Wefel et al, 2010), six were longitudinal. Five of the six had the 
largest sample sizes (Mar Fan et al, 2005; Hess et al, 2015, Vardy et al, 2015; Jenkins et 
al, 2006; Vearncombe et al, 2009), a total of 206, 231, 434, 177 and 159 participants 
respectively with one or more comparison group as outlined above.   
 
Six studies were graded as having high internal validity (i.e. unbiased) (Jenkins et al, 





1999; Vardy et al, 2015); ten as moderate and one as poor (Iconomou et al, 2004).  Only 
three studies were graded as having high external validity (van Dam et al, 1998; Vardy 
et al, 2015; Vearncombe et al, 2009); thirteen as moderate and one as having poor 
external validity (Iconomou et al, 2004).  
Methodological shortcomings mainly concerned three studies (Hurria et al, 2006; 
Jenkins et al, 2006; Wefel et al, 2010) that were exploratory in nature with no focussed 
objective. Seven studies (Cruzado et al, 2009; Freeman et al, 2002; Hess et al, 2015; 
Hurria et al, 2006; Reid Arndt et al, 2009; Reid Arndt et al, 2010; Vardy et al, 2015) 
failed to report the acceptance rate of invited participants, and eight (60%) of the 
longitudinal studies (Cruzado et al, 2009; Hess et al, 2015; Mar Fan et al, 2005; Vardy et 
al, 2015; Reid Arndt et al, 2010, Wefel et al, 2010; Whitney et al, 2008; Iconomou et al, 
2004) had attrition rates exceeding 20%.  
Of the three studies that reported a relationship between OCI and HRQoL one was 
cross-sectional (Mehnert et al, 2007) and two longitudinal in design (Reid-Arndt et al, 
2010; Vearncombe et al, 2009). As mentioned above, the focus of each was slightly 
different. For example, Mehnert and colleagues (2007) examined neuropsychological 
impairment and HRQoL in high-risk breast cancer survivors 5 years after treatment. 
Whereas Reid-Arndt and colleagues (2010) examined the relationship 1 month after 
treatment and followed up the participants for another 12 months and Vearncombe et 
al (2009) investigated whether HRQoL significantly contributed to cognitive 
impairment reported after chemotherapy, examining cognition pre-treatment and 4 






In interpreting the quality of the studies that found a statistically significant relationship 
between OCI and HRQoL, Mehnert’s cross-sectional study had a low quality rating (1), 
and therefore the results should be treated with caution. Both longitudinal studies 
(Vearncombe et al, 2009 and Reid-Arndt et al, 2010) received a higher overall quality 
score (3 and 4 respectively) suggesting that the results are more robust. All three 
studies examined OCI post treatment, although Vearncombe et al (2009) also assessed 
cognition prior to treatment. 
5.5 Conclusions 
This review set out to examine studies that explored the possibility of a direct 
relationship between the objectively measured cognitive effects related to 
chemotherapy treatment in cancer patients with solid tumours and their HRQoL. A 
critical examination of all identified studies exploring this relationship has shown that 
OCI is subtle and only occurs in a subset of cancer patients with solid tumours. The 
review established that there is limited evidence to suggest that such OCI following 
adjuvant chemotherapy is associated with poorer HRQoL.   
Whilst a few studies showed significant associations between OCI and aspects of HRQoL 
(Reid-Arndt et al, 2010; Vearncombe et al, 2009) after chemotherapy treatment the 
majority found no such association. However, there are a number of reasons why 
caution is required when considering the number of OCI studies that failed to find any 
such relationship. One reason, for example is the fact that most of the studies included 
in this review did not set out to explore this relationship; rather it typically features as 
an exploratory post-hoc analysis. Consequently, the design and conduct of the study is 





In addition, the tests used to assess objective cognition and the definition of impaired 
cognition were not performed or used consistently across studies, creating significant 
difficulties in making comparisons across studies. With regard to measuring objective 
cognitive decline, studies assessed a large number of cognitive domains and used an 
even larger array of tests.  The criteria for the classification of OCI also varied widely. 
This is not an uncommon problem in the assessment of objective cognitive change. 
However, in an attempt to bring some uniformity to future studies there are now 
specific recommendations for defining OCI and the cognitive domains to be assessed 
along with recommended tools to measure any deficits (Wefel et al, 2011). It is hoped 
that there will be more homogeneity of neuropsychological assessments between 
studies in the future but this will take some time to be adopted.  Going forward, 
consistent use of the recommended tests and definitions should provide a clearer 
picture of the type and extent of deficits suffered by different cancer patients 
undergoing chemotherapy treatment. 
A similar issue also relates to the definition and questionnaires used to assess HRQoL. 
There are many instruments available for assessing HRQoL, from generic (measuring 
multiple concepts relevant to a wide range of patients) to specific (a disease, population 
or health dimension) (Davies, 2009). All of the studies in this review used one of two 
instruments - the EROTC – QLQ C30 or the FACT battery. As shown in the results it is 
hard to draw meaningful comparisons between the results obtained by these two 
measures as the EORTC system offers multiple specific scales and symptom scores, 





It should also be noted that although almost every study in this review found some type 
of cognitive impairment in a small subset of participants, this often improved for some 
patients after treatment (Hurria et al, 2006; Mar Fan et al, 2005; Wefel et al, 2004; 
Whitney et al, 2008). It is common with repeated assessments of neuropsychological 
performance using tests of the same design that individuals show some improvement 
even when alternate forms of the same test are used.  In other words it is possible that 
improvements in neuropsychological test scores could have been a reflection of the 
effects of repeated exposure to the tests rather than clinically significant gains in 
cognitive function (Reid-Arndt, 2010). This emphasizes the need for a control or 
comparison group so as to be able to examine and compare the practice effects when 
repeatedly using these tests over time (Wefel, 2011). For example, Shilling et al, 2005 
who used the reliable change index with corrections for observed practice effects on 
each measure and had a control group were able to examine this. They found that the 
chemotherapy participants that were classified as impaired on the basis of showing 
reliable cognitive decline on two or more measures were 2.25 times more likely than 
controls to be classified as showing cognitive impairment.  
Finally, despite these methodological limitations, the studies were sufficiently robust to 
have established if a major impact of chemotherapy on HRQoL had occurred. A point 
further highlighted by Whitney et al (2008).  
The secondary aim of this review was to examine which affected cognitive domains 
were related to which particular aspects of HRQoL. Here there was insufficient data to 
answer the question, as only three studies reported relationships between specific 
domains (Mehnert et al, 2007; Reid Arndt et al, 2010; Vearncombe et al, 2009).  





examined it in any detail.  Even amongst the three that did find specific relationships it 
was not feasible to draw any meaningful comparisons between them as they used 
different HRQoL measures. As shown in the results above, Mehnert (2007) used the 
EROTC QLQ-C30, which has more QoL scores than the FACT B, that was used by Reid-
Arndt (2010) and Vearncombe (2009). It is therefore arguable that Mehnert (2007) was 
very likely to find more associations, although multiple comparisons could have led to 
an increase in Type I errors. On the other hand by using summary scores (as do the 
FACT measures) Reid-Arndt (2010) and Vearncombe (2009) could have missed the 
more subtle relationships (although it is worth noting here that Vearncombe et al, 2009 
was also rated the best quality study). For example by combining scores into summary 
scores, it is possible to mask the fact that the small more individual HRQoL domains (as 
measured by EROTC QLQ-C30 such as pain, nausea/vomiting etc)  may have significant 
associations with individual cognitive domains.  
Even though Mehnert et al (2007) found that declines in specific cognitive domains 
(such as working memory, simple reaction time and global attention) were associated 
with poorer physical, emotional, and social functioning, this study had significant 
methodological limitations and as a result these findings can be largely discounted.  
They reported that patients who had received standard dose chemotherapy consistently 
had the lowest HRQoL.  
5.6 Strengths and limitations of this review  
This review is not without its limitations. For example all studies irrespective of quality 
were included because it is an under researched area.  Most were of moderate quality at 





question. Although small sample sizes have always been a problem for this area of 
research, almost every study (other than Jenkins et al, 2006; Mar Fan et al, 2005; and 
Vearncombe et al, 2009) was underpowered. As well as small sample sizes, studies 
examining CRCI also suffer from high rates of attrition (for example anywhere between 
12% (Vearncombe, 2009) to 36% (Whitney, 2008)) as this can induce negative thoughts 
and feelings about possible relapse of disease or even death (Hodgson et al, 2013). 
5.7 Update post June 2016  
Whilst there has been an explosion of CRCI studies that have been published between 
June 2016 and August 2018 a scoping of the literature revealed that there were no more 
studies that fully examined the relationship between OCI and HRQoL.  
5.8 Publications 
This review has been published online by the journal Psycho-oncology on 23 November 
2016. The published manuscript for this study is presented in Appendix F. 
1. Dwek, M. R., Rixon, L., Simon, A., Hurt, C., & Newman, S. (2016). Is there a 
relationship between objectively measured cognitive changes in patients with 
solid tumours undergoing chemotherapy treatment and their health-related 
quality of life outcomes? A Systematic Review. Psycho-oncology, 24, 344-345. 
2. Poster Presentation of Review at the 2015 World Congress of Psycho-Oncology 






Chapter 6: Summary of the literature, rationale and aims of 
the present thesis  
 
6.1 Summary of the literature  
Chapter 1 highlighted the increase in survival rates of individuals diagnosed with CRC, 
its treatment, and the long list of possible side effects including cognitive impairment. 
Chapter 2 discussed cognition (objective and subjective), cognitive function in cancer 
patients with solid tumours, and highlighted the challenges involved in measuring 
cognition and cognitive impairment. 
As discussed in Chapters 3 and 4, objective and subjective impairments in cognitive 
functioning have mostly been reported in a subset of patients with breast cancer, who 
have completed chemotherapy treatment. Impairments are reported to occur across a 
range of cognitive domains including attention, executive function and motor function 
when compared to normative data, disease specific groups and/or healthy control 
groups. Despite a plethora of research, there remains a lack of clarity around the extent, 
course, nature and duration of any cognitive impairment (objective and/or subjective). 
The extent to which CRCI extends to other solid tumours such as CRC also remains 
unclear.   
The impact of CRCI on HRQoL in patients with solid tumour cancers has not been 
adequately explored as discussed in Chapter 5.  The results of a systematic review of the 
literature (described in Chapter 5) showed that only a limited number of studies have 
examined the relationship between OCI and HRQoL. To address this gap in the 
literature, this thesis explored cognitive functioning (objective and subjective) in the 





6.2 Methodological limitations of the existing literature  
There were several methodological limitations in the studies reviewed to date. Some of 
the significant methodological issues that arose from the review of the literature are as 
follows:  
1. Most research studies have explored cognitive function in patients with cancer 
after systemic treatment has been completed (Vardy, Wefel, Ahles, Tannock and 
Schagen, 2007).  
2. Few studies have prospectively measured patients’ cognitive function prior to 
the commencement of chemotherapy treatment and hence these studies do not 
have any baseline.  
3. Few studies measured cognitive function over the course of chemotherapy 
treatment and beyond. This would have made it possible to identify changes 
occurring during and after treatment so as to establish whether any deficits 
detected persist after treatment.   
4. Studies have often lacked a comparison/control group (e.g. patients diagnosed 
with the same cancer but who do not have chemotherapy treatment) against 
which to compare cognitive function scores. Most reviewed studies also had 
small sample sizes and/or were not informed by power calculations. 
5. Most cognitive research to date has focussed on female patients with breast 
cancer. (There have only been a small number of CRC studies that examined 
CRCI.) This has precluded any exploration of gender differences in relation to 





6.3 Rationale for the present study  
Further, longitudinal and adequately powered studies are required to examine CRCI in 
patients with solid tumours other than breast, which (as mentioned previously) make 
up the majority of studies in the research to date.  
This study uses a mixed method approach across multiple hospital sites to address an 
area of research that has previously received little attention. Given the recent increased 
incidences of cancer, improved rates of survival (particularly CRC) and the increasing 
use of chemotherapy drugs to treat different types of cancer (Wefel, Vardy, Ahles and 
Schagen, 2011), the effect of CRCI would benefit from further research and 
investigation. The present study is designed to comprehensively investigate cognitive 
functioning in patients with CRC prior to and over the course of systemic treatment. 
Few studies have investigated and compared cognitive impairment in CRC across 
different domains of cognitive functioning and there are no studies to date (of which the 
researcher is aware) that have used a mixed methods approach.  
This thesis utilised a set of core neuropsychological test measures including those 
recommended by the ICCTF (Wefel et al, 2011) in an effort to assess the extent to which 
cognitive impairment is a phenomenon associated with chemotherapy treatment. 
Importantly this study examined patients who had all been diagnosed with the same 
cancer (i.e. CRC), who all required and underwent curative surgery but only half of 
whom went on to have adjuvant chemotherapy treatment; allowing for a comparison 
between those who received adjuvant chemotherapy to those who did not on all 





this patient group, a wide range of clinical, psychosocial and demographic variables 
were included in the study. 
Impaired cognitive function (both objective and subjective) could affect patients’ HRQoL 
and potentially prevent a return to work and/or a normal social life (Wefel et al, 2011).  
The relationship between the type and extent of impaired cognitive function and HRQoL 
was therefore examined. This work has the potential to contribute towards the 
development of specific supportive and rehabilitative interventions to improve the 
HRQoL for patients that may be impacted. 
6.4 The current thesis  
This thesis examines CRC, a solid tumour cancer with a high prevalence that affects both 
men and women almost equally. Patients with CRC have a relatively high survival rate, 
which is beneficial for a longitudinal study exploring the nature and trajectory of CRCI.  
6.4.1 Sample size 
Recruitment to each study component of this thesis (i.e. the quantitative study and the 
qualitative study) was led by a sample size calculation (see Chapter 7, Sections 7.4.1 and 
7.4.2). To achieve the required samples the studies recruited participants from multiple 
hospital sites with the effect of increasing the generalisability of the findings.  
6.4.2 Aims, objectives and research questions 
Research question 1: What is the nature and extent of cognitive impairment in 






Aim 1: This thesis aimed to establish whether cognitive impairment (objective and/or 
subjective) is present in resected CRC patients prior to commencing chemotherapy 
treatment or at a similar point in time in the surgery only patients.  
Related objectives are to compare the “chemotherapy” patient group with the “surgery-
only” patient group regarding:  
1.1 The incidence of OCI.   
1.2 The most commonly affected cognitive domains  
1.3 The relationships between demographic, clinical and psychosocial factors 
and objectively measured cognitive functioning  
1.4 The relationship between perceived cognitive function (as measured by 
self-assessment questionnaires) and objectively measured cognitive 
function 
after surgery and before the start of chemotherapy (or at a similar point in time for the 
“surgery only” participants). 
Research question 2: What is the nature and trajectory of CRCI in patients with 
resectable CRC who do or do not receive adjuvant chemotherapy treatment?   
 
Aim 2: To investigate the nature, course and extent of cognitive impairment (both 
objective and subjective) in patients with resected CRC who go on to have systemic 
chemotherapy treatment compared to those who do not have any further treatment.  
Related objectives are to:  
2.1 Explore the extent and nature of both OCI and SCI pre-, mid- and post- 
chemotherapy treatment in resected CRC patients undergoing chemotherapy 





2.2 Explore the extent and nature of both OCI and SCI in resected CRC 
patients who require no further treatment at similar points in time to those 
undergoing chemotherapy treatments 
2.3 Explore the relationships between cognitive function (objective and 
subjective) and psychosocial outcomes in resected CRC patients in both the 
chemotherapy and “surgery-only” patient groups.   
2.4.  Examine the relationship between patients’ self-reported cognitive 
functions and their objectively assessed cognitive functions 
Research question 3: Is OCI in patients with CRC associated with lesser HRQoL?  
 
Aim 3: To explore whether OCI, if present in patients with resected CRC is related to 
HRQoL? If so, what cognitive domains are related to what aspects of HRQoL?  
Research question 4: Are patients with CRC aware of CRCI? How do those patients 
who perceive themselves to have CRCI (before, during and after chemotherapy 
treatment) experience such impairments?   
Aim 4: To explore the perceived cognitive changes experienced by patients with 
resected CRC before, during and after adjuvant chemotherapy treatment. 
Related objectives are to: 
4.1 Explore whether patients with CRC are aware of CRCI prior to the start of 
chemotherapy treatment and whether they are aware of having experienced any 





4.2 Explore the type and extent of individual experiences of CRCI and its perceived 
effects prior to, during and post chemotherapy treatment (Qualitative 
component). 
6.5 Structure of subsequent chapters 
Chapter 7 will describe the methodology used in this thesis, followed by the analyses, 
which will address each of the aims described above (Chapters 8 to 10 inclusive). A 
discussion of the findings is included immediately following each set of analyses and a 




Chapter 7: Methodology 
 
7.1 Introduction 
This chapter presents the methodology adopted in this thesis, including the study 
design, measures and an overview of the statistical strategy adopted for data analysis of 
each study. It begins by providing an outline of the different types of mixed method 
designs available, the method chosen for this PhD and why. It then goes on to discuss 
recruitment strategy and procedures and the measures utilised in each component 
study, followed by a brief overview of the planned analyses strategy.  
7.2 Mixed methods approaches  
7.2.1 Rationale for a mixed methods approach: 
Mixed methods approaches are increasingly used in health-related research, such as 
cardiology (Curry, Nembhard, & Bradley, 2009), paediatric oncology nursing (Wilkins & 
Woodgate, 2008), mental health services (Creswell & Zhang, 2009; Palinkas, Horwitz, 
Chamberlain, Hurlburt, & Landsverk, 2011) and disabilities (Mertens, 2014). Advocates 
of this approach discuss the potential to generate unique insights into multifaceted 
phenomena (Cresswell & Clark, 2011) such as health care. Other researchers (who have 
explored the use of mixed methods research in health services) consider these types of 
designs to be more comprehensive (O'Cathain, Murphy, & Nicholl, 2007). The different 
methods (i.e. qualitative and quantitative) are often used to address different questions 
or aspects of the overall research question so that the study is more comprehensive 




Whilst both quantitative and qualitative approaches have each been used in “cancer and 
cognition” studies they are rarely found together. One example where both methods 
were used is Downie and colleagues (2006) study with breast cancer patients. They 
used a neuropsychological assessment alongside a semi-structured interview and self-
report measures of fatigue and menopausal symptoms to examine the relationship 
between experience with symptoms and cognitive performance. However, they did not 
specifically examine the experience of living with cognitive impairment.  
Quantitative research in the context of “cancer and cognition” is often used to gather 
information and examine relationships among variables that yield numeric data and can 
be analysed statistically. This also allows for efficient data collection procedures, creates 
the possibility of replication and generalisation of results, which facilitates the 
comparison of groups, and can provide insight into a breadth of experiences (NIH Office 
of Behavioral and Social Sciences, 2018). Whereas, one of the major strengths of 
qualitative research is its  focus on the contexts and meaning of human lives and 
experiences for the purpose of inductive or theory-development driven research (NIH 
Office of Behavioral and Social Sciences, 2018).  
Where the quantitative studies’ use of validated measures and statistical approaches 
minimise researcher bias, they generally do not offer an in depth subjective 
understanding of the phenomenon, which qualitative approaches may offer (Lewis & 
Ritchie, 2003). The integration of quantitative and qualitative data therefore minimizes 
the weaknesses and maximizes the strengths of each type of data (NIH Office of 
Behavioral and Social Sciences, 2018). Triangulation is also a benefit of using a mixed 




qualitative results and examine similarities and differences (Curry, Nembhard, & 
Bradley, 2009). 
This thesis uses a mixed method concurrent approach in order to obtain a more in 
depth picture and understanding of CRCI in a solid tumour population. Research to date 
has shown that there is rarely any correlation between subjective and objective CRCI 
(Hutchinson, Hosking, Kichenadasse, Mattiske, & Wilson, 2012). The integration of two 
methods of data collection and interpretation will allow for the development of a more 
comprehensive understanding of the issue and examination of experiences along with 
the assessed outcomes (Plano Clark, 2010).  
7.2.2 Design   
As mentioned, since 1996, there has been a growing interest in mixed methods 
approaches in health-related research (Plano Clark, 2010). Johnson and colleagues 
(2007) found 19 definitions of mixed methods research with varying levels of 
specificity. An examination of all of these led to Johnson and colleagues’ (2007) general 
definition of mixed methods research as:  
The type of research in which a researcher or team of researchers combines elements of 
qualitative and quantitative research approaches (e.g., use of qualitative and quantitative 
viewpoints, data collection, analysis, inference techniques) for the broad purposes of 
breadth and depth of understanding and corroboration (P.123). 
Essentially, it involves the intentional collection and integration of both quantitative 
and qualitative data (Creswell, Klassen, Plano Clark, and Smith, 2011).  There is no gold 
standard formula for designing a mixed methods study. There are numerous 




the exploratory sequential design, the embedded design, the transformative design and 
the multiphase design (Creswell & Plano Clark, 2011), as briefly outlined below.   
Taking each in turn:  
The convergent (or parallel or concurrent) designs: This involves the merger of 
concurrent quantitative and qualitative data and a comparison of the two sets of data 
and results. The qualitative and quantitative components may be of equal status or one 
could be dominant.  
The sequential (explanatory or exploratory) designs: are two-phase studies where one 
dataset builds on the results of the other.  
Embedded (or nested) designs: use quantitative and qualitative approaches in tandem 
where one is embedded in the other to provide new insights or more refined thinking. 
They may be a variation of a convergent or sequential design.  
Multiphase designs: emerge from multiple projects conducted over time and linked 
together by a common purpose. They commonly involve convergent and sequential 
elements (Creswell & Plano Clark, 2011).  
This thesis follows a mixed methods concurrent longitudinal framework (Creswell & 
Plano Clark, 2011) (as shown in Figure 7.1), where the results of the qualitative 
component and quantitative component will be integrated in the general discussion 
(Creswell & Plano Clark, 2011) to provide further insights into the individual experience 
of CRCI. The data collection for the qualitative component took place concurrently with 
the quantitative assessments and quantifiable self-report questionnaires. The purpose 




CRCI; to develop a complementary picture, defined by Greene and colleagues (1989) as 
the use of quantitative and qualitative methods to “measure overlapping but also 
different facets of a phenomenon, yielding an enriched, elaborated understanding of that 
phenomenon.” The qualitative component within this thesis was to provide a fuller 
picture and deeper understanding (Johnson, Onwuegbuzie & Turner, 2007) of CRCI; to 
examine individual experiences over time  (Plano Clark, 2010).  
Figure 7.1: Pictorial representation of the concurrent research design used in this 
thesis 
   
   
 
 
The quantitative and qualitative approaches to data collection and analysis in this thesis 


















Quantitative study component: 
As can be seen in Figure 7.2, a longitudinal comparative study was employed. This 
involved collecting data using self-report questionnaires and neuropsychological (NP) 
assessments at 3 time points over a 9 month period, from a consecutive sample of 
resected (i.e. they had had surgery) CRC patients at a number of consenting NHS Trusts 
across London. Some participants required adjuvant chemotherapy treatment following 
surgery (the “chemotherapy group”) and others did not require any further systemic 
treatment (the “surgery only” patients). The “surgery only” participant assessments 
were administered to patients at similar points in time as for those participants 
undergoing chemotherapy, as indicated below. Full participant details are presented in 





Figure 7.2: Pictorial representation of the concurrent data collection for the 









As discussed in Chapter 2, adjuvant chemotherapy treatment for patients with a 
resectable CRC diagnosis starts once the patient has recovered from surgery, usually 
between 3 to 12 weeks later. The drugs are then administered either every two weeks 
(for intravenous drugs) or every three weeks (for oral drugs) for between 1 and 5 days 
followed by a break of two or three weeks. This constitutes one chemotherapy cycle and 
a complete treatment course usually takes up to a total of 6 months (Appendix B). 
Assessments were mapped to the chemotherapy timetable as far as was possible for the 
“chemotherapy group” and at similar points in time for the participants in the “surgery 
only” group, as follows:  
T1: (After surgery, before chemotherapy treatment) this baseline assessment captured 
patients experiences approximately 3 to 12 weeks after surgery;  
T2: (Mid chemotherapy treatment (i.e. after the first 3 or 6 cycles depending on the 
prescribed chemotherapy protocol). (Please see Appendix B for full details of all 
chemotherapy regimens). This assessment captured patient’s experiences at 
approximately the middle of the chemotherapy treatment course or approximately 3 
months after T1 for the “surgery only group”; 
T3: Three months post the last scheduled chemotherapy treatment (i.e. approximately 6 
months after T2).  
The use of NP assessments and questionnaires at these three time points enabled the 
collection of quantifiable data that were analysed using statistical tests as detailed in 





Qualitative study component: 
In tandem with the quantitative assessments, interview data was collected from a 
subset of the chemotherapy patient group at each of T1, T2 and T3 satisfying the same 
inclusion/exclusion criteria as those who were eligible for the quantitative study. It was 
the intention of this study to capture the in-depth experiences (pre-, mid- and post-
chemotherapy treatment) of CRC patients’ perceived cognitive impairment, its 
trajectory, and its impact on the individual. 
None of the reviewed interview/focus group studies to date (whether longitudinal or 
cross sectional) have focused on or included adults with CRC (Chapter 4, Table 4.1).  The 
majority of the studies (14 out of 20) reviewed in Chapter 4 have been in female breast 
cancer survivors (Becker et al, 2015; Boykoff et al., 2009; Cappiello et al, 2007; Cheung 
et al, 2012; Downie et al, 2006; Kanaskie & Loeb, 2015; Munir et al., 2010 & 2011; 
Myers, 2012; Player et al, 2015; Raffa & Martin, 2010; Rust & Davies, 2013; Shilling & 
Jenkins 2007; Von Ah et al, 2013). Twelve of the studies focused on patients who had 
already completed treatment (Boykoff et al., 2009; Cappiello et al, 2007; Cheung et al, 
2012; Kanaskie & Loeb, 2015; Munir et al., 2010 & 2011; Myers, 2012; Raffa & Martin, 
2010; Rust & Davies, 2013; Shilling & Jenkins 2007; Skoogh et al, 2012; Von Ah et al, 
2013). This study therefore adds to the longitudinal literature by interviewing cancer 
patients with a different solid tumour (involving both men and women) pre-, mid- and 
post chemotherapy treatment. 
This mixed methods approach provided a valuable all-encompassing strategy that 
overcame the limitations of using just quantitative or qualitative measures on their 




1. The longitudinal design enabled an examination of changes in cognitive function 
and psycho-social outcomes over time;  
2. The pre-chemotherapy treatment baseline enabled an examination of the impact 
of the chemotherapy on patients’ experiences and cognitive function as all 
patients had been through the shock of the diagnosis and curative surgery.  
7.3  Ethical approval 
Full ethical approvals for both the qualitative and quantitative studies were obtained 
from the NHS Health Research Authority – NRES Committee South-West Cornwall & 
Plymouth (REC reference number: 13/SW/0201) in August 2013 and June 2015 (see 
Appendix H for approval letters). Relevant approvals were also gained from the 
Research & Development (R&D) departments at University College London Hospitals 
NHS Foundation Trust (UCLH), Barts and the London NHS Trust (Barts), Imperial NHS 
Trust (Imperial), Royal Free London NHS Foundation Trust (Royal Free) and West 
Middlesex University Hospital NHS Trust (West Mid) (later it became the Chelsea and 
Westminster Hospital and West Middlesex University Hospital NHS Trust) (each a 
‘Participating Trust’).  
7.4 Study participants and sampling procedures 
7.4.1 Participants  
A consecutive series of outpatients (satisfying the inclusion criteria) attending medical 
oncology clinics under the care of the CRC team at each of the Participating Trust 
hospital sites were invited to take part in both the qualitative and quantitative study. 98 




chemotherapy patients and 35 “surgery only” patients) for participation in the 
quanitative study and 24 of the chemotherapy patients invited to participate also 
agreed to take part in the quantitative study. Full participant details can be found in 
Tables 8.2, 9.2 and 10.1 in Chapters 8, 9 and 10 respectively.   
7.4.2 Inclusion and exclusion criteria 
Specific inclusion/exclusion criteria were set for participation in the study. 
Inclusion criteria: 
 Aged between 18 years and 65 years (the upper age limit was removed on 1 
January 2015 following the Feasibility Trial) (please see Section 7.6 and 
Appendix J)   
 Diagnosed with resectable (i.e. suitable for surgery) CRC to be followed by 
adjuvant chemotherapy treatment or no further systemic cancer treatment. 
 Fluent in spoken and written English language, sufficient to complete self-report 
questionnaires and neuropsychological assessments. 
Exclusion criteria: 
 Prior exposure to chemotherapy  
 Significant psychiatric or medical comorbidities which could affect ability to 
participate  




7.4.3  Recruitment Strategy 
7.4.3.1 Identification of eligible participants for both the quantitative and 
qualitative studies. 
Between 1 April 2014 and May 2017, eligible participants were initially identified at the 
weekly CRC multi-disciplinary team (MDT) meetings held by each Participating Trust. 
The researcher kept careful track of each new eligible patient and post –operative 
patient discussed at the MDT with the help of the Colorectal Nurse Specialists (CNS) at 
each hospital site. The appropriate CNS would then provide the researcher with the 
date and time of all relevant outpatient appointments in order to enable the researcher 
to attend the appropriate clinic at the right time and recruit to the study. In order to 
minimise sample attrition and its impact on the current study, the researchers 
responsible for data collection attended all clinics to recruit the patients in person; and 
maintained rapport with all participants throughout the 9-month data collection period.  
All patients scheduled to have adjuvant chemotherapy treatment and satisfying the 
inclusion/exclusion criteria were invited to take part in both the quanitative study and 
qualitative study, as more particularly described below. Eligible patients who did not 
wish to take part in one or other of the studies were given the opportunity to participate 
in the other study should they have wished to do so. 
Chemotherapy patients: During the course of the post-surgery follow-up appointment, 
the oncology team mentioned both the qualitative and quantitative studies to the 
patient before making an introduction to the researcher who then provided the patient 
with the appropriate informational documents for them to take away and read 




48 hours after the introduction. They were invited to participate in the study, either at 
the applicable chemotherapy clinic or at home prior to the commencement of 
chemotherapy treatment.    
The longitudinal qualitative study was open to all of the chemotherapy participants 
from June 2015 (when there was a change in the study design, from cross sectional to 
longitudinal) until a sufficient number of participants had been recruited and consented 
into the study by the cut off date for recruitment (pleases see section 7.5.2 for the 
sample size calculation).   Consequently, only those participants who were interviewed 
for the first time after April 2015 were able to continue in the longitudinal qualitiative 
study and their data was the only data analysed for that study.  (Please see Appendix H 
for the change to the design and approval letter from ethics).  
Surgery only patients: A consecutive sample of CRC “surgery only” patients were 
recruited in the same way as the chemotherapy patients. These eligible patients were 
introduced to the researcher by either the surgeons or CNSs at the outpatient surgical 
follow-up appointment.  Patients were given appropriate informational documents and 
those who provided telephone numbers were contacted at least 48 hours later and 
invited to participate in the quantitative study at home or place convenient to the 
patient.  
Please refer to the published paper in Appendix J ‘Chemotherapy-related cognitive 
changes in colorectal cancer patients: a feasibility trial’ (Dwek, Rixon, Hurt & Newman, 
2016) (“Feasibility Trial” paper) for an account of the procedural hurdles that were 
encountered at the beginning of the study with a subset of the included participants and 




7.4.3.2 T1  
As mentioned in Section 7.4.3.1, a patient who had been approached in clinic and had 
taken any of the patient information sheets (Appendix I), was telephoned a few days 
later and asked if they wished to participate. Appointments were made with those who 
agreed to take part. The researcher then attended the patient’s home or they met at the 
hospital as agreed on the telephone. The patient completed the appropriate consent 
form(s) (Appendix I), which was/were counter signed by the researcher prior to the 
administration of assessments, questionnaires and/or interview (as applicable).  
7.4.3.3 T2 
The researcher contacted patients who completed T1, ten to twelve weeks later. If the 
patient was unreachable via the telephone (after leaving 2 further voice mail messages), 
the researcher sent out a letter to the home address asking if the patient would be 
willing to continue in the study and if so, to contact the researcher. Once a mutually 
convenient time, date and place had been agreed with the patient the researcher 
attended the appointment and administered the assessments, questionnaires and/or 
interview, as appropriate.  
7.4.3.4 T3 
The same process outlined in relation to T2 was carried out again approximately 3 
months after the last scheduled chemotherapy date or 6 months after T2 in the case of 




7.5 Sample size calculation 
7.5.1 Quantitative sample size 
A meta-analysis of chemotherapy and cognitive function (Jansen et al, 2005) estimated 
mean effect sizes in a range of cognitive domains. The effect sizes ranged from d= -0.11 
to -0.51. A sample size calculation was performed using GPower 3.1 (Faul, Erdfelder, 
Buchner, and Lang, 2009). Taking into consideration the resources constraints of this 
PhD study the sample size was calculated with the aim of detecting an effect size, with 
80% power and a significance level of 0.05 at T3. (Please see the published Protocol at 
Appendix K (Dwek, Rixon, Hurt, Simons and Newman, 2015) for a full account of the 
sample size calculation). Although a minimum sample size of 120 participants was 
indicated, given the time and resource constraints of undertaking this PhD, it was 
agreed with the study team that recruitment would be brought to a close in sufficient 
time to write up this thesis. It was therefore anticipated that a subset of the target 
number of participants would be analysed for this thesis.    
7.5.2 Qualitative sample size 
The approach to sample size in quantitative research, where larger numbers are 
generally more desirable, is not applicable to qualitative research, where the sample 
size reflects the depth and richness of information that describes a phenomenon 
(O'Reilly & Parker, 2013). The recruitment sample for this study was not fixed although 
it was estimated that an approximate sample of 20 chemotherapy patients (ideally 10 
male and 10 female) would be sufficient for exploring awareness and experiences of 
CRCI over the three time points (producing 60 interviews). This was based on Morse 




minimum of six participants and a review of previous interview studies in the “cancer 
and cognition” literature. For example, Downie and colleagues (2006), assessed and 
interviewed 21 breast cancer patients at one point in time in a mixed method design; 
and Player and colleagues (2014) interviewed nine breast cancer patients.  
Fugard and Potts’ (2015) tool for estimating a useful sample size for thematic analysis 
also produced a suggested sample of 19 or 20. This was calculated as follows:  
(a) the expected population theme prevalence of the least prevalent theme, derived 
either from prior knowledge or based on the prevalence of the rarest themes 
considered worth uncovering (was set at 30%). It was estimated that 50 % of people 
who could say something relevant about a theme would do so, providing an adjusted 
prevalence of 15% (0.3 x 0.5 = 0.15).  
(b) the number of desired instances of the theme (was set at 2); and  
(c) the power of the study (set at 80% to mirror the quantitative sample calculation).  
Using Fugard and Potts (2015) Table 1 for adjusted prevalence of 15%, 2 instances and 
80% power led to the suggestion that approximately 19 participants would be required 
for the qualitative interviews, although slightly less would be acceptable as each 
participant will be interviewed three times (Fugard & Potts, 2015).   
7.6  Feasibility Trial 
During the first 9 months of recruitment (i.e between 1 April 2014 and 31 December 
2014 (the “Trial Period”)) 42 consecutive patients satisfying the eligibility criteria were 
invited to take part in the study in order to examine the feasilibity of the Protocol and to 




alterations were necessary (the “Feasibility Trial”). (Please refer to Appendix J for a full 
account of the Feasibility Trial). Of the 42 eligible patients identified by the researcher 
(across 3 London NHS Trusts) and invited to participate, 23 agreed and were consented 
into the quantitative study. At the end of the Trial Period 18 patients had completed T1 
and 8 had completed T2 of the quanitative study and their data are incorporated into 
the results reported in Chapters 8 and 9. 
All adjustments made to the design of the study following the Feasibility Trial (i.e from 
January 2015 onwards), were as follows:  
 the removal of the upper age limit for eligibile participants (the 
inclusion/exclusion criteria remained the same in all other respects);  
 the removal of the pre-screening test; and  
 a change in the type of analysis conducted on the longitudinal quanitative data 
(as discussed in Chapter 9) from ANCOVA’s to multi-level modelling.  
The design of the quantitative study remained the same in all other respects. A full 
account of the Feasibility Trial can be found in Appendix J. 
7.7 Participation rates  
Of the patients that declined to take part in the Feasibility Trial, 4 of the eligible ‘surgery 
only’ patients approached by the researcher said that they had completed treatment 
and did not want to keep being reminded of their diagnosis. They also felt that they had 
‘nothing to offer’ the study; 1 patient agreed to take part but on the scheduled date 
simply refused without any explanation and 1 patient failed the MOCA so could not 
continue into the study. For the eligible patients who were scheduled to have 




anyway and only wanted to be interviewed, 1 patient had severe dyslexia and was 
unable to do any of the assessments, a further 3 patients only wanted to do an interview 
study and the rest just said that they were simply not interested in taking part. The 
reasons given for refusal to participate were very similar to those provided to 
Mandleblatt and colleagues (2014), which included “not interested” (133 out of 310 
patients approached provided this reason), “too busy” (82/310), “too sick” (14/310), 
“live too far away” (65/310).  
However, due to the number of hospital sites involved and the discrepancies that 
regularly arose between pre and post-surgical staging of CRC it was not possible to 
obtain an accurate estimation of the total number of eligible patients with a diagnosis of 
resectable CRC attending each of the hospitals. In addition, as a number of members of 
the supervision team were involved in participant identification and recruitment 
(following the Feasibilitly Trial) and due to the introduction of new data protection 
laws, it was not possible to obtain a complete list of all those who refused to participate. 
Please see Chapter 8 Section 8.4.1 and Chapter 9 Section 9.7.1 for full descriptions of the 
participant participation rates for each of the quantitative and qualitative studies. 
7.8 Measures  
Detailed demographic and clinical information were gathered for each participant at T1 
using a self-report form.  







• Marital status: married/in civil partnership, in relationship, single, 
divorced/separated, widowed 
• Educational level: Primary, secondary, tertiary, undergraduate degree, master’s 
degree, doctorate degree 
• Employment status: Employed, self-employed, seeking job, housewife/husband, 
student, retired, long-term sick leave, unable to work. 
Clinical information was also collected through electronic hospital records regarding co-
morbidities, surgery type, hospitalization days, CRC staging and pain, anti-depressant 
and anti-sickness medication (See Appendix L for clinical details form used by the 
researcher to collect clinical data from hospital records).  
7.8.1 Pre-screening test 
At T1 (during the Trial Period), consented participants over the age of 65 were asked to 
complete the Montreal Cognitive Assessment (MoCA) version 3 as a pre screening test 
in order to exclude those with mild cognitive impairment (MCI) from taking part in the 
study (so as not to skew the the results by including those with pre-existing cognitive 
conditions). A raw score of less than 26 indicated MCI and precluded entry into the 
study. The MoCA is a brief screening instrument that evaluates multiple cognitive 
domains including short-term memory, visuospatial abilities, executive function and 
attention in 10 minutes.  It has demonstrated sensitivity in detecting MCI (90%) and 
good specificity at 87% (Nasreddine, Phillips, Bédirian, Charbonneau, Whitehead, et al 
2005).  
However, after the Trial Period (i.e from 1 January 2015 onwards) this measure was 




with mild cognitive problems who may still have shown cognitive impairment over time 
had they undergone the full battery of tests, as well as those who wished to continue in 
the study (Appendix J).  
The data in relation to the potential participants that failed the MoCA is not reported in 
this thesis as there was not enough to be adequately analysised quantitatively and 
consequently it was not considered relevant once the test had been abandoned.   
7.8.2 Quantitative study measures: 
A wide range of measures were used to assess cognitive function and psychosocial 
outcomes. The following criteria were considered when selecting measures: 
(a) To obtain as comprehensive as possible assessment battery for the time 
available   
(b)  The three core measures as recommended by the ICCTF (Wefel et al, 2011), 
(c) The applicability of the measure to the patient group (e.g. the Functional 
Assessment of Cancer Therapy-Colorectal (FACT C) quality of life measure which 
contains items specifically related to CRC),  
(d) Favourable reliability and validity reported in previous studies (reported where 
available), and   
(e) Availability of measures. 
A description of all of the measures included in the questionnaire booklets (the 




domains assessed. The Battery took approximately 2 hours and 30 minutes to complete 
at T1 and 1 hour and 30 minutes at each of T2 and T3.  
7.8.2.1 NP measures 
All participants underwent a detailed NP assessment as described below (See Table 
7.1). The Battery included the three core measures recommended by the ICCTF (Wefel 
et al, 2011), namely: 
 The Trail Making Test (Part A and B)(TMT A & B) (Reitan & Woolfson, 1985; 
Reitan, 1992);  
 Hopkins Verbal Learning Test – Revised (HVLT-R) (Brandt & Benedict, 2001); 
and 
 The Controlled Oral Word Association Test (COWA) (Ruff, Light, Parker & Levin, 
1996.).  
These were supplemented with the Digit Span subtest of the Wechsler Adult 
Intelligence Scales – Third Edition, (WAIS - III Digit Span) (Wechsler, D, 1981); The 
Symbol Digit Modalities Test (SDMT) (Smith, 1968; Smith, 1982); Grooved Pegboard 
Test (GP) (Klove, 1963; Matthews & Klove, 1964) and The Benton Visual Retention Test 
(BVRT) (Sivan, 1992). All measures were standardised, validated and taken from 
published test batteries with population norms. 
The Battery was ordered in such a way as to alternate and distribute the more difficult 
(cognitively challenging) tasks with the less difficult ones and to avoid the 
administration of any language and verbal memory tests during the 20–25 minute 




T3 alternate forms of the HVLTR, BVRT and TMT were used, with the aim of reducing 
participant practice effects. 
As discussed in Chapter 2, there are often overlaps in the cognitive domains assessed by 
each test. The tests used in the quantitative study were therefore classified into 
overarching domains adapted from Strauss, Sherman and Spreen (2006) and the ICCTF 
(Wefel et al, 2011). These overarching domains include tests that largely assess some 
aspect of a similar cognitive function as illustrated in Table 7.1 and described below. 
Table 7.1: Table detailing the tests included in the Battery: Neuropsychological 
tests grouped by principal cognitive domains, self-reported cognition, mood, and 
fatigue and quality of life measures  
NP measures 




The ability to 
selectively concentrate 
on one aspect of the 
environment, while 
ignoring other things 
Trail Making 
Test A 





SDMT Smith, A., 1982. 
Digit Span 




DS Wechsler, D 1997 
     
Domain Description Test/measure Abbreviation Reference 
Concentration The ability to 
concentrate mental 
powers on an object 
Symbol Digit 
Modalities Test 
SDMT Smith, A., 1982. 
     
Executive 
Function 
Cognitive abilities that 
control and regulate 
Trail Making 
Test B 





other abilities and 
behaviours 







COWA Benton, Hamsher 
& Sivan, 1989 
     
Motor Function The ability to perform 
body motor 
movements 











     
Processing Speed The ability to 
automatically and 
fluently perform 
relatively easy or 
overlearned cognitive 
tasks 
 TMT Reitan and 
Wolfson, 1985; 
Tombaugh, 2004 
     
Working Memory The ability to actively 
monitor, temporarily 








Smith, A., 1982. 
     
Verbal Memory The ability to retain 
linguistic information 
for a designated time 






Schretlen, et al, 
1998; Brandt and 
Benedict, 2001 
     
Visual Memory The ability to create an 




BVRT Benton, & Sivan, 
1992 




Reaction Time The ability to react 
and/or make decisions 







     
Measure of subjective cognition 
 Description Test/measure Abbreviation Reference 
Participants own 
perception of  
mental 
capabilities  
4 scales - perceived 
cognitive impairments 
(20 items); impact on 
QoL (4 items);  
Comments from others 
(4 items);  perceived 




Cancer Therapy  
Cognitive Scale  
FACT-Cog 
Version 3 
Wagner et al 2009 
Psychosocial measures 
 Description Test/measure Abbreviation Reference 
Anxiety and 
Depression 
 Hospital and 
Depression 
Scale 
HADS Zigmond and 
Snaith, 1983 
     












Yellen et al, 1997 
     
Health Related 
Quality of Life 




Being, and Functional 
Well-Being. 
Considered 
appropriate for use 
with patients with any 
form of cancer. 
Combined with FACT C 
specifically for CRC 
Functional 
Assessment of 
Cancer Therapy  
General and  
Colorectal 
Symptom Index  
FACT-G & C 
(Version 4) 





7.8.2.1.1 Measures of attention 
Symbol Digit Modalities Test (SDMT) 
Description 
The SDMT (Smith, 2002) assesses divided attention, visual scanning, tracking (Shum, 
MacFarland and Bain, 1990) and motor skills. It has demonstrated sensitivity in 
detecting the presence of brain damage, as well as changes in cognitive functioning over 
time and in response to treatment (Smith, 2002). 
A paper and pencil test that comprises rows of 110 blank squares each with an assigned 
symbol. Above the rows there is a coding key which consists of nine numbers (from 1-
9), each paired with an abstract symbol. The participant is required to use the key in 
order to match each symbol with a corresponding number and write these down as 
quickly as possible, consecutively in the order presented. The sequence of symbols is 
random (Strauss, Sherman, & Spreen 2006). Participants are asked to perform a 
practice trial on the first 10 symbols and are then given 90 seconds to complete the test. 
Premorbid Intelligence measure 
  Test/measure Abbreviation Reference 







Reasoning - only 
at T1. 




The test is administered twice. In the first trial responses are written down by the 
participant (SDMT Written) and in the second they are given orally and written down 
by the administrator (SDMT Oral). This allows drawing comparisons between visual-
motor and oral responses (Lezak, 1995; Strauss, Sherman and Spreen, 2006). 
Scoring 
A written and oral score is calculated by totalling the number of correct answers for 
each section in order to provide two differing indices of functioning, which assess 
attention, scanning abilities, and motor skills (Lezak, 2004). A higher score on each 
section indicates better performance.  
Psychometric properties 
The test-retest reliability of the SDMT has been shown to be high (0.91) (Hinton-Bayre 
Geffen, Geffen, McFarland, & Frijs, 1999). 
Trail Making Test: Forms A and B (TMT)  
Description 
The TMT (Reitan & Wolfson, 1985) is a two-part paper and pencil measure of attention, 
psychomotor speed and aspects of executive function and tests spatial organisation, 
visual pursuits, recall, and recognition. Part A (TMT A) requires the participant to 
connect 25 encircled randomly arranged numbers in ascending order without lifting the 
pencil from the paper in order to test visuo-scanning, numero-sequencing, and visuo-
motor speed. When completing Part B (TMT B) the participant is required to connect 25 




as possible. TMT B tests cognitive demands including visuo-motor, visuo-spatial 
abilities and mental flexibility.   
The participant first completes short practice exercises for Parts A and B in order to 
ensure familiarity with the test and comprehension of the test instructions. Both parts 
of the test are timed. The TMT-B subtest is terminated if the respondent takes over 5 
minutes to complete. 
Scoring 
Results for both TMT A and B are reported as the number of seconds required to 
complete the task; therefore, higher scores reveal greater impairment. Part B is more 
difficult than Part A; it takes longer to complete and may indicate difficulties in divided 
attention, executive functioning and cognitive flexibility along with conceptual motor 
tracking (Bremmer, Wert, Durica, & Weaver, 1997). Both scores (TMT-A and TMT-B) 
are reported in this study. 
Psychometric properties 
The test-retest reliability of the TMT varies with age-range and population (Strauss, 
Spreen & Sherman, 2006). Dikmen and colleagues (1999) examined 384 healthy 
individuals and who were retested 11 months after the first test and reported reliability 
coefficients as 0.79 for Part A and 0.89 for Part B. The inter-rater reliability has been 






The Digit Span subtest of the Wechsler Adult Intelligence Scales – Third Edition, 
(WAIS - III Digit Span) (Wechsler, D, 1981)  
Description 
The Digit Span measure of the WAIS III Scale consists of two mental activity tests 
involving auditory attention and short-term memory retention capacity. For each test, 
the administrator reads out random number sequences, which increase in length. There 
are two trials for each span length.  
The ‘Digit Span Forward’ test is a measure of focused attention where the participant is 
asked to repeat the random numbers to the administrator in the exact order given, 
continuing until the participant fails a pair of sequences or repeats the highest sequence 
correctly.  The ‘Digit Span Backward’ test demands more effort from working memory.  
The participant repeats the number pairs in exactly the reverse order until the 
participant fails a pair of sequences or repeats the highest sequence correctly.  
Scoring 
To score, no digits may be omitted or be in the wrong order. The maximum total digit 
forward score is 16 and the maximum total digit backward score is 14. The final score is 
obtained by adding the total forward score to the total backward score (for a maximum 







7.8.2.1.2 Measure of executive function 
Controlled Oral Word Association Test (COWA) 
Description 
The COWA of the Multilingual Aphasia Examination (Benton, Hamsher, & Sivan, 1989) is 
a test of executive functioning, verbal association and fluency (Benton, Sivan, Hamsher, 
Varney, & Spreen, 1994). Each participant is administered three trials of a phonemic 
fluency task that measures the spontaneous production of words within a restricted 
timeframe (Strauss, Sherman & Spreen, 2006).  The participant is asked to produce as 
many words as possible, beginning with each of the letters ‘C’, ‘F’ and ‘L’ excluding 
proper nouns (e.g. Bob, Boston) and repetitions of the same word with different endings 
(e.g. big, bigger and biggest). Participants are allocated sixty seconds for each letter (C, 
F, and L). The researcher records a list of all the words named by the participant. All 
errors, including repetitions and intrusions, are recorded along with correct words in 
the order in which they were generated. 
Scoring 
The total score is the sum of all admissible words for all three letters. A higher score 
indicates better performance. 
Psychometric properties 
The COWA-CFL has been shown to have moderate to high internal reliability (r=0.83) 




7.8.2.1.3 Measures of motor functioning and dexterity 
Grooved Pegboard (GP) (Klove, 1963; Matthews & Klove, 1964) 
Description 
The Grooved Pegboard task (Matthews & Klove, 1964) is a manual dexterity test 
measuring visuo-motor coordination. It has been useful in detecting motor dysfunction 
in cancer patients (Wieneke & Dienst, 1995). 
The test consists of a small metal board containing a 5x5 set of randomly positioned 
slots and 25 metal pegs that each has a ridge along one side. Participants are required to 
rotate the pegs in order match the groove of the peg with the groove of the hole for 
insertion, as quickly as possible consecutively across and down the grid (right to left for 
the left hand and vice versa) (See Figure 7.3). The participant continues until all pegs 
have been placed. The participant is required to complete two trials, one with the 
dominant hand and then the second with the non-dominant. A maximum of 5 minutes 
are allowed for test completion, after which the test is terminated. 







The score is computed for each hand and is the time taken to place the pegs. Some 
researchers also record the number of pegs dropped and the number of pegs not 
inserted. These two scores may be considered for clinical use as such errors are rarely 
seen in neurologically intact individuals, but they are less useful for population research 
purposes (Heaton, Miller, Taylor, & Grant, 2004; Strauss, Sherman and Spreen, 2006). In 
the present study, time taken to complete was the only score utilized. A higher score on 
each hand indicates poorer performance. 
Psychometric properties 
With retest intervals ranging from four to twenty-four months, the reliability 
coefficients of the GP are marginal/high (0.67 to 0.86) in normal populations aged 15 
years and older (Strauss, Sherman, and Spreen, 2006). 
7.8.2.1.4 Measures of memory 
Hopkins Verbal Learning Test - Revised (HVLT-R) (Benedict, Schretlen, et al, 
1998; Brandt and Benedict, 2001) 
Description 
The HVLT-R assesses verbal short-term learning and memory performance.  The test 
includes three learning trials (Trials 1-3), a delayed recall (25 minute delay) (Trail 4), 
and a yes/no recognition trial.  Six distinct forms of the HVLT-R are available, 
minimizing practice effects on repeated administrations. Form 1 was used at T1, Form 2 




Each form of the HVLT-R consists of a list of 12 nouns, with four items drawn from each 
of three semantic categories. A list is read to the participant who then attempts to recall 
as many words as possible in any order. The administrator records each response 
verbatim including intrusions and repetitions. This task is repeated two more times. 
After an interval of 20 to 25 minutes, a delayed recall trial is administered. Again, 
responses are recorded verbatim. Finally, a list of 24 randomly ordered words that 
consist of the 12 target words and 12 non-target foils is read. The participant is asked to 
identify as many target words as possible with a “yes” response and to respond to the 
non-target words with a “no” response.  
Scoring 
The number of correct words recalled are counted as correct for each trial up to a 
maximum score of 12. The total recall score is the sum of the Trials 1 to 3. The delayed 
recall score is the number correct on Trial 4. The percentage retention score is 
calculated as Trial 4 divided by the best of Trials 2 and 3 and multiplied by 100; and the 
recognition discrimination index is the number of true positives minus the number of 
false positives on the last trial administered.  
Psychometric properties 
The HVLT-R is reportedly useful in screening for dementia (Hogervorst, Combrinck, 
Lapuerta, et al, 2002; Shapiro, Benedict, Schretlen, & Brandt, 1999; Carey, Woods, 
Gonzalez, et al, 2004), although the authors of the test reported reliability coefficients as 
follows: 0.74 for Total Recall; 0.66 for delayed recall; 0.39 for % retention and .40 for 
recognition discrimination index. Forty older adults had completed different forms of 




The Benton Visual Retention Test (BVRT) (Sivan, 1992)  
Description 
The BVRT is a measure of visual perception, visual memory and visuo-constructive 
ability. There are three near-equivalent forms (Forms C, D, and E) of the BVRT. Each of 
the three test forms consist of 10 designs presented one-by-one.  Form C was used at 
T1, Form D at T2 and Form E at T3, which allowed for retesting while minimizing 
practice effects. Administration A (of the four possible methods) was used throughout.  
The participant viewed each design for 10 seconds before reproducing it from memory. 
The test was not timed and the results were scored by form, shape, pattern and 
arrangement on the paper.  
Scoring 
There are two scores for describing a participant’s performance. The Number Correct 
Score which is a measure of the participant’s overall level of performance; and the 
Number Error Score which provides information about the frequency of specific types 
of errors made by the participant.  
Number Correct Score: The participant’s reproduction of each design is judged on an all 
or none basis. If the reproduction contains no errors, it is scored as correct and awarded 
1 point. If the reproduction contains any errors, it receives 0 points. The range of 
possible scores for any single form of the test (10 designs) is 0 to 10 points.  
Number Error Score: In any less than perfect reproduction the number of errors is 
recorded and each error is classified and recorded by type. The specific types of errors 




Misplacements and Size Errors. Within these are 56 specific error types. An incorrect 
reproduction may contain as many as four specific errors.  
Psychometric properties 
The test-retest reliability of the BVRT is 0.85, and alternate form reliabilities range from 
0.79 to 0.84 (Benton, 1992). Correlation between immediate and delayed memory recall 
(Administration A and D, respectively) range from 0.40 to 0.83, depending on the 
combinations of forms used. Total errors on the test have been shown to increase with 
age, especially after 70 (Emilien, Durlach, Antoniadis, Van der Linden, & Maloteaux, 
2004). 
7.8.2.2 Self-reported cognitive assessments 
Functional Assessment of Cancer Therapy-Cognitive scale (FACT-Cog, Version 3) 
Subjective cognition was measured using the Functional Assessment of Cancer Therapy-
Cognitive scale (FACT-Cog, Version 3) (Wagner et al, 2009). It is a validated self-report 
measure of cognitive function, which aims to evaluate the “real-world” impact of CRCI. It 
evaluates mental acuity, attention and concentration, memory, verbal fluency, 
functional interference, deficits observed by others; change from previous functioning, 
and impact on quality of life. Items developed for the FACT-Cog were based on 
interviews and focus groups with oncology patients and providers (Wagner, Sweet, 
Cella & Doninger, 2003); they included behavioural examples of cognitive dysfunction, 




In all ‘FACT’ assessments, the participant responded on a 5-point scale from “not at all” 
to “very much” as to the extent to which they had been affected by the item in the prior 
7 days. 
Scoring 
The FACT-Cog contains 37 items, with subscales created by the developers consisting of 
1) patients’ perceived cognitive impairments, 2) perceived cognitive abilities, 3) 
noticeability or comments from others, and 4) impact of cognitive changes on quality of 
life (Webster, Cella, Yost, 2003). A global or summary score is obtained by summing all 
the item scores. The total scores for each of the FACT Cog subscales have the following 
ranges: 
Perceived Cognitive Impairment (PCI): 0-72 
Perecieved Cognitive Abilities (PCA): 0-28 
Impact of PCI on quality of life (CogQoL): 0-16  
Comments from Others (Oth): 0-16   
FACT Cog Total: 0-132 
with higher scores denoting better function and less cognitive symptoms. It was 
administered to all participants’ at all three time points.  
Psychometric properties 





7.8.2.3 Psychosocial measures   
Psychosocial self-report questionnaires assessing mood and quality of life were also 
included in the quantitative component of the study. As discussed in Chapter 2 some of 
these measures, such as depression and anxiety are known to have the potential to 
influence cognitive functioning and hence were selected to assess their relationship to 
cognition (Lezak. Howieson, Bigler, & Tranel, 2012).  
Measures of Mood: Anxiety and depression: 
The Hospital Anxiety and Depression Scale (HADS) (Zigmond & Snaith, 1983)  
Description 
Anxiety and depression were measured at each time point using the Hospital Anxiety 
and Depression Scale (HADS) (Zigmond & Snaith, 1983), developed specifically for the 
measurement of depression and anxiety in physically ill populations. Participants were 
asked to reflect upon the past 7 days and to rate 14-items on a 4-point Likert scale 
(seven items measured anxiety and seven measured depression). The scores for each 
subscale were summed together to obtain a measure of the amount of anxiety and 
depression experienced in the week prior to test administration.  
Scoring 
The scores can range from 0-21. Separate scores for depressive and anxious 
symptomology were calculated with scores ≤ 7 = no depression/anxiety; 8-10 = 






The HADS measure usually takes approximately five minutes to complete and has been 
widely used in research with breast cancer patients (e.g. Hermelink, Untch, Lux et al., 
2007; Weis, Poppelreuter, & Bartsch, 2009). The subscale scores of depression and 
anxiety have been validated in cancer patients. For example, principal components 
analysis in a sample of 568 cancer patients revealed a 2 factor solution corresponding to 
anxiety and depression and high internal consistency (anxiety subscale, α = 0.93; 
depression subscale, α = 0.90) (Moorey, Greer, Watson, et al, 1991). 
Fatigue 
The Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-F, version 
4) (Yellen et al, 1997) 
Description 
The Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-F, version 4) 
FACIT-F is a commonly used measure of cancer-related fatigue in clinical trials (Cella et 
al, 1993; Yellen et al, 1997; Wu & McSweeney, 2001; Passik, Kirsh, Donaghy et al, 2002). 
It is a 13-item self-report subscale of the FACT-G (see below) and is a well-validated 
quality of life instrument.  The items include physical and functional consequences of 
fatigue (Yellen et al, 1997). It usually takes no more than 5 minutes to complete.  
Scoring  
Participants are asked to rate the intensity of fatigue and its related symptoms 




‘very much’. The total score ranges between 0 and 52, with higher scores denoting less 
fatigue. It was administered to all participants’ at all three time points.  
Psychometric properties 
This measure has demonstrated excellent internal consistency in a study of 1,011 
cancer patients (α = 0.93) (Lai, Cella, Chang, Bode, & Heinemann, 2003).  
Health Related Quality of Life measure: 
The Functional Assessment of Cancer Therapy - General (FACT-G, Version 4) and 
FACT C  
Description 
FACT-G is a 27-item self-administered questionnaire used to measure four quality of life 
domains (Cella et al, 1993): physical (PW), emotional (EW), family/social (SW) and 
functional well-being (FW) in the previous 7 days. Participants also completed the 9-
item FACT-C subscale (CCS) that evaluates symptoms related specifically to CRC 
including energy, pain, weight, diarrhoea, nausea, swelling or cramps in the stomach 
area, appetite, ability to enjoy life, and overall quality of life. All the items are based on a 
5-point Likert scale except for the one investigating the presence of stoma (yes/no). 
These scales provide reliable measures in patients with CRC and have been extensively 
validated (Ward, Hahn, Mo et al, 1999; Cella et al, 1993).  
Scoring  
Items are summed to give scores for each domain and can also be summed to provide 






Concurrent validity of the FACT-G has been provided with the Functional Living Index–
Cancer (r = 0.80) (Schipper, Clinch, McMurray, & Levitt, 1984) and the Quality of Life 
Index (r = 0.74) (Ferrans, 1990) in a sample of 854 adult participants with 15 different 
types of cancer. Internal consistency has been satisfactory for the FACT-G (α = 0.89), as 
well as individual dimensions (α = 0.65 to 0.82) (Cella et al., 1993). Ward and colleagues 
(1999) reported higher internal consistency for FACT-C (0.91) than for FACT-G (0.88) 
as measured from 2 separate samples (n= 60 and n=63). Similarly, Yost and colleagues 
(2005) reported internal consistency separately for three different samples 
(observational, preliminary and clinical trial sample). Overall, Cronbach’s alpha was 
reported between 0.87-0.92 for the FACT-C total and a low 0.59-0.76 for CCS. 
7.8.2.4 Measure of IQ – only at T1  
Sub-scales from the Wechsler Abbreviated Scale of Intelligence – second edition 
(WASI – II)  
Description 
The WASI-II is used to measure general intellectual function in individuals between the 
ages of 6 and 90 years. The WASI-II is comprised of four subtests, which require 
approximately 30 minutes to complete. However, where time is a constraint only two 
subtests are needed to estimate general cognitive functioning in less than 15 minutes – 
namely Vocabulary and Matrix Reasoning. 
To reduce patient burden, this study utilized the shorter recommended administration. 




been established in the literature (Jeyakumar, Warriner, Raval, & Ahmad, 2004). This 
method of reducing the number of subscales rather than items per subscale was 
considered a more reliable technique to reduce test burden without compromising the 
overall assessment (Jeyakumar et al, 2004). 
The vocabulary subtest involves the administrator asking the participant to define 
words that are presented visually and orally (E.g. – Please could you me what shirt 
mean?). The matrix reasoning subtest assesses the participant’s fluid intelligence, broad 
visual intelligence, classification and spatial ability, knowledge of part-whole 
relationships, simultaneous processing and perceptual organisation (Groth-Marnat, 
2003; Kaufman & Lichtenberger, 1999; Sattler, 2008)   
Scoring 
The total raw score for each subtest is calculated by summing the item scores. The raw 
scores are then converted to T scores based on age and provided in the test manual. The 
Full Scale IQ-2 is calculated by summing the T scores for vocabulary and matrix 
reasoning and then by reference to the composite score conversion table provided in 
the manual.   
7.8.3 Qualitative study measures 
Semi structured interviews were used at each time point. The topic guides and 
interview schedules (See Appendix M) were developed by the researcher in 





Table 7.2: Semi-structured interview topic guides at each time point  











Aware of side 
effects? Aware of 
CRCI? 
Information received 
about side effects. 





Now Changes Continuing? 
Experience of 
cognitive changes 
Have you been aware 




diagnosis or surgery? 
Have you been aware 
of any changes in the 
way your 
mind/thoughts 




Continuing since end 
of treatment? 
Tiredness Do you have any 
problems with 
sleeping 
Do you have any 
problems with 
sleeping 





Do the changes 
bother you or 
interfere with your 
everyday life in 
anyway? 
Do the changes 
bother you or 
interfere with your 
everyday life in 
anyway? 
Do the changes 
bother you or 
interfere with your 
everyday life in 
anyway? 
Effect on social life
  
How is your social 
life? 
How is your social 
life? 
How is your social 
life? 
Is there anything 
else you would like 
to share about your 
experience? 
Is there anything else 
you would like to 
share about your 
experience? 
Is there anything else 
you would like to 
share about your 
experience? 
Is there anything else 
you would like to 






7.9 Data analyses  
The following is a brief overview of the analyses that were carried out for each study 
included in this thesis. Full descriptions can be found in the following Chapters 8, 9 and 
10. 
7.9.1 Quantitative analysis 
All of the data collected from the NP measures and self-report questionnaires were 
entered into SPSS and all analyses were conducted using IBM SPSS (Statistical Package 
for the Social Sciences) version 25.  
Once all of the data (for all time points) had been entered on SPSS it was cleaned and 
checked for missing values. Preliminary analyses were conducted to check assumptions 
of normality. This process is fully described in the following Chapter 8. An alpha level of 
.01 was used for all analyses, unless otherwise stated. Effect sizes statistics are reported 
where relevant as detailed in Chapter 8. 
Multiple imputation procedures were then conducted for data missing at item and scale 
level rather than ANCOVA’s as was originally discussed in the Protocol (Appendix K) for 
the reasons outlined in Chapter 9. Preliminary analyses compared baseline scores of 
OCI, SCI, anxiety, depression, fatigue and HRQoL across the 2 participant groups. 
Multilevel modelling was used to assess change in cognitive functioning and 
psychosocial outcomes over the nine-month study period; and correlational analyses 
were used to explore all potential relationships between important outcomes. Please 
see Chapters 8 and 9 for a full account of the rationale and analysis strategy employed 




7.9.2 Qualitative analysis  
All interviews were conducted and transcribed verbatim by the researcher. A two-stage 
process of analysis was then applied to the data.  First, inductive thematic analysis was 
conducted for each interview. This is a method of identifying, analysing, and reporting 
patterns (themes) within data (Braun & Clarke, 2006). This was then followed by 
further analyses of the data inspired by Saladans (2003) in order to examine the 
changes that emerged over time.  The rationale and analytical steps are fully described 
in Chapter 10.  
7.10 Summary 
This chapter has described the design and recruitment strategies involved in this 
research as well as the measures used for each of the quantitative and qualitative 
studies. A detailed account of the analysis used and the results obtained in the 




Chapter 8: BASELINE ANALYSIS AND RESULTS  
Cognitive function prior to adjuvant chemotherapy treatment 
in patients with CRC 
 
8.1 Introduction  
This chapter presents the analysis strategy and results for Research Question One: 
“What is the nature and extent of cognitive impairment in patients with resectable 
colorectal cancer (CRC) prior to adjuvant chemotherapy treatment?” together with the 
related objectives as detailed in Chapter 6. Following an account of the analysis strategy, 
an examination of data assumptions are presented before the description of participant 
demographic, clinical, neuropsychological and psychosocial characteristics along with 
an examination of the potential differences between the surgical and chemotherapy 
groups at baseline. 
8.2 Preliminary statistical analysis 
8.2.1 Data screening  
Data for all time points were screened to ensure that all variables fell within possible 
ranges, that there were no errors in data entry or missing values. All manual errors 
and/or values that were out of range were crosschecked using the raw data and 
corrected where necessary. The types of missing data that were identified included NP 
raw scores and individual items and entire sub-scales in questionnaires.  
8.2.2 Missing value analysis  
Missing value analysis was performed at item and scale level. The overall amount of 




number of chemotherapy cycles administered, variations in chemotherapy treatment 
administered and anti-sickness drugs administered) was not available for all 
participants (Appendix N). These items were therefore not considered in the analysis.  
In demographic characteristics, five items (0.43%) were missing out of 1176.  
Mean item replacement was undertaken when calculating scale scores on the Hospital 
Anxiety and Depression Scale (HADS) for cases that had ≤ 50% of items missing before 
conducting scale imputation, as suggested by Graham (2009). In cases where more than 
50% of items were missing the scale score was considered missing and missingness was 
treated at scale level. The Functional Assessment of Cancer Therapy–Cognitive Function 
(FACT Cog), Functional Assessment of Cancer Therapy -General and Colorectal (FACT G 
& C) and Functional Assessment of Chronic Illness Therapy Fatigue Scale (FACIT 
Fatigue)(together the “FACT battery”) have scoring manuals that are each 
supplemented by SPSS syntax which addresses missing data prior to scoring the 
subscales. For the present study, the official scoring syntax was used as per the scoring 
manuals.  
When participants missed an entire time point or a whole questionnaire at a given time 
point, missing data were not replaced. Only fully completed sub-tests of the NP 
measures at any time point were used in the analyses. There were no cases where data 
was considered not applicable. If someone chose not to complete a subtest it was 
considered missing. For example, if a participant was unable or refused to do the 
Grooved Pegboard (GP) with one of his/her hands due to arthritis or some other pain 




For missing data at the scale level and item level (where scales were not viable), 
multiple imputation (MI) was conducted using MCMC procedures within the SPSS 
MULTIPLE IMPUTATION procedure (m=10). Data from all time points was used to 
predict the missing data, but the three time points were imputed separately only for 
participants who provided data at that time point. The resultant 10 datasets were 
individually analysed using the regular statistical procedures. Rubin’s rules for 
combining multiple imputations (Rubin, 1987; Schafer & Olsen 1998) were then utilised 
to combine the results from the 10 datasets. In analyses including only variables where 
<10% data was missing, a single imputation was analysed. 
8.2.3 Data assumptions 
8.2.3.1 Normality 
 
Although it has been argued that parametric tests tend to be robust to moderate 
violations of assumptions in relatively large samples (i.e. over 30)(Field, 2009; 
Tabachnick & Fidell, 2007) a number of steps were taken to check the normality of data 
for all dependent variables (DVs). The significance (p< .001) as suggested by Tabachnik 
& Fidell, 2007) of the Shapiro Wilk test was considered, as shown in Appendix O. A 
significant result indicates non-normal distribution.  It was significant for most NP 
measures, HADS anxiety and depression, FACT-C physical wellbeing (PWB), emotional 
wellbeing (EWB) and social wellbeing (SWB) subscales, FACIT fatigue and all of the 
FACT Cog subscales at all time points as shown in Appendix O.  The distribution of the 
variables was also examined visually by exploring the data using histograms and Q-Q 
plots.  It is usual for measures such as depression and fatigue not to be normally 




depressed or fatigued in the general population, although as discussed in Chapter 2 
Section 2.4.3, in the context of cancer patients a larger proportion may be feeling 
fatigued and/or depressed.  
Although data that is non-normally distributed may be transformed (using mathematic 
formulas to attain a more normal data distribution) when conducting statistical analysis 
only the NP measures were transformed, in this study.  Unless stated otherwise, non-
parametric tests were used where the data was not normally distributed.  
8.2.3.2 Outliers 
 
Boxplots and standardised z scores greater than ±3.29 (Tabachnick & Fidell, 2007) 
revealed a number of outliers on the NP tests (in particular TMT B, HVLT-R retention 
and GP). Outliers are observations that lie an abnormal distance from other 
observations. An outlier may be due to variability in the measurement or it may indicate 
experimental error, which can cause serious problems in statistical analyses. 
Researchers disagree on whether outliers should be removed from the analysis. Unless 
they are erroneous data entries, outliers may contain valuable information and can 
represent the inherent variability of the variable in question (Orr, Sackett, & DuBois, 
1991). In addition, removing cases that have random outlying scores may greatly 
reduce the sample size. Therefore, outliers were retained in order to maximise sample 
size and because it was believed that in this study, they would provide valuable 





8.2.3.3 Floor and ceiling effects 
Floor and ceiling effects in all measures were assessed. A floor effect occurs when the 
majority of the participants score near the bottom of the scale. Whereas a ceiling effect 
occurs when most of the participants score at the top of the scale. Such effects indicate 
that the measure does not have the sensitivity or range of scores to differentiate the 
group of participants well. It therefore limits the utility of the scale. For example, in a 
longitudinal study a questionnaire may be unable to detect further deterioration or 
improvement in a group of participants if a high proportion of the group scored at the 
scale minimum or maximum (respectively).   
In the present study, there were no median values the same as the minimum or 
maximum values of any NP measure. On the questionnaire measures, however there 
was one subscale on the FACT Cog, which asked participants to report on what others 
had said to them about their cognition (‘Comments from Others’ FACT Cog (Oth)), 
where 68 participants (83%) said that they had never been told by other people that 
they were having any cognitive difficulties. On all of the other measures less than 25% 
of the participants scored at the minimum or maximum so floor and ceiling effects were 
not considered to be substantial.  
8.2.3.4 Scale reliability  
 
All scales and subscales of the psychosocial questionnaires used in the study showed 
good internal reliability based on Cronbach’s alpha scores (Table 8.1) ranging from 





Table 8.1 Internal reliability of all scales at each time point 
Scales & Subscales 
 
No of Items Cronbach alpha 
  T1 T2 T3 
HADS     
HADS Anxiety 7 
 
.840 .881 .895 
HADS Depression 
 
7 .720 .711 .766 
FACT C      
PWB 7 .800 .842 .828 
SWB 7 .784 .791 .801 
EWB 6 .727 .789 .792 
FWB 7 .815 .864 .879 
CCS 7 .632 .638 .744 
91 .4102 .376 .692 
FACT Cog     
PCI 18 .9773 .951 .958 
Oths 4 .767 .912 .764 
PCA 7 .918 .900 .928 
QoL 4 .916 .921 .923 
FACIT Fatigue 13 .923 .931 .952 
Key: FACT C CCS1 = the extra 2 items are in relation to a stoma which not all patients had fitted 
FACT C CCS2 = the extra 2 items only applied to a small number of patients  
PCI3 = Scales with a large number of items may cause an inflated Cronbach’s alpha;  
FACT C subscales: PWB: Physical wellbeing; SWB: Social wellbeing; EWB: Emotional wellbeing; FWB: functional 
wellbeing; CCS: Additional colorectal concerns; FACT Cog subscales: PCI: Perceived cognitive impairments; Oths: 





Although the FACT C CCS scale has a poor alpha coefficient when the additional 2 items 
relating to the stoma are added, the scale was still used in this study. The reason being 
that the items of concern are very different from the rest of the items and only apply to 
a small number of participants.  
8.2.3.5 Level of statistical significance 
For all preliminary and main analyses the level of statistical significance was set at  
p<0.01. This significance level was considered most appropriate in light of the large 
number of tests performed and the risk of obtaining a false-positive result i.e. rejecting 
the null hypothesis when it is in fact true (Type 1 error).  
8.3 Statistical analysis strategy for Research Question One 
8.3.1 Demographic and clinical characteristics of the sample 
Differences in socio-demographic characteristics between participant groups (IV: 
(chemotherapy and “surgery only”) were analysed using independent sample t tests for 
continuous variables (DVs: anxiety, depression, fatigue, and subjective cognitive 
function) and Chi-square (χ2) tests for independence for categorical variables (e.g. 
gender, English as a first language and type of surgery). The Fisher’s exact probability 
test was reported where cell counts were lower than 5 and for 2x2 analysis. Cramer’s V 
(φc) (.10= small, .30= medium, .50= large) and Cohen’s d (0.2= small, 0.5= medium, 0.8= 
large) effect size measures were reported for χ2 tests and t-tests respectively. Means 
and standard deviations for continuous variables and frequencies with percentages for 




8.3.2 Cognitive impairment at T1 
As an initial step, analyses were conducted on the post-surgery pre-chemotherapy 
baseline data (T1) to identify  
1.1 Prevalence of OCI prior to systemic treatment in each group; 
1.2 The most commonly affected domains of cognitive functioning in each group; 
and 
1.3 Differences between the participant groups on the following DVs: anxiety, 
depression, fatigue and self-reported cognitive function.  
8.3.2.1 NP data scoring 
To judge the nature of performance on a test relative to the normative data, the raw 
score was converted to a standardised score for each test (except for the Benton Visual 
Retention Test (BVRT) and Digit Span as described below). Following the procedure of 
the ICCTF (Wefel et al, 2011), raw scores on the NP tests were converted into z scores 
(mean=0, SD=1) using published normative data adjusted for age, education, and gender 
as shown in Appendix P. The z score is expressed in terms of standard deviation units 
from the mean of the general population.  Such conversion allows the researcher to 
determine the participants’ relative standing compared with the normative group, it 
also allows for a direct comparison of scores across different tests. 
In relation to the Digit Span forward and backward tests, the raw scores were used to 
establish impairment, in accordance with Lezak’s advice that it ‘makes more sense to 
deal with the data in raw score form than to convert them’ (Lezak 2004, p 404) for this 




establishing impairment on the BVRT in accordance with the guidelines provided in the 
manual also detailed in Appendix P. 
8.3.2.2 Criteria used for establishing cognitive impairment  
After evaluating each participant’s test performance in order to determine if there was 
OCI, one out of the two following criteria had to be met:    
1) z scores of ≤−1.5 SD below the normative mean score for two or more NP tests 
(1.5 SD criteria); or  
2) z scores of ≤−2.0 SD below the normative mean score for just one NP test (2 SD 
criteria)  
as recommended by the ICCTF (Wefel, 2011).  
It is important to bear in mind that cognitively intact individuals are likely to vary in 
their performance on any cognitive test battery and may score in the impaired range by 
chance on 1 to 2 tests in any given cognitive test battery (Taylor and Heaton, 2001, 
Lezak, et al, 2012). In addition, the probability that individuals will have deviant test 
scores rises as the number of tests in the battery is increased (Ingraham & Aitken, 
1996). Therefore, when using multiple measures in test batteries additional factors such 
as the risk of overestimating the extent of cognitive impairment needs to be taken into 
account.  Ingraham and Aitken, (1996) suggest that a mathematical formula based on 
binominal theory should be used to calculate the probability of finding impairment in 
the normal population based on the number of tests utilized, and the established cut-off 
criteria for cognitive impairment employed (i.e. 1.5 and 2SD). Although this approach 
assumes independence between the tests, they justify the formula even when the tests 




provided of the percentage of the population exhibiting impairment may be reported as 
being higher than expected. (I.e. they acknowledge that the binomial approach can 
overestimate the required percentages, due to the additional variance, correlated scores 
may add).  
The present study included seven measures each with a number of subscales that 
produced 15 scores in total. As the size of the test battery could influence the number of 
abnormal test results obtained, the equations of Ingraham and Aiken (Ingraham & 
Aiken, 1996) were used (in accordance with the recommendations of the ICCTF (Wefel 
et al, 2011) to determine  whether the frequency of observed OCI exceeded expectation 
based on use of multiple measures.  In order to determine if the proportion of 
participants found to be impaired was higher than the expected value (for each criteria) 
a one-sample proportions test for the total sample was undertaken.  
8.3.3 Relationships between NP measures and psychosocial outcomes 
Bivariate correlational analysis (Pearson’s correlations for parametric data and 
Spearman’s rho for non-parametric data) was used to assess the relationships (if any) 




8.4 PRE-CHEMOTHERAPY TREATMENT RESULTS 
Research Question One: What is the nature and extent of cognitive 
impairment in resected CRC patients prior to chemotherapy 
treatment? 
8.4.1 Participation rates  
One hundred and twenty patients meeting the study inclusion criteria provided written 
consent to take part in the quantitative study. However, of the 120 consenting patients, 
6 (5%) were ineligible based on the inclusion/exclusion criteria and 16 (13.33%) 
withdrew from the study prior to the first assessment as illustrated in Figure 8.1 Due to 
ethical reasons in relation to accessing the patient records of individuals who did not 
consent, examining differences in key demographic and clinical characteristics between 
participants and non-participants was not possible. The final sample in the quantitative 
analyses at T1 consisted of 98 participants: 63 chemotherapy participants and 35 






8.4.2 Demographic and clinical characteristics of the sample  
Table 8.2 summarises the demographic characteristics for the two participant groups 
(i.e. the chemotherapy group and “surgery only” group) after surgery at (T1). 
Demographic and clinical information was reported for all participants with available 





Table 8.2: Demographic and medical characteristics for all participants at T1  








df Significance Effect size 
       




t=1.574 96 .119 Cohens d = 
-.30 
Age range in years 31-80 25-84 
       






t=-.404 91 .274 Cohens d = 
.08 
       
Education       
 < 12 years 17 10 Fishers 
exact test 
 1.00 V=.017 
 > 12 years 46 25 
       
Gender       





 Female 34 (54%) 15 (43%) 
       
Marital Status       
 Single1 25 18 χ²=.829 1 .363 V=.113 
 Married2 38 17 
       
Occupational Status       
 Employed3  25 14 Fishers 
exact test 
 .833 V=.028 
 Not employed4 36 21 
 Student6 2 0 
       
Nationality        
 UK5 54 24 Fishers 
exact test 
 .066 V=.204 
 Other 9 11 
       
Native English Speaker       
 Yes 51 25 Fishers 
exact test 
 .318 V=.109 
 No 12 10 
       
Tumour stage 7       
 Stage I 2 9 χ²=44.195 4 .000 V=0.672 












df Significance Effect size 
 Stage III 43 2 
 Stage IV 4 0 
       
Tumour site7       
 Colon 44 24 χ²=1.185 2 .110 V=0.553 
 Rectal 12 9 
 Colon & rectal 7 2 
       
Type of surgery        
 Keyhole 37 24 χ²=.425 1 .514 V=-.088 
 Open  25 11 
       
Stoma       
 Yes 18 9 Fishers 
exact test 
 .817 V=0.31 
 No 45 26 
       
Comorbidities       
 None 17 12 t=-1.063 96 .290 Cohens d = 
.24  1 or 2  31 17 
 3 or 4 15 6 
       
Mean (SD)  number of 






t=-1.248 96 .005 Cohens d = 
-.21 
Key: CT: Chemotherapy group; 1 Includes divorced and widowed participants; 2Includes defacto couples; 
3Employed includes full and part time; 4Not employed includes unemployed, retired & homemaker; 5 UK 
includes English, Welsh, Scottish, Northern Irish, British; 6Students were counted as being employed in 
the analysis; 7Tests not run for these variables because of the low cell counts. V= Cramer's V  
 
As can be seen in Table 8.2 there were no significant group differences found for gender, 
marital status, English as a first language or nationality. The overall mean age for the 
whole sample was 63.10 years (SD 11.26) (range: 25-84) with 49 (50%) males and 49 
(50%) females in the total sample. The mean age for the chemotherapy group was 
slightly younger at 61.78 compared to a mean age of 65.49 years in the “surgery only” 




than the “surgery only” group (57%) and more than half of the participants in the 
chemotherapy group were married or in a relationship (60.3%) (Figure 8.2) and the 
majority were unemployed in both groups (57% and 60% respectively).   










N = 63 N=35 
Age: 31 - 80 Age: 25 - 84 
M= 61.8 ; SD = 1.28 M= 65.5 ; SD = 2.18 
Male: 29 (46%); Female: 34 (54%) Male: 20 (57%); Female: 15 (43%) 
 
There was no significant difference in years in education or IQ scores for the two groups 
(Table 8.2). The level of education of the study sample was initially classified into seven 
sub-groups but due to the small proportion in many categories (e.g. primary, secondary 
school, degree, masters and doctorate) groups were combined into a dichotomous 
variable (≤12 years and > 12 years, as this was how the norms used were split), with 
most of the study sample having been in education more than 12 years.   
Sixty three percent of the participants had keyhole surgery but the groups did not differ 




Although as expected, the cancer diagnosis was more advanced in the chemotherapy 
group with 74.6% having stage 3 or above compared to 5.71% in the “surgery only” 
group.  Just over half of the individuals in the chemotherapy group (54%) were 
scheduled to have 12 chemotherapy cycles (i.e. FOLFOX/5FU), and the rest were 
scheduled to have 8 cycles.  73% of the chemotherapy group had at least one 
comorbidity. However, there were no significant differences between the groups in the 
number of co-morbidities reported by participants, t (96) = 1.13 p= .290; or in time 
from surgery to the first assessment t (96) = 1.248 p= .005. 
8.4.3 Research Objective 1.1: Prevalence of cognitive impairment prior to 
systemic treatment in each group  
 
There was cognitive impairment in both groups after surgery and prior to the start of 
the chemotherapy treatment (T1) as shown in Table 8.3.   
Table 8.3: The number and percentage of participants found to be cognitively impaired at 
T1 according to the ICCTF criteria:    
 1.5 SD criteria 2 SD criteria 

















1.003 1 .317 .101 29 
(46.03%) 














    50 (51%)     
Key: CT: Chemotherapy patient group 
There was no statistically significant difference between the groups in terms of 
impairment (Table 8.3) at T1 (irrespective of the criteria): 




 2 SD criteria: χ² (1, n=98) =1.757, p=.185.  
52.38% of the chemotherapy patient group and 62.86% of the sample “surgery only” 
patient group showed impairment on the ICCTF’s 1.5 SD criteria. Whereas a smaller 
proportion of participants in each group (46.03% and 60% respectively) exhibited 
impairment on the ICCTF’s 2SD criteria. 
These findings appear to show that there is no association between type of treatment 
and cognitive impairment, as measured in this study sample.  
Based on the number of test scores and the impairment criteria used in the present 
study, the estimation provided by Ingraham and Aiken (1996) suggests that 
approximately 30% of the sample can be expected to exhibit impairment on at least two 
tests using an impairment criterion of 1.5SD and 34% of the sample can be expected to 
exhibit impairment on at least one test using an impairment criterion of 2SD.    
A chi square goodness of fit test indicates that there was a statistically significant 
difference in the proportion of impaired participants identified in the whole sample 
(56.1%) as compared with Aiken’s 30%, (when using the 1.5 SD criterion), χ² (1, n=98) 
=31.845, p=.00. 
There was also a statistically significant difference in the proportion of impaired 
participants identified in the whole sample (51%) as compared with Aiken’s 34%, 
(when using the 2 SD impairment criterion), χ² (1, n=98) = 12.652, p=.00. 
So, although there is no statistically significant difference between the groups (i.e. both 




impaired at T1 compared to what would be expected in a normal population matched 
for age, gender and education.   
8.4.4 Research objective 1.2: The most commonly affected domains of 
cognitive functioning in each group.  
As can be seen in Table 8.4 the most commonly affected cognitive domain(s) for the 
whole sample were executive function, motor function and verbal memory. The 
“surgery only” group were proportionally more impaired than the chemotherapy group 
at T1 on both tests of executive function and on the verbal memory recall and 
recognition tests (HVLR – recall and recognition) on both criteria of impairment.  Also, 
26.98% and 25.71% in the chemotherapy and “surgery only” groups respectively were 
found to be impaired on the Digit Span backwards when using the 1.5 SD criteria. 
When using 2 SD criteria, no one in the “surgery only” group and very few in the 
chemotherapy group were found to be impaired in attention as measured by Digit Span 




Table 8.4. The number and percentage of participants in each group found to have  









Total number (%) of  
participants1  who scored 1.5 
SD below normative mean on 
each measure 
Total number (%) of  
participants1 who scored 2 
SD below normative mean 
on each measure 
CT (n=63) Surgery only 
(n=35) 






TMT A 3 (4.76) 5 (14.29) 2 (3.17) 5 (14.29) 
DS forward  4 (6.35) 3 (8.57) 0 0 
DS 
backward 





4 (6.35) 1 (2.86) 4 (6.35) 0 
SDMT  oral 6 (9.52) 5 (14.29) 5 (7.94) 2 (5.71) 
Executive 
Function 
TMT B 8 (12.70) 5 (14.29) 7 (11.11) 5 (14.29) 
COWA 12 (19.04) 10 (28.57) 5 (7.94) 5 (14.29) 
Motor 
Function 
GP dom  14 (22.22) 5 (14.29) 11 (17.46) 4 (11.43) 
GP non 
dom  





13 (20.63) 13 (37.14) 9 (14.29) 6 (17.14) 
HVLT R 
delay 
14 (22.22) 11 (31.43) 9 (14.29) 4 (11.43) 
HVLT R 
retention 
13 (20.63) 6 (17.14) 10 (15.87) 5 (14.29) 
HVLT R 
recognition 





4 (6.35) 1 (2.86) 1 (1.59) 0 
BVRT - 
Error  
9 (14.29) 3 (8.57) 6 (8.06) 2 (5.71) 
Key: Participants1: these numbers came from pooled imputed dataset, they have been rounded down if below .5 and 
up if above. TMT A/B: Trail Making Test; DS forward/backward: Digit Span forward/backward; SDMT written/oral: 
Symbol Digit Modalities Test written/oral; COWA: Controlled Oral Word Association Test: GP dom hand: Grooved 
Pegboard dominant hand; GP non dom Grooved Pegboard non dominant hand; HVLT R: Hopkins Verbal Learning 
Test -Revised; BVRT: Benton Visual Retention Test.   
 
As can be seen in Table 8.5 there were no statistically significant differences between 




groups show more deficits across all tests at baseline (i.e. after surgery and pre-
chemotherapy treatment/3-8 week’s post-surgery) than would be expected by chance.  
Table 8.5 Mean z scores and standard deviations at T1 on each of the NP measures 



















TMT A .2969 (3.27) .0166 (1.44) .480 96 .631 .19 
DS forward1  9.95 (2.47) 9.54 (2.43) .791 96 .429 .17 
DS 
backward1  





.2212 (1.20) .0646 (.87) .724 96 .469 .18 
SDMT  oral .1841 (.122) -.2029 (.98) 1.632 96 .103 .39 
Executive 
Function 
TMT B .2479 (1.92) -.0644 (2.79) .631 96 .515 .11 
COWA -.3369 (1.27) -.3488 (1.46) .042 96 .966 .01 
Motor 
Function 
GP dom  -1.2012 
(3.64) 
-.6459 (1.42) -.864 96 .387 -.39 
GP non dom -1.2618 (3) -1.3252 
(1.73) 





-.7179 (1.14) -.9356 (1.10) .915 96 .360 .20 
HVLT R 
delay 
-.7369 (1.43) -.7698 (1.15) .117 96 .907 .03 
HVLT R 
retention 
-.5638 (1.95) -.4048 (1.24) -.435 96 .664 -.13 
HVLT R 
recognition 





6.22 (1.84) 6.56 (1.46) -.894 96 .372 -.23 
BVRT – 
Error1  
5.68 (3.71) 5.85 (2.56) -.231 96 .817 -.07 
Key: 1the mean raw scores are reported for this measure; CT: chemotherapy patient group; TMT A/B: Trail Making 
Test; DS forward/backward: Digit Span forward/backward; SDMT written/oral: Symbol Digit Modalities Test 
written/oral; COWA: Controlled Oral Word Association Test: GP dom hand: Grooved Pegboard dominant hand; GP 
non dom Grooved Pegboard non dominant hand; HVLT R: Hopkins Verbal Learning Test -Revised; BVRT: Benton 





8.4.5 Research objective 1.3: The relationships between demographic, 
clinical and psychosocial factors and objectively measured cognitive 
functioning  
Anxiety 
An independent samples t –test was conducted to compare the anxiety scores for the 
“chemotherapy” group and “surgery only” group. It showed that the two participant 
groups did not significantly differ on levels of anxiety (M= 5.8, SD = 3.93) for 
chemotherapy participants and (M=6, SD =3.94) for “surgery only” participants at T1; t 
(96) = .238, p = .813. The magnitude of the difference in the means was very small (eta 
squared = .05) 
A similar proportion of participants in each group reported feelings of definite anxiety: 
Eight (12.70%) in the chemotherapy group and four (11.43%) in the “surgery only” 
group (scored > 11 on the anxiety subscale (i.e. definite anxiety)). A larger proportion of 
participants in both groups: 12 (19%) in the chemotherapy group and eight (22.90%) in 
the “surgery only” group scored in the ‘doubtful case’ range (Zigmond & Snaith, 1983).  
Depression 
An independent samples t –test also showed that the two participant groups did not 
significantly differ on levels of depression (M= 4.1, SD = 4.17) for “chemotherapy” 
participants and (M=4.1, SD = 4.11) for “surgery only” participants at T1; t (96) = -0.86, 
p = .932. The magnitude of the difference in the means was also very small (eta squared 
= .02) 
Fewer participants (than had reported experiencing anxiety) in each group scored more 




(3.17 %) and 6 (9.52%) participants respectively in the chemotherapy group and one 
(2.86 %) and three (8.57%) in the “surgery only” group.  
Table 8.6 Means and standard deviations for fatigue, mood and HRQoL 
 
Key: CT: Chemotherapy; HADS: Hospital Anxiety and Depression Scale; FACT C subscales:  
PWB: Physical Well Being; SWB: Social Well Being; EWB: Emotional Well Being;  




As mentioned in Chapter 7, higher scores on the FACIT Fatigue scale indicate less 
fatigue. A score of < 37 was used to define significant fatigue in two studies that used 
this scale for patients with breast cancer (Wratten et al, 2004; Lange et al, 2014). The 
use of this score to define significant fatigue was based on the work of Cleeland and 
colleagues (1999). Therefore on that basis 41.2% of the entire sample (24 (38.09%)) 
patients in the chemotherapy group and 16 (47%) in the “surgery only” group) in this 





Surgery only  
(n=35) 
T- stat p df Effect 
size 
Mean  SD Mean  SD 
FACIT Fatigue 
(0-52) 
36.89 10.65 36.50 11.06 -.169 .866 95 0.04 
HADS Anxiety  
(0-14) 




4.17 3.03 4.11 3.11 -.086 .932 96 0.02 
FACT C  
Global score 
(0-136) 
105.9 17.29 102.58 14.36 -.965 .334 96 0.23 
PWB (0-28) 
 
22.04 4.87 21.56 5.62 -.440 .660 96 0.09 
SWB (0-28) 
 
24.53 4.96 23.21 3.76 -1.366 .172 96 0.35 
EWB (0-24)  
 
19.14 4.20 19.32 3.83 .213 .813 96 -0.05 
FWB (0-28) 
 
19.64 5.53 17.63 6.12 -1.656 .101 96 0.33 
CCS (0-28) 
 




score was just over 36 for participants in both participant groups. There were no 
statistically significant differences between the “chemotherapy” and “surgery only” 
groups in levels of fatigue (p=.866).  
HRQoL 
There were no statistically significant differences between the chemotherapy and 
“surgery only” groups in relation to any of the FACT C quality of life subscales.  
 
As mentioned in Chapter 7, higher scores on each of the FACT C subscales indicate 
better quality of life. A comparison of normative mean scores found in the general U.S. 
adult population sample (Brucker et al, 2005) (see Appendix Q) showed that this 
sample of participants had comparable scores to the general U.S. adult population 
sample. Very small differences in PWB (chemotherapy M=22.04; “surgery only” 
M=21.56; US general population M=22.7), EWB (chemotherapy M=19.14; “surgery only” 
M=19.32; US general population M=19.9) and FWB (chemotherapy M=19.64; “surgery 
only” M=17.63; US general population M=18.5) were noted in relation to both groups. 
However there was a meaningful difference (i.e., > 2 points) on the SWB subscale 
between the general U.S. adult population norms (M = 19.1) and the chemotherapy 
group (M=24.53) and the “surgery only” group (M=23.21). This suggests that both 
participant groups in this study diagnosed with CRC (whether or not scheduled for 
adjuvant chemotherapy treatment) are actually comparable to those in the general US 
population in respect of physical, emotional, and functional wellbeing at T1 but not 
social well being which is actually better in this study. It may be that the participants in 









Table 8.7: Table of correlations between each NP measure and mood, fatigue, HRQoL and perceived cognitive impairment 





Written Oral A B Recall Delay Reten Rdi Correct Error Dom Non 
Dom 
 HADS Anxi- 
ety 
0.083 -0.139 -0.017 0.014 -0.174 -0.099 0.004 -0.144 -0.224 -0.020 0.004 0.072 -0.031 0.096 0.126 
Dep 
 
0.092 -0.139 0.015 0.013 -0.098 -0.098 -0.003 -0.090 -0.145 0.087 0.025 0.005 -0.081 -0.084 0.152 
FACIT  Fatigue 0.012 0.032 -0.016 -0.030 0.048 0.073 -0.073 -0.069 -0.031 -0.098 -0.065 0.100 0.042 -0.055 -0.085 
FACT 
C 
PWB 0.057 0.109 0.149 0.038 0.069 0.105 0.084 0.108 0.045 -0.106 0.004 0.108 0.033 0.030 0.061 
SWB -0.062 0.016 0.027 0.097 0.121 0.167 0.088 0.048 -0.120 -0.112 0.041 -0.046 0.185 0.107 -0.042 
EWB -0.063 0.154 0.039 0.081 0.254 0.184 -0.086 0.033 0.105 -0.136 -0.030 -0.086 0.165 0.076 -0.146 
FWB 0.045 0.132 0.070 0.167 0.190 0.087 0.035 0.055 -0.031 -0.020 0.026 -0.056 0.188 0.088 -0.098 
CCS -0.189 -0.059 -0.033 0.034 -0.047 0.113 -0.043 -0.085 -0.099 -0.227 0.000 -0.052 0.122 0.010 -0.186 
Total 
Score 
-0.030 0.101 0.055 0.151 0.165 0.189 0.053 0.060 -0.046 -0.142 0.020 -0.017 0.173 0.074 -0.138 
FACT 
Cog  
PCI -0.079 -0.014 -0.053 -0.116 -0.097 -0.129 -0.086 -0.075 -0.036 -0.065 -0.150 0.140 0.066 0.015 -0.077 
PCA 0.018 -0.003 0.047 0.036 -0.086 -0.054 0.052 0.001 -0.031 0.025 -0.064 0.088 -0.054 -0.117 0.000 
Oths  -0.053 0.109 0.004 -0.041 -0.056 -0.097 0.113 -0.001 -0.020 0.018 -0.134 0.083 -0.008 0.028 -0.047 
QoL -0.017 -0.017 0.091 0.000 0.042 0.150 0.019 0.075 0.163 -0.030 -0.287 0.225 0.134 0.056 -0.088 
Key: RED = significant at .01; Blue = significant at .05; HADS Dep= depression subscale; FACT C subscales: PWB: Physical Well-being; SWB: Social Well-being; EWB: Emotional Well-
being; FWB: Functional Well-being; CCS: Colorectal Cancer Subscale; FACT C total = PWB + SWB + EWB + FWB +CCS; FACT Cog subscales: PCI: Perceived Cognitive Impairment; Oths: 




Relationship between psychosocial outcomes and objective cognitive function 
 
The relationship between anxiety, depression, fatigue, quality of life and subjective 
cognitive impairment was investigated using Spearman Rho correlation coefficient, 
after having carried out preliminary analyses to ensure no violation of the assumptions 
of normality, linearity and homoscedasticity.  
Weak correlations were found between verbal memory (as measured by the HVLT-R) 
and anxiety and verbal memory and perceived colorectal cancer symptoms/concerns 
(FACT C CCS) (Table 8.7). There was also a weak positive correlation between attention 
(as measured by the TMTA) and perceived emotional wellbeing (FACT C EWB).  
There was a weak-moderate negative and a weak positive correlation between visual 
memory (as measured by the BVRT correct and error) and perceived cognitive 
impairment impact on quality of life (FACT Cog QoL) rho =-0.287, p<0.01, and rho= 
.225, p<0.05 respectively; with lower perceived QoL associated with less correct and 




8.4.6 Perceived Cognitive Impairment  
 
There were no statistically significant differences between the groups on any of the 
FACT Cog subscales: perceived cognitive abilities (PCA); perceived cognitive 
impairment (PCI); impact on quality of life (QoL) or comments from others (Oth). The 
mean scores for the Fact Cog subscales found in each group are presented in Table 8.8. 
As discussed in Chapter 7, the higher the score the less percieved cognitive 
impairments. 
 
Table 8.8: Table of means and standard deviations for perceived cognitive 








T- stat p df Effect 
size 
Mean SD Mean  SD 
PCI (0-72) 57.37 13.10 57.79 12.48 .160 .873 96 -.03 
PCA (0-28) 20.82 6.44 20.37 7.14 -.320 .749 96 .07 
QoL (0-16) 11.95 4.39 11.34 4.28 -.664 .520 96 .14 
Others  
(0-16) 
14.90 2.04 15.52 1.08 1.945 .098 95.77 -.58 
Key: CT: Chemotherapy; FACT Cog subscales: PCI: Perceived Cognitive Impairment; PCA: Perceived Cognitive 
Ability; QoL: Impact on Quality of Life; Others: Comments from others 
 
Anxiety, depression and fatigue were all significantly moderately associated with the  
FACT-Cog PCI subscale (rho = -0.261, -.308 and .548 respectively) (Table 8.9) and also 
with FACT Cog QoL.   
FACT Cog QoL was significantly moderately associated with PWB, EWB, FWD, CCS and 





Table 8.9: Table of correlations between each perceived cognition (FACT Cog) and 











HADS Anxiety -.261 -.140 -.252 -.411 
HADS 
Depression 
-.308 -.283 -.184 -.362 
FACIT Fatigue .548 .204 .423 .415 
FACT C - PWB .416 .196 .241 .418 
FACT C - SWB .115 .119 .218 .141 
FACT C - EWB .206 .099 .225 .431 
FACT C - FWB .201 .126 .198 .326 
FACT C CCS .203 .174 .217 .255 
FACT C Total .271 .172 .293 .421 
Key: Red = significant at .01 (2 tailed); Blue = significant at .05 (2 tailed) 
Interpretation should be r < |0.30| is no to minimal association, |0.30| ≤ r ≤ |0.60| is moderate association, and r > 
|0.70| is strong association  
CT: Chemotherapy; FACT Cog subscales: PCI: Perceived Cognitive Impairment; PCA: Perceived Cognitive Ability; QoL: 
Impact on Quality of Life; Others: Comments from others; HADS: Hospital Anxiety and Depression Scale; FACT C 
subscales: PWB: Physical Well-being; SWB: Social Well-being; EWB: Emotional Well-being; FWB: Functional Well-
being; CCS: Colorectal Cancer Subscale;   
 
8.4.7 Research objective 1.4: The relationship between perceived cognitive 
function (as measured by self-assessment questionnaire FACT Cog) and 
objectively measured cognitive function. 
As can be seen in Table 8.7 there were no significant relationships between the PCI, PCA 




8.5 Discussion  
This chapter described the demographic, clinical, and psychosocial characteristics of the 
study sample at T1 (after surgery and prior to the start of adjuvant chemotherapy 
treatment). It then went on to examine the nature and extent of OCI in the sample as 
well as in each of the groups. It also examined whether there was a relationship 
between OCI and SCI, anxiety, depression, fatigue and quality of life.   
8.5.1 Participant characteristics 
The study sample was split almost equally between males and females with an age 
range of 25 to 84 years. More than half of the participants were not working at the time 
of diagnosis. Clinically, the majority of participants were Stage 2 and 3 patients; with a 
larger proportion of the sample requiring adjuvant chemotherapy treatment. This could 
partly be explained by the difficulties experienced in recruiting “surgery only” patients 
to the study, as detailed in Dwek and colleagues (2016) feasibility study carried out as 
part of this thesis (Appendix  J). 
This study sample was similar to other CRC studies regarding the demographic and 
clinical characteristics of the sample such as Cruzado and colleagues (2014) who 
assessed 81 patients pre-chemotherapy treatment with Stage 2 and 3 CRC, between the 
ages of 38 and 85; 62% of which were male. 
8.5.2 Cognition 
In this study, we found that using the ICCTF’S criteria of a z score of: 
 ≤1.5 SD below the normative mean on at least 2 NP tests; and  




56.1% and 51% respectively of the participants were found to have cognitive 
impairment, which was 26.1% and 17% above the expected level of impairment. These 
data also indicate a higher incidence than the 37% and 43% observed by Cruzado and 
colleagues (2014) and Vardy and colleagues (2015) respectively, in a similar size 
sample of patients with CRC and with those documented in breast cancer patients at a 
similar point in time (i.e. before the start of chemotherapy treatment) (17to 33 %) 
(Ahles et al., 2008; Bender et al., 2006; Hermelink et al., 2007; Hurria et al., 2006; Mar 
Fan et al., 2005; Paraska & Bender, 2003; Quesnel, Savard, & Ivers, 2009; Verncombe et 
al, 2009; Wefel et al, 2004; Wefel et al, 2011). Such differences may have been 
attributable to the NP measures used in the different studies. For example, neither 
Cruzado (2014) nor Vardy (2015) measured motor speed, which accounted for a lot of 
the impairment found in this study even at baseline; both used fewer pencil and paper 
tests than this study.  
Data from this study suggests that when examining mean pre-chemotherapy treatment 
performance across multiple measures and domains of cognitive functioning, patients 
with CRC who are scheduled for chemotherapy treatment do not differ from those that 
are not required to have any further systemic treatment. Therefore, based on this 
analysis it is reasonable to conclude that there are no pre-chemotherapy treatment 
differences in NP performance between the patients in the chemotherapy group and 
those in the “surgery only” group included in this study. 
Consistent with other studies, this study found that executive function, motor function 
and verbal memory were the most commonly involved domains (Argyriou et al, 2011; 
Janelsins et al, 2011; Jim et al, 2009).  Although it is unclear whether lower than 




itself or to other unidentified factors, these results underscore the importance of 
designing studies with a pre-systemic chemotherapy treatment baseline evaluation 
(Cruzado et al, 2014).    
There were no self-reported differences in cognition between the groups. There was 
only one statistically significant (p<0.01) association found between NP performance 
(in the domain of visual memory) and self-reported cognitive symptoms as measured by 
the FACT Cog CCS. (See Chapter 10 for patients’ in depth perspectives on cognitive 
impairments.) 
8.5.3 Mood 
12% and 3% of the total sample exhibited anxious and depressive symptoms 
respectively, which is similar to what would be expected from a healthy population 
(Chapter 2). Anxiety was significantly (p<0.05) related to verbal memory (HVLR 
Retention). Whereas there was no significant correlation between any of the NP 
measures and depression which is often the case in the “cancer and cognition” studies 
(van Dam et al, 1998; Schagen et al, 1999; Brezden et al, 2000; Ahles et al, 2002; Tchen 
et al, 2003; Castellon et al, 2004; Bender et al, 2005; Jenkins et al, 2006; Mar Fan et al, 
2005; Wefel et al, 2004; Wieneke et al, 1995; Cimprich et al, 2005; Cull et al, 1996; 
Eberhardt, et al, 2006). Although consistent with many other studies in the literature 
anxiety and depression were statistically significantly related to percieved cognitive 
impairment (as measured by the FACT Cog PCI).  
8.5.4 Fatigue 
Fatigue was self-reported by 42.85% of the whole sample; which was less than the 52% 




that reported fatigue in Vardy and colleagues study (Vardy 2014) (although it must be 
noted that a different cut off was used to define significant fatigue). The mean scores 
were very similar to those that Vardy and colleagues (2014) found in her study of 
patients with CRC. There was no significant difference between the groups in this study. 
Fatigue was significantly moderately associated with percieved cognitive impairment 
for the whole sample.  
8.6 Summary 
Researchers examining CRCI have emphasized the importance of using longitudinal 
designs that include pre-treatment NP assessments. However, in order to interpret 
longitudinal change, it is critical to understand whether cognitive performance is lower 
than expected prior to the initiation of treatment (Ahles et al, 2008).  Data from the 
current study shows that over 50% of the patients diagnosed with and operated for 
CRC, compared to normative data based on age, gender and education, had cognitive 
impairment mainly epitomised by impaired verbal memory, motor function and 
executive function before any adjuvant chemotherapy treatment, which is significantly 
higher than what would be expected considering healthy population norms.  
CRC patients about to receive chemotherapy and those who were not to receive any 
further systemic treatment reported similar levels of depression, anxiety, fatigue and 
subjective cognitive function at pre-chemotherapy treatment baseline.  
Overall, the findings suggest that the present sample of people with CRC is comparable 
to previous studies in the literature, in relation to pre-chemotherapy measures of 




to the OCI observed. The next chapter will address the second and third aims of the 




Chapter 9: LONGITUDINAL ANALYSIS AND RESULTS 
Longitudinal analysis of cognitive performance in resected 
patients with CRC comparing those who receive 
chemotherapy treatment with those who do not.  
 
9.1 Introduction 
This chapter begins by discussing the methodological challenges associated with the 
longitudinal assessment of cognitive functioning and the different techniques commonly 
used to assess change in cognitive functioning. It then presents the strategy that is 
applied to the longitudinal quantitative analysis in this thesis before detailing the 
results found for: 
Research Question 2: What is the nature and trajectory of CRCI in resected CRC 
patients who do or do not receive adjuvant chemotherapy treatment? And  
Research Question 3: Is OCI in patients with CRC associated with lesser HRQoL?  
9.2 Cognitive functioning in the normal adult population 
As discussed in Chapter 2, cognition may be affected by many factors even in the 
absence of cancer and/or its associated treatments.  Cognitive domains such as 
memory, processing speed and executive function all tend to show age related decline 
(Deary et al, 2009). Research has shown that such declines in cognitive functioning can 
begin as early as ones thirties or even sooner (Park and Reuter-Lorenz, 2009). It may 





Cognitive functioning and changes in cognitive functioning can influence many different 
areas of an individual’s life such as the ability to work, maintain meaningful 
relationships, self-care and overall wellbeing. Assessing the extent (if any) of 
impairments in cognitive functioning during the course of cancer treatment and shortly 
afterwards is very important given the effect that impairments may have on an 
individual’s ability to live, make decisions (including those relating to health care) and 
sustain independent and fulfilling lives. A decline in cognitive functions following a 
diagnosis of cancer and systemic treatment may have wide spread implications for 
cancer survivors’ quality of life (Mehnert et al, 2007). 
9.3 Longitudinal assessment of cognitive functioning  
Longitudinal cognitive assessments involve examining the same set of individuals on 
more than one occasion, using the same or psychometrically matched equivalent 
measures. As discussed in Chapters 3 and 4, the length of time between these 
consecutive assessments varies greatly across the ‘cancer and cognition’ studies and 
relates to resources (e.g. funding, time constraints); the disease itself (e.g. life 
expectancy, recurrence, extent of side effects) and to the research question (i.e. 
researchers may be exploring short term and/or long term effects, such as “Is cognitive 
impairment present 3, 6, 12 or 24 months post systemic treatment?”). 
9.4 Methodological considerations  
Practice effects are characteristic of almost all NP tests when repeated during serial 
assessments (Bartels et al, 2010; Goldberg et al, 2015). They refer to improvements in 
test scores, which may result from several different factors. Practice effects could be 




procedure involves (e.g., that letters and numbers alternate in TMT B) and some 
knowledge of the sequence of a task (e.g., that multiple trials of a word list in the HVLT-
R will be administered) (Goldberg et al, 2015).  Prior exposure and familiarity may also 
lead to a reduction in test anxiety, which could improve performance.  
The period between the assessments can also be a contributing factor to the extent of 
practice effects. The shorter the duration between assessments the more likely the test-
taker is to remember the test and the strategy applied when being reassessed. Evidence 
shows that practice effects may persist for as long as two years after the initial 
assessment (Lezak et al, 2012). The presence of practice effects makes it difficult to 
establish a distinction between a ‘real change’ and change due to prior exposure to the 
test being administered (or how much of any change observed is attributable to each). 
It is for this reason that the ICCTF recommended the use of tests where alternate forms 
are available (such as HVLT-R) (Wefel et al, 2011). The alternate forms could help 
reduce the presence of any practice effects that may occur due to familiarity with the 
original test. Although the ICCTF acknowledges that the use of alternate forms will not 
necessarily eliminate all confounding due to practice effects (Wefel et al, 2011); 
alternate forms of tests such as the recommended HVLT-R were studied in the context 
of serial testing (which consisted of four testing sessions separated by a 14 +/– 3- day 
interval) and there was no significant evidence of residual practice effects found 
(Benedict & Zgaljardic, 1998). When using an alternate form, it is essential to check if 
the reliability and validity of the measure has been assessed in comparison to the 
original form, in order to ensure that it assesses the same function. Alternate forms 
must be the same style, have an equivalent number of items, type of content and method 




that alternate forms are not available for all NP tests and consequently researchers 
often have to repeat the same measure at different time points and manage practice 
effects via procedural design. 
As mentioned, the use of alternate test versions may not entirely eliminate the problems 
of repeated testing (Lezak et al, 2012). Some task familiarity effects may be due to 
procedural learning. Whilst the content of a test is changed in an alternate form, the 
examinee may have still learned the style and format of the test. For example, with the 
TMT B whilst the numbers and letters may appear in a different position on the page the 
principle of alternating between the two remains the same. This is so that the two test 
forms are comparable. Thus making it relatively easy for the test-taker to replicate the 
strategy previously applied, given that the ‘novelty’ of the test may be lost upon 
reassessment, due to familiarisation with the test and its execution (Groth-Marnat, 
2009).  Whilst practice effects may be considered an interference when interpreting test 
results, they could also reflect some level of cognitive ability. The ability to learn and 
remember a strategy previously applied, and to re-apply it upon re-assessment is in 
itself indicative of some cognitive skills. 
Fatigue effects also need to be taken into consideration when designing a study that will 
involve repeated testing. Fatigue effects refer to a decrease in performance over the 
course of a study particularly if the task is too long, boring or difficult. However, they 
can be minimised by arranging the order in which assessments are presented as was 
done in this study (Chapter 7, Section 7.7.1). 
Another challenge often associated with repeated testing is that of the statistical 




measurement, it will tend to be closer to the mean or average on its second (i.e. on a 
repeated measure) thus showing a  relatively larger change compared to those with a 
moderate score at the first assessment (Barnett, Van Der Pols and Dobson, 2005).  This 
can make a natural variation in repeated data look like a real change, and can therefore 
affect the true magnitude of change observed (Barnett, Van Der Pols and Dobson, 2005). 
If there is regression to the mean and it is not taken into account, an improved (or 
worse) test score could be interpreted as an improvement (or decline) in the underlying 
cognitive domain when there has not actually been such an improvement (or decline).  
One way to deal with this issue is by using residualised change scores, as these scores 
control for baseline variance (as described below) (Levine et al, 2007). 
9.5 Measurement of change in cognitive functioning over time 
In order to assess whether there is a decline or improvement in cognitive function over 
time the researcher needs to be able to reliably quantify the difference between the 
assessment scores at each time point, while controlling for the influence of confounding 
factors that may be responsible for the observed change. There are several ways to 
detect a statistically significant change in cognitive functioning over time but each 
technique has advantages and disadvantages.  
The ICCTF (Wefel et al, 2011) recommends several of ways of analysing longitudinal 
data. Taking each of the recommendations in turn:  
1. The use of a pre-specified Reliable Change Index (RCI) to determine change in 
cognitive function (Jacobsen & Truax, 1991; Chelune, Naugle, Lüders, Sedlak, 
Awad, 1993; Temkin, Heaton, Grant, Dikmen, 1999).   RCI scores, are derived by 




treatment/3 months post T1) and T3 (post-chemotherapy treatment/6 months 
post T2) scores, and dividing this value by the standard error of the difference of 
the test scores, to obtain a standardized score (See Figure 9.1). A modified 
version of the RCI, RCIPE has been developed in order to control for practice- 
induced effects (Chelune et al, 1993). Calculating the RCIPE involves calculating 
the difference between the discrepancy of test scores (T2 and T3) and the 
discrepancy of the mean from the control group (M2 and M3), divided by the 
standard error of the difference (See formula below). 
Figure 9.1: 
 
2. The use of residualised change scores. This approach utilizes a regression 
equation by regressing T3 scores onto T2 scores resulting in a standardized 
change score (derived from the two scores of each participant). These 
residualised change scores are adjusted for baseline variance by removing the 




and might be more sensitive to changes in cognitive function over time (Temkin 
et al, 1999; Reynolds, Gatz, Pedersen, 2002; Ouimet et al,. 2009). 
3. Longitudinal modelling techniques. ICCTF suggested that growth curve, growth-
mixture modelling, or linear mixed-effects models could also be applied to assess 
effects at group and individual levels simultaneously (Wefel et al, 2011).  Growth 
models (also known as random coefficients models, multilevel models, and 
mixed effect models) are well suited for the purpose of studying change at the 
group as well as the individual level (Hesser, 2015) particularly when there are 
more than 2 time points (Hesser, 2015).  
As mentioned, each of these methods have advantages and disadvantages.  Whilst the 
RCI method is one of the ICCTF’s recommended approaches (Wefel et al, 2011) it is not 
without its methodological challenges. The RCIPE method assumes that the change in an 
individual test score equals the mean score of the normative group; this assumes that 
the degree of change in the measure over time is equal across different groups (i.e. 
chemotherapy patients and “surgery only” patients) which is what is being investigated 
here. Given that the level of cognitive functioning in patients with cancer may not be the 
same as the normative group, the assumption that the degree of change due to practice 
effects over time will be the same, could lead to an incorrect estimation of change. 
The recommended multilevel modelling (MLM) technique controlling for baseline 
differences was used in this study rather than ANCOVAs as stated in the Protocol. 
Although this technique meant that an examination of changes from T1 would be 
forfeited the research team was of the opinion that this technique would produce a 
better analysis of group differences at subsequent time points. MLM allows the 




ANOVA) and accounts for all available data without dropping cases (again unlike 
ANOVA or any change indice). MLM can be used as an alternative to ANCOVA, where 
scores on the dependent variable are adjusted for covariates (e.g. individual differences) 
before testing treatment differences (as was done in this study). With ANCOVA’s, 
subject’s data must be excluded if they are missing a single data point. So potentially too 
much data would have been lost in this study. In addition MLM has less stringent 
assumptions, it can be used if the assumption of constant variances (homogeneity of 
variance, or homoscedasticity), constant covariances (compound symmetry), or 
constant variances of differences scores (sphericity) are violated.  
9.6 Analyses strategy   
This section details the statistical strategy applied to assess the aims and objectives of 
Research Question 2: What is the nature and trajectory of CRCI in resected CRC patients 
who do or do not receive adjuvant chemotherapy treatment? And then  
Research Question 3: Is OCI in patients with CRC associated with lesser HRQoL? 
9.6.1 Measures utilised at each assessment time point 
As described in Chapter 7, the complete test battery used at T1 was re-administered to 
each participant at T2 and T3. To control for practice effects, alternate versions of the 
NP tests were used where available (TMT (2 versions), HVLT-R (Forms 1, 2 & 3) and 
BVRT (Forms C, D& E)). All of the other NP tests were re-administered using the original 
test used at T1 (DS, SDMT and Grooved pegboard). The IQ test (WAIS-III) was the only 
measure that was not re-administered at follow-up. Intelligence as a construct has been 
reported as being stable over time, with tests producing similar scores upon 




short timeframe of this study there was no expectation of change in IQ. Nevertheless it 
did provide a good measure of overall cognitive ability that could be controlled for in 
other tests such as the BVRT where it was used as a control variable for calculating the 
normative score as required in the manual (Benton, 1991)).  The entire test 
administration procedure including the order of assessments and the test-taking 
environment were consistent with those at T1 (see Chapter 7 for details). 
9.6.2 Scoring procedures used for all measures included in the test battery 
All NP tests at T2 and T3 were scored using the same scoring procedures as were used 
at T1 (Chapter 8, Section 8.3.2) i.e. all NP raw scores (other than for the Digit Span and 
BVRT measures) were converted to z scores (mean=0, SD=1) using published normative 
data adjusted for age, education, and gender as shown in Appendix P.   The normative 
data used at T1 was also used at T2 and T3 (Appendix P) but was adjusted wherever a 
participant’s age changed such that they crossed into a different boundary.  All self-
report questionnaires were also scored using the same procedures as at T1 (Chapter 8).  
9.6.3 Preliminary data analysis 
All T2 and T3 data was entered on IBM SPSS (version 25) and screened in accordance 
with the procedures outlined in Chapter 8, Section 8.2 for T1 data. Missing value 
analysis was also performed at item and scale level in accordance with the procedures 
outlined in Chapter 8, Section 8.2.2. for all T2 and T3 data. For missing data at the scale 
level and item level (where scales were not viable) multiple imputation (MI) was 
conducted using MCMC procedures within the SPSS Multiple Imputation procedure 




9.6.4 Cognitive impairment at second and third assessment 
As an initial step, analyses were conducted on each of T2 and T3 data to identify  
1.1 Prevalence of OCI; and 
1.2 The most commonly affected domains of cognitive functioning 
in each patient group at each time point.  
The ICCTF specifically encourages the reporting of data on the frequency of impairment 
for each test (Wefel et al, 2011).  
The ICCTF’s recommended criteria (Wefel, 2011) was used to establish cognitive 
impairment at T2 and T3, following the same procedures as at T1 (Chapter 8). The 
frequencies of impairment for each NP test were then calculated to see which domains 
were the most affected. 
9.6.5 Differences between the participants who remained in the study and 
those that withdrew after the first assessment.  
An analysis was conducted to assess whether there were any differences between 
patients that participated in T2 and T3 and those that did not. T-tests and Pearson’s chi 
square tests were performed to compare demographic and clinical characteristics and 
overall OCI of patients who had only completed T1 assessment and those that 
completed T2 and T3.  
T tests were also performed to compare the means scores for anxiety, depression and 





9.6.6 Multilevel modelling (MLM) 
MLM was used to assess change in cognitive functioning over the 9-month study period 
for each NP outcome variable (Marques and Hamilton, 2014).  The use of MLM is 
increasing in psychological research and was the method of choice in this thesis for the 
following reasons. It  
a) allows the hierarchical structure of the data to be considered, by accounting 
for the non- independence of scores given on the same test/questionnaire by 
the same participant at multiple time points, i.e. data points are more similar 
within individuals over time than they are between individuals  (Cartwright, 
Traviss and Blance, 2012); and   
b) is able to include all collected data points despite missing data, which if 
excluded listwise can cause biases and reduce power.  
The application of MLM approaches are increasingly being recommended in designs 
where the data has been collected from individuals on more than one occasion, as  
multilevel models imply that scores are clustered within each individual (Queńe and 
Van den Bergh, 2004). Heck and colleagues (2014) recommendations for dealing with 
repeated measures data using SPSS software were used to guide the analysis within this 
study. In preliminary steps to prepare the data for analysis, the data was restructured 
by the three administration time points to recognize its hierarchical nature of the 
different assessments within individuals. This resulted in a vertical arrangement of the 
data points for all participants at T1, T2 and T3 for each variable, with covariates 
(baseline measures) repeated for each time point. This stacking of the data resulted in a 




Each NP score was used as the dependent variable (DV) in the main MLM analysis, with 
the baseline scores and participants’ years of education, age and gender used as 
covariates, where they had not already been taken account of in the z scores. A first-
order ante-dependence covariance structure (COVTYPE (AD1)) was chosen to represent 
the relationship between the repeated measures. 
The main effect of time (a difference in scores between two assessments (T2 & T3)), 
main effect of group (a difference between the groups irrespective of time-points) and 
the time x group interaction (difference in the pattern of means between the 2 groups 
across time points or change in the means of the groups across time) were assessed 
using adjusted mean scores (estimated marginal means in SPSS).  
9.6.7 Relationships between OCI and SCI 
A point-biserial correlation was run to examine whether there was a relationship 
between deficit/no deficit OCI and SCI (as measured by FACT Cog) after first checking 
that the following assumptions were not violated:   
o There were no outliers for any of the FACT Cog subscales or for each category of 
the OCI deficits. 
o The FACT Cog subscales were approximately normally distributed for each 
category of the NP variables.  






9.6.8 Research Question 3: An examination of the relationship between OCI 
and HRQoL 
 
A point-biserial correlation was run to examine whether there was a relationship 
between deficit/no deficit on each of the NP measures and HRQoL (as measured by 
FACT C) at T2 and at T3. 
9.6.9 Level of statistical significance 
For all preliminary and main analyses the level of statistical significance was set at 
p<0.01 (Chapter 8, Section 8.2.3.6). 
9.7 LONGITUDINAL RESULTS 
Research question 2: What is the nature and trajectory of CRCI in patients with 
resectable CRC who do or do not receive adjuvant chemotherapy treatment?   
Aim 2: To investigate the nature, course and extent of cognitive impairment (both 
objective and subjective) in patients with resected CRC who go on to have systemic 
chemotherapy treatment compared to those who do not have any further treatment.  
9.7.1 Participant demographic and clinical characteristics at follow up 
assessments 
11 (17.46%) participants from the chemotherapy group and 8 (22.86%) from the 
“surgery only” group did not complete any of the mid-chemotherapy/3 months post T1 
(T2) assessments. At 3 months after the end of treatment/6 months post T2 (T3) one of 
the “surgery only” participants and one of the chemotherapy participants that had 




10 chemotherapy participants and 6 “surgery only” participants had dropped out. 
Reasons provided for non-participation are outlined in Table 9.1.  
Table 9.1: Reasons for study participant exclusions and refusals at T2 and T3 
 T2  
(Mid CT/3 months post T1) 
T3  
(3 months post CT/6 months 
post T2) 
CT  Surgery only  CT1  Surgery only1 
Could not make 
contact 
- 1 3 1 
Health reasons 
(recurrence of 




hospital with other 
issues) 




1 2 - 3 
Declined to 
participate again 
5 5 10 6 
Operation (e.g. 
stoma reversal) 
   1 
Deceased -  - 2 - 
Total number of  
participants 
(cumulative rate 
of attrition)  
52 (17.46%) 27 (22.86%) 40 (36.51%) 22 (37.14%) 
Key: CT: chemotherapy; 1This figure also includes T2 losses. Note. Attrition rates calculated from  
baseline value (T1). 
 
Two of the chemotherapy participants’ cancer metastasized (i.e. spread to other organs) 
during chemotherapy and they passed away before T3. Most participants (in both 
groups) simply withdrew from the study at T2 and T3 without providing a reason for 
withdrawal and by T3 there were 4 participants who were simply not contactable and 




Table 9.2 summarises the demographic characteristics for the two participant groups 
after surgery at each time point. Demographic and clinical information was reported for 
all participants with available data in those variables.   
 
Table 9.2: Demographic and medical characteristics for all participants at each 
assessment 
















       














Age range in years 31-80 25-84 31-80 26-82 32-81 54-84 
       
Education       
 Less than 
12 years 
17 10 16 7 11 6 
 More than 
12 years 
46 25 36 20 29 16 
       
Gender       
 Male  29 (46%) 20 (57%) 25 (48%) 17 (63%) 23 
(57.5%) 
13 (59%) 
 Female 34 (54%) 15 (43%) 27(52%) 10 (37%) 17(42.5%) 9(41%) 
       
Marital Status       
 Single1 25 (40%) 18 (51%) 21(40%) 13 (48%) 15 (38%) 11(50%) 
 Married2 38 (60%) 17(49%) 31(60%) 14(52%) 25 (62%) 11 (50%) 
       





















 Employed3  25 14 21 10 16 7 
 Not 
employed4 
36 21 29 17 22 15 
 Student 2 0 2 0 2 0 
       
Nationality       
 UK5 54 24 46 20 34 18 
 Other 9 11 6 7 6 4 
       
Native English 
Speaker 
      
 Yes 51 25 43 23 32 19 
 No 12 10 9 4 8 3 
       
Tumour stage        
 Stage I 2 9 2 8 2 7 
 Stage II  14 24 11 17 10 14 
 Stage III 43 2 36 2 27 1 
 Stage IV 4 0 2 0 1 0 
 
Differences between those participants that continued in the study and those that 
withdrew after T1 
There were no statistically significant differences (p<0.01) between those participants 
who withdrew from the study at T2 and those who had completed T1 in terms of age, 




comorbidities, education or IQ. There were proportionately more male participants in 
both groups at T2 and T3 than there were at T1, suggesting that more females than 
males withdrew from the study as time progressed although this was not statistically 
significant at (p<.01) (Fishers Exact test = 0.02).  
There were also no statistically significant differences (p<0.01) between those 
participants who withdrew from the study at T3 and those who had completed T1 in 
terms of age, gender, nationality, English as a first language, marital status, number of 
reported comorbidities, education or IQ. Neither were there any statistically significant 
differences between those participants who withdrew from the study at T2 or at T3 and 
those who completed T1 assessments in terms of anxiety, depression or fatigue.  
9.7.2 The extent of OCI at T2 and at T3 in each patient group 
As shown in Table 9.3, at T2 there were no statistically significant differences between 
the groups in the proportion who were found to have cognitive impairment: 
• 1.5 SD criteria:  χ² (1, n=79) = 1.241, p= V =.125;  
• 2 SD criteria: χ² (1, n=79) = 0.885, p=.347, V =.106;  
Although a smaller proportion of chemotherapy patients (61.54% and 57.69% 
depending on the criteria used) were found to be cognitively impaired at T2 compared 







Table 9.3: The number and percentage of participants found to be cognitively 
impaired according to the ICCTF’s criteria at T2  
 
T2 

















1.241 1 .265 .125 31  
(57.69%) 

















Key: CT: Chemotherapy 
There was also no statistically significant difference between the groups in the 
proportion of participants who were found to be impaired at T3 (Table 9.4):  
 1.5 SD criteria:  χ² (1, n=62) = 1.564, p=.211, V =.159;  
 2 SD criteria: χ² (1, n=62) = 2.078, p=.149, V =.183 
Table 9.4: The number and percentage of participants found to be cognitively 
impaired according to the ICCTF’s criteria at T3  
 
T3 

















1.564 1 .211 .159 16  
(40%) 





















However, as can be seen in Tables 9.3 and 9.4, the overall percentage of participants 
that were found to be impaired (on both ICCTF criteria) in each group was greater at T2 
than at T3. This suggests that cognitive function improves 3 months after chemotherapy 
for a subset of chemotherapy patients and at a similar point in time in relation to 
“surgery only” patients. 
9.7.3 Nature of OCI at T2 and at T3 in each patient group 
The frequency of impairments for each NP test at T2 and T3 can be seen in Tables 9.5 
and 9.6.  
The most commonly affected cognitive domains in both the chemotherapy patient 
group and “surgery only” patient group at T2 (when using either ICCTF criteria) (Table 
9.5) were: 
 verbal memory (as measured by the HVLT-R),  
 visual memory (as measured by BVRT error),  
 motor function (as measured by the GP), and  
 executive function (as measured by the TMTB).  
In the chemotherapy patient group the frequency of impairments in verbal memory 
ranged from 13 to 23% across the subscales. In the “surgery only” patients’ 
impairments in verbal memory ranged from 25.9% to 40% across the subscales.  
The pattern was similar at T3 (Table 9.6). After chemotherapy treatment the most 
affected domains were: 
 verbal memory (as measured by the HVLT-R),  




The frequency of impairment in motor function as measured by the GP non dominant 
hand test was 32.5% in the chemotherapy patient group and 30% in the surgery only 
patient group.  
Whilst verbal memory was still affected at T3 in both groups, it was proportionally less 
affected than at T2.  
At T3 there was proportionately more impairment found in executive function on both 
the COWA (15%) and TMT B (12.5%) in the chemotherapy group when the 1.5SD 
criteria was used to define OCI.  
Attention, concentration and visual memory were the least affected domains in both 




Table 9.5. The number of participants in each group found to have cognitive impairment at T2 on each of the NP measures 
 Domain NP measure 1.5 SD criteria 2 SD criteria 












Number (%) of Surgery 





TMT A 9 (17.3) 6 (22.2) 6 (11.5) 2 (7.4) 
DS forward  1 (1.9) 3 (11.1) 0 (0) 0 (0) 
DS backward  10 (19.2) 7 (25.9) 4 (7.7) 1 (3.7) 
Concentration SDMT written 4 (7.7) 4 (14.8) 2 (3.8) 2 (7.4) 
SDMT  oral 5 (9.6) 3 (11.1) 2 (3.8) 2 (7.4) 
Executive 
Function 
TMT B 13 (25) 7 (25.9) 10 (19.2) 5 (18.5) 
COWA 7 (13.5) 0 (0) 5 (9.6) 0 (0) 
Motor 
Function 
GP dom 15 (28.8) 7 (25.9) 12 (23.1) 7 (25.9) 
GP non dom  18 (34.6) 5 (18.5) 14 (26.9) 4 (14.8) 
Verbal 
Memory 
HVLT R recall 11 (21.2) 7 (25.9) 5 (9.6) 4 (14.8) 
HVLT R delay 12 (23.1) 11 (40.7) 6 (11.5) 6 (22.2) 
HVLT R retention 11 (21.2) 7 (25.9) 6 (11.5) 5 (18.5) 
HVLT R 
recognition 
7 (13.5) 9 (33.3) 4 (7.7) 5 (18.5) 
Visual 
Memory 
BVRT - Correct 13 (25) 6 (22.2) 2 (3.8) 1(3.7) 




Table 9.6. The number of participants in each group found to have cognitive impairment at T3 on each of the NP measures 
 Domain NP measure 1.5 SD criteria 
 
2 SD criteria 












Number (%) of Surgery 






TMT A 0 (0) 0 0 0 
DS forward  3 (7.5) 0 0 0 
DS backward  4 (10) 4 (18.2) 0 0 
Concentration SDMT written 1 (2.5) 0 0 0 
SDMT  oral 1 (2.5) 1 (4.5) 0 1 (4.5) 
Executive 
Function 
TMT B 5 (12.5) 1 (4.5) 3 (7.5) 1 (4.5) 
COWA 6 (15) 1 (4.5) 3 (7.5) 1 (4.5) 
Motor 
Function 
GP dom  9 (22.5) 5 (22.7) 5 (12.5) 4 (18.2) 
GP non dom  13 (32.5) 7 (31.8) 12 (30) 6 (27.3) 
Verbal 
Memory 
HVLT R recall 5 (12.5) 7 (31.8) 3 (7.5) 2 (9.1) 
HVLT R delay 10 (25) 5 (22.7) 5 (12.5) 2 (9.1) 
HVLT R retention 7 (17.5) 3 (14.3) 3 (7.5) 2 (9.1) 
HVLT R 
recognition 
3 (7.5) 2 (9.1) 3 (7.5) 2 (9.1) 
Visual 
Memory 
BVRT - Correct 0 2 (9.1) 0 1 (4.5) 
BVRT - Error 1 (2.5) 4 (18.2) 0 3 (14.3) 
Key for Tables 9.5 & 9.6: Participants1  these numbers came from pooled imputed dataset, they have been rounded down if below .5 and up if above; TMT A/B: 
Trail Making Test; DS forward/backward: Digit Span forward/backward; SDMT written/oral: Symbol Digit Modalities Test written/oral; COWA: Controlled Oral 
Word Association Test: GP dom hand: Grooved Pegboard dominant hand; GP non dom Grooved Pegboard non dominant hand; HVLT R: Hopkins Verbal Learning 




9.7.4  Changes in OCI over time 
The following sections detail the results of the MLM analysis conducted to investigate 
changes in objectively measured cognitive functioning in CRC patients over time.  The 
MLM results are presented separately for each cognitive domain: executive functioning, 
attention, motor function and memory. 
Changes in executive function over time 
The results of the MLM analysis in relation to executive functioning are detailed in Table 
9.7.  The only test of executive functioning that showed a significant difference between 
time-points was the TMT B, with a significant main effect for time (F =10.126, p=0.002). 
The mean difference across the two time points showed a gain in the scores (i.e. more 
time taken to complete the task, which is a deterioration in performance) from T2 to 
T3, demonstrating a worsening in performance upon re-assessment, with small effect 
sizes. 
There was no significant difference on the COWA: The main effect of treatment group 
was not significant (p>.01) and neither was the main effect of time (p>.01) 
demonstrating no differences in the test performance of patient groups; irrespective of 
time or treatment.  However, as can be seen in Table 9.7 the mean difference across the 
two time points showed a gain in the scores on the COWA (i.e. more words correctly 
recited) from T2 (to T3, suggesting an improvement in the scores upon re-assessment, 
although these were not statistically significant. 
Furthermore, the time x group interaction did not reach significance on either the 




between the two groups at each time-point and ii) no differential change in the means of 





Table 9.7: Results of the MLM analysis (main and interaction effects): Treatment differences over time in executive function as 
measured by the COWA and the TMT B   
  T2 T3 Treatment Time Treatment x Time Effect size 
  Mean1 
z scores 
St Error Mean 
z scores 
St Error T2 T3 
COWA Surgery 
only 
0.151 0.133 0.241 0.189 F=0.605 
 
P=0.438 F = 1.332 
 
P= 0.251 F = 0.272 P= 0.603 -0.27 -0.04 
CT -0.034 0.094 0.203 0.136 
TMTB Surgery 
only 
-1.111 0.476 0.739 0.366 F=0.278 
 
 
P=0.599 F=10.126 P=0.002 F=2.211 P=0.140 0.32 -0.21 
CT -0.323 0.337 0.368 0.270 




Table 9.8: Results of the MLM analysis (main and interaction effects): Treatment differences over time in attention and concentration as 
measured by Digit Span, SDMT and TMT A   
 T2 T3 Treatment Time Treatment x Time Effect size 
Mean 
z scores 
St Error Mean 
z scores 
St Error T2 T3 










P=0.159 0.36 -0.13 











P=0.453 0.01 0.29 
CT 6.7042 0.255 6.9982 0.294 
TMTA Surgery 
only 
0.2711 0.185 1.0281 0.180 F=6.294 
 
P=0.013 F=20.387 P=0.000 F=0.061 
 
P=0.805 -0.46 -0.51 













P=0.284 0.19 0.43 














P=0.565 -0.06 -0.19 
CT 5.9291 0.480 4.9791 0.447 
Key:  DS forward/backward: Digit Span forward/backward; TMT A: Trail Making Test A; SDMT written/oral: Symbol Digit Modalities Test written/oral; CT: Chemotherapy; Mean1 is the estitmated 




Changes in attention and concentration over time 
The results of the MLM analysis in relation to attention and concentration (as measured 
by Digit Span forwards and backwards, TMT A and SDMT) are detailed in Table 9.8.  
With regard to the TMT A the main effect of time was significant for TMT A score (F 
=20.387, p<.001) with T2 scores being lower than T3 scores (i.e. less time taken for 
completion at T2) demonstrating a decline in performance over time, although the 
magnitude of the difference in the means was moderate.   The main effect of the 
treatment group and the time x treatment group interaction did not reach significance, 
thus demonstrating i) no difference in the pattern of means between the two groups at 
each time-point and ii) no differential change in the means of the groups across time.  
Changes in motor function over time 
With regard to the motor function as can be seen in the Table 9.9, the main effect of 
treatment was significant for the non-dominant hand in the Grooved Pegboard task (F 
=16.075, p<.001) with the “surgery only” group mean scores being lower than the 
chemotherapy group mean scores (i.e. it took less time to complete the task). This 
demonstrates an improvement in performance with the non-dominant hand due to 
treatment.   The magnitude of the difference in the means was moderate. The main 
effect of time and the time x treatment group interaction did not reach significance, thus 
demonstrating i) no difference in the pattern of means between the two groups at each 




Table 9.9: Results of the MLM analysis (main and interaction effects): Treatment differences over time in motor function as measured by the 
Grooved Pegboard   
 T2 T3 Treatment Time Treatment x Time Effect size 
Mean1 
z scores 
St Error Mean1 
z scores 
St Error T2 T3 
GP dom Surgery 
only 






P=0.253 0.07 0.36 
 
CT 0.887 0.300 0.901 0.210 
GP non dom Surgery 
only 
0.281 0.375 0.303 0.486 F= 
16.075 
P=0.000 F= 0.604 P=0.439 F= 0.940 P=0.335 0.66 0.69 
CT 1.567 0.264 1.878 0.352 




Changes in memory over time 
The results of the MLM analysis in relation to changes in memory over time are 
presented in Table 9.10. There was one significant difference over time in verbal 
recognition (p<.01) but no significant differences over time in visual memory, between 
the chemotherapy participants and the “surgery only” participants.   
The main effect of the treatment on verbal and also visual memory was non-significant 
(all p>0.01) showing no differences in the test performance of the two groups 
(irrespective of time). The time x treatment interaction term did not show any 
significant effects across any of the subscales of the HVLT-R or the BVRT. 
The main effect of time on verbal memory: Recall (p=0.030), Delayed recall (p=0.068) 
and Retention (p=0.467) were non-significant showing no difference in most aspects of 
verbal memory over time. However, the main effect of time on delayed verbal 
recognition was significant (p=0.004). The mean difference across the two time points 
showed a decline in the scores (i.e. fewer words correctly recognised after a 20-minute 




Table 9.10: Results of the MLM analysis (main and interaction effects): Treatment differences over time in memory as measured by the 
HVLT–R (z scores) and BVRT (raw scores) 




St Error Mean 
z scores 
St Error T2 T3 










P=0.906 -0.13 -0.03 











P=0.200 0.22 -0.23 











P=0.280 0.21 -0.17 












P=0.082 0.37 -0.25 
CT -0.478 0.150 -0.262 0.161 










P=0.565 0.19 0.42 






6.1481 0.690 5.5271 0.609 F=0.528 
 
P=0.467 F=2.087 P=0.149 F=0.086 P=0.769 -0.06 -0.19 
CT 5.9291 0.480 4.9791 0.447 




9.7.5 Changes in perceived cognitive function over time 
After controlling for baseline, the mean scores for FACT Cog subscales QoL and Others 
were relatively high as shown in the Table 9.11. As discussed in Chapter 7, a higher 
score on the FACT Cog indicates less perceived cognitive symptoms. These scores 
therefore suggest that neither the chemotherapy group nor the “surgery only” group 
perceived themselves as having experienced worse QoL due to poor cognition during 
the 9-month study period. These results are very similar to the results that Vardy and 
colleagues (2017) reported in their study that also examined perceived cognitive 
impairment (using the FACT Cog) in people with CRC who do and do not receive 
chemotherapy treatment. 
Mean cognitive symptom scores were very similar in both groups. Means scores on the 
FACT Cog PCI and PCA subscales were worse at T3 than at T1 for both groups.   
The results of the MLM analysis in relation to perceived cognitive functioning over time 
are presented in Table 9.11. There were no significant differences over time in any of 
the FACT Cog subscales between the chemotherapy participants and the “surgery only” 
participants.   
The main effect of treatment on FACT Cog PCA (p=0.786), FACT Cog PCI (p=0.854), 
FACT Cog QoL (p=0.251) and FACT Cog Oths (p=0.077) were also non-significant 
showing no difference in perceived cognitive function over time. Similarly, the time x 
treatment interaction term did not show any significant effects across all subscales of 




Table 9.11: Results of the MLM analysis (main and interaction effects): Treatment differences over time in perceived cognitive 





















20.931 1.113 19.097 1.160 F=.074 P=.786 F=.074 P=.786 F=1.214 
 
P =.271 -0.30 0.08 





56.113 1.874 53.361 2.050 F=.034 P=.854 F=.034 P=.854 F=.502 P=.478 -0.35 -0.10 





13.479 0.667 13.454 0.737 F=.1.320 P=.251 F=.1.320 P=.251 F=.488 P=.485 -0.54 -0.30 





15.128 0.450 14.842 0.408 F= .004 P=.949 F= .004 P=.949 F=.125 P=.724 -0.20 -0.20 






111.938 2.842 114.642 3.090 F=3.136 P= .077 F=3.136 P= .077 F=.264 
 
P= .607 -0.81 -0.65 
CT 99.936 2.023 105.253 2.240 




9.7.6 Psychosocial outcomes: Changes in fatigue, anxiety and depression 
over time 
The results of the MLM analysis in relation to feelings of fatigue, anxiety and depression 
are presented in Table 9.15. 
 
Fatigue:  
As can be seen in Table 9.12, there was a significant main effect of time on fatigue 
(p=0.002), with a small effect size. The mean difference across the two time points 
showed an increase in scores from T2 to T3 demonstrating an improvement in feelings 
of fatigue at T3 (i.e less fatigue). The main effect of treatment on fatigue was not 
significant, showing no difference in the amount of fatigue between the two groups 
(irrespective of time). The time x treatment interaction did not show any significant 
effects.   
As discussed in Chapter 8, a score of <37 indicates clinical fatigue on the FACIT Fatigue 
scale. Based on the estimated marginal means, the mean fatigue score as measured by 
the FACIT Fatigue scale for the chemotherapy patient group was 31.48, whereas the 
mean score for the surgery only group was 42.67. At T2 (i.e. mid chemotherapy 
treatment/3 months post T1) 65.38% of the chemotherapy participants reported 
feelings of clinical fatigue whereas only 18.32 % of the “surgery only” patient group 
were found to be clinically fatigued.  
By T3 (3 months after the last chemotherapy treatment), the mean score for the 
chemotherapy participants improved to 38.06 and 35% reported feelings of clinical 




(suggesting that they were on average more fatigued than at T2) and 25% of the group 
were found to be clinically fatigued.  
 
Depression:  
As can be seen in Table 9.12, there was a significant main effect of treatment on 
depression (p=0.001) with the “surgery only” group mean scores being lower than the 
chemotherapy group mean scores (i.e. there was less depression). This demonstrates an 
increase in depression due to treatment. The main effect of time and the time x 
treatment group interaction did not reach significance, thus demonstrating i) no 
difference in the pattern of means between the two groups at each time-point and ii) no 
differential change in the means of the groups across time. 
The mean depression score for the chemotherapy participants mid-treatment (i.e. at 
T2) was 5.099 (i.e. no depression) and was only 2.701 for the “surgery only” group. 
However, this was the highest depression group mean score for the chemotherapy 
group across all time points and the lowest for the “surgery only” group. At T2, 5.76 % 
of the chemotherapy participants reported feelings of clinical depression (i.e. score ≥11) 





Table 9.12: Results of the MLM analysis (main and interaction effects): Treatment differences over time in fatigue, anxiety and 
depression and HRQoL 
 Participant 
group 













Surgery only 42.674 1.673 39.994 2.407 F= .417 P=.518 F=9.715 P=0.002 F=6.719 P=0.010 -1.28 -0.17 










P=0.654 0.18 0.30 









P=0.206 0.92 0.46 




Surgery only 24.408 0.938 24.739 0.861 F=4.253 P=.039 F=14.950 P=.000 F=4.259 P=.039 -1.10 -0.55 
CT 19.027 0.671 22.536 0.617 
FACT C 
SWB      
(0-28) 
 
Surgery only 23.051 0.694 24.395 0.808 F=3.001 P=.083 F= .680 P=.410 F=2.336 P=.126 0.06 
 
-0.46 







Surgery only 19.514 0.665 20.595 0.654 F=3.054 P=.081 F=.449 P=.503 F=1.830 P=.176 0.03 
 
-0.47 




Surgery only 22.775 1.016 22.690 1.242 F= 2.669 P=.102 F=2.795 P=.095 F=1.062 P=.303 -0.86 -0.44 
CT 18.242 0.722 20.156 0.899 
FACT C 
CCS    
(0-28) 
Surgery only 22.421 0.822 21.697 0.994 F=.071 P=.789 F=2.828 P=.093 F=2.123 P=.145 -0.61 -0.07 




Surgery only 111.938 2.842 114.642 3.090 F= 5.941 P=.015 F=3.136 P= .077 F=.264 
 
P= .607 -0.81 -0.65 
CT 99.936 2.023 105.253 2.240 
Key: HADS: Hospital Anxiety and Depression Scale; FACT C subscales: PWB: Physical wellbeing; SWB: Social wellbeing: EWB: Emotional wellbeing;  







As can be seen in Table 9.12, there were no significant main effects of treatment or time 
on anxiety and the time x treatment group interaction did not reach significance, thus 
demonstrating i) no difference in the pattern of means between the two groups at each 
time-point; ii) no difference in the amount of anxiety between the two groups 
(irrespective of time and iii) no differential change in the means of the groups across 
time. 
The mean anxiety scores in both groups remained roughly the same at each time point.   
At T2 13.46 % of the chemotherapy participants reported feelings of clinical anxiety (i.e. 
score ≥11) and 11.11% of the “surgery only” group. At T3, this was 15% and 9.09% 
respectively.   
HRQoL: 
As can be seen in Table 9.12, the mean scores for the chemotherapy patient group on 
the physical, functional, social and colorectal symptom wellbeing scales were better at 
T3 than at T2 (a higher score on each subscale represents a better quality of life).  
There was a significant main effect of time on PWB (p=0.000). The mean difference 
across the two time points showed an increase in scores from T2 to T3 demonstrating 
an improvement in feelings of physical well-being at T3 (i.e. better HRQoL). The main 
effect of treatment on HRQoL was not significant, showing no difference in the any of 
the wellbeing subscales between the two groups (irrespective of time). The time x 




9.7.7 Relationships between psychosocial outcomes and perceived 
cognitive function  
The relationship between anxiety, depression, fatigue, quality of life and subjective 
cognitive function was investigated using Spearman Rho correlation coefficient, after 
having carried out preliminary analyses to ensure no violation of the assumptions of 
normality, linearity and homoscedasticity (Please see all Tables of correlations in 
Appendix R).  
As can be seen in Appendix R, HRQoL in the whole participant sample was significantly 
related to FACT Cog PCA and PCI at T2 and T3. As FACT Cog PCI and PCA improved (i.e 
increased scores on each subscale) so did physical, emotional and functional wellbeing 
as measured by the FACT C. Depression, anxiety and fatigue were also significantly 
correlated with FACT Cog PCI and FACT Cog PCA at T2 and T3 for the whole sample.  
When exploring the relationships within each patient group correlational analysis 
showed that at T2 fatigue was significantly correlated with FACT Cog PCI and PCA in 
each patient group. As the scores for fatigue increased so too did FACT Cog PCI and PCA 
scores. However, anxiety and depression were each significantly negatively correlated 
with PCA and PCI  of the FACT Cog in the chemotherapy patient group but not in the 
“surgery only” group; such that as anxiety and also depression increased, the scores on 
the FACT Cog subscales decreased indicating more perceived cognitive symptoms. 
At T3 depression and fatigue were significantly correlated with FACT Cog PCI and PCA 
in each patient group. However, anxiety was significantly negatively correlated with 




“surgery only” group; such that as anxiety increased the scores on the FACT Cog 
subscales decreased indicating more perceived cognitive symptoms.  
9.7.8 Relationship between OCI and subjective cognitive function 
There were no statistically significant relationships between any of the FACT Cog 
subscales and overall OCI for the sample as a whole at T2 (Table 9.13). However, at T3, 
there was a statistically significant negative relationship between those participants 
found to be impaired according to the ICCTF’s 2 SD criteria and PCA (rho = -.440; 
p<0.01); and also, a statistically significant negative relationship between OCI and QoL 
(rho = -.328) (Table 9.13). This indicates that as the occurrence of OCI increases 
perceived cognitive abilities and perceived quality of life get worse (they decrease). It 
was not possible to explore the relationships between specific cognitive domains (i.e 
each NP measure) and each of the subjective domains (i.e each FACT Cog subscale) in 
each of the chemotherapy and “surgery only’ patient groups as the samples were too 
small at T2 and T3.  
Table 9.13: Table of point biscerial correlations (Spearman’s rho) for OCI (according to 
each of the ICCTF’s criteria) and SCI (as measured by FACT Cog subscales) for the entire 
participant sample 
T2  T3 
 OCI: 1.5 SD 
criteria 
OCI: 2 SD 
criteria 
 OCI: 1.5 SD 
criteria 
OCI: 2 SD 
criteria 
PCI -0.179 -.258 PCI -0.178 -.284 
PCA 0.002 -0.071 PCA -.290 -.440 
QoL -0.098 -0.128 QoL -0.233 -.328 
Oth 0.078 0.042 Oth -0.128 -0.104 
Key: Blue=Correlation is significant at the 0.05 level (2-tailed). Red = Correlation is significant at the 0.01 level (2-
tailed); FACT Cog subscales: PCI: Perceived Cognitive Impairment; PCA: Perceived Cognitive Ability; QoL: Impact on 




When looking at each of the patient groups separately there were no significant 
relationships at T2 or T3 (p<.01) between overall OCI and any of the Fact Cog subscales 
(Table 9.13) when OCI was defined by the ICCTF’s 1.5 SD criteria.  
Table 9.14: Table of point biscerial correlation coefficients (Spearman’s rho) for OCI 
(according to the ICCTF’s 1.5 SD criteria) and SCI (as measured by FACT Cog subscales) in 
each of chemotherapy and “surgery only” groups 
T2  T3 
FACT Cog 
subscale 
CT Surgery only  FACT Cog 
subscale 
CT Surgery only 
PCI -0.104 -.476* PCI -0.026 -.518* 
PCA -0.119 -0.170 PCA -0.142 -0.221 
QoL 0.104 -0.092 QoL -0.189 -.483* 
Oth 0.109 -0.331 Oth -0.306 -0.216 
Key: Blue=Correlation is significant at the 0.05 level (2-tailed). Red = Correlation is significant at the 0.01 level (2-
tailed). FACT Cog subscales: PCI: Perceived Cognitive Impairment; PCA: Perceived Cognitive Ability; QoL: Impact on 
Quality of Life; Others: Comments from others; CT: Chemotherapy.  
 
However, as can be seen in Table 9.15 there was a statistically significant negative 
relationship between OCI and FACT Cog PCI (rho = -.540) at T2and at T3 (rho=-.650) in 
the “surgery only” group but no statistically significant correlations in the 
chemotherapy group (Table 9.15). There was also a significant negative relationship 







Table 9.15: Table of point biscerial correlation coefficients (Spearman’s rho) for OCI 
(according to the ICCTF’s 2 SD criteria) and SCI (as measured by FACT Cog subscales) in 
each of chemotherapy and “surgery only” groups 
T2  T3 
FACT Cog 
subscale 
CT Surgery only  FACT Cog 
subscale 
CT Surgery only 
PCI -0.182 -.540 PCI -0.114 -.650 
PCA -0.134 -0.238 PCA -0.182 -0.053 
QoL 0.073 -0.134 QoL -0.306 -.695 
Oth 0.043 -.411 Oth -.322 -.463 
Key: Blue=Correlation is significant at the 0.05 level (2-tailed). Red = Correlation is significant at the 0.01 level (2-
tailed). FACT Cog subscales: PCI: Perceived Cognitive Impairment; PCA: Perceived Cognitive Ability; QoL: Impact on 
Quality of Life; Others: Comments from others; CT: Chemotherapy.  
 
9.7.9 Research question 3: Is OCI associated with lesser HRQoL in patients 
with CRC?  
 
Aim 3: To explore whether OCI in patients with CRC affects HRQoL? If so, which 
cognitive domains relate to what aspects of HRQoL?  
At T2 there were no statistically significant correlations found between any of the 
cognitive domains and HRQoL (as measured by the FACT C) when using the ICCTF’s 1.5 
SD criteria.  However, when OCI was defined by the 2 SD criteria, verbal memory (as 
measured by HVLT-R delay) was found to be negatively statistically significantly related 
to perceived emotional wellbeing scale (as measured by FACT C EWB) (rho = -.293) at 
T2 (Please see Appendix S for the table of correlations). In addition, attention (as 
measured by the Digit Span backwards) was found to be significantly correlated with 





At T3, the only statistically significant correlations were found between: 
 Motor function (as measured by PG dominant hand) and physical wellbeing (rho 
= -.334) (when OCI was defined by ICCTF 1.5 SD criteria); and   
 Verbal memory (as measured by HVLT R delay) and social wellbeing (rho = -
.344) (when OCI was defined by 2 SD criteria) (Appendix S). 
It was not possible to examine the relationships between OCI and HRQoL in each of the 
participant groups as the samples were too small at T2 and T3.  
9.8  Discussion 
 
This chapter firstly examined the nature and extent of OCI mid chemotherapy 
treatment/3 months after the first assessments were carried out and again 3 months 
after the last scheduled treatment/6 months after the second assessment in the two 
patient groups   before examining any changes over time. It then explored the 
relationships between cognitive function (objective and subjective) and psychosocial 
outcomes; and the relationship between subjective cognitive function and overall OCI. 
Lastly, it examined the relationship between OCI and HRQoL.   
9.8.1 OCI  
Overall, the results of this longitudinal study demonstrated that OCI continues to occur 
during and for at least 3 months after chemotherapy treatment/9 months after the first 
assessment in a subset of all patients with resected CRC. There was no significant 
difference in OCI between the participants that withdrew from the study after the first 
assessment, so there was no suggestion that the non-responders were poorer 




time point proportionately more “surgery only” patients were found to have OCI than 
chemotherapy patients (based on the ICCTF’s criteria), although this was not a 
statistically significant finding.  
OCI was most prevalent at T2 in each of the patient groups and for the sample as a 
whole. As discussed in Chapter 8, after surgery (and prior to chemotherapy treatment) a 
significantly higher proportion of participants in this study were found to have OCI 
compared to normative data based on age, gender and education. The proportion of 
participants found to have OCI was the highest at T2 and by T3 the proportion of 
participants found to have OCI was less than it had been at T1. These findings are 
similar to previous studies that found that OCI improves/resolves with time in a subset 
of patients diagnosed with breast cancer (including Mar Fan et al, 2005; Jenkins et al, 
2006; Vardy et al, 2006; Jansen et al, 2008; Collins et al, 2009; Mehlsen et al, 2009; 
Quesnel et al ,2009; Vearncombe et al, 2009; Weiss et al, 2009; Ahles et al, 2010, Debess 
et al, 2010, Reid-Arndt et al, 2010; Wefel et al 2010; Hedayati et al, 2012; Cruzado et al, 
2014).  However, 3 months post chemotherapy treatment is not a very long time after 
treatment and further assessments are warranted over a longer period of time to 
ensure that there is a real improvement and that patients haven’t simply developed 
temporary compensatory cognitive strategies as suggested by Ono and colleagues 
(2015). There were no statistically significant differences found between those 
participants who withdrew from the study and those that continued in terms of 
demographic, clinical or psychosocial characteristics.  
Given the extent of the impairment in a subset of patients (most notably in verbal 
memory and motor function) in both groups, ongoing assessment of these domains is 




was a commonly affected domain at T2 and T3 in the chemotherapy group as 
Oxaliplatin is believed to cause CIPN (Chapter 2) which often lasts for more than a year 
after the end of chemotherapy treatment; and many of the chemotherapy patients 
anecdotally complained of neuropathy in their fingers and toes. It is somewhat 
surprising therefore that it was also a commonly affected domain in the “surgery only” 
patient group at the second and third assessments. Although a number of the older 
participants may have been affected by other co-morbidities such as poor eyesight 
and/or arthritis, which would have affected performance on the Grooved Pegboard. As 
expected, the MLM analysis did show that an improvement in performance on the 
Grooved Pegboard (non-dominant hand) was due to treatment (moderate effect size). 
Although these results should also be interpreted with caution, as the norms used did 
not cover the older ages included in this study sample (they only went up to 70 years 
old). 
It is also worth noting here that the ICCTF (Wefel et al, 2011) reports that memory, 
processing speed, and executive function seem to be most vulnerable to adverse effects 
of chemotherapy. However, as discussed in Chapter 3, this could partly be because 
memory is the most commonly assessed domain in the literature (Cheung, Tan and 
Chan, 2012). It could also be due to the researcher’s choice of which domains to 
investigate. In this study, for instance the tests specifically recommended by the ICCTF 
were used to assess what the task force had found to be the most affected domains. 
Although the recommended tests were supplemented with a few others, the sample size 
in this study may not have been large enough to find any effects for attention and 




The extent of OCI reported at each time point and the most commonly affected domains 
did vary according to the cut off used to define OCI. This is a common methodological 
problem in “cancer and cognition” studies (Chapter 2). Consequently, further studies 
with additional control groups would help to validate the results of the present study 
and enable a better understanding of the course and duration of OCI in this patient 
population. 
The MLM showed that there appears to be very little change in cognitive function 
(neither objective nor subjective) over time. Although a main effect of time was 
significant for executive function (as measured by TMT B), attention (TMT A) and verbal 
memory (HVLT -R recognition) –performance in these 3 domains declined over time; 
but treatment made no difference. However, the effect sizes were small to moderate for 
all of the significant results.  
9.8.2 Subjective cognitive function  
Overall, cognitive symptom scores were similar in patients who received adjuvant 
chemotherapy for CRC and those who did not. The scores on the self-report measure 
were very similar to Vardy and colleagues (2017) study. However, it was not possible to 
examine whether the scores suggested significant SCI in the absence of any cut off 
criteria for the FACT Cog and/or a healthy control group. Consistent with other “cancer 
and cognition” studies (Schagen et al, 1999; Hermelink et al, 2007; Bender et al, 2008; 
Jansen et al, 2008; Schagen et al, 2008; Schilder et al, 2009: Klemp et al, 2017) this study 
does show that all of the psychosocial outcomes (depression, anxiety, fatigue and 




examines the experience of cognitive changes in a sample of the chemotherapy 
participants in more depth through semi-structured interviews.  
9.8.3 OCI and subjective cognitive function 
There were no statistically significant relationships found between overall OCI and any 
of the subjective cognitive function subscales; or between OCI and anxiety, depression, 
fatigue or HRQoL. 
9.8.4 OCI and HRQoL 
In line with the findings of the systematic review in Chapter 5 (and Dwek et al, 2016) on 
the whole OCI did not appear to be related to poorer HRQoL during or after 
chemotherapy treatment or at similar points in time in this patient group.  
9.9 Summary 
Overall, the findings from these longitudinal analyses suggest that the present sample of 
patients with CRC is comparable to previous literature in relation to breast cancer 
patients. However, there do appear to be some slight differences that are particular to a 
diagnosis and the treatment of CRC such as the continued motor function impairments, 
which could possibly be related to the chemotherapy regimen used to treat patients 
with this particular cancer. Further larger studies are warranted to examine the effect 
on cognition of each of the CRC treatment protocols (which not only use different 





Chapter 10: An exploration of the knowledge and perceived 
experiences of cognitive changes in patients diagnosed with 
CRC, prior to, during and several months following 
chemotherapy treatment: A Qualitative Study  
10.1 Introduction 
Chapters 8 and 9 described the findings from the quantitative component of this thesis 
examining CRCI in patients diagnosed with resectable CRC. To complement and expand 
the findings of the quantitative study an in-depth account of the impact of 
chemotherapy on perceived cognition was sought by conducting a qualitative study that 
elicited participants’ narrative of their individual experiences prior to, over the time of 
and after their chemotherapy treatment.  
The overall purpose of this qualitative study was to explore the knowledge and 
experiences of patients with resectable CRC concerning CRCI over time. Thus obtaining 
data describing patients’ experiences and their interpretations, not the incidence, extent 
or severity as measured by quantitative tools (Mitchell & Turton, 2011). A longitudinal 
design was chosen, as it would provide the researcher with ‘unfolding stories’ as told by 
the patients over the course of their chemotherapy treatment and recovery rather than 
snapshots of expectations and/or experiences at a particular point in time. Thereby 
providing a more comprehensive level of information regarding individual experiences 
and perceptions (Saldaña, 2003) than has previously been the case. The rationale and 
purpose of this thesis’ mixed methods approach is discussed in Chapter 6.  
As detailed in Chapter 6, Section 6.4.2 the aims of this qualitative study were to:  
1) Explore whether patients with CRC are aware of CRCI prior to the start of 
adjuvant chemotherapy treatment and whether they are aware of having 




2) Explore the type and extent of individual experiences of CRCI and its perceived 
effects prior to, during and post chemotherapy treatment. 
10.2 Method  
10.2.1 Ethical approval  
As detailed in Chapter 7, final ethical approval for this mixed method thesis which 
includes this longitudinal qualitative study was granted by the NRES Committee London 
– South-West Cornwall & Plymouth (REC reference number: 13/SW/0201) in June 2015 
(see Appendix H for approval letters). Relevant approvals were also gained from the 
Research & Development (R&D) departments at University College London Hospitals 
NHS Foundation Trust (UCLH), Barts Health NHS Trust (Barts) and Imperial College 
Healthcare NHS Trust (Imperial).  
10.2.2 Design  
This qualitative study utilised semi-structured interviews with participants who in the 
main also completed the quantitative study. Individual interviews were selected over 
focus groups because the purpose of this study was to gain individual in-depth accounts 
of the participants’ experiences over time and it is likely that experiences of CRCI will be 
varied. A further practical reason against using a focus group approach was that the way 
in which patients were recruited to the study and the treatment trajectory would have 
made it impossible to arrange focus groups for patients who were at the same stage in 




10.2.3 Participants and consent  
Participants who were eligible for the quantitative study were eligible for participation 
in this study. The researcher recruited and consented the participants to this study in 
accordance with the procedures outlined in full in Chapter 7.  
In tandem with the quantitative NP assessments and various questionnaires, interview 
data was collected from a subset (n=24) of the chemotherapy patients at the same three 
time points. Interviews lasted approximately 5 minutes at T1 and between 20 and 40 
minutes at T2 and T3, allowing participants to share as much as they wished about their 
perceived experiences. It was the intention of this qualitative study to capture the 
patients’ in-depth feelings and experiences of perceived cognitive impairment, its 
trajectory, and perceived impact on the patient over a period of 9 months covering pre-, 
mid- and post chemotherapy treatment. 
Interested participants received an information sheet in relation to the qualitative study 
(Appendix I) when approached by the researcher and medical team at their post-
surgery follow up appointment. Interviews were arranged at a time convenient to each 
of the participants and coincided with hospital appointments post-surgery  and pre-
chemotherapy treatment (T1), 3 months later (i.e. mid chemotherapy treatment) (T2) 
and again 6 months after the second interview (i.e. approx. 3 months post the last 
scheduled chemotherapy treatment) (T3). Written consent was obtained before the first 
interview (Appendix I). Participants were also reminded prior to each interview that 
they were to be audio-recorded, that all interviews would be confidential and 





10.2.4 Location of the interviews and safety protocol  
Participants were offered a choice of location either at home or at the treating hospital 
at a time convenient for them. Interviews were conducted in quiet rooms/areas at home 
or at the treating hospital. The researcher carried a working mobile telephone with her 
at all times (in accordance with City University’s lone worker policy) so that she could 
easily contact the supervisory team in the event of any safety concerns.  
10.2.5 Topic guide  
The researcher in collaboration with the supervisory team developed the interview 
schedules (See Appendix N). The interview schedules were designed to cover topics 
relating to the knowledge, experiences and future expectations of CRCI. The schedules 
were developed by firstly establishing the subjects to be covered following a review of 
the relevant literature (e.g. Downie et al., 2006; Mitchell & Turton, 2011) and further 
issues raised by participants at T1 and during informal conversations whilst carrying 
out the quantitative study. The subjects were discussed with the supervisory team, in 
terms of how questions should be phrased, prompts, and subject coverage. Two 
members of the supervisory team with experience in qualitative research then reviewed 
the interview schedules and made recommendations on practicality and the, wording, 
and length of each of the schedules.   
A semi-structured interview style rather than open-ended questions was selected in 
order to narrow down the area being investigated, namely cognition and cognitive 
function. It was thought that a completely un-structured interview might elicit too much 
information on the side effects of chemotherapy generally and not necessarily cognitive 




consideration. This approach allowed for key topics of interest to be explored and for 
new related themes to emerge (Ritchie & Lewis, 2003). The semi-structured schedules 
permitted some flexibility in the order that the questions were asked. A few general 
questions were also included to elicit conversation together with additional questions 
designed to probe for information related to cognition if it was not mentioned. Follow 
up questions were also used in order to obtain clarification and a deeper understanding 
where needed. All interviews were conducted and transcribed verbatim by the 
researcher.  
10.2.6 Data analysis  
Various approaches to data collection and analysis were reviewed and compared. 
Grounded theory (Glaser & Strauss, 2009) is concerned with generating theory for a 
particular phenomenon and often requires larger sample sizes to reach data saturation 
(O'Reilly & Parker, 2013). Since it was not the purpose of the present study to generate 
theory, grounded theory was deemed inappropriate. Interpretative Phenomenological 
Analysis (IPA) was not selected because it generally requires a small homogeneous 
sample (3-6 participants), which within the purpose of the present study was not 
deemed appropriate for exploring the range of participants’ cognitive experiences 
(Smith et al., 2009). The present study used Thematic Analysis and content analysis. 
Thematic analysis has been successfully employed by other researchers in the area of 
“cancer and cognition”, specifically in relation to the impact of CRCI on breast cancer 
patients’ daily functioning (e.g. Cheung, Shwe, Tan, Fan, Ng, & Chan, 2012). It has 
therefore been shown to be suitable in a similar patient group. It is considered “a 
flexible and useful research tool that can potentially provide a rich and detailed, yet 




study was informed by previous literature and the quantitative study components of the 
thesis. It involved a two-step approach: an inductive thematic analysis was undertaken 
(Braun & Clark, 2006), followed by a content analysis inspired by Saladans (2003).  
10.3 Step One: Inductive thematic analysis and results 
10.3.1 Thematic analysis 
As a first step, inductive thematic analysis was conducted for each interview in order to 
identify, analyse and report patterns within the data (Braun & Clark, 2006).  An 
inductive rather than deductive mode of analysis was chosen, as this study is 
exploratory in nature and consequently data driven. The focus of the analysis was 
knowledge, perceptions and perceived experience of CRCI at each time point. It involved 
the six-step process described by Braun and Clarke (2006) (see below) and was 
conducted using paper-based methods and the computer software NVivo, version 11 for 
Windows by QSR International.  
Familiarisation of the data was the first step undertaken in the analysis and involved 
transcribing the interviews, re-reading the transcripts and noting initial ideas. This 
enabled the initial identification of meaningful units of text relevant to the research 
topic. The second step involved systematically organising the entire data set (at each 
time point) into meaningful groups and developing initial codes. Collating similar codes 
together enabled the development of potential themes. The third step involved a 
systematic review of the coded data extracts to ensure that a name, definition and data 
to support each theme were identified. A second researcher from the supervisory team, 




the data in order to validate the coding. The researchers compared the naming of the 
themes and differences in opinion were resolved through discussion. The fourth step of 
the analysis involved reviewing and the fifth step led to defining and refining the 
specifics of each theme so that clear definitions of the themes were generated 
culminating in step six, which is the current report presented in this Section 10.3.  
10.3.2 Results 
The following section details selected verbatim extracts from the interview data to 
illustrate the themes and subthemes that emerged at each time point within an analytic 
narrative. This process acts as a reliability check to demonstrate how the data fits the 
initial analysis (Smith, 1996; Elliot, Fischer & Rennie, 1999). 
10.3.2.1 Sample characteristics  
Between April 2015 and May 2017, 24 participants who were scheduled to undergo 
adjuvant chemotherapy treatment and were eligible to take part in the quantitative 
study agreed to be interviewed for this study. As mentioned above everyone who was 
eligible to take part in the quantitative study was also invited to participate in the 
interview study. Two participants who did not wish to take part in the quantitative 
study consented to take part in this qualitative study.  
In total, three participants withdrew from the study after T1. Two did not provide a 
reason for withdrawal and one participant was temporarily unavailable due to travel 
plans at T2 but continued in the study at T3.  Five more withdrew after T2. Other than 
one participant whose cancer progressed necessitating additional chemotherapy 
treatment prior to T3, and another participant who unfortunately passed away, no 




quantitative study. At T3, the final sample size included 17 participants, 15 of which 
completed all three-time points.   
A total of 62 semi-structured interviews were conducted. As described in Chapter 7, 
Section 7.5.2, the approach to sample size in quantitative research, where larger 
numbers are generally more desirable, is not applicable to qualitative research, where 
the sample size reflects the depth and richness of information that describes a 
phenomenon (O'Reilly & Parker, 2013). (Please refer to Chapter 7 Section 7.5.2 for a full 
discussion of the sample size calculation). Therefore, this sample size was considered 
sufficient for the qualitative phase of this thesis (Castro et al., 2010).  
Participants’ ages ranged from 36 to 78 years, with a sample mean age of 63.17 years. 
There were a total of 15 male participants and 9 females. Participants’ were mostly 
retired and educational status varied widely across individuals. The majority of the 
participants were Stage 3 CRC (Please refer to Chapter 1 for a full description of CRC 
staging); 18 participants were due to receive 12 cycles of intravenous chemotherapy 
whilst 6 were scheduled to receive 8 cycles of oral chemotherapy treatment; 15 of the 
24 participants completed the scheduled course of treatment. One participant 
developed metastatic disease and went onto a second course of chemotherapy whereas 
the remaining participants stopped the treatment early due to severe adverse physical 
side effects. Basic demographic and clinical characteristics of the participants are 
presented in Table 10.1. Participant ID numbers were assigned to each participant to 




Table 10.1: Participant demographics and clinical characteristics prior  
to the start of chemotherapy treatment (T1)  
 Characteristic Number of Participants (unless 
otherwise indicated: n=24) 
Age in years, mean (s.d) 63.17 (8.19) 
FSIQ, mean (n =19)  102 
Education  
 Less than 12 years 1 
 More than 12 years 21 
Gender  
 Male  15 
 Female 9 
Marital Status  
 Single/divorced/widowed 10 
 Married/partnered 14 
Occupational Status  
 Working  10 
 Unemployed/Home maker 3 
 Retired 10 
 Student 1 
Native English Speaker  
 Yes 19 
 No 5 
  
Tumour stage /TNM Stage  
 Stage I 0 




 Characteristic Number of Participants (unless 
otherwise indicated: n=24) 
 Stage III 16 
 Stage IV 2 
Tumour site  
 Colon 15 
 Rectal 5 
 Colon & Rectal 4 
Stoma   
 No 17 
 Reversible 6 
 Permanent 1 
Comorbidities   
 0 5 
 1 7 
 ≥ 2 12 
 
10.3.2.2 Themes 
Following the initial thematic analysis of the data, a number of codes were created and 
responses categorized into three main broad themes: ‘participants’ perceptions of the 
phenomenon of CRCI’, ‘participants’ perceived experience of cognitive changes’ and 




Table 10.2: Themes, subthemes, codes present across T1, T2 and T3 
Themes Subtheme 
 




awareness of CRCI 
as a phenomenon 
Heard of it  
 
 X X 
May have heard of it  X X 
Concern  Concerned   X X 
Concern related to duration  X X 
Perceived causes of 
cognitive changes  
Operation and/or 
anesthetic 
  X 
Just one of those things  X X 
Shock of diagnosis  X X 
Priming effect X  X 
Age related X  X 
Unexplainable/ 
something else 








Memory     
Language    
Concentration    
Attention/ 
distraction 
   





Changes to daily 
life 
Social activities restricted due 
to things other than CRCI 
X  X 
Modified social activities 
 
X X  












Not concerned X X  
Frustrated X  X 
Dementia worry X X  
 
10.3.2.2.1 T1 (Post surgery, pre-chemotherapy treatment)  
Theme 1: Perceptions of CRCI  
This major theme emerged at T1 with three subthemes that highlight the fact that this is 
not a phenomenon usually associated with CRC and/or its treatment. The subthemes 
included the following: knowledge/awareness; concern and attributable causes of CRCI 
(Table 10.2).  
i) Knowledge/awareness of the phenomenon of CRCI 
The first subtheme “knowledge/awareness” relates to participants’ general awareness 
of the existence of the phenomenon of CRCI. None of the participants recalled having 
received specific information from their medical teams about CRCI. The first mention of 
it was when they read the information sheets for this study. Nevertheless, when asked 
about it at T1, the majority of participants (18/24) said that they had never heard of 
CRCI. Unlike breast cancer patients, CRC patients appear (in the main) to be unaware of 
any potential cognitive impairments associated with CRC and/or its treatment. Only one 





“Yes I did hear from a colleague who had a similar er diagnosis ……he in 
conversation mentioned … He mentioned that he had cognitive problems, and 
fatigue were his two…the two main things" (66 at T1). 
 
Whereas two others thought that they may have heard of CRCI: 
I  have a friend… I…..She is 65 years old and she was having chemo and she was 
having radiotherapy and I think that she …she has been complaining that she 
forgot things that she lost her memory and all that….(44 at T1). 
ii) Concern 
Even though only a few participants had heard of CRCI, most said that they would be 
very concerned if it existed. Only one participant provided a reason for the concern, 
which was worry that such impairment would affect a return to work. 10 (approx. 42%) 
of the participants had been in employment up until their diagnosis and surgery for 
CRC).  
“Ummm yeah…I would be… cause its…. I want to go back to work…. my memory has 
to has to be… pretty good because of what I do for a living…..I have to be on the ball 
...” (79 at T1). 
 
A few participants were not at all concerned about the possibility of CRCI and four who 
felt that as long as it was only temporary then it did not matter if it occurred. For 
example:  
“………., if it had a lasting effect I would be very concerned about it. Umm yes. But if 
it was a side effect during the treatment that went I would accept it as a side effect 




iii) Causes of cognitive impairments 
When participants were asked, what they thought might cause such cognitive 
impairments most did not have an answer. However, some people attributed possible 
causes to the operation itself and the effects of the associated medication:  
The trauma of the operation. General stress about the condition, and possibly the 
anaesthetic (31 at T1). 
…that was the morphine (122 at T1). 
 
Whilst others believed it to be the result of the shock of the diagnosis:   
Only to know that you have cancer and you are going to pass through to a lot of 
things is confusing and I think you have too much information in your head and too 
much thinking and worries that you get confused and sometimes you say oh I don’t 
remember this, I forgot this, I don’t remember that …so ….it’s only because of that. I 
think it’s confusing and too much pressure....(44 at T1). 
Theme 2: Participants experience of CRCI 
This major theme emerged with several subthemes that elucidate the specific cognitive 
impairments experienced along with their consequences from pre- to three months post 
chemotherapy treatment. They included problems with memory, finding the right 
words, concentration, paying attention. A summary of this theme, its subthemes and the 
codes used in the analysis at each time point together with representative quotes are 




Table 10.3: Perceived experiences of CRCI, subthemes, codes and selected quotes across T1, T2 and T3 
Themes Subtheme 
 
Codes Sample quotes 









Memory  "Since I had the operation at the beginning 
of March, my memory is much worse than 
it used to be. ...............(31).    
                       
Sometimes you say oh I don’t remember 
this, I forgot this, I don’t remember 
that.....yes sometimes I forgot things.. 
Sometimes my children say ‘Oh mummy but 
you said something’ and I say ‘no’. ‘Yeah 
you said yesterday’ and that is is worrying 
(44)  
 
ummm just I am having issues with 
….walking into a room and thinking what 
did I come in here for (121). 
General forgetfulness: I just think that 
little by little I lost my memory. I do 
things when I no have to do it and I put 
things where I cannot remember where I 
put it and I forgot appointments or I have 
to write down everything or I have to ask 
somebody to remind me because I think I 
been lost a lot of my memory… I can’t 
remember sometimes things…. (44). 
 
…. getting confused just lately about 
meetings and things in yeah things in the 
diary that I’ve gotten wrong or things 
that I’ve forgotten to do that I wouldn’t 
necessarily have forgotten before… (121).  
 
Losing things:  
I’ve had a couple of incidents where …..I 
think I might have sort of forgotten 
things and I mistake things for ….objects 
for other things, like pens and pencils… I 
get... It’s happened a few times, …... Like I 
would forget where I’d put my phone 
quite a bit....(55) 
I’d forget simple things you know, like I’d 
go downstairs in the morning and find I’d 
left my watch or whatever, and I’d go 
back upstairs to get my watch and then 
come back down again and forget about 
the blasted thing you know… those sorts 
of things (30A).   
 
I have a lot of trouble remembering 
things…..It’s worse. In the past if I tried to 
remember a name it would come 
eventually. At the moment it’s as though 
somebodys put a black sheet of paper 
over it and I just can’t see it, it’s not 
there…. (31) 
 
It’s just a bit…. like every time I leave I 
usually have to come back because I’ve 
forgotten something….. But that’s been 
happening for years (55) 
 
I still kind of walk into a room and think I 






Codes Sample quotes 
T1 T2 T3 
I tend to leave things in the same place… 
but if for some reason my keys, if they’re 
not where I usually put them then I can’t 
then remember where I put them (57) 
 
..where I put things, yeah, because I put 
my hearing aid somewhere, I’m damned if 
I can find them….(30A) 
 
Forgetting to pass on information:  
Sometimes somebody says something to 
me and I’ve forgotten to pass the 
message, or something like that… (58 ) 
 
Forgetting to pay a bill: Oh I’d certainly 
forgotten to make a payment on my 
credit card that I thought I’d paid (121). 
can’t remember … walk backwards and 
then it comes to me (121). 
Language I’ll be sort of searching for the name but 
then I’ll completely forget what the 
sentence was it was involved in.” (31)  
 
For the first three months, I found it very 
hard to pick out the right word and …. 
Sorry not the first three months, the three 
cycles (31) 
 
Sometimes in finding the right word to 
say. Sometimes I’d use the wrong word 
(laughs). So I’d say something and 
somebody would look at me and go ‘Is 
that what you meant?’ (laughs) so….I 
think it got gradually worse throughout 
the chemo.....Now ….I still have that 






Codes Sample quotes 
T1 T2 T3 
I’m sort of …..yeah, not as clear in my 
thinking and speech (57). 
 
I am having issues with grasping for the 
right word ……. I think the grasping the 
word has been feeling as if it’s been getting 
worse (121) 
I do crossword puzzles and sometimes I 
look at it and I know the answer but I 
can’t bring it into my head and….er (57) 
 
..kind of phenomenon of saying ‘Where’s 
the doo-hickey that goes along the what’s 
it called’ kind of thing’ I just said several 
words in a row, not even in a row, like 
several sentences at different times I just 
couldn’t think of the right word. That 
happens to me occasionally…(68). 
Christmas, I spent Christmas with my 
family and I called people by the wrong 
name so I called my sister by my 
daughter’s name (laughs). My son by my 
partner’s name… just came out (57). 
 
I am having issues with grasping for the 
right word ……. I think the grasping the 
word has been feeling as if it’s been 
getting worse… (121). 
Concentration Umm, concentration seems to have gone 
down a a bit… I’ve just noticed once or 
twice I’m sort of … (57)  
 
.. I mean I like reading books, but … 
ummm I found it errr I found a sort of 
reading a sort of novel or something was 
too much on one go so I tended to read a 
errrr newspapers or things… (67a). 
….I lack in concentration although I can 
find it, if you know what I mean. If I really 
need to think ‘I must think about this’, um 
I tend to be able to concentrate a bit. 
….Yeah I don’t read very much….yeah …. I 
can’t find the concentration for that....... 
(57). 
Concentration is limited..... I can read so 
long as there’s not too many characters 
in it. But now if I try and watch anything 
that’s a little too complex I just give up, I 
can’t follow who the characters are. 
..[but] I’m doing something now that I 
wasn’t doing when I was on the chemo. 
I’m attempting to do more complicated 
things (31) 
Attention/ …I noticed it over the last few months 
actually (before the operation) …I have 
some some little failures you know could be 
........it was difficult to keep up with other 
people’s conversations. ..... (31) 
One day I left the front door open and 
jumped in the car and drove off…...But I 






Codes Sample quotes 
T1 T2 T3 
distraction distraction I don’t know…occasional 
ones.....Well there…Yeah there was one …. 
(laughs) er I found myself going down the 
stairs, I live on the second floor. I was … I 
was about to go out the door when I 
noticed I was wearing odd shoes…… they 
weren’t the same colour or anything… one 
was a trainer and one was a black shoe 
(laughs)…totally different shoes… (131).  
 
 
(laughing).....Because when we came 
back, went to open the door and it was 
wide open…(66) 
I might start doing something in one 
room and then I’ll get distracted and go 
and forget what I was doing… and then 
probably go back …errm probably about 
half hour …say I go in the bedroom and 




 When I was on the Oxaliplatin I did feel 
that my brain was sort of going asleep, it 
wasn’t as alert as it used to be, and I 
wasn’t as quick at doing things. Since 
that stopped its improved but I’m 
certainly not up to the standard I was 
before I started on the chemo. ...(31) 
….I had to think a little bit harder….I  I 
was struggling reading which I do a lot of 
and I didn’t I didn’t want to read it….. 
because it just…my mind it felt… I don’t 
know how to explain… the heaviness in 
my head and it was just like ….a bit dazy 







Affected cognitive domains:  
Even before chemotherapy treatment had started, some patients reported experiencing 
problems with memory and language. However, very few patients thought that their 
concentration was worse than it was prior to the cancer diagnosis. 
Memory  
As can be seen in Table 10.3 prior to starting chemotherapy treatment a number of 
(although not all) participants felt, that their memory was worse than it was prior to 
diagnosis. Sometimes this involved difficulties remembering certain conversations:  
Sometimes my children say ‘Oh mummy but you said something’ and I say ‘no’. 
‘Yeah you said yesterday’ and that is is worrying (44 at T1);  
At other times, it consisted of difficulty in remembering steps in a familiar activity 
(Table 10.3).   
It was also interesting to note that two participants reported not noticing any 
impairment in memory yet spontaneously provided examples of walking into a room 
and not remembering why.   
Language  
Four of the participants that had mentioned changes in memory also tended to have 
trouble with word retrieval. This included examples of forgetting the names of people 
and things or not being able to find the right words to explain something as highlighted 
in Table 10.3. For example: 
I am having issues with grasping for the right word ……. I think the grasping the 





Participants were specifically asked about concentration but very few said that they had 
noticed any difference at any point in time. Only two people appeared to be affected by 
changes in concentration at T1.  
10.3.2.2.2 T2 (mid-chemotherapy treatment)  
Theme 1:  Perceptions of CRCI at T2  
The T1 theme regarding perceptions of CRCI also emerged at T2 with some slight 
differences.  For example in relation to perceived causes of cognitive impairments, as 
time progressed different participants started attributing changes to different causes, 
such as age:   
It’s the occasional you know …what you call, a senior moment (66 at T2). 
There was also some suggestion that there was a priming effect for those who were 
participants in the study and had already been interviewed about their knowledge and 
experience of CRCI. An example of this awareness of CRCI particularly on the pre-
arranged interview day and the possible effect that it had can be seen in the following 
quote:   
Well I don’t know whether it was because I was aware of this meeting today but 
this morning I was I was trying to update my diary and I was making all sorts of 
mistakes (laughs) and I don’t know if that was a psychological ‘… oh my god I am 
going to be tested later’ or whether it really is… (88 at T2). 
 
One woman appeared to attribute perceived experiences of changes in memory to an 




illness) rather than it being related in any way to her chemotherapy treatment: 
don’t know if that’s down to the chemo, it could have been just some weird other 
thing...... like my husband would say, ‘have you taken your pills?’ …..I’d even bring 
them and have them in front of me on the table here and I just…. later on I’d go ‘oh 
my god I forgot to take my pills’. That might be forgetfulness…But then again it 
might be I can’t describe what I mean, some sort of psychological bulking… I don’t 
like being sick, part of me doesn’t want to take the pills, I might just have been. I 
don’t know if it’s memory failure or if it’s a psychological problem (68 at T2). 
Theme 2: Participants experience of CRCI at T2 
Whilst impairments in memory, language and concentration continued to be reported at 
T2, further implicated domains such as attention/distraction and general fogginess 
were revealed that had not occurred at T1 (Table 10.3).  
Affected cognitive domains: Memory, language, concentration and attention 
By T2, eight participants expressed problems with memory; four of whom had also 
mentioned this problem at T1, so there was no change for these participants. However 
not everyone who mentioned problems were able to provide any examples, whilst 
others provided one or two which were very similar to those reported at T1. The most 
often cited example was forgetting appointments (four out of the eight reported this 
experience).  Other examples of memory loss included losing things, forgetting to pass 
on information and forgetting to pay bills.  
At T2, six participants described difficulties in concentrating. Four of them talked about 
not being able to read anymore and one described how it now took him longer to do a 




often takes longer to complete tasks. One participant, who mentioned experiencing 
impaired concentration at T1, felt that it had further deteriorated at T2 although she 
described how when she really needed to do something she would put more effort into 
concentration.  
….I lack in concentration although I can find it, if you know what I mean. If I really 
need to think ‘I must think about this’, um I tend to be able to concentrate a bit (57 
at T2). 
Problems with paying attention were also reported by some participants in this study, 
and although very similar to concentration, participants were able to distinguish 
between the two. There was an implicit understanding that concentration is the ability 
to focus or sustain attention on one task, whereas directing attention requires the 
ability to focus on certain tasks in the presence of competing stimuli (Jansen et al, 
2005). Some participants acknowledged that their ability to pay attention had changed 
(Table 10.3).  
One participant also mentioned that she now had difficulty in multi-tasking:  
I find it hard….I can only do 1 thing at a time now, whereas before I could I could 
probably juggle about 3 or 4 things at one go but now I can only do one thing at a 
time (91 at T2). 
Which is actually indicative of changes in executive function (Von Ah et al., 2013).   
Dull head/fogginess 
Although most of the participants who reported experiencing cognitive impairments of 
one type or another gave specific examples of memory failure and/or reduced 
concentration and attention, several also mentioned a general feeling of dullness or 




Theme 3: Impact of cognitive changes during chemotherapy treatment (T2) 
At T2, participants were asked how any cognitive changes that had been experienced 
affected their lives, in particular social activities.   
Social activities 
Although social activities were restricted throughout chemotherapy treatment for all 
participants except four, who said that it was the same as it was prior to treatment, no 
one attributed the changes to CRCI.  Nearly all participants reported having restricted or 
stopped activities due to feelings of tiredness:  
I think socially is more affected by the um…by the tiredness (57 at T2). 
I’m totally wrecked, like … tonight I’m meant to go to a social event that I’m really 
looking forward to but it’s beginning to dawn on me, do you know …you’re not 
going to be able to go, ……...I have also on purpose cut back on my relationships (68 
at T2). 
One man stopped all social activity purely because of his feelings towards his stoma and 
another woman described how her social life had previously been inextricably linked to 
her work which she had had to give up due to undergoing chemotherapy treatment:   
Well I don’t have much social life now than before when I used to go to work and I 
used to share with my colleagues and things like that. Obviously now I I spend most 
of the time at home (44 at T2). 
Work/Study 
Most participants in this study were not working either because they were retired or 
had taken sick leave prior to surgery and had not yet returned to work at T2 (Table 




continued studying throughout although his attendance was restricted due to his 
physical side effects rather than any perceived cognitive changes.   
most weeks, for example this week, I’ve been in three days….. So if there’s not a 
pressing reason for me to go in, I wouldn’t go in. Whereas before I would just go in. 
I just sort of try and take it a bit easier (55 at T2). 
Emotional impact of perceived CRCI 
The only emotion mentioned in connection with experienced cognitive changes at T2 
was frustration and it was in relation to memory:  
I get frustrated when I cannot remember things or I forget things or I have to pay 
bills and I forgot the day or …sometimes if they don’t remind me I forgot 
appointments, or things like that so it bothered me a lot (44 at T2) 
It got very frustrating because normally I’ve got a good memory (30A at T2).  
10.3.2.2.3 T3 (Three months post chemotherapy treatment)  
Theme 1: Perceptions of CRCI at T3.  
By T3 knowledge/awareness of CRCI was no longer an issue for the participants and 
was not discussed so no one mentioned what he or she thought might have caused any 
cognitive impairments experienced up until then. The researcher concentrated on 
experience of CRCI and its impact at this time as illustrated in Table 10.2.  
Theme 2:  Participants experience of CRCI at T3 
Seven of the participants who had experienced CRCI at T2, continued to do so at T3, 




Continuing impairments in the previously affected cognitive domains:  
Some participants continued to report experiencing impairments in memory 3 months 
after their last scheduled chemotherapy treatment. They provided examples similar to 
those described at T2 such as forgetting where things were or had been put and/or why 
they had walked into a room. Only one person mentioned that her memory had actually 
deteriorated since finishing treatment (rather than having experienced such 
impairment during her chemotherapy journey).  For the remaining participants the 
impairments appeared to be the same as during chemotherapy (T2) although two 
described their memory as being worse (Table 10.3).   
By T3, no one reported experiencing any impairment in concentration suggesting that 
any perception of noticeable changes in concentration may resolve once treatment is 
completed.  In addition, impairment in attention/distraction appeared to have 
improved in those patients who had reported it previously. Only one participant who 
had mentioned decreased attention and/or becoming easily distracted at T2 did so 
again at T3 (Table 10.3).   
One participant did mention feeling something akin to the fogginess that had been 
described by others at T2, but he related that to the whole chemotherapy experience 
and going from being very busy with treatment and hospital visits to doing nothing at 
all:  
I do find sometimes I feel a bit say with my head in the clouds but probably like I 
said I’ve stopped working and I’ve stopped going to the hospital and I find I have 





Theme 3: Impact of cognitive changes at T3 
Social activities 
By T3, all participants except one recounted resuming normal activities and/or positive 
experiences surrounding their social life. Only one participant said that she had to 
modify her social activity post treatment but this was not connected to cognitive 
challenges rather to fear of recurrence or catching something or feeling a bit depressed 
by the whole experience:  
I still don’t go in the…. crowded places…..A little bit… ummm for the time being…. 
Until I find that I am fine. I get scared because I got my granddaughter I want to 
see her grow up so I don’t want to recur or anything else…you know? For my 
precautions I don’t go (58 at T3) 
it’s okay yeah…..Ummm …..yeah it’s a bit…sometimes I find it difficult to sort of 
motivate myself to go, go out out and things like that…but the majority of …I think 
it’s just me feeling sorry for myself, I think, sometimes. I think it’s just me sort of 
dwelling on stuff which I shouldn’t be now because at the moment things are fine… 
(91 at T3) 
Return to work 
However, perceived cognitive impairments did have an impact on those participants 
who had taken sick leave for the duration of treatment. On a return to work some 
participants found that their perceived cognitive impairments were highlighted, making 
it difficult to resume usual activities (Table 10.3). 
…. when I went back to work when the kids were coming and asking miss how do 




with you’ , you know that sort of thing. So it was …that’s…it was only when I went 
back to school, to work....with the children that I realised that my.. that sort of thing 
is sort of really starting to sort of get thingy. .., it’s  so frustrating (laughs) it really 
is (91 at T3). 
Emotional impact of perceived CRCI 
By T3, there was also less of an emotional response to the experience of CRCI. Only one 
person mentioned frustration this time. Rather a number of participants described the 
perceived cognitive changes that had been experienced as unimportant: 
My view about memory has always been that if you can look it up it doesn’t matter 
(122 at T3). 
I mean so what if you forget something, it’s not the end of the world (30A at T3).         
 
Another was more concerned and upset about the loss of physical fitness experienced 
(he did not appear to notice any cognitive changes):  
my main disappointment ….is ….the degree of loss of fitness and the slowness 
recovering it …..ummm…Definitely not as strong.. (122 at T3) 
 
In line with the breast cancer research one lady attributed her perceived experience of 
cognitive impairments to the menopause:  
I’d come through my menopause so I ..I always related it to that and just to getting 
older…(121 at T3). 
Only one participant expressed worries about dementia: 




10.3.3 Changes over time  
It is evident from the above results that a sub-set of patients with CRC who were 
interviewed for this study experience some impairment in various cognitive domains 
before, during and after adjuvant chemotherapy treatment. However it is important to 
note that patients may experience adverse effects of surgery and anesthesia (Newman, 
Stygall, Hirani, Shaefi, & Maze, 2007), following a cancer diagnosis, which could 
influence cognitive ability at the pre-chemotherapy stage.  
Although most participants were unaware of the existence of CRCI when they were first 
interviewed, a few did report experiencing impairments in memory (5/24 (21%)), 
language (3/24 (12.5%)), concentration (2/24 (8%)) and attention (2/24 (8%)) prior 
to starting chemotherapy, which is a lot less than the proportion who were found to 
have OCI on the NP assessments at T1. Some participants (7 out of the 24 (29%)) did 
not perceive experiencing any cognitive impairment at any time. As in Mitchell and 
Turton ‘s study (2011) some participants were keen to attribute cognitive impairment 
to everyday causes such as aging or the trauma of the illness and treatment, which they 
could understand, explain and justify. 
Impairments in concentration, attention and feelings of dullness were reported with 
more frequency during chemotherapy treatment (i.e at T2) (Table 10.4) than at either 
of the other times (T1 or T3).  Although it is important to note here that by T3 not all 
participants were interviewed again.  
Changes in memory were reported by more of the participants both during (10/22 
(approx. 43%) and after chemotherapy treatment (10/16 (approx. 62.5%) than any 




although interviewed at T3 reported memory issues relating to T2 (as he missed T2) so 
his memory issue has been counted here rather than at T3 since he only spoke about the 
week following his first chemotherapy treatment.) Interestingly 3 out of 17 (approx. 
18%) chemotherapy participants reported memory problems at T3 but not at T2, 
suggesting that for some chemotherapy patients’ issues with memory may have become 
more noticeable after the chemotherapy treatment had finished and normal daily 
activities resumed.  It is worth noting here that participants were asked to talk freely 
about their experience of changes (if any) in cognition, so it could also be argued that 
many simply used language that suggested memory impairment rather than any other 
impairment. The word “memory” is a familiar one, which is used in everyday 
conversation, whereas something like ‘executive function’ is quite a technical term that 
is rarely (if ever) used.  
Memory issues contrast with other perceived impairments that reportedly improved 3 
months after chemotherapy treatment, such as concentration and attention/distraction. 
Three of the participants (interviewed at both T2 and T3) who had mentioned poor 
concentration during chemotherapy did not mention it again several months after 
finishing chemotherapy treatment. Also 2 of the 3 participants interviewed at T2 who 






Table 10.4: A table of each participant’s experience of the cognitive domains that were affected over time  
Partici
pant  
Memory Language Concentration Attention/Distraction Dull/heavy head 
T1 T2 T3 T1 T2 T3 T1 T2 T3 T1 T2 T3 T1 T2 T3 
30a X Y Y X X X X X X X X X X X X 
31 Y X Y Y Y Y X X Y X Y X X Y X 
38 X X  X X  X X  X X  X X  
44 Y Y  X X  x Y  x X  X X  
55 X Y Y X X X X X X X Y X X X X 
57 X Y Y Y Y Y Y Y X Y X X X X X 
58 X Y Y X X X X X X X X X X X X 
59 X X X X X X X X X X X X X X X 
62 Y Y Y X X X Y X X X X X X X X 
66 NR X X NR X X NR X X NR X Y NR X X 
67a X X X X X X X Y X X X X X X X 
68 NR X Y NR Y X NR X X NR X X NR X X 
69 X   X   X   X   X   
72 X X  X X  X X  X X  X X  
73 X X X X X X X X X X X X X X X 
79 X X  X X  X Y  X X  X Y  
83 X X X X X X X X X X X X X X X 
88 X NR NR X NR NR X NR NR X NR NR X NR NR 
91 X Y Y X X X X Y X X Y Y X X X 
94 X Y  X X  X Y  X X  X X  
102 X  Y1 X  X X  Y1 X  X X  X 
121 Y Y Y Y X Y X X X X X X X X X 
122 Y X Y X X X X X X X X X X X X 
131 X   X   X   Y   X   
Key: T1: Post surgery, pre chemotherapy treatment; T2: Mid chemotherapy treatment; T3: 3 months post last scheduled chemotherapy treatment; NR: No response.  102 Y1this participant 





10. 4 Step Two: Content analysis and results 
10.4.1 Analysis 
The initial analysis was successful in building crosscutting themes and clearly 
illustrated the perceived cognitive experiences of some of the participants at each time 
point. It did not, however, enable an examination of the changes that emerged over time 
as the context of the treatment changed (Murray et al, 2009). Therefore, the researcher 
conducted further analysis in order to explore the individual trajectories and examine 
whether there were any identifiable patterns in change in perceptions and experiences 
of CRCI in individuals across time (Saladans, 2003). An inductive qualitative analysis 
(Graneheim & Lundman, 2004) was conducted for each interview. 
Once the content of an entire interview had been grasped (i.e. a sense of the whole had 
been grasped), meaning units were identified, consisting of words, sentences or 
paragraphs containing aspects that were related to each other through their content 
and context (Graneheim & Lundman, 2004). The meaning units for each interview for 
each participant were then condensed (i.e. shortened while still preserving the core) 
and labelled with a code. An example of meaning units, condensed meaning units and 








Table 10.5. An example of the analytical steps from meaning units to theme (31) 
Meaning unit Condensed meaning unit Code 
It was difficult to keep up with other 
people’s conversations and I totally lost 
interest in current affairs so I wasn’t 
reading newspapers which also made 
the brain feel a bit dull. ....For the first 
three months I found it very hard to 
pick out the right word  
Difficulties in following 
conversations, current 
affairs, reading newspapers, 
and word retrieval.  
Experiencing problems 
with concentration and 
memory 
 
The whole context was taken into consideration during the condensing and labelling of 
the meaning units with codes. The various codes were compared based on differences 
and similarities and sorted into sub-categories and categories. Lastly, the underlying 
meaning, of the categories, was formulated into a theme, which Graneheim and 
Lundman (2004) described as being a thread of an underlying meaning through, 
condensed meaning units, codes or categories, on an interpretative level.  
A summary for each interview was then formulated based on the content of the 
subcategories, categories and themes for each interview. The three time points for each 
participant were considered as a whole and reflected upon in light of the focus of this 
study – ‘how can the cognitive journey for this person be described?’ A consideration of 
the changes and similarities for each persons’ experiences, thoughts and feelings about 
their cognition lead to the emergence of three main patterns as described in Section 
10.4.1. 
Following a further analysis of the themes (as described in section 10.3) over the nine-






Three main patterns were distinguished as a result of this further analysis. They were: 
1) No concern at any time and life continued as usual; 2) Concern with cognitive 
challenges were constant throughout the chemotherapy journey influenced by notions 
of dementia or concerns about work; 3) Cognitive issues were secondary to other 
concerns. Two participants did not fall into any of the patterns because they only did 
one interview at T1 and were therefore excluded from this analysis, as there was no 
journey to follow.  
1) No concern at any time and life continued as usual 
Three of the six participants who fell into this category had mentioned that they knew of 
the existence of CRCI (specifically changes in memory) prior to starting chemotherapy 
treatment but were unconcerned. Five of the participants were married and all six were 
retired or not working. Three participants did not experience any physical side effects 
at all during the treatment and did not perceive any noticeable changes in cognition at 
any time (38, 66, and 72). They all mentioned that nothing in their lives had changed 
and no one around them had noticed anything different either. It was interesting to note 
that two of the participants didn’t give much thought to the cancer diagnosis possibly 
due in part to the fact that they did not experience any side effects (which for others 
were quite debilitating), they were just thankful that it was now gone:  
“We’ve had the operation, the tumour’s taken out, so that’s the end of that. ….. So I 
don’t dwell on the fact that I had cancer or whatever. It doesn’t really come into my 




“By the grace of God I was lucky that it was caught in time and what was done ..” 
(38, T2). 
The other three participants who fell into this pattern, did experience some physical 
side effects (such as tiredness, sensitivity to the cold and diarrhoea) during the 
treatment, which disappeared as soon as it finished; and although some social activities 
were restricted due to the tiredness nothing else changed and they did not experience 
any issues with cognition (other than what one of them called “usual” forgetfulness 
(73)) at any time (67a, 73,122).   
2) Concern with cognitive challenges throughout the chemotherapy journey and the 
possibility of future dementia 
Three participants reported having experienced both physical and some cognitive 
impairments prior to, during and after chemotherapy treatment although the overriding 
concern appeared to be about the possible future consequences of the cancer itself.  
For example, in response to a question about the impact that any perceived changes in 
memory and concentration may have had, one participant said:  
hopefully the cancer is over now and you want to go forward. I think well what can 
I go forward doing? How much of the energy will come back? How much of the 
mobility will come back? How much of the cognitive powers are going to come 
back? (31, T3) 
For the participants in this second pattern there appeared to be some sort of link 
between perceived CRCI and the physical side effects experienced. The more severe the 
physical side effects experienced during the treatment the more cognitive impairments 




that by virtue of participating in the study they had been primed to the idea of 
experiencing CRCI.  It is also worth noting that these participants were not working 
during the treatment and/or study period and may have had more time to think about 
all of their side effects both physical and cognitive.  In addition their cognition was less 
likely to have been tested as they were not in a work environment and also others were 
less likely to notice or report cognitive impairments if they were not working.  
Two of the participants in this second pattern were female and went on sick leave 
following the cancer diagnosis. Both had children and expressed a wish to return to 
work after treatment was completed, although only one of them actually did. However, 
both continued to report experiencing poor concentration and memory loss three 
months after treatment, to the extent that one was signed off work and the other found 
herself experiencing more memory impairments on her return to work.  
3) Cognitive issues were secondary to other concerns (such as tiredness, stomas or 
severe physical side effects) 
Eight participants who described experiencing severe tiredness or fatigue were not 
aware of very much else during the chemotherapy journey. So even when specifically 
asked if they had noticed any changes in memory or concentration the conversation 
always turned to fatigue or tiredness.  Three of the eight acknowledged occasional 
forgetfulness but said that they were “no more than prior to the operation” (58, T2); they 
were “nothing major” (55, T2); “annoying but no big deal” (57, T3). 
For one participant who experienced significant physical side effects during treatment, 




The truth is … my everyday activities are so limited, I’m lucky in that I can assign 
myself to do nothing. … So I just spend my time laying around. If I were out in the 
community trying to do something, it might be that I would fall apart, mentally. 
But…just as I say, laying around watching Big Bang Theory you don’t even know if 
your capacity to express yourself is good or bad, you’re just in a place of rest (68, 
T2). 
Once healing and physical side effects subsided and life routines returned to a relatively 
normal state of activity, the cognitive changes became more evident. However, two 
other participants had such severe side effects following the first chemotherapy cycle 
that the treatment was stopped and normal life resumed for them in all respects. 
Neither reported any issues with cognition were experienced after the first few days of 
having had chemotherapy (79, 102). 
One participant who had a permanent colostomy bag (stoma) although aware of having 
experienced some forgetfulness, it really paled into insignificance as he was 
overwhelmingly concerned about his stoma and the embarrassment that it caused him 
to the extent that he stopped all social life and didn’t tell any of his friends or family that 
he had been diagnosed with cancer:  
“ I have no, my social life is dead…..Because of this (points at stoma)….” (62).  
10.5 Discussion  
As reported by Staat & Segatore (2005) this study found that the potential for 
impairment in cognition is rarely (if ever) discussed with patients who are diagnosed 
with CRC prior to adjuvant chemotherapy treatment. This was apparent from the 




and a recounting of all of the possible physical side effects. However, as it was a 
phenomenon perceived to have been experienced by a number of patients who had 
been successfully treated for CRC it is reasonable to suggest that there is a clinical need 
to address this issue with patients. None of the participants in this study mentioned 
having discussed their experiences of cognitive impairments with the medical teams yet 
it was evident from this study that such changes were a source of frustration that also 
presented social and employment challenges.  
Research has shown that informing participants that “chemobrain” might occur 
increases the incidence of reporting cognitive impairment during treatment (Schagen et 
al. 2009), and there was some suggestion of this occurring in this study. One participant 
did wonder whether simply knowing that he was to be assessed for the study made him 
more aware of his forgetfulness that day.  Mitchell & Turton (2011) draw comparisons 
between the experience and reporting of “chemobrain” to the emergence of fatigue as a 
significant symptom experienced by patients with cancer. They describe how initially 
fatigue was ignored by clinicians but over the past 20 years fatigue has been 
increasingly recognised as a side effect of both cancer and chemotherapy and the 
incidence of patients reporting it has escalated.  
This study highlights the fact that subjective experiences of cognitive change is a 
complex phenomenon. It is a continuing and evolving experience, which also, appears to 
be inextricably linked for some patients to the severity of the physical side effects 
experienced (as seen in the patterns that emerged over time). Approximately one third 
of the participants in this study felt that their memory and/or attention had been 
affected at some point along the chemotherapy journey (i.e. between T1 and T3) (Tables 




focus group/interview studies with breast cancer patients (Shilling & Jenkins, 2006), 
although slightly fewer participants appear to have reported experiencing such changes.  
However not all participants took part in all three interviews so it is possible that this 
affected the overall prevalence in this group of patients.  
 
This study therefore builds upon the existing evidence in relation to CRCI in another 
type of cancer that is not breast, as is most often researched. One of the strengths is that 
it offers some insight into a range of people’s experience of the changes from before the 
start of chemotherapy treatment until 3 months after.  It is difficult to truly understand 
the trajectory and effect of perceived cognitive impairments without hearing from the 
participants on more than one occasion. Data from questionnaires do not fully capture 
the nuances or patterns that emerge in the same way that these interviews do.  In 
corroboration of Kanaskie and Loeb’s (2014) interview study with seven breast cancer 
patients, it was evident from the participants in this study that the experience of 
cognitive impairment could not be isolated or studied separately from the context of the 
participants’ reality of having cancer. Where participants had severe fatigue for example 
there was no escaping this new reality (which caused them to sleep during the day and 
withdraw from all social activities etc) it was a constant reminder for them.  
Similarly, to Von Ah et al’s (2013) findings, although participants reported that 
cognitive changes had a negative impact on social activities and work ability, they still 
expressed gratitude and even satisfaction with their life. Many indicated that they were 
grateful that they were cancer free. In answer to a question about whether overall life 




“No. I would say improved by the whole thing really. With my outlook on stuff, yeah 
there’s been no negative effects really at all” (55, T3) 
It would be interesting to see if the patterns change, again one-year post chemotherapy 
treatment as three months is quite a short period where survival rates are in excess of 
10 years.  
10.6 Summary  
The present study explored the perceived changes in cognitive impairments over time 
in a subset of patients with CRC who underwent chemotherapy treatment.  
The overall narrative indicated that some patients with resectable CRC do experience 
impairments in several cognitive domains such as memory, attention and concentration, 
which persist for at least 3 months after chemotherapy treatment, has finished. For 
some this was a frustrating experience and one that also caused problems on a return to 
work. The findings of this study could help inform psychological support especially in 
relation to illness and treatment progression. This study also highlighted the need for, 
further research related to employment challenges among cancer survivors who 
experience CRCI (Kanaskie & Loeb, 2015).  
The following chapter will now bring together the findings from the quantitative and 
qualitative studies in order to discuss the contribution of the thesis to existing 






Chapter 11: General Discussion  
11.1 Introduction 
This final chapter provides a discussion of the key findings of the quantitative and 
qualitative studies reported in Chapters 8 to 10 and how they fit with previous research 
reported in Chapters 3, 4 and 5. The discussion begins with the main aims of the thesis 
followed by an integrated synthesis of the findings from the quantitative and qualitative 
studies. The overall aims are discussed in relation to how these studies contribute to the 
literature in the area. The strengths and limitations of the current research are then 
outlined, followed by a discussion of the implications of the findings and 
recommendations for future research. 
11.2 Aims of the thesis 
This thesis examined CRCI (objective and subjective) in patients diagnosed with CRC.  In 
particular, cognitive, psychosocial and HRQoL outcomes were considered using a 
comparative longitudinal, mixed methods design.  The cognitive function and 
experiences of patients diagnosed with CRC scheduled to undergo adjuvant 
chemotherapy treatment were compared with a “surgery only” control group (prior to, 
during and after chemotherapy treatment) over a period of 9 months. Data were 
collected using NP assessments, self-report questionnaires and interviews and the 
findings of each component part of this thesis (as outlined in Chapter 6) were discussed 






11.3 Study set up 
 
Setting up the study took a considerable amount of work, before the PhD began. It was 
necessary to obtain at least one patient’s perspective on the proposed study prior to 
requesting NHS ethics committee approval.  Given the limited resources available at 
that time, it was difficult to obtain patient and public involvement (PPI). Nevertheless, 
adverts were posted on Beating Bowel Cancer’s patient forum and MacMillan’s Cancer 
Support online community, inviting members of the public who had been diagnosed 
with CRC to give their thoughts and opinions on the quantitative study design. It would 
most likely have been a more effective use of time (and had the resources been 
available) if PPI had involved the use of focus groups enabling a broader discussion with 
a larger group of people.   
Nevertheless, the feedback received in relation to the design was positive. It was felt 
that the study was needed particularly if CRCI was found to be a side effect and 
something could be done about it to help future patients. Cancer survivors report 
oncologists and other health professionals rarely mention the possibility of CRCI prior 
to commencing cancer treatment (Boykoff, et al, 2009; Mitchell, Woodward & Hirose, 
2008), despite survivors advising the health care professionals, that knowing about this 
possible problem would help them to prepare for it. Ethics approval of the Protocol 
(Appendix H) was granted in August 2013. Due to the limited PPI obtained, it was 
decided that a “feasibility trial” would provide the researcher with more insight as to 
the suitability and acceptability to CRC patients of the study design and measures. In 
addition, it was important to understand the feasibility of implementing the Protocol in 




made it possible to determine the resources required to perform the study and to assess 
whether the Protocol could be implemented as designed or whether significant 
alterations would be required.  If no significant changes were to be made to the 
Protocol, the data obtained from the participants during the course of the feasibility 
trial could be (and was) incorporated into the full study (Appendix J: the “Feasibility 
Trial”).   
It is arguable whether more extensive PPI would have led to greater success in 
recruitment. Perhaps individuals of differing ages who had experienced CRC and its 
treatment would have been able to provide the researcher with more valuable insight 
into the best way of approaching eligible participants. However, the Feasibility Trial 
provided this insight and although it entailed ‘learning on the job’, recruitment rates 
were on a par with other studies of this type conducted in the same patient group (e.g. 
Vardy et al, 2014).  In addition, without having conducted the Feasibility Trial, the 
researcher would not necessarily have discovered through PPI alone that the age limit 
of 65 was too restrictive. This information came to light after attendance at the MDT’S. It 
became clear that potentially eligible participants needed to be carefully tracked from 
screening to post surgery in order to ensure eligibility, as final staging was not 
confirmed until after surgery. It is also unlikely whether a larger feasibility trial would 
have led to greater retention rates given the nature of the disease and its course.  
11.4 Feasibility Trial  
As mentioned in Chapter 8, the upper age limit on recruitment was lifted and the MOCA 
was abandoned as a result of carrying out the Feasibility Trial. Both changes were 




MOCA there were people who failed to score sufficiently high to be allowed to continue 
into the study but who nevertheless wished to continue. There were also those who 
scored only a point or two lower than the cut-off but were simply not permitted to 
continue, which required a skillful exit on behalf of the researcher, as it may well have 
been considered to be unethical to tell the patient that he/she had a score suggesting 
MCI. As mentioned in Chapter 7, the MoCA is a screening tool that has been specifically 
designed to assess MCI and dementia in first line specialty clinics (Nasreddine, et al., 
2005). Whilst it has a high sensitivity to detect probable MCI in older patients 
(Naserdine et al, 2005), its sensitivity and specificity have been found to vary in 
different clinical populations (McLennan, Mathias, Brennan, Stewart, 2011). It is 
arguable that the MOCA can be used to screen for cognitive impairments that may have 
other conditions that are ultimately diagnosed including delirium, long-standing 
cognitive impairment (Libert, Dubruille, Borghgraef, Etienne, Merckaert, et al, 2016). 
The patients who scored just below the cut off in this study may not have had the same 
risk of progression to dementia and it would have been unfair if a diagnosis such as MCI 
or dementia was communicated. It was therefore considered inappropriate to use the 
MOCA as a pre-screening tool in this study.  
As the population ages, increasing numbers of patients with pre-existing MCI or 
dementia will be diagnosed with cancer, so examining the role that cancer and its 
treatment may play in the exacerbation of cognitive impairment in older adults will be 
very challenging (Gupta & Lamont, 2004). It would have been interesting to examine 
those patients who were already assessed as having MCI (according to the MOCA) and 
the effects of chemotherapy treatment on them over time if the sample size had been 




may receive a score suggesting MCI. This is an area that could be examined further in a 
larger study of this type.   
11.5 Integration of the findings from the quantitative and qualitative 
studies  
 
The following sections seek to integrate the findings from the quantitative and 
qualitative studies and discuss the overarching conclusions within the existing 
literature and the main implications of the study as a whole. The integration of the 
findings from mixed methods at the interpretation stage is considered important for 
achieving the full potential of this approach (O'Cathain, Murphy, & Nicholl, 2010). The 
assimilated findings provide various insights with regards to CRCI (objective and 
subjective) and its effects on patients with CRC. 
11.5.1 Pre-chemotherapy  
Cognitive Impairment: 
 
As indicated in Chapters 2, 3 and 4, cognitive impairment (objective and subjective) has 
been measured and defined in numerous ways in the “cancer and cognition” literature, 
which has no doubt contributed to the inconsistent findings to date. In the literature 
reviews in Chapters 3 and 4 it became evident that the concentration on female breast 
cancer patients and the numerous methodological issues encountered produced 
inconsistent findings across all studies (quantitative and qualitative) that examined 
CRCI. These issues have limited the ability to draw clear inferences about the 
prevalence, extent, course, or lived experience of CRCI. The present study sought to 




time using some of the evolving recommendations of the ICCTF (Wefel et al, 2011) 
alongside some semi-structured interviews.  
Early studies often assumed that patients diagnosed with cancer would have normal 
cognitive functioning prior to treatment, which would be adversely affected by 
exposure to certain chemotherapeutic agents (Ahles & Root, 2018). However, in this 
study, a higher than would be expected percentage of individuals diagnosed with CRC 
were found to have OCI at the first assessment (i.e. post-surgery and pre-chemotherapy 
treatment) in both groups. It is possible that this was due to the effects of the surgery. 
Postoperative cognitive dysfunction (POCD) affects surgical patients in all age groups on 
a short-term basis, but resolves faster in a younger population (Steinmetz, Christensen, 
Lund, Lohse, Rasmussen, 2009). Therefore, it is possible that the participants in this 
study (who had an average age of 63) were suffering from POCD at the time of the first 
assessment. However, it should be bourne in mind that most research in POCD has been 
carried out on cardiac patients who often endure long duration of cardiopulmonary 
bypass, which has been reported to be a significant risk factor for POCD (Krenk, 
Rasmussen, & Kehlet, 2010). Nevertheless both cardiac and non-cardiac research has 
shown that in individuals over the age of 60, POCD can last for months and may result in 
a reduced ability to handle everyday tasks and hold a job (Dijkstra, Houx, & Jolles, 
1999). 
The baseline assessment took place just several weeks after surgery (mean = 47.76 days 
in the chemotherapy group and 52.74 days in the “surgery only” group) as have many 
other longitudinal studies in the literature. For example, in Jenkins and colleagues 
(2006) study with breast cancer patients the first assessments took place a mean of 




chemotherapy group. Also, Vardy and colleagues (2015) assessed patients with 
localised CRC scheduled to have chemotherapy at approximately 6.8 weeks post-
surgery and those who were not scheduled for further treatment were assessed a mean 
of 9.2 weeks after-surgery. The reason for the later assessments in the “surgery only” 
patient groups could be due to hospital follow up appointments being scheduled later 
than for the chemotherapy patients who have a relatively short window within which 
time adjuvant chemotherapy has to commence. Although there was a statistically 
significant difference between the groups in time from surgery to first assessment in 
this study, it was a small effect size and there was no significant difference between the 
groups in relation to the type of surgery performed (i.e keyhole ‘v’ open surgery) or in 
the proportion of impaired individuals.  
Although a higher than expected percentage of participants were found to have OCI at 
the first assessment in this study than would be expected by chance, the findings 
corroborate other studies that have examined pre-chemotherapy OCI in patients with 
CRC. For example, Cruzado and colleagues (2014) and also Vardy and colleagues (2015) 
found 37% and 48-52% impairment respectively using ICCTF criteria on NP tests in 
patients with localised CRC. Vardy and colleagues (2014) found no significant difference 
in rates of cognitive impairment between patients’ pre and post-surgery arguing that 
causes other than surgery and anaesthesia, fatigue or anxiety and depression are 
responsible for the high rates of OCI in patients with CRC at baseline. Similarly, OCI was 
not found to be related to anxiety, depression or fatigue in this study. It may be that 
there is something about CRC itself that causes changes in cognition (Vardy et al, 2014). 
Although, the stress and shock of receiving a diagnosis of cancer was mentioned by 




starting chemotherapy treatment. Hermelink and colleagues (2007 and 2015) found 
that post-traumatic stress symptoms mediated the relationship between breast cancer 
diagnosis and cognitive performance on an NP test prior to chemotherapy treatment.  
Preliminary analyses of baseline quantitative data revealed no significant differences in 
objectively measured cognitive function between the chemotherapy group and “surgery 
only” group, which is in line with previous findings (e.g. Bender et al., 2006, Jenkins et 
al., 2006; Schagen et al, 2006; Vearncombe et al, 2009). However, these findings are 
opposite to a number of other studies in breast cancer patients. For example, Stewart 
and colleagues (2008) found a threefold greater risk of cognitive decline in the 
chemotherapy patients compared to hormonal patients (31 and 12%, respectively) 
although very few participants fell in the impaired range at any time (1.3% 
chemotherapy patients, 0.8% hormonal patients). Once again, this raises the possibility 
that CRC itself shares a common aetiology with cognitive impairment. Consequently, 
this finding adds to the debate surrounding pre-chemotherapy cognitive function in 
patients diagnosed with solid tumours other than breast cancer. 
There were also no statistically significant differences found between the two groups in 
relation to perceived cognitive abilities or impairments at baseline (as measured by the 
FACT Cog PCA and PCI subscales). However, as mentioned previously, in the absence of 
any normative data it is not possible to say whether there was a greater incidence of SCI 
found in either group at baseline in this study than would be expected in the general 
population. Dhillon and colleagues (2018), found that the prevalence of cognitive 
symptoms reported pre-chemothearpy treatment in patients with CRC was 18 -24% 
which was less than the OCI that they found at that time. It would be interesting to 




colleagues definition; particularly as there was a higher percentage of participants that 
scored below normative ranges on NP assessments in this study, than in Dhillon’s study. 
If a lesser incidence of SCI than OCI were to be found at baseline in this study, it is 
possible that some participants would simply not have realised just how many lapses in 
memory or concentration they experienced prior to the first chemotherapy treatment. If 
they already have OCI it is arguable whether they would notice that they were 
experiencing any cognitive problems; they would not be able to remember what they 
could not remember.  There is evidence of this in the interview study. For example, one 
participant described how her memory problems (of which she was not totally 
unaware) had been commented on by family members prior to the start of 
chemotherapy treatment:    
Sometimes my children say ‘Oh mummy but you said something’ and I say ‘no’. 
‘Yeah you said yesterday’ and that is is worrying…… but no not much …….but it 
don’t affect my activities yet and I hope don’t happen because it’s terrible (44 at 
T1). 
Most commonly affected cognitive domains:  
As discussed in the literature review, memory, processing speed and executive function 
appear to be the most affected cognitive domains (Wefel et al, 2011). Similarly, the most 
commonly affected domains (in both groups) in the NP testing in this study were verbal 
memory, motor function and executive function. Impairments in verbal memory were 
also implicated in the interviews prior to the start of chemotherapy treatment, with 
some of the chemotherapy participants reporting experiencing problems with memory 




Schagen, Das and van Dam (2009) demonstrated that priming or pre-existing 
knowledge regarding the concept of CRCI significantly increases the reporting of 
cognitive complaints. However, for ethical reasons, it was necessary to inform 
participants of the purpose of the research and so the association between 
chemotherapy and possible cognitive impairment is evident in the Participant 
Information Sheets (Appendix I). Priming may not be an issue in this work because 
although a few chemotherapy participants reported that they believed chemotherapy to 
be the cause of their cognitive difficulties, others dismissed this idea and described how 
these difficulties existed prior to the start of the chemotherapy treatment and instead 
were age-related or related to the surgery (Chapter 10). Additionally, unlike breast 
cancer patients who may have knowledge about CRCI through the media or cancer 
support groups (Schagen, Das and van Dam, 2009), the possibility of cognitive 
impairment is not often associated with CRC and its treatment and the interview 
findings confirmed this. 
Mood, fatigue and HRQoL 
It is interesting to note that the percentage of participants in both treatment groups 
reporting clinical levels of anxiety and depression at baseline were comparable to the 
estimated percentages found in the general adult population (Crawford et al, 2001; 
Keating et al, 2005). There were no significant differences between the two groups in 
baseline measures of anxiety or depression. It is possible that having recently 
undergone curative surgery meant that the participants in this study were not very 
anxious or depressed at the time of the first assessment. All participants having just 
recovered from major surgery to remove the cancer had a good prognosis (with 




The greatest rates of depression have been found in those with advanced forms of 
cancer (40-50%) (Honda & Goodwin, 2004; Hewitt & Rowland, 2002; Fallowfield et al, 
2001; Derogatis et al, 1983). There was however, evidence of feelings of anxiety prior to 
the start of chemotherapy in some of the interviews with the chemotherapy participants 
(Chapter 10), which may have been linked to some of the cognitive lapses experienced. 
For example, one participant described how:  
Only to know that you have cancer and you are going to pass through to a lot of 
things is confusing and I think you have too much information in your head and too 
much thinking and worries that you get confused and sometimes you say oh I don’t 
remember this, I forgot this, I don’t remember that …....(44 at T1). 
In corroboration of Dhillon’s (2017) findings SCI (as measured by the FACT Cog PCI 
subscale) in this study was significantly associated with depression, anxiety, fatigue and 
poorer HRQoL, yet neither FACT Cog PCI nor PCA were associated with NP performance 
at the first assessment. Shilling and Jenkins (2007) suggested that reports of memory 
problems are more indicative of psychological distress rather than objectively 
measureable memory change.  
There were also no significant differences between the two groups in baseline measures 
of fatigue and HRQoL (Chapter 8). Although 38% of the chemotherapy participants 
reported having experienced clinically significant symptoms of fatigue after surgery at 
T1 (i.e. a score of < 37 on the FACIT Fatigue questionnaire), this was actually a smaller 
percentage than the 52% in Vardy and colleagues’ study (2014) who were found to have 
reported fatigue. This could be partly because Vardy defined fatigue differently to the 




standardised FACT F subscale score of < 68/100 which is 1 SD below the mean for the 
general US population”.  
It may also be that a large percentage of patients with CRC are more anaemic than 
patients with other solid tumours and consequently are more tired leading to poorer 
cognitive function at baseline. For example, Tas and colleagues (2002) found that 71% 
of patients with CRC had anaemia before the start of chemotherapy treatment, as 
opposed to 44% of patients with breast cancer.  It would be have been interesting 
therefore, to monitor haemoglobin levels in both participant groups in this study at each 
assessment time point.  
11.5.2 CRCI trajectory  
OCI: 
The “cancer and cognition” literature provides evidence of subtle OCI in a subset of 
breast cancer patients undergoing chemotherapy. The quantitative findings from this 
study revealed non-significant differences in the prevalence of OCI in those who 
received chemotherapy and those who did not, during or after chemotherapy. There 
were proportionately more people in both groups (compared to normative data based 
on age, gender and education) who were found to be cognitively impaired pre, during 
and after chemotherapy than would be expected in the general population.  
Of particular interest in this study is the finding that there was a greater proportion of 
patients (in both groups) who were found to have OCI at T2 than there were at T3, 
suggesting that cognition improves with time for a subset of patients. This trend has 
been reported in a number of the breast cancer studies (e.g. Collins et al, 2009; Wefel et 




this is not a surprising finding given that chemotherapy drugs are often administered 
with a host of other medications including opioids and/or anti-sickness drugs both of 
which have been found to be associated with poorer cognitive functioning (Kurita, 
Lundorff, de Mattos Pimenta, and Sjøgren, 2009). The use of medications before and 
after chemotherapy is not at all well documented in the literature (Phillips & Bernherd, 
2003) and this data was also missing from this study; although it is thought that use of 
antiemetics can affect the central nervous system it is unlikely that they have a 
prolonged effect (Phillips & Bernherd, 2003). As this pattern was also found in the 
“surgery only” patient group, even though these participants did not continue on any 
further systemic treatment after surgery it could be linked to the cancer itself or 
perhaps these patients were also taking pain killers for a prolonged period of time.  
The results of the longitudinal analysis showed that after controlling for the baseline 
assessments there was very little change in objectively measured cognitive function 
over time. There was no statistically significant improvement. This could partly be due 
to the relatively large number of tests that were administered to a small sample of 
participants. 
SCI: 
Similar results were found in relation to the subjective reports of cognitive function as 
measured by the FACT Cog questionnaire. There were subtle but non-significant 
differences in the scores between the two groups, and over time. After controlling for 
baseline, the means scores on the FACT Cog in both groups were very similar at all 




Interviews from the qualitative study provided more detailed insight than the 
questionnaire data. They suggested that perceived difficulties in memory that had been 
experienced during chemotherapy treatment continued (and in some cases worsened) 3 
months after chemotherapy for some participants. Whereas by 3 months post-
chemotherapy treatment any problems with concentration that had been experienced 
during treatment had resolved.  In addition, impairments in attention/distraction 
appeared to have improved in those patients who had reported it previously. During the 
interview’s participants were gently probed about issues with memory and/or 
concentration and were allowed to talk freely about any cognitive issues that they had 
experienced. So, whilst the FACT Cog assesses memory and concentration it is done in a 
more focused fashion by a combination of negatively and positively worded questions. 
There is a suggestion that the negatively worded items of the FACT Cog PCI subscale 
might be tapping into more of the negative affect such as depressive symptoms, distress, 
etc (Von Ah & Tallman, 2015). Whereas in interview the participant is not necessarily 
thinking about mood when concentrating on discussing/describing experiences of 
memory lapses or difficulties with word retrieval. In addition, the questionnaires ask 
participants about experiences relating to the past seven days whereas in interview 
people talk about what they can remember has happened since the last interview (i.e. 
over a period of several months).  
It is important to recognise that even subtle cognitive changes can have a detrimental 
impact on daily functioning and quality of life (Meyers & Perry, 2008; Vardy & Tannock, 
2007), as evidenced by the qualitative findings. Findings from the interview study 
revealed that a subset of participants experienced cognitive difficulties, in particular 




revealed that participants (i.e. the chemotherapy patients) experienced these cognitive 
difficulties more frequently than was perhaps suggested by the Fact Cog, and most 
notably between pre and mid chemotherapy treatment. Similar findings have been 
reported in previous qualitative work (e.g. Cheung et al, 2012; Downie et al, 2006; 
Munir et al, 2010; Myers, 2010). Furthermore, the impact of these cognitive difficulties 
on daily functioning included difficulty returning to the work: 
 
“when I went back to work….I have to really think and I think ‘whats the matter 
with you? You know that sort of thing’” (91 at T3)  
 
which corroborates findings reported by Myers (2010) and Thielen (2008). 
Chemotherapy patients in the current study also described difficulty reading a book and 
word-finding ability, as did the participants in Boykoff and colleagues (2009) and 
Cheung and colleagues (2012) studies.  
In support of the quantitative findings, the qualitative findings also illustrated that for 
some individuals cognitive function improved by the final follow-up assessment, as 
documented by one chemotherapy patient: 
 
“Now…its 100%. It’s good” (102 at T3)  
 
when talking about memory.  Although for others, issues with memory were only 
noticed after chemotherapy treatment had finished. Several chemotherapy patients 
noticed a decline in cognitive function while receiving chemotherapy, which is reflected 




very similar at T3 and did not return to pre- chemotherapy levels indicating that SCI 
may continue for a long time for some patients with CRC. This similar pattern was also 
found to occur in the “surgery only” patients which tends to point once again to a 
common aetiology between CRC and SCI. Perhaps the “surgery only” group were still 
taking painkillers and/or opiods at the second assessment? There were no significant 
differences found between the groups on any of the FACT Cog subscales irrespective of 
time and treatment.  
11.5.3 Changes in mood, fatigue and HRQoL over time 
Feelings of anxiety did not change over time and there were no significant differences 
between the groups. There were very few participants who scored in the clinically 
anxious range on the HADS scale. It may have been that anxiety levels were no more 
than would be expected to be found in the general population following surgery because 
patients were told that the cancer had been removed and any chemotherapy to be 
scheduled was merely a precautionary step to stop possible re-occurrence. 
Depression however did change over time. There was a significant effect of treatment in 
relation to feelings of depression irrespective of time (i.e. there was an increase in 
depression during chemotherapy treatment) with a large effect size. This finding 
suggests that chemotherapy treatment may have an acute impact on depression. During 
chemotherapy treatment only 5.76% of the chemotherapy patients reported feelings of 
clinical depression (as measured by the HADS) which corroborates the findings in  
studies that have found no difference in the incidence of depression in patients with 
cancer and the general population (approximately 6%) (Keating, et al, 2005). However, 




in fact much less than would be expected, possibly because those patients who have 
completed chemotherapy treatment feel that they have been through the worst of the 
medication, and things really should start to improve.  
Feelings of anxiety and depression were not really discussed in the qualitative 
interviews (possibly, because on average the chemotherapy group were not anxious or 
depressed, as indicated by the cut offs indicative of low mood or anxiety on the HADS) 
although some patients did allude to such feelings. 
In addition, it was clear from the interview study that the combination of the diagnosis, 
subsequent operation and the fitting of a permanent stoma often caused feelings of 
depression (rather than any cognitive lapses that may have been experienced) and 
resulted in a complete withdrawal from social activities: 
….it’s the cancer that upset me ….. I always say ‘why me? I worked so hard for 40 
years looking forward to enjoying my retirement and look what happened now…. I 
am alone’. At Christmas ….yeah I am alone it’s my choice….My social life is 
zero….Cos I am hiding… (55 at T3). 
It is not unusual for patients with CRC to experience associated changes in bowel habit, 
or have sexual or micturition problems after surgery whereas breast cancer patients do 
not have the same symptoms. So, it could be that for patients with CRC these symptoms 
may be related to psychological problems, which could persist throughout the years 
(Schag, et al, 1994) and remain a problem even among long-term survivors who achieve 
remission of CRC (Ramsey et al, 2000).  However, physical function in patients with CRC 
would be expected to have stabilized 1 year after surgery (Ramsey et al, 2000) but this 




would be interesting to examine whether psychosocial factors might more strongly 
predict depression and psychological distress than any perceived issues with cognition 
or physical factors at least 1 year after surgery. 
Feelings of fatigue also changed over time in relation to the whole participant sample. 
There was a significant improvement in reported feelings of fatigue at the third 
assessment (irrespective of treatment group). The qualitative findings provide further 
support for this trend by showing a more in-depth account of the subtle temporal 
fluctuations of participants’ experiences. For example, a number of the participants 
reported a cyclical experience of feeling fatigued that coincided with each 
administration of chemotherapy, as illustrated by the following extracts: 
“the side effects that was more…like more hard in the first week of the chemo” 
(44);     
“those three or four days, all the symptoms…. the concentration the tired…..are 
slightly worse” (57)  
“in the week immediately after the dose, then for several days I am pretty much laid 
up at home…. and then I gradually come out of it” (88).  
Taken together, the findings from the questionnaires and the interviews suggest that 
chemotherapy treatment can have a profound impact on the daily lives of patients with 
CRC, particularly the fatigue.  This side effect inhibits patients from carrying out simple 
daily tasks and leaves patients needing to sleep a lot more than would be usual. Cancer 
related fatigue cannot always be alleviated by rest (Cella, et al 2002). This finding was 




severe tiredness/fatigue during treatment and consequently they were not aware of 
very much else during the chemotherapy journey.  
Feelings of physical well being improved significantly over time but there was no 
significant change over time in relation to functional, social or emotional well being or 
colorectal symptoms and there were no statistically significant differences between the 
two groups. The mean scores recorded for all domains of QoL suggest that undergoing 
adjuvant chemotherapy treatment for CRC affects feelings about all aspects of HRQoL, as 
they were lower on all domains mid-chemotherapy than they were before or after 
chemotherapy treatment. As indicated in the interviews very few people were able to 
continue with work or their usual daily activities during this period. Those that did 
continue to work/study reduced their hours. The mean scores of the chemotherapy 
patients on all subscales were also lower at 3 months post chemotherapy than they 
were for the “surgery only” patients (although they were not statistically significantly 
different).  
Consistent with the literature in this area feelings of fatigue, anxiety and depression and 
HRQoL were all significantly related to subjective cognitive function at each time point 
(e.g.  Castellon et al, 2004; Shilling & Jenkins, 2007; van Dam et al, 1998; Vardy et al, 
2015).  However, as this study only looked at relationships it was not possible to 
conclude whether those participants who felt that their cognition was impaired over the 
course of the study were more likely to experience feelings of depression or if the 
feelings of depression caused feelings of compromised cognition at any time. Castellon 
and colleagues (2004) studied breast cancer survivors two to five years after surgical 
treatment and found that those with self-reported cognitive impairments (e.g., lapses in 




(depression and anxiety). Similarly, Jenkins and colleagues (2004) found that self-
reported problems in cognitive functioning were related to depression in a sample of 94 
breast cancer survivors enrolled in a randomized trial of antihormonal therapy 
(anastrozole, tamoxifen, alone or in combination). 
11.5.4 Relationship between OCI and SCI 
As expected, and commonly reported in the literature, there were no significant 
relationships found between subjective cognitive function (as measured by the FACT 
Cog) and OCI in this study pre-and mid chemotherapy treatment. However, 3 months 
following the last scheduled chemotherapy treatment there was a statistically 
significant negative relationship between those participants found to be impaired 
(according to the ICCTF’s 2 SD criteria) and PCA as measured by the FACT Cog for the 
sample as a whole; indicating that as the occurrence of OCI increases perceived 
cognitive abilities get worse. This corroborates Dhillon and colleagues (2018) findings 
who suggested that PCA might better reflect cognitive ability than PCI, which may have 
stronger associations with other symptoms such as anxiety and depression. However, 
they qualified their findings by stating that the associations found between PCA and 
objective testing of NP performance were at best moderate and limited to specific 
cognitive domains (Dhillon et al, 2018). Unfortunately, it was not possible to explore the 
relationships between specific cognitive domains and each of the subjective domains in 
each of the participant groups, as the samples were too small, in this study.  
A quantitative analysis of the interview data however, did go some way towards 
mirroring the findings from the quantitative study in terms of the most affected 




affected cognitive domains as measured by the NP assessments in both the 
chemotherapy and “surgery only” patient groups (when using the 1.5 SD criteria) were 
verbal memory (chemotherapy group: 21%; “surgery only” group: 25%), visual 
memory, motor function, and executive function. Similarly, when talking about 
perceived cognitive changes experienced during the period prior to the start of 
chemotherapy treatment up until the middle of chemotherapy treatment in the 
qualitative interview, 43% of the participants mentioned experiencing issues with 
memory (Table 10.4 and Section 10.3.3). It is interesting that memory was found to be 
the most affected cognitive domain in both the NP assessments and the interviews. 
There has been a recent suggestion that patient reported memory complaints are driven 
by initial learning difficulties that are misinterpreted as actual forgetting by patients in 
daily activities (Ahles & Root, 2018). Ahles and Root (2018) propose that when patients 
describe memory deficits but score within the normal range on NP tests of memory it is 
not because their perceptions of their memory problems are inaccurate but rather that 
they are related to deficits in earlier stages of information processing connected to 
attention rather than to memory per se.  
It is perhaps also not surprising that a higher percentage of participants in the interview 
study than in the NP assessments were found to have memory issues given the 
fundamental differences in the measurement, the timelines and also the way in which 
the two data sets are gathered. NP assessments are carried out in a quiet room under 
controlled conditions at a particular point in time where the patient is required to 
concentrate on the task at hand. So, whilst there was measureable OCI, perhaps the NP 
assessments did not accuarately capture the extent of the impairments experienced or 




individual) may experience over time whilst still falling within a normal population 
range of scores?  
In addition, during the interview study, one man described how he had inadvertently 
put on completely different types of shoes one day: 
I was about to go out the door when I noticed I was wearing odd shoes…I was 
wearing… they weren’t the same colour or anything… one was a trainer and one 
was a black shoe (laughs)…totally different shoes… (131 at T1) 
He put this down to general distraction, yet this type of lapse would not have been 
identified by an NP assessment, which requires one to join dots in ascending order or 
match symbols to prescribed numbers.  
11.5.5 Cognitive function and HRQoL   
Despite the ever-increasing literature regarding the functional impact of cognitive 
impairment among patients with solid tumours, there is very little research that 
examines the effects of cognitive impairment on QoL/HRQoL. As more and more people 
are diagnosed with cancer and given the changing demographic of the workforce many 
individuals over the age of 65 will continue to work and lead active lives. Consequently, 
more cancer survivors now expect to recover and return to previous responsibilities 
(Ahles & Root, 2018) and cognitive function making the nature and extent of cognitive 






Subjective cognitive function and HRQoL:  
Subjective reports of cognitive function as measured by FACT Cog PCI were significantly 
related to various HRQoL subscale scores in each patient group at every assessment 
time point in this study. However, it is interesting to note that FACT Cog PCI and PCA 
were only significantly related to fatigue in the “surgery only” group as opposed to each 
of anxiety, depression and fatigue in the chemotherapy group. This could be due to the 
fact that chemotherapy treatment most likely provokes a more emotional response than 
surgery alone in a lot of patients. In addition, cognitive issues alone may not have been 
of such great concern to the chemotherapy participants as they were going through the 
treatment cycles. Shilling and Jenkins (2007) found that when breast cancer patients 
were interviewed regarding their cognitive difficulties and asked to provide multiple 
examples of difficulties encountered, many were unable to do so. The same was true in 
this qualitative study, with a number of participants unable to recount specific examples 
of memory loss during interviews particularly mid chemotherapy treatment. They also 
often forgot what incident they wanted to talk about, Shilling and Jenkins (2007) 
concluded that this was because these accounts were not meaningful to the participants. 
However, an alternative interpretation is that subtle memory difficulties are frequent 
and can have an emotional impact, affect confidence and QoL. 
OCI and HRQoL 
The results of this study are congruent with the results of the systematic review 
(Chapter 5) which found limited evidence in the literature of a relationship between OCI 
and HRQoL. There were very weak negative relationships found between verbal 




As problems with verbal memory increased perceived emotional well being and 
perceived social well being decreased mid-chemotherapy and 3 months post 
chemotherapy treatment respectively. Similarly, objective measures of verbal memory 
were found to be associated with poorer HRQoL five years after chemotherapy 
treatment for breast cancer in Mehnert and colleagues (2007) study. Further studies 
with larger sample sizes are warranted in this area as it was not possible to fully explore 
the relationships between each cognitive domain as measured by the NP tests and each 
domain of HRQoL (as measured by the FACT C) in each of the participant groups due to 
the small sample sizes at the second and third assessment time points.   
11.6 Contribution to current knowledge 
The findings from this research provide further evidence of the occurrence of cognitive 
impairment in patients diagnosed with a different solid cancer tumour, even prior to 
chemotherapy treatment. This thesis adds to the suggestion that cognitive impairment 
is not caused solely by undergoing chemotherapy treatment nor is it exclusive to 
chemotherapy treatment. It is more correctly labelled as “cancer related cognitive 
impairment”. Its strength lies in the longitudinal comparative design and it 
demonstrates that men as well as women may experience impairment (objective and/or 
subjective) whether or not they undergo adjuvant chemotherapy treatment.   
This thesis could help (a) health professionals to provide clear information to patients 
with CRC about the possibility of cognitive impairments associated with the cancer and 
its treatment; (b) identify appropriate interventions to support patients with CRC to 
effectively manage their daily tasks; and (c) inform employers of this potential deficit 




be necessary to improve the successful transition back into the workplace. This 
research also exemplifies the value of employing a mixed-methods approach, which is 
currently under-utilised within psycho-oncological research, to provide a holistic 
understanding of side effects among CRC patients. 
11.7 Methodological Considerations 
As outlined in Chapter 7, the ICCTF has recommended that future research in this area 
adopts longitudinal designs (including pre-treatment baseline) with both treatment and 
healthy control groups to address the limitations associated with previous work (Wefel 
et al., 2011). This study addressed as many of the recommendations as was possible in 
light of the limited resources available for a PhD study. Although there were no 
significant between-groups differences at baseline in terms of gender, age or education, 
they were controlled for in the quantitative longitudinal analysis in order to ensure that 
any subtle differences did not affect the results.  
The “Feasibility Trial” was beneficial in confirming that the Protocol was acceptable to 
both the patients and the medical staff at the participating hospitals. It also allowed for 
minor changes to be implemented fairly early on in the study which ensured that 
recruitment was not impeded by a restrictive age limit or pre-screening test. Whilst the 
MOCA could have been used to examine the effect of chemotherapy treatment on 
inidividuals with MCI, this study was limited in resources and participant numbers. 
However, future larger studies should consider using the MOCA in addition to the NP 
assessments in order to examine if chemothapy treatment exacerbates cognitive 




Furthermore, the mixed-methods approach proved valuable, although it was not 
without its challenges. For example, several participants noted a cyclical nature to their 
side effects, such as feeling particularly tired and/or sick for several days following 
chemotherapy administration. However, the questionnaire survey did not capture these 
subtle temporal fluctuations due to the 3 and 6 months that elapsed between 
assessments. This is important to recognise when interpreting findings from 
longitudinal research.  
The qualitative interviews took place immediately prior to the NP assessments, which 
may or may not have caused those participants to concentrate more whilst doing the 
assessments, as their impairments would have been at the forefront of their minds at 
that time. Although by the second assessment all participants (whether or not they were 
going to take part in the interview study) knew what would be expected of them in 
terms of the types of tests that they would be undertaking, so perhaps would have been 
more prepared to concentrate in any event. Even if it would have been more valuable to 
split the interview date from the NP assessments, it may not have been logisitically 
possible to do so and it would have been more burdensome for the participants who 
were already undergoing a time consuming and physically tiring treatment regimen.   
There are issues regarding the generalisability of the findings to the wider CRC 
population in the UK for several reasons. Firstly, metastatic patients were excluded 
from the current study and secondly, patients were recruited only from London NHS 
Trusts.  Due to the limited timeframe and resources inherent in a PhD project, it was not 
possible to recruit a larger cohort of patients to provide generalisable findings to this 
subpopulation. It is acknowledged that future studies with sufficient resources should 




investigate this subpopulation. As outlined in the Feasibility Study (Dwek et al, 2015; 
Appendix J ) this is a very hard to reach group of patients with approximately 1 out of 2 
patients approached refusing to take part in the study. Potential reasons for this low 
uptake may be poor health and competing priorities in terms of work and family; and in 
relation to the “surgery only” eligible patients, it may just be a wish to forget about 
having had cancer. Whilst recruitment from eight NHS hospitals around London was 
advantageous, further multi-centre research, spanning larger geographic areas is 
necessary in order to obtain larger samples and broaden the generalisability of the 
findings to the UK CRC population. 
Nevertheless the overall sample size in this study is comparable to recent longitudinal 
studies examining cognitive difficulties in patients with CRC (Cruzado et al, 2014; Vardy 
et al, 2015). Although the “surgery only” group was relatively small, such small sample 
sizes are a common limitation in psycho-oncological research (e.g. Jansen, Dodd, 
Miaskowski, Dowling, & Kramer, 2008). Findings from the power calculations (Chapter 
7) suggest that larger samples sizes than obtained would have been able to detect a 
larger effect size for all analyses conducted. Therefore, the findings from this thesis 
should be interpreted with caution. With regards to the interview study, the sample size 
was comparable to other qualitative work (for example, Downie et al, 2006; Mitchell et 
al, 2007;Munir et al, 2011; Myers, 2012; Von Ah, et al, 2013) and the rate of attrition 
was relatively low. 
The attrition rate in longitudinal cognitive function studies in other illnesses range from 
22 to 34% at the first follow-up assessment (Levin et al., 2000; Newman et al., 2001; 
Van Beijsterveldt et al., 2002). The attrition rate in this study is better than that for the 




(22.86%) and at first follow-up assessment. It is believed that the benefits of the 
longitudinal design, in terms of the information that is yielded, outweigh the problem of 
attrition. Future, larger studies will need to over-sample to balance the effects of 
attrition and ensure adequate power to detect changes in cognitive function (Levin et 
al., 2000; Bender et al, 2005).  
A shortcoming in this study however is the use of convenience samples. Although a 
highly popular recruitment strategy (e.g. Jansen, Dodd, Miaskowski, Dowling, & Kramer, 
2008), convenience samples may not always result in a representative sample and 
findings must therefore be interpreted with caution. Although the sample 
characteristics of the chemotherapy group were similar in terms of gender, age and 
education as the “surgery only group” and also previous studies (e.g. Jansen et al., 
2008), the “surgery only” participants had a lesser stage cancer or refused 
chemotherapy treatment. Those patients who refuse chemotherapy may possess 
characteristics that make them different from those who accept, however it was not 
possible to explore this given the small number of participants to whom this applied.   
In addition, the literature reviewed in Chapter 3 suggested a dose response relationship 
with OCI. Patients with CRC may be assigned to a number of different treatment 
protocols (Chapter 2) some of which involve oral chemotherapy drugs others 
intravenous. However, the small sample precluded an evaluation of the differential 
effects of the treatment modes and dosages on cognitive function. In addition, a lack of 
resources and some logistical problems that were encountered meant that it was not 
possible to obtain sufficient information about each chemotherapy participant’s 
treatment protocol and any changes made to it along the way.  Future studies are 




mechanisms underlying OCI may differ from one chemotherapeutic agent to another 
(Wefel et al 2004). 
It is also important to remember that CRC is treated with multiple modalities that 
complicate the study of cognitive impairment and the identification of components of 
treatment responsible for the same. Insufficient data was collected on this study in    
relation to steroid use, analgesics and painkillers. One reason for this was the difficulties 
encountered in accessing the medical records at one of the participating Trusts for some 
of the participants. Although all of the participants in this study had undergone surgery, 
some may have been more affected by it than others, as surgery with general anesthetic 
can cause delirium and lasting cognitive changes particularly in older patients (Le Strat, 
2012). There was also insufficient data to determine whether there was a relationship 
between co-morbidities and cognitive impairment or if co-morbidities were a predictor 
of cognitive changes over time.  The more co-morbidities an individual has the worse 
the burden on cognition in illnesses such as Alzheimers for example (Haaksma, et al, 
2017). In this study people with brain tumours and other medical conditions (such as 
stroke) known to have an impact on cognition were excluded. Perhaps future studies 
should also examine whether chemotherapy treatment makes more or less of a 
difference to the cognitive functions of those individuals who already have cognitive 
decline?  
11.8 Implications of findings and ethical considerations 
CRC is the fourth most commonly diagnosed cancer in the UK (Chapter 1). The survival 
rate is increasing and so individuals look to maintain a normal life during and beyond 




associated with the diagnosis, disease and its treatment, which includes cognitive 
impairment (whether it is objective or subjective).  
11.8.1 Implications of findings for health professionals 
This thesis has expanded the current knowledge of CRCI issues for patients diagnosed 
with CRC. Recent research has documented that health professional’s lack information 
on CRCI (Cheung, Shwe, Tan, Fan, Ng, & Chan, 2012; Munir, Kalawsky, Lawrence, Yarker, 
Haslam, & Ahmed, 2011; Myers & Teel, 2008). However since the aetiology of CRCI is 
currently unclear, it is important that all patients are informed that psychosocial 
factors, systemic treatment and the cancer itself may contribute to cognitive changes. By 
providing this information, at an early stage, it could help to improve patients’ 
management of these side effects. For example, they could implement coping strategies 
(Bender et al., 2008).  
 
Most oncologists do not screen for CRCI during or after CRC treatment, for fear of 
priming or not believing that it is real or a common experience, and lack of knowledge 
about CRCI and how to treat it (Smidt, et al 2016). This study has gone some way to 
examining the effect of priming on patients, and it was clear from the interview study 
that the medical teams did not discuss the possibility of CRCI with the patients. 
However further studies are required to examine these issues in more detail.  
It is also important that further qualitative work be conducted on the lived experiences 
of patients with CRC and other solid tumours so that healthcare professionals can 
provide patients with useful information on possible effects of cancer, surgery and 




want information about specific side effects of treatment as well as the impact of 
treatment on their lives. Future work could also explore whether there is a relationship 
between particular chemotherapeutic agents and dosages used in the treatment of CRC 
and objective or subjective CRCI. 
11.8.2 Implications of findings for patients  
It has been suggested that by health professionals acknowledging cognitive impairment 
as a problem associated with cancer and its treatment and providing emotional support 
it could help to reduce the stress that these patients live with (Vardy and Dhillon, 2017). 
Therefore, although no relationship was found between OCI and HRQoL in this study 
due to the very small sample sizes further exploration is required. However, even in the 
absence of a definite relationship between OCI and HRQoL, patients’ perceptions of 
impairment are no less important than OCI, affecting all areas of life such as social 
activities and work and therefore there is still an argument for informing all patients of 
the possibility of CRCI following a colorectal cancer diagnosis, particularly as a large 
percentage of participants scored below normal ranges in this study on the NP 
assessments.  It is possible that these individuals may be making mistakes without 
awareness which could have associated risks. People should know about the possibility 
of cognitive impairment even if it does not necessarily get worse over time.  
The finding that cognitive function did not significantly differ between the two groups 
or over time is a somewhat reassuring finding for prospective chemotherapy patients, 
although qualitative findings suggested more subtle temporal changes could have a 




This study has also raised the question as to whether there is something about the 
particular cancer itself that means that a higher proportion of CRC patients experience 
both objective and subjective cognitive impairment prior to the start of any adjuvant 
chemotherapy treatment?  
11.9 Future research directions  
These findings highlight the need for future research to:  
Explore the longer term effects of treatment on objective and subjective cognition 
particularly as subtle cognitive difficulties may become more pronounced once 
patients resume functional ability, such as social and work activities (Ferguson, 
McDonald, Saykin, & Ahles, 2007; Meyers & Perry, 2008; Vardy & Tannock, 2007). It 
would be helpful to introduce diaries as part of the qualitative study in the future. 
They can be a very useful tool that would capture the temporal fluctuations in side 
effects. Such in-depth data could then be used to develop further measures; based on 
a comprehensive understanding of the treatment on a daily basis in order to help to 
inform interventions in a patient focussed manner. The qualitative findings in this 
study provided insightful contextual information relating to the cyclical nature of the 
side effects, which were experienced as being the worst during the first few days 
after the chemotherapy treatment was administered and gradually improved over 
the following week. It might also be useful to interview all participants who take 
part in the quantitative study (including the “surgery only” patients) in future 
studies rather than just a sub-set of the chemotherapy participants. This would 
provide a more complete picture of both participant groups and allow more 
comparisons to be drawn across the quantitative and qualitative studies and 




breast cancer patients who had completed NP assessments at T2 and T3 and 
consequently obtained some very rich data.   
Undertake collaborative studies as suggested by the ICCTF (Wefel, et al, 2011). As 
described in Chapters 3, 4 and 5, researchers examining CRCI have employed a 
diverse range of methodological designs (Vardy et al., 2008). Consequently, it is very 
difficult to compare findings across studies. Despite the growing literature on CRCI 
in all cancer populations, there is a need for greater collaborative efforts involving 
multicentre (possibly even multinational) recruitment sites to undertake large-scale 
standardised research (Hurria, Somlo, & Ahles, 2007; Wefel et al, 2011), using the 
same definitions and methods of assessing impairment.  
Examine in more detail levels of anaemia in both participant groups by taking blood 
samples at the beginning of every assessment. Does chemotherapy treatment affect 
levels of anaemia? Does anaemia in patients diagnosed with CRC improve in either 
group over time? If so, when? Does it improve faster in the “surgery only” 
participants? 
Further research needs to be conducted in other cancer populations, as these are 
currently under-researched and the findings of this thesis suggest that it occurs in 
individuals with cancers other than breast cancer.  
11.10 Conclusion  
To summarise, the findings from this study extend the literature in this area to a 
different solid tumour. The higher than expected prevalence of OCI suggests that it is 
not limited to female breast cancer patients. However, larger and more representative 
samples are required to validate the current findings. Perhaps if possible including a 




medications administered and haemoglobin levels prior to surgery and immediately 
afterwards, in order to more accurately assess whether cognitive impairment is present 
prior to any treatment at all.  
The interviews offered valuable supplementary data to the quantitative analyses. 
Patients with CRC undergoing chemotherapy report some temporal changes to their 
physical and cognitive function, which reflect the course of their treatment. However, 
the aetiology of these experiences is unclear and further research is required to 
establish the exact causes.  
In particular, as the survival rate for patients with CRC is increasing and prognosis 
improves, many patients look to resume pre-diagnosis levels of cognition and daily 
functioning following treatment and/or try to continue undertaking typical activities 
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